<SEC-DOCUMENT>0000906709-20-000009.txt : 20200508
<SEC-HEADER>0000906709-20-000009.hdr.sgml : 20200508
<ACCEPTANCE-DATETIME>20200507212654
ACCESSION NUMBER:		0000906709-20-000009
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		52
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200508
DATE AS OF CHANGE:		20200507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEKTAR THERAPEUTICS
		CENTRAL INDEX KEY:			0000906709
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943134940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24006
		FILM NUMBER:		20858438

	BUSINESS ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		4154825300

	MAIL ADDRESS:	
		STREET 1:		455 MISSION BAY BOULEVARD SOUTH
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS INC
		DATE OF NAME CHANGE:	19980723

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INHALE THERAPEUTIC SYSTEMS
		DATE OF NAME CHANGE:	19940303
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nktr-20200331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:0794ac43-98cf-4d2f-9c7f-9f499c0d4858,g:07e3bb7c-ce78-4710-acc8-c80ed5139092,d:f0957f1cf80a4889940736b29ad56c63--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nktr="http://www.nektar.com/20200331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nktr-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180L2ZyYWc6MTgxYzY4ZWRkMWQxNDQxMWI0YmVhMmIzODU1YjAzZWEvdGFibGU6MDAyOTg1M2U0M2M2NDU0OGE4ZmYyY2ZjY2U3MzhhNWIvdGFibGVyYW5nZTowMDI5ODUzZTQzYzY0NTQ4YThmZjJjZmNjZTczOGE1Yl8yLTEtMS0xLTA_045bf8b0-37a3-4bd8-bfbc-49f92897fe13">false</ix:nonNumeric><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180L2ZyYWc6MTgxYzY4ZWRkMWQxNDQxMWI0YmVhMmIzODU1YjAzZWEvdGFibGU6MDAyOTg1M2U0M2M2NDU0OGE4ZmYyY2ZjY2U3MzhhNWIvdGFibGVyYW5nZTowMDI5ODUzZTQzYzY0NTQ4YThmZjJjZmNjZTczOGE1Yl80LTEtMS0xLTA_45a2c005-ac0c-476e-9445-f8dd42227f78">2020</ix:nonNumeric><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180L2ZyYWc6MTgxYzY4ZWRkMWQxNDQxMWI0YmVhMmIzODU1YjAzZWEvdGFibGU6MDAyOTg1M2U0M2M2NDU0OGE4ZmYyY2ZjY2U3MzhhNWIvdGFibGVyYW5nZTowMDI5ODUzZTQzYzY0NTQ4YThmZjJjZmNjZTczOGE1Yl81LTEtMS0xLTA_a0e5f5f6-8562-4e58-afa0-679020ee5680">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180L2ZyYWc6MTgxYzY4ZWRkMWQxNDQxMWI0YmVhMmIzODU1YjAzZWEvdGFibGU6MDAyOTg1M2U0M2M2NDU0OGE4ZmYyY2ZjY2U3MzhhNWIvdGFibGVyYW5nZTowMDI5ODUzZTQzYzY0NTQ4YThmZjJjZmNjZTczOGE1Yl84LTEtMS0xLTA_7b72853b-5794-46fb-9b66-5e28176d979c">0000906709</ix:nonNumeric><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180L2ZyYWc6MTgxYzY4ZWRkMWQxNDQxMWI0YmVhMmIzODU1YjAzZWEvdGFibGU6MDAyOTg1M2U0M2M2NDU0OGE4ZmYyY2ZjY2U3MzhhNWIvdGFibGVyYW5nZTowMDI5ODUzZTQzYzY0NTQ4YThmZjJjZmNjZTczOGE1Yl85LTEtMS0xLTA_751823af-2dee-4728-bfc0-790c0ddbd13e">12-31</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMS0xLTEtMS0w_b3c032fc-d829-4864-aa9b-adadcaf24dab">0.0001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMS0xLTEtMS0w_bb06fa5a-3a0d-4bce-af96-4ea1d339f698">0.0001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMy0xLTEtMS0w_169b6dc8-dcda-4a13-93e5-9ecaf36d9a2b">10,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMy0xLTEtMS0w_c82d90cf-1382-4ac0-a597-61c11fd7dbb7">10,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfNS0xLTEtMS0w_15d2710d-51b2-40cb-9c21-9eb95f21d5cc">0</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" name="nktr:PreferredStockShareDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfNS0xLTEtMS0w_7e185be8-d6de-44d5-b8da-39a4b9541bf2">0</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" name="nktr:PreferredStockShareDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfNS0xLTEtMS0w_b3a6f2c0-ee5e-4159-8560-6f737523cfda">0</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfNS0xLTEtMS0w_ee53525d-82a9-422e-a9ad-8f72d3df92ca">0</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfOS0xLTEtMS0w_5fc6c4fc-0fa3-40ee-ac26-6031e7999888">0.0001</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfOS0xLTEtMS0w_ebd08346-db55-4be8-8874-4e78242ed29a">0.0001</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMTEtMS0xLTEtMA_31c9c414-dfae-47f7-850c-66eab1b8d3b9">300,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMTEtMS0xLTEtMA_48ddbc38-7457-46bd-97e3-755a409b3c68">300,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMTMtMS0xLTEtMA_bce84bdc-a1a7-45cd-8065-dc7a41c4a1c2">177,863,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMTMtMi0xLTEtMA_52ba1a00-4416-4898-b42c-c43ea67c7c59">176,505,000</ix:nonFraction><ix:nonNumeric contextRef="i632345d08db6484894d70ab3ce958364_D20190101-20191231" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTUz_40a91577-8b0a-499f-ace6-b778d1948c9f">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ib5116a61e3b14a5f838ca99d6f39919b_D20200101-20200331" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTUz_d3c2600b-5a29-4044-88bc-bc0629d86f53">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i632345d08db6484894d70ab3ce958364_D20190101-20191231" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180OS9mcmFnOjA5YWVmZTE2NzI1ODQ4NDVhNjI5YTkwN2ZmMDkxYjY3L3RleHRyZWdpb246MDlhZWZlMTY3MjU4NDg0NWE2MjlhOTA3ZmYwOTFiNjdfODU_40a91577-8b0a-499f-ace6-b778d1948c9f">one year</ix:nonNumeric><ix:nonNumeric contextRef="ib5116a61e3b14a5f838ca99d6f39919b_D20200101-20200331" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180OS9mcmFnOjA5YWVmZTE2NzI1ODQ4NDVhNjI5YTkwN2ZmMDkxYjY3L3RleHRyZWdpb246MDlhZWZlMTY3MjU4NDg0NWE2MjlhOTA3ZmYwOTFiNjdfODU_d3c2600b-5a29-4044-88bc-bc0629d86f53">one year</ix:nonNumeric><ix:nonNumeric contextRef="i9c8f5c54957945ab9e0c8833712982bb_D20200101-20200331" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180OS9mcmFnOjA5YWVmZTE2NzI1ODQ4NDVhNjI5YTkwN2ZmMDkxYjY3L3RleHRyZWdpb246MDlhZWZlMTY3MjU4NDg0NWE2MjlhOTA3ZmYwOTFiNjdfOTI_807909cc-ac55-4f36-a902-7ae5c98fcc10">two years</ix:nonNumeric><ix:nonNumeric contextRef="id43bdc0f960a40e680fd02bc07f10995_D20190101-20191231" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180OS9mcmFnOjA5YWVmZTE2NzI1ODQ4NDVhNjI5YTkwN2ZmMDkxYjY3L3RleHRyZWdpb246MDlhZWZlMTY3MjU4NDg0NWE2MjlhOTA3ZmYwOTFiNjdfOTI_838bd4e0-3e1e-4f1e-99e0-afe09f21c067">two years</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i94931dcc4c3342aaab0d9fa72b183bd4_I20200331" decimals="INF" name="us-gaap:ContractWithCustomerLiability" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183My9mcmFnOmIxNDU4MTFhOWIwNzQ5YjI5Y2E2NTYxYTdhMjM1MWYyL3RhYmxlOjVhNjYxM2I2MDlhYzRhZjk4YzI2NDBlZDZhNDdkMGQwL3RhYmxlcmFuZ2U6NWE2NjEzYjYwOWFjNGFmOThjMjY0MGVkNmE0N2QwZDBfNC0xLTEtMS0w_4494ca6b-5d1a-4796-94d6-25f11257e555">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nktr-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0d9e59819bcb48b9afca31437d7dd506_I20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ifbb4be8e78984f9b982e39128071667a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b3ad4ac67b4455a3c9802320152891_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i206c822e44844e6d8c9a8878d54cdb82_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a678b6b3e864f2eb9b2e381794c4da8_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0efadd0052274204bbd4eee79288b4ea_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579879be3d9d4e9ba231135652799fc0_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i019e7c29ebdc411b8f4ab036df57ab24_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fbbd193f91f4e33836cd1cc651690b0_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia710b16c060f49b094bdb84fe9f40c6d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5bc0b330b3b43cd89330149bc3a1b21_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5fdaed97d5a4bbd8922f30a1bd1e928_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i241a6ffe64d345b9b815f1b853ee9a79_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6be903b189ea47d2b3464ca31dbef069_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fbb869dd6324f779968528868504d9f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0d62a4e534478a8f3dbd0b9c4a9d82_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c2a3f7bdb424534b926f3598ed9653a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ab56b00693644e9a5c6ff7f3dc0c0b3_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id49c1db014fc497d8472960ad4070a17_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768ed2c4850c48f6a6500688f1a016e3_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc5d122cc68f41fc93209ede839c32a7_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9b47f5237864755aefc5562482c7fbd_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8547a8cca34a4758b81996732bc8f2f1_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1121ec1c4f3499a8e410586cc1cbf3d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i941b5c3651924990ab68ad8cb3e8b2de_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ea8909183e4a519a2620f8ba50b115_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic76656708b514c009c3d779f4b128f64_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15e5dfd53d9c4e07acc0e26501a67651_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaabcaf066d24b2686f0349b89851a2e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7873bda1e2354f1ab9d6905b20c6b9e4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea1dfe0226d44464a9003812ad216e56_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9377ff38abc4416a7a66a775c05241e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0278c7d606b04e5eba2f454a342be177_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6500865a65a8437f8ee292f8fd4d7655_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida2d9e34320a44d7aa3415f6dd51c7fd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78ccec663024b2cb3701efac4a6e73c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2052866c6650444f9b65d63e1fe916eb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i617c906b489448d0a219e5d6dd99ee13_D20200413-20200413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-13</xbrli:startDate><xbrli:endDate>2020-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nktr:Segment</xbrli:measure></xbrli:unit><xbrli:context id="ie5764993ab504d65aacd5098dfb7222c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i657f08c144a940829954faa0eeb0ad80_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25dac032704d462cb271e24170497260_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ec364a7590642378be3d04fe71fb93b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68abed833c9c4661bbe068761870699a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i632345d08db6484894d70ab3ce958364_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5116a61e3b14a5f838ca99d6f39919b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c8f5c54957945ab9e0c8833712982bb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id43bdc0f960a40e680fd02bc07f10995_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51acd3b95c4149dc8cd83ecdfa9b12b1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7f7eb1f87944780a02ca9ee1d9db1bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5afc4a43bd794ef8adb57279613cc1dd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i938a9e31f4a64af492d8c31056483e3f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07085c452e9e46fe9f8b9074ea3df31a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia82602267fa24e74b8fe2c74cf36b690_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1849ac1a92f46c5ae1b8a55162ddd3c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i392410be9f884e3dba660113995bcb25_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c61034529c24a02ad03caceb320bacc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848f5b28c13943a9a8360104ac654571_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55ebaedb84964cd4b5712ade47ad52d9_D20120223-20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-23</xbrli:startDate><xbrli:endDate>2012-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i420c7f47313d4e2793bf297d5ef97ff1_I20120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia994984450184042ba5fc3190eb272a1_D20120223-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-02-23</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife966253eae849efaf2c94d1e31949be_D20171001-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39de4441ca0e49f2a86c258e4f2b6611_D20181001-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia10a44927680469a914aaa3781e9e7dd_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i428e2157a70c43f3a299cacec891a04c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8757df3c4b9949b5a56ec0f462c39d45_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1492124b62b94996a7f0d95f8f8f292c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8b3e65156e43079d5d07536ba9b742_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32189417fc6405184490d6c99a30561_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473c9cb95deb4ee889c81eb1819eea3d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id516ba896043456c9bdbb51852afcdc0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2341951fc6949bb9192ad91d2f02f07_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefc95f69692243d1831202814f3ecaef_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f3a718f036485cabdfa41cfb7ef6b3_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f7bf13694b434da50607cc92511ae6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba0f97bcb4b4439498c18a0cee8d7459_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9195970c9dc0457185dab641c8cb1b46_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7669b30a20914aa29e59f95f80c6ce1d_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60c9630119f2431abfe04edb5e2fb3ed_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd93624e0fb543c2b0ac79d91fd72357_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoAndYervoyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4279aa6d740d409f9971a4360326a569_D20180212-20180213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoAndYervoyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-12</xbrli:startDate><xbrli:endDate>2018-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78cc054f78e14454a10bbf7594a284a7_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife19b7e801a54e7aaa7298b8de21446d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0111201aa93e4b82bb4611c26ba6b748_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f27473571a48dd830b6f580001f835_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if758da7137704b02aeb393bbd5f6d719_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5a5a0cd127f4c7bb5c3c685ed7d0af3_I20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc7fd90c5f154037a6e40bfef3b6fc10_I20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfbf1bae2fe14c92aa3559eb0012ec75_I20200109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i013cfcd2f2bd4e028e742adb05277f94_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a469ebee04424493829d25d002dafe_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6952cb9044694778b60945d87960f80d_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i502169e6083e4ed8aadfa58300dc99f2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i176a8a9518ea4b9299405db0af88f09a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc208f913d540b49395ca3743b4185d_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib630cc6da28d48d4b7c4878a9fd1f551_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29f2903dd705405e9a99ce471b09643c_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4abc773305a245a49879e92f7a2d8ec1_I20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6cffd33a538441793df552a4a634722_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ef8d2feff24382b89a963a955b7de1_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e09065b9a0547db82bcbd6ba0330136_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7543f99a1365490685fe0784be6399be_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie216ce51a8a24a0baa754fcee329ca73_D20170822-20170823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-22</xbrli:startDate><xbrli:endDate>2017-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca1ed110b144083ad7a0642944f0a64_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93c4b0f432a74b2e864cfce6498f7af2_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f7397d7d354dbca02775665425aeb3_D20170901-20170930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7621d431c964328a7a71c7e9d1ac4bb_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7101cc04dec54a90adf4cbd5b102e5a2_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25fc7508773c488c99f151c7421c27ad_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">nktr:AnnualSalesLevelMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444f981b5fcd4ae183f9670a94a6d5c7_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice87715efb8248b3aa2edabd0ba0a78d_D20101001-20101231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-10-01</xbrli:startDate><xbrli:endDate>2010-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92df06331eee42a4bf5033fe820ebed9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aee212710ce422485f665ac0f228b73_D20090901-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-09-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c7aa64c9624c1aafe571608dc6df48_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134e5ae7cfac48ccac7b40ae651a24b6_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3701e7bc10234eaba431f6c02eacf26f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94931dcc4c3342aaab0d9fa72b183bd4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88cf58db52e049eab981ed11e7041d46_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied569ed2fa4643aabebcfeb1c89e3250_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5081eafe45545ac99082fad3b96d97f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902932094c3b42388c75a5e0aea65f9b_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e337f5f20f943c6924b26a84f75f97c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if378fd08692e42a096dc6f036e090dde_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4abfc9f996224586a3e2de8b4adc9c6f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af1e965432744c6bcbe50332144c39c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f68d2ae466140aeb768fa1c116b8abb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa8cd256275e4cdfa9d8471075320759_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic56f9fb40dd94e43b2208c0ab8ecd6b1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b46e908641040b989f8c417b89ce173_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i432c6f2272a94bb69701de1fc16655e2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib127735d3b564c8089872b75e9382773_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idba37b08c6a74db5a4d1979fcb50d818_I20151005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08a1e29f68774a94850704062f4a83db_D20200413-20200413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000906709</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-13</xbrli:startDate><xbrli:endDate>2020-04-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if0957f1cf80a4889940736b29ad56c63_1"></div><div style="height:36pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:4pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">WASHINGTON, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">_______________________________________________________________________</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY2_667ef543-0afd-4cc5-a194-6f771a59e894">10-Q</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">_______________________________________________________________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.741%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:93.259%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6MmQyZjYzZGM3MTBlNGQxMThjMzM3ZjllZjdjNWZjYzgvdGFibGVyYW5nZToyZDJmNjNkYzcxMGU0ZDExOGMzMzdmOWVmN2M1ZmNjOF8wLTAtMS0xLTA_c97c9c5c-8b3c-468e-8fb7-c88ca45d31d7">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8xNDg0MzQwNjk3NzM2NQ_a2db98ea-ef11-400f-8e77-1bad09680af5">March&#160;31, 2020</ix:nonNumeric></span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">or</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.741%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:93.259%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6MmExMWNjNWEyYjRmNDNkMjg0YTdhYzZhNjRkMWFiOWUvdGFibGVyYW5nZToyYTExY2M1YTJiNGY0M2QyODRhN2FjNmE2NGQxYWI5ZV8wLTAtMS0xLTA_416bbfc2-b4ae-4528-8ab9-44350a626c1b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission File Number: <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjc0_e6dcf6e7-0e76-413c-bc6f-388ffa44e0ae">0-24006</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">_______________________________________________________________________</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY3_36a653b6-24af-4c04-a267-2f7a346e5685">NEKTAR THERAPEUTICS</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">_______________________________________________________________________</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:46.275%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.591%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.134%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZThlMDZlOTU4ZWVlNGMzOWJmOWIxYWU3MjI0OWY5ZGQvdGFibGVyYW5nZTplOGUwNmU5NThlZWU0YzM5YmY5YjFhZTcyMjQ5ZjlkZF8wLTAtMS0xLTA_2740b605-11d0-4c96-bdd6-1fab4cdd45ac">Delaware</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZThlMDZlOTU4ZWVlNGMzOWJmOWIxYWU3MjI0OWY5ZGQvdGFibGVyYW5nZTplOGUwNmU5NThlZWU0YzM5YmY5YjFhZTcyMjQ5ZjlkZF8wLTItMS0xLTA_2de5f720-2d12-4939-a078-6597c6d4c571">94-3134940</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY4_a5cc07f8-b9f4-4ee9-9c05-01ae74f7416d">455 Mission Bay Boulevard South</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY5_acf30b5f-9ed4-4734-9ef3-49781f4a3086">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjcw_b1704ab6-2c62-4c7b-9d10-d36653d8692c">California</ix:nonNumeric> <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjcx_0fa11a27-e6af-4c2f-8eaa-56fde14fdbba">94158</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Address of principal executive offices)</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjcy_c3851416-816b-4aaf-b4d9-01214c5f48e4">415</ix:nonNumeric>-<ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjcz_6e1fa01d-27cb-4af6-98e4-6aa9e0dd51f8">482-5300</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.275%;"><tr><td style="width:1.0%;"></td><td style="width:28.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:18.906%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.100%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Securities registered pursuant to Section 12(b) of the Act:</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZjI4ZmNjZjJjODJiNGI1Y2FjZjk5MWJmOWIwNDNhMTUvdGFibGVyYW5nZTpmMjhmY2NmMmM4MmI0YjVjYWNmOTkxYmY5YjA0M2ExNV8yLTEtMS0xLTA_f57c6f22-7ca8-452d-8140-ce886c9aab9c">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZjI4ZmNjZjJjODJiNGI1Y2FjZjk5MWJmOWIwNDNhMTUvdGFibGVyYW5nZTpmMjhmY2NmMmM4MmI0YjVjYWNmOTkxYmY5YjA0M2ExNV8yLTItMS0xLTA_ca717d52-218b-4eb7-80f0-89bb76398377">NKTR</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;border-bottom:1pt solid #000;border-left:1pt solid #000;padding-left:1pt;border-right:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZjI4ZmNjZjJjODJiNGI1Y2FjZjk5MWJmOWIwNDNhMTUvdGFibGVyYW5nZTpmMjhmY2NmMmM4MmI0YjVjYWNmOTkxYmY5YjA0M2ExNV8yLTMtMS0xLTA_d7ef98ef-6982-40de-b194-552a11445fdd">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:54pt;"><span><br/></span></div><div style="text-indent:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjYz_2e0274d1-d518-42ca-870f-744ef26e9b35">Yes</ix:nonNumeric> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY0_9d562f42-0733-4fd2-b4c7-bbfe5b5ac016">Yes</ix:nonNumeric> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;No &#9744;</span></div><div style="text-indent:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.856%;"><tr><td style="width:1.0%;"></td><td style="width:20.302%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.165%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:21.165%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.677%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:20.302%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:1.456%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZDAzNWE0NjhjNzQwNGE5Njk2Y2JjOTc0ZWNlOTg2YzAvdGFibGVyYW5nZTpkMDM1YTQ2OGM3NDA0YTk2OTZjYmM5NzRlY2U5ODZjMF8wLTAtMS0xLTA_c4496b77-0ff1-4448-874a-944756d1cc3c">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated&#160;filer</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZDAzNWE0NjhjNzQwNGE5Njk2Y2JjOTc0ZWNlOTg2YzAvdGFibGVyYW5nZTpkMDM1YTQ2OGM3NDA0YTk2OTZjYmM5NzRlY2U5ODZjMF8yLTYtMS0xLTA_9157f0bb-0d21-4ecd-b7de-01f9919393eb">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:11pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZDAzNWE0NjhjNzQwNGE5Njk2Y2JjOTc0ZWNlOTg2YzAvdGFibGVyYW5nZTpkMDM1YTQ2OGM3NDA0YTk2OTZjYmM5NzRlY2U5ODZjMF80LTItMS0xLTA_f8a9a104-8b8d-435a-85dd-13dae87f1fc1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY1_9968a968-d9e0-4e5c-9acd-6985bb3f47dd">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="text-indent:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The number of outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value, was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="shares" contextRef="i0d9e59819bcb48b9afca31437d7dd506_I20200501" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF83MTQ2ODI1NTgyOTE5_fe184798-d501-45bc-9bd5-f40208aa4cc6">177,989,857</ix:nonFraction> o</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">n May&#160;1, 2020.</span></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_7"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NEKTAR THERAPEUTICS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:5.851%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:86.980%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.169%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_13">PART I: FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_16">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_16">Condensed Consolidated Financial Statements &#8212; Unaudited:</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_16">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_19">Condensed Consolidated Balance Sheets &#8212; </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_19">March</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_19"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_19">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_19">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_19">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_19"> and December 31, 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_19">9</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_25">Condensed Consolidated Statements of Operations for the three</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_25"> months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_25">March</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_25"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_25">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_25">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_25">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_25"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_25">9</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28">Condensed Consolidated Statements of Comprehensive </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28">Loss</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28"> for the three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28">months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28">March</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_28">9</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_28">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_31">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_31">months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_31">M</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_31">arch</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_31"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_31">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_31">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_31">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_31"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_31">9</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34">Condensed Consolidated Statements of Cash Flows for the </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34">three</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34"> months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34">M</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34">arch</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_34">9</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_34">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_37">9</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_82">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_82">22</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">Item 3.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_1249">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_1249">51</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_97">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_97">51</a></span></div></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_100">PART II: OTHER INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_103">Item 1.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_103">Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_103">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_106">Item 1A.</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> </span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_106">Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_106">33</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_109">Item 2.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_109">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_109">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_112">Item 3.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_112">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_112">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_115">Item 4.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_115">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_115">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_118">Item 5.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_118">Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_118">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_121">Item 6.</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_121">Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_121">54</a></span></div></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_124">Signatures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><a style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: none;" href="#if0957f1cf80a4889940736b29ad56c63_124">55</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_10"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Forward-Looking Statements</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This report includes &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (Securities Act), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (Exchange Act). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this quarterly report on Form 10-Q, including any projections of market size, earnings, revenue, milestone payments, royalties, sales or other financial items, any statements of the plans and objectives of management for future operations (including, but not limited to, preclinical development, clinical trials and manufacturing), any statements related to our financial condition and future working capital needs, any statements regarding potential future financing alternatives, any statements concerning proposed drug candidates, any statements regarding the timing for the start or end of clinical trials or submission of regulatory approval filings, any statements regarding future economic conditions or performance, any statements regarding the initiation, formation, or success of our collaboration arrangements, timing of commercial launches and product sales levels by our collaboration partners and future payments that may come due to us under these arrangements, any statements regarding our plans and objectives to initiate or continue clinical trials, any statements related to potential, anticipated, or ongoing litigation, any statements concerning estimates and predictions of the COVID-19 pandemic's impact on our business and clinical trials and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, such expectations or any of the forward-looking statements may prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including, but not limited to, the risk factors set forth in Part II, Item&#160;1A &#8220;Risk Factors&#8221; below and for the reasons described elsewhere in this quarterly report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this report are made as of the date hereof and we do not intend to update any forward-looking statements except as required by law or applicable regulations. Except where the context otherwise requires, in this quarterly report on Form 10-Q, the &#8220;Company,&#8221; &#8220;Nektar,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Nektar Therapeutics, a Delaware corporation, and, where appropriate, its subsidiaries.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Trademarks</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Nektar brand and product names, including but not limited to Nektar</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, contained in this document are trademarks and registered trademarks of Nektar Therapeutics in the United States (U.S.) and certain other countries. This document also contains references to trademarks and service marks of other companies that are the property of their respective owners.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_13"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I: FINANCIAL INFORMATION</span></div><div id="if0957f1cf80a4889940736b29ad56c63_16"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1.&#160;Condensed Consolidated Financial Statements&#8212;Unaudited:</span></div><div id="if0957f1cf80a4889940736b29ad56c63_19"></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NEKTAR THERAPEUTICS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except par value)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.137%;"><tr><td style="width:1.0%;"></td><td style="width:69.159%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.057%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.060%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ASSETS</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current assets:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and cash equivalents</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMy0xLTEtMS0w_78d23329-4657-44bd-aff9-6e6468149c5f">227,035</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMy0zLTEtMS0w_591d0a48-79ce-4fbd-9868-17050863f3a5">96,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Short-term investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNC0xLTEtMS0w_9857e3de-f527-49d5-8c4b-f29ec9218561">1,118,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNC0zLTEtMS0w_081c994b-f44a-46c5-963a-016660cc2858">1,228,499</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts receivable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNS0xLTEtMS0w_edfed25e-904c-49dd-a3d0-4eec3aeca577">42,031</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNS0zLTEtMS0w_de75bd51-8311-4696-9c89-1e9b1e102953">36,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNi0xLTEtMS0w_a2c4036e-7671-490e-840e-a02a300f72d8">14,320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNi0zLTEtMS0w_f2d0a471-b323-410b-89ea-8387cc766f74">12,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Advance payments to contract manufacturers</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:AdvancePaymentsToContractManufacturers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNy0xLTEtMS0w_c914dea3-de39-4aee-8c84-a26606d2c872">13,280</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AdvancePaymentsToContractManufacturers" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNy0zLTEtMS0w_e49854ed-0483-418d-a9f3-de316453464a">31,834</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfOC0xLTEtMS0w_b491c13f-0366-440f-9ec0-c9df76a7c555">13,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfOC0zLTEtMS0w_91446030-a792-4af9-b8a2-3e89488fa811">15,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfOS0xLTEtMS0w_a89c0a9e-96a6-49a9-8344-50a2b8283dda">1,429,324</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfOS0zLTEtMS0w_7b2fda26-c28f-456b-a166-320eb9a4bb8b">1,421,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Long-term investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTAtMS0xLTEtMA_96c2e485-b9c6-44ad-9470-c2e17e6c491a">185,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTAtMy0xLTEtMA_55d1ba21-bf98-41c4-884d-1109a0bd1f85">279,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property, plant and equipment, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTEtMS0xLTEtMA_edb978a0-a84c-4b21-b7ad-3e2df1c8c8f2">62,307</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTEtMy0xLTEtMA_c4c137b3-0baa-4ad6-9ad2-52f08d99f8f2">65,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTItMS0xLTEtMA_e54311d3-f5bb-4f6b-8b41-1de21a226c3e">133,901</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTItMy0xLTEtMA_14cd3f39-2f79-4522-bf68-90dca6fdb621">134,177</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Goodwill</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTMtMS0xLTEtMA_144fa8d1-dcb6-4eee-ba24-6a22a61c33d7">76,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTMtMy0xLTEtMA_410ebf21-4e47-4874-9733-c8b39cc488c1">76,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total assets</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTUtMS0xLTEtMA_c58d3543-c016-493e-8183-fce3cce7f905">1,887,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTUtMy0xLTEtMA_4781a655-7e7f-4cf4-a99d-6c9c52b154b7">1,977,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Senior secured notes, net and interest payable (see Note 9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SeniorNotesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTctMS0xLTEtMzE3MA_21c8ca83-58e0-4e36-bb4f-c87559e9f08c">254,144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SeniorNotesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTctMy0xLTEtMzE3Mg_9833d780-211a-4cbd-bea1-95fa6224880c">252,891</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTgtMS0xLTEtMA_16921e66-7b24-45e4-a6fc-64dd94481496">21,789</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTgtMy0xLTEtMA_0b3bb4e4-b82b-4610-b97f-4a7e9a1f5848">19,234</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued compensation</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTktMS0xLTEtMA_3d16f82c-b88b-4e93-8594-9161d810234c">22,412</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTktMy0xLTEtMA_132b86b5-5608-4c36-8a3f-e9db0de02ae2">11,467</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued clinical trial expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedClinicalTrialExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjAtMS0xLTEtMA_e6c1f23d-fd1c-4671-a940-7c08214c3831">38,624</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedClinicalTrialExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjAtMy0xLTEtMA_e671b9d8-6c04-441f-a42f-4de938eb18a2">32,626</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued contract manufacturing expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedContractManufacturingExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjEtMS0xLTEtMA_b67f07a2-b727-4479-bf3a-38f02e1b4333">8,579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:AccruedContractManufacturingExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjEtMy0xLTEtMA_379ff9d1-0855-4c2d-be2e-8d56d73fabec">7,304</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other accrued expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjItMS0xLTEtMA_fc5db28a-0687-4bd3-90e7-f732200e5379">11,844</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjItMy0xLTEtMA_24ca4565-4230-4814-afcb-7c8629f7988f">11,414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities, current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjQtMS0xLTEtMA_fbd101d5-3982-4a5f-a44b-24893dff95dc">15,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjQtMy0xLTEtMA_11a9971c-fd6b-46b4-82eb-0c87c5b38c7e">12,516</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred revenue, current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjUtMS0xLTEtMA_b0e2b3fc-e2f2-4c76-9ad8-59954a651345">3,007</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjUtMy0xLTEtMA_be4f4dd6-8901-4157-8037-72e08424b22d">5,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjctMS0xLTEtMTMy_eb6c1ed5-ca4f-41c0-8d0a-8786bdbe9f05">1,459</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjctMy0xLTEtMTM1_65d69e1d-f9ea-40d7-a6b8-aa6d4ef6ff16">1,692</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjYtMS0xLTEtMA_556b8e1e-375f-411b-b347-fd0f3861b13f">377,471</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjYtMy0xLTEtMA_4da7748c-18fb-4d94-a61b-207ab0ce2786">354,661</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjgtMS0xLTEtMA_ac2f2690-36d6-44bc-be3e-2ec46e37b8c2">142,297</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjgtMy0xLTEtMA_e948764a-7d14-47a3-a62f-df3c58a062fb">142,730</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Liability related to the sale of future royalties, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjktMS0xLTEtMA_005b2a17-6c2b-46a2-8084-725dd5480056">69,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjktMy0xLTEtMA_52e0e033-6be5-48b6-b6d6-12f674886d38">72,020</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred revenue, less current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzAtMS0xLTEtMA_2c72cad9-51c3-46a2-9fae-2a2e6b695785">2,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzAtMy0xLTEtMA_c9fb5154-6c84-4e39-a11f-6b8730923804">2,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzItMS0xLTEtMA_60759658-7aad-4e0a-aba7-c276a1f8344e">591,507</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzItMy0xLTEtMA_84d48038-e9c9-4721-b177-0a6469502be7">571,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commitments and contingencies</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span><br/></span></div><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzMtMS0xLTEtMA_7cf505a1-13e0-43fd-9711-cab1f930b30a"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzMtMy0xLTEtMA_c03c1df4-3943-4140-bb28-206a2c1fd19d"></ix:nonFraction>Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA2OTE_b3c032fc-d829-4864-aa9b-adadcaf24dab"><ix:nonFraction unitRef="usdPerShare" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA2OTE_bb06fa5a-3a0d-4bce-af96-4ea1d339f698">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjE_169b6dc8-dcda-4a13-93e5-9ecaf36d9a2b"><ix:nonFraction unitRef="shares" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjE_c82d90cf-1382-4ac0-a597-61c11fd7dbb7">10,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjU_15d2710d-51b2-40cb-9c21-9eb95f21d5cc"><ix:nonFraction unitRef="shares" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PreferredStockShareDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjU_7e185be8-d6de-44d5-b8da-39a4b9541bf2"><ix:nonFraction unitRef="shares" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PreferredStockShareDesignated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjU_b3a6f2c0-ee5e-4159-8560-6f737523cfda"><ix:nonFraction unitRef="shares" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjU_ee53525d-82a9-422e-a9ad-8f72d3df92ca">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares designated or outstanding at March 31, 2020 or December 31, 2019</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMS0xLTEtMA_8899405b-d29f-494e-bdbe-8cb54a4a72ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMy0xLTEtMA_65b549b2-8409-4856-b512-d13102883a15">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjUwMjkwM2VmNGFhNjRiYWZhYjIzNDgwNjI0MjA0MGFmXzcxNDY4MjU1ODA3MTY_5fc6c4fc-0fa3-40ee-ac26-6031e7999888"><ix:nonFraction unitRef="usdPerShare" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjUwMjkwM2VmNGFhNjRiYWZhYjIzNDgwNjI0MjA0MGFmXzcxNDY4MjU1ODA3MTY_ebd08346-db55-4be8-8874-4e78242ed29a">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjUwMjkwM2VmNGFhNjRiYWZhYjIzNDgwNjI0MjA0MGFmXzcxNDY4MjU1ODA3MjU_31c9c414-dfae-47f7-850c-66eab1b8d3b9"><ix:nonFraction unitRef="shares" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjUwMjkwM2VmNGFhNjRiYWZhYjIzNDgwNjI0MjA0MGFmXzcxNDY4MjU1ODA3MjU_48ddbc38-7457-46bd-97e3-755a409b3c68">300,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjUwMjkwM2VmNGFhNjRiYWZhYjIzNDgwNjI0MjA0MGFmXzcxNDY4MjU1ODE5MzE_bce84bdc-a1a7-45cd-8065-dc7a41c4a1c2">177,863</ix:nonFraction> shares and 176,505 shares outstanding at March 31, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMS0xLTEtMA_bca12fb0-b436-4412-9f26-67858e0b880b">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMy0xLTEtMA_a23beccd-8fdf-458b-b64d-812befbe7018">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Capital in excess of par value</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzctMS0xLTEtMA_76908fb6-ae54-4b1a-8cf4-b74d92e4872b">3,306,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzctMy0xLTEtMA_b6d7d498-0f3e-4176-b180-f23ed8f2d678">3,271,097</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzgtMS0xLTEtMA_44245161-3d14-4670-b593-6ee41520ff06">6,877</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzgtMy0xLTEtMA_55c20a9d-f271-4e5f-bc61-caee2b70991e">1,005</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accumulated deficit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzktMS0xLTEtMA_5960de22-22c1-4a2e-9d49-69d88ffdb16a">2,003,369</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzktMy0xLTEtMA_635a9130-3f59-482a-9039-e33f2dcb07bd">1,864,718</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNDAtMS0xLTEtMA_deb52846-3da6-4b97-8fbf-747a4d2f0687">1,296,426</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNDAtMy0xLTEtMA_434784bc-aecd-4249-ac2e-689b35e82c4d">1,405,391</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNDEtMS0xLTEtMA_f82c3b8b-c338-4001-b170-fb7cba22b6ec">1,887,933</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNDEtMy0xLTEtMA_6037e7c9-28e3-4769-9466-108e84440d08">1,977,356</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_25"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NEKTAR THERAPEUTICS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands, except per share information)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:71.478%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.898%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.900%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product sales</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i206c822e44844e6d8c9a8878d54cdb82_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMy0xLTEtMS0w_6b63a69f-a3a4-40de-a008-add91155fb4f">3,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5a678b6b3e864f2eb9b2e381794c4da8_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMy0zLTEtMS0w_f4984c25-3157-45eb-ba1c-536836237f47">4,398</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Royalty revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0efadd0052274204bbd4eee79288b4ea_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNC0xLTEtMS0w_41ef7d11-c9e1-4eb8-a013-609d1f9dcc63">9,719</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i579879be3d9d4e9ba231135652799fc0_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNC0zLTEtMS0w_ef7eca45-4225-44fb-bc0b-1d3894d58235">11,390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i019e7c29ebdc411b8f4ab036df57ab24_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNS0xLTEtMS0w_cd6204d2-9f74-4b3c-936f-1d5205f12301">9,895</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5fbbd193f91f4e33836cd1cc651690b0_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNS0zLTEtMS0w_a1b5f381-af2b-4fbc-9a99-4d818998ec7a">8,230</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">License, collaboration and other revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia710b16c060f49b094bdb84fe9f40c6d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNi0xLTEtMS0w_6c96d918-147c-4ab4-8fa9-acc9a6921db3">27,515</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5bc0b330b3b43cd89330149bc3a1b21_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNi0zLTEtMS0w_f6bc23dd-a70d-4f5c-bc19-905fea1cf688">4,204</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNy0xLTEtMS0w_1f5775d6-d6fe-4f75-b99e-02dd74494f75">50,573</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNy0zLTEtMS0w_cd9a647d-9b1a-42d4-bbd3-c5659b0fc672">28,222</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating costs and expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfOS0xLTEtMS0w_ee003a05-afc9-4ab1-887c-e8d758747404">3,811</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfOS0zLTEtMS0w_298026a3-5d5b-42db-9216-e4162ef73dfd">5,440</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTAtMS0xLTEtMA_7f85e89d-48ac-436a-a5fe-90f5ec33f950">108,987</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTAtMy0xLTEtMA_a73ca9ac-038d-4320-be92-5f01ba5d18fa">118,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTEtMS0xLTEtMA_3134cf2e-a462-465e-8dee-588ca03041ad">26,217</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTEtMy0xLTEtMA_0f9ce2dd-47bd-438b-8c0d-ed309d17d5a1">25,006</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTItMS0xLTEtOTI0_209c76df-92db-4032-a3ca-9c10d454ba97">45,189</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTItMy0xLTEtOTI0_a96cdd62-f127-4420-826b-a20638aa3d27">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total operating costs and expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTItMS0xLTEtMA_11f1823b-a9da-432a-9bb6-b76c7626e68f">184,204</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTItMy0xLTEtMA_e1dde7bb-4b10-417c-aa80-dedbb0da36e5">148,909</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTMtMS0xLTEtMA_87122ec5-d85a-4c44-9315-ab8e1c3f10e4">133,631</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTMtMy0xLTEtMA_3ad22c67-58b7-4502-b63d-c5d8685b90d9">120,687</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-operating income (expense):</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTUtMS0xLTEtMA_e27b4e10-0672-4893-bc0f-81ec75548afd">6,204</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTUtMy0xLTEtMA_f9347927-46f6-4af6-95aa-f5f435dbd744">5,226</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTYtMS0xLTEtMA_ccbc393e-5898-4192-be2d-7bbd152f4127">6,968</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTYtMy0xLTEtMA_c03583f2-2099-4def-aed2-6f7de3499cfc">6,065</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income and other income (expense), net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTctMS0xLTEtMA_215e15f1-37b4-40de-86c5-5807c36f46fa">8,352</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTctMy0xLTEtMA_25df1d49-b934-47b3-835b-58a03e50875d">12,483</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total non-operating income (expense), net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTgtMS0xLTEtMA_5467e223-a0e6-49d3-ae53-204e20f64030">4,820</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTgtMy0xLTEtMA_e759d5ea-141e-4a94-b6b0-8b5f5f2c8391">1,192</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before provision for income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTktMS0xLTEtMA_142fb4ac-1f4e-40b5-9b2c-105ce2f154bc">138,451</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTktMy0xLTEtMA_951e3ed3-efbe-4d8d-bbf8-23d8f7efd5d5">119,495</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjAtMS0xLTEtMA_87d2c655-22b8-4ef3-8936-6ed9e5c9c702">200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjAtMy0xLTEtMA_6ace3d3d-8a85-42b6-9760-b77011f035a7">137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjEtMS0xLTEtMA_884a2d3a-7e45-4223-94f7-a8371b86e6c2">138,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjEtMy0xLTEtMA_bb901078-84fa-4006-824f-10abae2d3566">119,632</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjQtMS0xLTEtMA_34481762-4efc-42ec-83c8-7f4cef6c25fc">0.78</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjQtMy0xLTEtMA_da5a8816-805c-44ed-923f-abdefe6dca38">0.69</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding used in computing basic and diluted net loss per share</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjctMS0xLTEtMA_63e114b9-bcb8-4a6e-8342-98bc87bdf810">177,185</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjctMy0xLTEtMA_ebf9bafa-7dd0-4f5d-9eda-9081983a823a">173,859</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center;margin-top:10pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_28"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span><br/></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NEKTAR THERAPEUTICS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.850%;"><tr><td style="width:1.0%;"></td><td style="width:68.494%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.389%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.391%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfMi0xLTEtMS0xNzU1_b270297b-9ee8-4dca-a108-38ee45194706">138,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfMi0zLTEtMS0xNzU1_96186e66-7f08-48fa-b12c-c91a42679018">119,632</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net unrealized gain (loss) on available-for-sale investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNC0xLTEtMS0xNzUx_b3f7db49-16ae-409d-8f10-6387402e7793">5,121</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNC0zLTEtMS0xNzUx_feab4c82-9667-4e6c-84bf-0422616ccbbe">4,685</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net foreign currency translation gain (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNS0xLTEtMS0xNzUx_0674c720-f6e4-4322-aeca-bb2f820e6308">751</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNS0zLTEtMS0xNzUx_b7d8d1a9-93f9-4507-9af3-b139a6937ffd">35</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNi0xLTEtMS0xNzUx_cfc0d953-0c83-49e5-ba52-5f358b1484e5">5,872</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNi0zLTEtMS0xNzUx_7333f9cc-441b-4cc7-b7c4-0152db8e694f">4,720</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfMi0xLTEtMS0w_962080c8-63c1-4948-b423-5a7f6417fde4">144,523</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfMi0zLTEtMS0w_c6363303-0c00-4013-b652-48989e890b3f">114,912</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_31"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NEKTAR THERAPEUTICS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:25.410%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.121%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.039%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.019%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.019%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.488%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.019%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.039%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.019%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.315%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.024%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie5fdaed97d5a4bbd8922f30a1bd1e928_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi0xLTEtMS0w_0b91bde2-03ad-4e70-a237-c200f07c8930">173,530</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie5fdaed97d5a4bbd8922f30a1bd1e928_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi0zLTEtMS0w_65407806-081b-4f90-9f8d-3355b2f54289">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i241a6ffe64d345b9b815f1b853ee9a79_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi01LTEtMS0w_d59db208-2b26-4250-ad95-03ed960361f7">3,147,925</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6be903b189ea47d2b3464ca31dbef069_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi03LTEtMS0w_48a78440-f391-4206-b27b-d9f4f563b58d">6,316</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8fbb869dd6324f779968528868504d9f_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi05LTEtMS0w_9f832e1e-5c02-41fc-b644-4009e6a20b62">1,424,051</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a0d62a4e534478a8f3dbd0b9c4a9d82_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi0xMS0xLTEtMA_f77fdb38-8481-4ac3-8331-d5b3b458ca31">1,717,575</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares issued under equity compensation plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0c2a3f7bdb424534b926f3598ed9653a_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMy0xLTEtMS0w_ad4636ce-7379-413e-a80a-d14917d5bc0e">698</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ab56b00693644e9a5c6ff7f3dc0c0b3_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMy01LTEtMS0w_d813a0f4-b9c8-4e18-9492-ebc621b4b778">5,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMy0xMS0xLTEtMA_5d5c2199-fc3e-4d7e-976f-33938e534f22">5,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ab56b00693644e9a5c6ff7f3dc0c0b3_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNC01LTEtMS0w_199312ef-42df-42e9-92af-83ce8feef85e">25,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNC0xMS0xLTEtMA_be829131-8c92-4e49-b39e-27de6f896942">25,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id49c1db014fc497d8472960ad4070a17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNS03LTEtMS0w_334af554-d4d6-4b7f-a317-3637d6c1ea51">4,720</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i768ed2c4850c48f6a6500688f1a016e3_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNS05LTEtMS0w_9c36c295-6c7b-4fc3-a190-3d85ccc51fa8">119,632</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNS0xMS0xLTEtMA_0e524bba-3c7d-434d-b71d-2c901ef7e6c2">114,912</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibc5d122cc68f41fc93209ede839c32a7_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy0xLTEtMS0w_3d0937bd-759a-4511-946e-80210b5de668">174,228</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibc5d122cc68f41fc93209ede839c32a7_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy0zLTEtMS0w_42589fb8-c5ec-4385-b46f-d41ad5660894">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic9b47f5237864755aefc5562482c7fbd_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy01LTEtMS0w_e7b63068-7262-44ab-9d61-1ac1f04cb678">3,178,773</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8547a8cca34a4758b81996732bc8f2f1_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy03LTEtMS0w_f422e99e-9d94-4401-b085-a2036dbbe76b">1,596</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1121ec1c4f3499a8e410586cc1cbf3d_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy05LTEtMS0w_15de197f-4221-42fd-a1b8-4c576bd8a65c">1,543,683</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i941b5c3651924990ab68ad8cb3e8b2de_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy0xMS0xLTEtMA_ca446f9e-bc86-4867-8b7a-1699a2fcec14">1,633,511</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="height:15pt;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Par<br/>Value</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i86ea8909183e4a519a2620f8ba50b115_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS0xLTEtMS0w_932aae0d-aac9-4c97-b4aa-9a8c357eb927">176,505</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i86ea8909183e4a519a2620f8ba50b115_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS0zLTEtMS0w_d1a55cfb-41fa-4a02-8d95-acb24c88c37c">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic76656708b514c009c3d779f4b128f64_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS01LTEtMS0w_52d9c6ea-3b08-47dd-b311-1e316ba35e74">3,271,097</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i15e5dfd53d9c4e07acc0e26501a67651_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS03LTEtMS0w_66dc92b5-16df-4993-b3a6-06b9054d75a2">1,005</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifaabcaf066d24b2686f0349b89851a2e_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS05LTEtMS0w_40b8489a-e027-45f5-9b1b-8d8b346e8d3a">1,864,718</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS0xMS0xLTEtMA_4c37ade7-a0cb-4803-8d5d-3bf1d8142bec">1,405,391</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares issued under equity compensation plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7873bda1e2354f1ab9d6905b20c6b9e4_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTAtMS0xLTEtMA_fb2ccf0c-9a21-4c7e-88c0-1714e668b721">1,358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea1dfe0226d44464a9003812ad216e56_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTAtNS0xLTEtMA_fc0b232c-c716-41dc-9e2d-de9b0cf4a651">11,347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTAtMTEtMS0xLTA_e18bad5a-dc1d-4f35-8bdc-25d18941dcb8">11,347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iea1dfe0226d44464a9003812ad216e56_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTEtNS0xLTEtMA_23a4f680-2e11-43b0-b23d-2205d496ac28">24,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTEtMTEtMS0xLTA_b1cb957c-c24d-4ddc-bd51-140b94268785">24,211</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia9377ff38abc4416a7a66a775c05241e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTItNy0xLTEtMA_1146ed6c-400e-46e7-8d23-325d7992a8bc">5,872</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0278c7d606b04e5eba2f454a342be177_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTItOS0xLTEtMA_f476251c-1ca9-47c5-bf1c-730844de3a3d">138,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTItMTEtMS0xLTA_37743885-8858-4bcb-8a19-c053fa17d889">144,523</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i6500865a65a8437f8ee292f8fd4d7655_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtMS0xLTEtMA_d975a248-b69c-4122-9d53-d8c864b7a2f7">177,863</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6500865a65a8437f8ee292f8fd4d7655_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtMy0xLTEtMA_334de747-5a83-4860-b983-878a44e21592">17</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ida2d9e34320a44d7aa3415f6dd51c7fd_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtNS0xLTEtMA_da4c8ca7-06be-4b39-a3d9-e2fbd65fb8e4">3,306,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie78ccec663024b2cb3701efac4a6e73c_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtNy0xLTEtMA_ed015cad-88db-4c72-9657-334b723fd5c6">6,877</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2052866c6650444f9b65d63e1fe916eb_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtOS0xLTEtMA_b01e261d-86ac-4280-ad92-137a4819b940">2,003,369</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtMTEtMS0xLTA_3b464537-b3c2-4018-ad10-48162bb245f7">1,296,426</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span><br/></span></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_34"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NEKTAR THERAPEUTICS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:72.788%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.253%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.504%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.255%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMy0xLTEtMS0w_ea416e2c-bc2a-4ae8-86c6-639842fb6121">138,651</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMy0zLTEtMS0w_e74ef3cf-56a6-4cba-98ac-5cc9bc8ba979">119,632</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash royalty revenue related to sale of future royalties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNS0xLTEtMS0w_e77355ba-495c-49a9-b7d2-472aef5890e9">9,895</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNS0zLTEtMS0w_fd21be6f-a894-41c8-a8b7-189c5ccf6795">8,230</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash interest expense on liability related to sale of future royalties</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNi0xLTEtMS0w_9f7dc4ce-996d-4afd-9ef9-f735da05d9ed">6,968</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNi0zLTEtMS0w_c629bf66-00b6-4671-a005-1e456f10306c">6,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNy0xLTEtMS0w_36e5770e-df9d-4be7-83fe-5478f71560ac">25,236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNy0zLTEtMS0w_258d9d3a-45d8-4391-ad57-d61b83f61cab">25,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOC0xLTEtMS0w_f19fd8b4-8876-47a3-ae2d-c6b899493c76">4,502</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOC0zLTEtMS0w_fa66beb3-b92e-4324-831d-f0ab9e8505bd">3,077</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impairment of advance payments to contract manufacturers and equipment for terminated program</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOS0xLTEtMS0zMjYy_64a6803d-ea4e-4694-931a-afc42ee0f9d7">20,351</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="nktr:ImpairmentOfEquipmentFromTerminatedProgram" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOS0zLTEtMS0zMjY0_10eff2f5-d9b6-4b25-bc60-0736fa303e8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accretion of premiums (discounts), net and other non-cash transactions</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOS0xLTEtMS0w_f63caf8a-61a5-45bb-ac6d-d6720c369c90">1,289</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOS0zLTEtMS0w_9d68d505-ae2f-462f-b505-0925081c0dbb">3,183</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTEtMS0xLTEtMA_1155d163-cc67-4875-8f8d-187f2250364e">5,229</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTEtMy0xLTEtMA_b8d97f4e-8520-4933-916d-2450b084fab2">319</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventory</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTItMS0xLTEtMA_b4d6c257-4ea7-4a98-a965-73ec8cd9aefa">1,655</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTItMy0xLTEtMA_77b95930-948c-4704-a49c-b01a53773909">397</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating leases, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTQtMS0xLTEtOTQ4_b8dbd8d2-3441-49e3-acdd-f87ae16e75cb">2,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTQtMy0xLTEtOTQ4_2ffe92b7-6a2f-4598-b6f7-bb88ba15d108">1,168</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTMtMS0xLTEtMA_6256a2d3-5a3b-4f4f-a31b-87518e93c9ff">1,067</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTMtMy0xLTEtMA_53d60d3c-0c3a-427d-95d0-c22994d693bb">4,209</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTQtMS0xLTEtMA_5d31a051-ec6f-41a3-bedf-5842a7f55461">2,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTQtMy0xLTEtMA_f44121a1-3959-4583-95bc-bd9cc8bcfbf1">5,156</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTUtMS0xLTEtMA_0f52079a-8468-4d53-b371-863d4793399c">9,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTUtMy0xLTEtMA_707499e5-cd36-4df0-9f9f-7c66323381fd">8,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTYtMS0xLTEtMA_2174a998-80e4-4818-ac7b-635546c8bf00">7,716</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTYtMy0xLTEtMA_93f5b20b-2b7f-44e3-b3c7-e35c132a5039">774</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTctMS0xLTEtMA_5e875593-cfc3-4c59-babc-6b31bdbcd606">2,510</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTctMy0xLTEtMA_b95b481b-9834-483b-9c71-c55326b82b1f">4,204</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTgtMS0xLTEtMA_b09cfacb-fe00-4bbb-a677-26ac456c3dbd">233</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTgtMy0xLTEtMA_4a2caaf5-e35f-4644-b2a3-8dc769095e93">164</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTktMS0xLTEtMA_280683af-189a-4afe-b640-b40ec246141c">78,075</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTktMy0xLTEtMA_bf0c4473-0856-4428-82c8-e79b8429b428">80,895</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjEtMS0xLTEtMA_4d9b7ec3-c8f4-410e-930d-2955444e2e04">241,068</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjEtMy0xLTEtMA_3802080d-6e68-490c-9ac0-6b861c3628f7">368,739</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturities of investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjItMS0xLTEtMA_5646320c-d90c-4bec-a47f-457b080aa8d9">439,735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjItMy0xLTEtMA_47564f4a-54e1-4c3b-916f-00429a61e7e1">362,249</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property, plant and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjQtMS0xLTEtMA_52bb663f-92d1-4d41-b7b7-0c9156d144c6">900</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjQtMy0xLTEtMA_61aaa18b-94bc-45d5-a462-b01dbe7eebad">5,648</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjYtMS0xLTEtMA_58e1eb44-b2b1-4fee-9ddb-962f85d37875">197,767</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjYtMy0xLTEtMA_e8e8a2c6-5faa-44ab-879b-7456c7cae819">12,138</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from shares issued under equity compensation plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjktMS0xLTEtMA_f5941e5f-136b-4926-8c9d-9e981689d183">11,077</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjktMy0xLTEtMA_0fd16df7-b9f5-497e-8d09-177a96cda5a9">4,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzAtMS0xLTEtMA_164db39e-9985-4926-9782-54b5f8f7653d">11,077</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzAtMy0xLTEtMA_5ce21e24-6c0b-42ae-a886-6cdc4302d1eb">4,894</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzEtMS0xLTEtMA_86401d68-0870-4b6d-a71b-115868056caa">97</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzEtMy0xLTEtMA_58ec73f6-65b7-4cfe-80a5-f73722217969">14</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzItMS0xLTEtMA_caa1f130-8145-44bb-b5c9-55782497dca0">130,672</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzItMy0xLTEtMA_305dd0e0-5db8-44c8-acee-32940fca6558">88,153</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzMtMS0xLTEtMA_ed883e3c-c3b3-4d20-b87e-1c5a191a8fbe">96,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8a0d62a4e534478a8f3dbd0b9c4a9d82_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzMtMy0xLTEtMA_ea4f9cc0-4fbf-4dca-8ec2-54e6e3d54fa6">194,905</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzQtMS0xLTEtMA_ae380ad0-e00f-45fa-b147-1d584c2f7ecd">227,035</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i941b5c3651924990ab68ad8cb3e8b2de_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzQtMy0xLTEtMA_72f23c55-0d6f-4870-8146-05f9bd61120b">106,752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for interest</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzYtMS0xLTEtMA_5a0108e8-6664-4062-8a36-fa19bf6da575">4,951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzYtMy0xLTEtMA_b320f315-13f7-4476-b938-8c47ef9d2d1a">4,805</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use asset recognized in exchange for lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzctMS0xLTEtMA_dd446798-b5fd-4299-b3a4-788f62fac2e7">2,133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzctMy0xLTEtMA_2f3b9f56-8e34-4f2e-9b8f-e41e7335b0ed">1,289</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_37"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NEKTAR THERAPEUTICS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">March&#160;31, 2020</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="if0957f1cf80a4889940736b29ad56c63_40"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 1 &#8212; <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4OTY_468eb2d4-b796-4c11-a15c-babe0cc1cc4c" continuedAt="i711abe050bbb4df0bd82576f6a989cb4" escape="true">Organization and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i711abe050bbb4df0bd82576f6a989cb4" continuedAt="ia0f2aedddd10427fa048cd8a0ea6a50f"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="nktr:OrganizationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4OTc_6d790cb0-4e6f-44d7-842b-001533dc3d3b" continuedAt="i2c12fa5f370a4f72a8404b925efcc6d9" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Organization</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer and autoimmune disease.</span></div></ix:nonNumeric><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i2c12fa5f370a4f72a8404b925efcc6d9">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</ix:continuation> At March&#160;31, 2020, we had approximately $<ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-8" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMTAyNg_1dff61a0-3158-4b91-abf8-7b62768fe1e4">1.5</ix:nonFraction> billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $<ix:nonFraction unitRef="usd" contextRef="i617c906b489448d0a219e5d6dd99ee13_D20200413-20200413" decimals="-5" format="ixt:numdotdecimal" name="nktr:RepaymentsOfLongTermDebtIncludingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTI2Mw_68ccf2d9-ee5a-4d1a-9e0d-66190fa5e8b7">254.8</ix:nonFraction>&#160;million. See Note 9 for additional information.</span></div><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4ODI_1eaddfe0-c44d-45a0-a4f9-fd98430ec2c5" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Principles of Consolidation</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2020 and 2019.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2019 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 filed with the SEC on February 28, 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4NzU_68578dc1-7564-41de-b21c-384ef3e195c6" continuedAt="i29fac8db3da9437c98d17c15674ac18c" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><ix:continuation id="ia0f2aedddd10427fa048cd8a0ea6a50f" continuedAt="iab8fb7e830d24e65ace33ff2344757c8"><ix:continuation id="i29fac8db3da9437c98d17c15674ac18c"><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div></ix:continuation><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTI3OA_c23d0f49-977d-4a3b-8271-211a466c6ba2" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassifications</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss), which totaled $<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTI4MA_e3680c6b-adbb-465a-b876-a7ff746e40b8">1.1</ix:nonFraction>&#160;million for the three months ended March 31, 2019. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4OTI_2b7ad6da-83f7-4db5-9b30-0595681ae979" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment Information</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate in <ix:nonFraction unitRef="segment" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNDc0Ng_1951a8de-b982-438f-a8cc-bdb4b72d56e6">one</ix:nonFraction> business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as <ix:nonFraction unitRef="segment" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNTA4OA_cbf26954-5f25-48c8-8ab6-95a01b7f2cae">one</ix:nonFraction> business segment by our Chief Executive Officer.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4OTA_c61dcdda-b7bc-4a98-91da-aacef8afa6b2" continuedAt="i1d29da6c39294fe4b1f0d654db7af8bb" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Concentrations</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of March 31, 2020, our accounts receivable includes $<ix:nonFraction unitRef="usd" contextRef="ie5764993ab504d65aacd5098dfb7222c_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTY2Mg_4d392d2d-efe9-4403-a890-3ed3c39fbed6">10.9</ix:nonFraction>&#160;million under customer contracts from our collaboration partners and $<ix:nonFraction unitRef="usd" contextRef="i657f08c144a940829954faa0eeb0ad80_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMTM3NDM4OTUzOTAzNjI_aefc8e70-c726-43b4-ade5-959a643ad26a">31.2</ix:nonFraction> million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $<ix:nonFraction unitRef="usd" contextRef="i25dac032704d462cb271e24170497260_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTY3Nw_1050d462-3a1c-4844-adba-376ad07a047c">12.8</ix:nonFraction>&#160;million from customer contracts and $<ix:nonFraction unitRef="usd" contextRef="i4ec364a7590642378be3d04fe71fb93b_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMTM3NDM4OTUzOTAzNzU_1dd3e62c-f02a-4258-bc79-6af4a86b3feb">24.0</ix:nonFraction> million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable. We have not recorded a reserve for credit losses at March 31, 2020 or December 31, 2019.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services, automotive and food and beverage industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><ix:continuation id="iab8fb7e830d24e65ace33ff2344757c8" continuedAt="i8a5f16369e1b4ab3b5b018d43582184d"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i1d29da6c39294fe4b1f0d654db7af8bb">downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</ix:continuation></span></div><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4Nzg_8ed71eff-0238-4c39-bc89-cb811483d47f" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaborative Arrangements</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4Nzk_45f121d8-85bb-4964-a283-46ddbd6a49ab" continuedAt="i9bbdeddc91e04936a99688014510d345" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product Sales</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalty Revenue</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><ix:continuation id="i8a5f16369e1b4ab3b5b018d43582184d" continuedAt="iaefafa15d22b4536904e2a6650b18214"><ix:continuation id="i9bbdeddc91e04936a99688014510d345"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License, Collaboration and other Revenue</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">License Grants</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone Payments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. Our partners generally pay development milestones</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">subsequent to</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">achievement of the triggering event.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Services</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div></ix:continuation><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4ODY_bf2f9900-ad74-4633-9d60-5812ef5b2260" continuedAt="i61410d9317bc4e07b2984b382ffb89ac" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expense</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><ix:continuation id="iaefafa15d22b4536904e2a6650b18214"><ix:continuation id="i61410d9317bc4e07b2984b382ffb89ac" continuedAt="i88377aedd0c347bf82592ffdd5f2493a"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div></ix:continuation><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i88377aedd0c347bf82592ffdd5f2493a">As a result, in the three months ended March 31, 2020, we wrote off $<ix:nonFraction unitRef="usd" contextRef="i68abed833c9c4661bbe068761870699a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:WriteOffOfPrepayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTYzMg_29121db9-679f-44bd-b709-00a5818101c8">19.7</ix:nonFraction>&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $<ix:nonFraction unitRef="usd" contextRef="i68abed833c9c4661bbe068761870699a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTY0Nw_1080d280-6d36-4fa2-b94c-5c37ce0ed061">25.5</ix:nonFraction>&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4ODM_291b0190-2796-4923-800e-c8eda4205f8a" escape="true"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div></ix:nonNumeric><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. We do not expect that the CARES Act will have a material effect on our results of operations or financial position.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4ODQ_db03b480-6ca8-48fa-bed2-8390b23222c6" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_46"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 2 &#8212; <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfMjcxMQ_14929329-1b6d-4983-8bf6-1d8c37e0f1e3" continuedAt="i9594c13d41aa41b98022be804f9057bc" escape="true">Cash and Investments in Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i9594c13d41aa41b98022be804f9057bc"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfMjcxMw_3a080a73-d7d9-47bf-b6f2-54335062871b" escape="true"><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.545%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.367%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.370%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value at</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfMi0xLTEtMS0w_dd4fb041-248e-4e8a-8cdf-2b56d8e2e33c">227,035</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfMi0zLTEtMS0w_c1049a3b-9299-48d2-9ab3-f00435090185">96,363</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfMy0xLTEtMS0w_ce42cea7-0c2b-4184-b952-346c5b3a0da3">1,118,847</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfMy0zLTEtMS0w_b8f88b8a-15e5-4962-bbc9-66ed7368ec35">1,228,499</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfNC0xLTEtMS0w_863b7476-cef6-4f94-a74a-2b83779c533e">185,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfNC0zLTEtMS0w_11d14e14-01c1-496e-8f33-ddfb08443691">279,119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and investments in marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfNS0xLTEtMS0w_23b217fd-5d41-466f-ba5d-7d84f42b3dc3">1,531,782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfNS0zLTEtMS0w_164eb8b5-7e42-4b18-9856-7433f1f8f87a">1,603,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:durwordsen" name="nktr:DebtInvestmentMaximumMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfMTE1NDQ4NzIwOTQzNzU_0565b32d-d495-4a96-87d4-74bb4687bb87">two years</ix:nonNumeric> or less and maintain a weighted average maturity of <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" format="ixt-sec:durwordsen" name="nktr:DebtInvestmentMaturityTerm" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfMTE1NDQ4NzIwOTQzOTI_4efb5670-7a06-4edc-8b34-173f9a4bd0a3">one year</ix:nonNumeric> or less. As of March&#160;31, 2020 and December&#160;31, 2019, all of our long-term investments had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTUz_40a91577-8b0a-499f-ace6-b778d1948c9f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTUz_d3c2600b-5a29-4044-88bc-bc0629d86f53">one</span></span> and <ix:nonNumeric contextRef="i9c8f5c54957945ab9e0c8833712982bb_D20200101-20200331" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTYw_807909cc-ac55-4f36-a902-7ae5c98fcc10"><ix:nonNumeric contextRef="id43bdc0f960a40e680fd02bc07f10995_D20190101-20191231" format="ixt-sec:durwordsen" name="nktr:LongTermInvestmentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTYw_838bd4e0-3e1e-4f1e-99e0-afe09f21c067">two years</ix:nonNumeric></ix:nonNumeric>.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March&#160;31, 2020 and March&#160;31, 2019, we sold <ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzA4_56d98363-158e-46f4-b63f-fac271e167fa"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzA4_9ca08e40-8ef9-463e-9b44-3b0227e315cf">no</ix:nonFraction></ix:nonFraction> available-for-sale securities. The cost of securities sold is based on the specific identification method. To repay our senior notes and accrued interest of $<ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SeniorNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzE0NjgyNTU4NzE5NQ_2a8d058a-49d1-47ed-850b-a2e736c1ce88">254.8</ix:nonFraction>&#160;million on April 13, 2020, we did not sell any available-for-sale securities.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We report our accrued interest receivable, which totaled $<ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzE0NjgyNTU4NzE2Nw_688d32c7-ed89-44c2-9af1-aafb7e8a9040">6.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzE0NjgyNTU4NzE4MQ_98752dd9-3173-47f6-8455-c1981e0b0ca9">6.5</ix:nonFraction>&#160;million at March 31, 2020 and December 31, 2019, respectively, in other current assets on our Condensed Consolidated Balance Sheets.</span></div><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfMjcwOQ_a995261e-8a58-4ef7-88e1-a1771eecfd5e" escape="true"><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:25.729%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.626%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.374%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.374%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.494%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.367%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes and bonds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51acd3b95c4149dc8cd83ecdfa9b12b1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMi0zLTEtMS0xNzcz_b44e9bc6-5b3c-4398-80f1-491c70d76e5f">989,511</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51acd3b95c4149dc8cd83ecdfa9b12b1_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMi01LTEtMS0xNzcz_9139b52e-9826-46bf-9ee6-adfe24148f23">736</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i51acd3b95c4149dc8cd83ecdfa9b12b1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMi03LTEtMS0xNzcz_ce8d46be-7fdd-4d16-8b90-2b48d048e724">4,010</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51acd3b95c4149dc8cd83ecdfa9b12b1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMi0zLTEtMS0w_62dbc076-d492-4a55-a0f0-f58b0547f21d">986,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id7f7eb1f87944780a02ca9ee1d9db1bf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMi01LTEtMS0w_d4b9794a-8ebd-4f1a-a205-3a171f6f15ba">1,132,182</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5afc4a43bd794ef8adb57279613cc1dd_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMy0zLTEtMS0xNzcz_a2b09ac0-0701-4df9-8c86-9f0066acdc21">373,237</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5afc4a43bd794ef8adb57279613cc1dd_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMy01LTEtMS0xNzcz_54ca7ebe-9421-4a43-8cc5-3c823a1c8aa7">94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5afc4a43bd794ef8adb57279613cc1dd_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMy03LTEtMS0xNzcz_a11628ac-b12b-47d5-bfdf-b6c2669c776b">108</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5afc4a43bd794ef8adb57279613cc1dd_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMy0zLTEtMS0w_8be862a4-c123-41d7-95a7-6b8a608a5f80">373,223</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i938a9e31f4a64af492d8c31056483e3f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMy01LTEtMS0w_2857ed96-238a-444a-8ea2-dc7957388c49">375,473</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i07085c452e9e46fe9f8b9074ea3df31a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNC0zLTEtMS0yMTc3_d04b2b26-cd79-451b-81c5-478ff25d2395">1,362,748</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i07085c452e9e46fe9f8b9074ea3df31a_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNC01LTEtMS0yMTc4_ac7838cb-bcf7-4fcc-af90-08037be230c4">830</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i07085c452e9e46fe9f8b9074ea3df31a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNC03LTEtMS0zOTAw_a374474a-ddc4-4204-8d61-a388efec1f93">4,118</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i07085c452e9e46fe9f8b9074ea3df31a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNS0zLTEtMS0w_3f5d8c03-1a49-4312-a751-87cdae15da2e">1,359,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia82602267fa24e74b8fe2c74cf36b690_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNS01LTEtMS0w_635bde17-ab7f-4e07-98ad-7c160a0ae504">1,507,655</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib1849ac1a92f46c5ae1b8a55162ddd3c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNi0zLTEtMS0w_73030d6e-e525-48a6-bfad-351589a8d0d5">158,080</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i392410be9f884e3dba660113995bcb25_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNi01LTEtMS0w_e043a0a6-1c67-4b2a-b148-2739a468f513">83,546</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6c61034529c24a02ad03caceb320bacc_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNy0zLTEtMS0w_8aa763fd-6df8-45f5-aee1-3f248649cbc0">8,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i848f5b28c13943a9a8360104ac654571_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNy01LTEtMS0w_201b3ecf-48c2-4f02-95c3-e1e91eb4e962">6,951</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfOC0zLTEtMS0w_6b65719f-9201-46f1-a4e3-ff67c65a4b17">5,994</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfOC01LTEtMS0w_acbb3171-303f-4405-ae7a-7b50dabee3ae">5,829</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfOS0zLTEtMS0w_bca9b2b4-2751-43cb-bcd2-452878f2ce49">1,531,782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfOS01LTEtMS0w_17bb1fab-b833-48a2-94c0-cba6df54e25b">1,603,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;1&#160;&#8212;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-63pt;padding-left:63pt;"><span><br/></span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;2&#160;&#8212;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. </span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;3&#160;&#8212;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:continuation><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At December 31, 2019, our gross unrealized gains and losses totaled $<ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzE0NjgyNTU4NzIxMQ_0e8fd8fe-1893-44ac-bb7b-54d293c53040">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzE0NjgyNTU4NzIyNQ_0ca219dc-81da-4a1f-8fbb-e9effb379c3a">0.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on our procedures under the expected credit loss model, including an assessment of unrealized gains on our portfolio after March 31, 2020, we concluded that the unrealized losses for our marketable securities were not attributable to credit and therefore we have not recorded an allowance against for credit losses for these securities as of March 31, 2020.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_52"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 3 &#8212; <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RleHRyZWdpb246ZDY4M2QyZDM1NzJiNDFiZWI0MGM4MTUyOTcwZmVjZThfMTA4OA_e0c4e21a-156c-4d89-983c-1841f871b00a" continuedAt="i64e79d49a8ae4f8b8a3a40dfa2b81ab1" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i64e79d49a8ae4f8b8a3a40dfa2b81ab1"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RleHRyZWdpb246ZDY4M2QyZDM1NzJiNDFiZWI0MGM4MTUyOTcwZmVjZThfMTA5MA_a22d3614-93a3-48a2-a7b9-90f2f74b945a" escape="true"><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.545%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.367%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.518%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.370%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMS0xLTEtMS0w_21a6e118-9367-4e92-a26d-112a10aa8e08">1,198</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMS0zLTEtMS0w_ab136da0-2d12-4916-86a3-e1c6d7b2c0da">1,673</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMi0xLTEtMS0w_181b1424-3c9c-4ca1-9a25-20630531320d">11,463</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMi0zLTEtMS0w_c5504c6b-321e-476d-985a-7db8da80794f">8,267</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMy0xLTEtMS0w_7e36a477-3fbc-4065-9ff2-6b5cf42a8481">1,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMy0zLTEtMS0w_47fc3b91-394a-488b-ab00-44ebc15f7b52">2,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfNC0xLTEtMS0w_9e5d7451-df7d-44b3-81a7-aca11babcddd">14,320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfNC0zLTEtMS0w_7ae32da0-976b-422d-b531-bbc4865c79cf">12,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RleHRyZWdpb246ZDY4M2QyZDM1NzJiNDFiZWI0MGM4MTUyOTcwZmVjZThfMTE1NDQ4NzIwOTI3NDE_db60b192-c523-4c78-9d66-6c7aa59af8b8" escape="true">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</ix:nonNumeric> Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div></ix:continuation><div id="if0957f1cf80a4889940736b29ad56c63_61"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 4 &#8212; <ix:nonNumeric contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" name="nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMzE2MQ_72d43524-90ec-4178-9ec8-dc79e0df2ce0" continuedAt="i5391d55653ba4b3f8ec9800989f7d392" escape="true">Liability Related to Sale of Future Royalties</ix:nonNumeric></span></div><ix:continuation id="i5391d55653ba4b3f8ec9800989f7d392"><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February&#160;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i55ebaedb84964cd4b5712ade47ad52d9_D20120223-20120224" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfNjk4_9246a229-c031-445b-97f0-d9fe6c954378">124.0</ix:nonFraction> million for the Royalty Entitlement.&#160;As part of this sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i420c7f47313d4e2793bf297d5ef97ff1_I20120224" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfNzc4_d519b7f9-447c-48ee-90b2-6886d5ad7b03">4.4</ix:nonFraction> million in transaction costs, which are amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $<ix:nonFraction unitRef="usd" contextRef="i55ebaedb84964cd4b5712ade47ad52d9_D20120223-20120224" decimals="-5" format="ixt:numdotdecimal" name="nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE4MA_f9f14294-fb30-4c22-b5e9-970fe8952eb3">124.0</ix:nonFraction> million in proceeds from this transaction as a liability (Royalty Obligation) that is amortized using the interest method over the estimated life of the Purchase and Sale Agreement as royalties from the CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> products are remitted directly to RPI. During the three months ended March&#160;31, 2020 and 2019, we recognized $<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTQ4NDM0MDY5Nzg3NzY_cb8c8abd-d7dc-49e3-8998-69f07dbc2787">9.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTQ4NDM0MDY5Nzg3ODM_dfbd5265-3486-4692-abc6-871ad4e72087">8.2</ix:nonFraction> million, respectively, in non-cash royalty revenue from net sales of CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and we recorded $<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTQ4NDM0MDY5Nzg3OTI_b5a1f58d-55da-4436-a307-e2e6e26f3a98">7.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTQ4NDM0MDY5Nzg4MDI_5891ca51-91e0-4de5-a652-72216cb15439">6.1</ix:nonFraction>&#160;million, respectively, of related non-cash interest expense.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMzE2Mw_e64d7566-1f06-4f8a-a84e-284e5ba3f730" escape="true">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation.</ix:nonNumeric> From inception through 2017, our estimate of the total interest expense on the Royalty Obligation resulted in an effective annual interest rate of approximately <ix:nonFraction unitRef="number" contextRef="ia994984450184042ba5fc3190eb272a1_D20120223-20171231" decimals="2" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUxODQ_c4e8ea73-abc6-45ff-91e9-e67cf4a75cd5">17</ix:nonFraction>%. During the three months ended December 31, 2017, our estimate of the effective annual interest rate over the life of the agreement increased to <ix:nonFraction unitRef="number" contextRef="ife966253eae849efaf2c94d1e31949be_D20171001-20171231" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUxODk_692f2603-b06f-424e-ba66-8f354d32755b">17.6</ix:nonFraction>%, which resulted in a prospective interest rate of approximately <ix:nonFraction unitRef="number" contextRef="ife966253eae849efaf2c94d1e31949be_D20171001-20171231" decimals="2" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUxOTY_f6ba92d6-6dfa-4592-91cd-ef79a973b81e">21</ix:nonFraction>%.&#160;&#160;During the three months ended December 31, 2018, primarily as a result of increases in the forecasted sales of MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, our estimate of the effective annual interest rate over the life of the agreement increased to <ix:nonFraction unitRef="number" contextRef="i39de4441ca0e49f2a86c258e4f2b6611_D20181001-20181231" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUyMDE_4a82af76-98fe-42da-8799-81b059cc5298">18.7</ix:nonFraction>%, which results in a prospective interest rate of <ix:nonFraction unitRef="number" contextRef="i39de4441ca0e49f2a86c258e4f2b6611_D20181001-20181231" decimals="2" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUyMDg_74b97ed4-03f6-44bd-bf86-b0be26657f82">29</ix:nonFraction>%. During the three month period ended December 31, 2019, primarily as a result of increases in the forecasted sales of CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, our estimate of the effective annual interest rate over the life of the agreement increased to <ix:nonFraction unitRef="number" contextRef="ia10a44927680469a914aaa3781e9e7dd_D20191001-20191231" decimals="3" name="nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUyMTM_36c6f783-bbb5-4a3a-ae3a-0eeeeef6418c">19.5</ix:nonFraction>%, which results in a prospective interest rate of <ix:nonFraction unitRef="number" contextRef="ia10a44927680469a914aaa3781e9e7dd_D20191001-20191231" decimals="2" name="nktr:ProspectiveInterestRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUyMjA_8b34f09b-9f77-4db0-8ada-a6385f89bc85">38</ix:nonFraction>%. This rate remains unchanged for the three months ended March 31, 2020.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty Entitlement and contains other representations and warranties, covenants and indemnification obligations that are customary for a transaction of this nature. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement; however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_64"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 5 &#8212; <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182NC9mcmFnOjIyZDc3Zjg0NTkxZDRlZjNiODc4ZTY2NzY5ZDY2YTFkL3RleHRyZWdpb246MjJkNzdmODQ1OTFkNGVmM2I4NzhlNjY3NjlkNjZhMWRfNDM2OA_1eb9aca9-036d-4b58-a05e-11ac8b8c9d6d" continuedAt="i48d447e6eec74f0285c6ca5579c1ed92" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i48d447e6eec74f0285c6ca5579c1ed92"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Matters</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on May 15, 2019. Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of Nektar&#8217;s board. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California naming the CEO, CFO and certain members of Nektar&#8217;s board. These class action and shareholder derivative actions assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. All of these cases are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Condensed Consolidated Balance Sheets at either March 31, 2020 or December 31, 2019.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnifications in Connection with Commercial Agreements</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 4. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded <ix:nonFraction unitRef="usd" contextRef="i428e2157a70c43f3a299cacec891a04c_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182NC9mcmFnOjIyZDc3Zjg0NTkxZDRlZjNiODc4ZTY2NzY5ZDY2YTFkL3RleHRyZWdpb246MjJkNzdmODQ1OTFkNGVmM2I4NzhlNjY3NjlkNjZhMWRfNDI2Nw_d2acc95a-86ae-4c03-b9b2-8763de2ee296"><ix:nonFraction unitRef="usd" contextRef="i8757df3c4b9949b5a56ec0f462c39d45_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182NC9mcmFnOjIyZDc3Zjg0NTkxZDRlZjNiODc4ZTY2NzY5ZDY2YTFkL3RleHRyZWdpb246MjJkNzdmODQ1OTFkNGVmM2I4NzhlNjY3NjlkNjZhMWRfNDI2Nw_ec72c793-2bbf-41f6-a715-e1de9aac435d">no</ix:nonFraction></ix:nonFraction> liabilities for these obligations in our Condensed Consolidated Balance Sheets at either March&#160;31, 2020 or December&#160;31, 2019.</span></div></ix:continuation><div id="if0957f1cf80a4889940736b29ad56c63_70"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 6 &#8212; <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTk3NTk_1312a227-9c8d-455a-bc54-878591eb5469" continuedAt="i268d83e36d3f4b07903485236ffbec57" escape="true">License and Collaboration Agreements</ix:nonNumeric></span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i268d83e36d3f4b07903485236ffbec57" continuedAt="i91bb34afdc1047d78147cc44d3122294">We have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. </ix:continuation></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><ix:continuation id="i91bb34afdc1047d78147cc44d3122294" continuedAt="i2b72cb7664284f80844cdde4a061d979"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTk3NTU_b1edaacc-0579-4e6b-9689-7355b676d4ea" escape="true"><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.856%;"><tr><td style="width:1.0%;"></td><td style="width:41.597%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.519%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:29.223%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.519%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.510%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.519%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.513%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Partner</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Drug or Drug Candidate</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Bristol-Myers Squibb Company</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1492124b62b94996a7f0d95f8f8f292c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfMi00LTEtMS0w_1bdf1c78-e9c9-4e50-97c4-9ebd225370a9">25,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4c8b3e65156e43079d5d07536ba9b742_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfMi02LTEtMS0w_20ff9ae2-e212-4218-8bb1-955598042e56">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Eli Lilly and Company</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NKTR-358</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie32189417fc6405184490d6c99a30561_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfMy00LTEtMS0w_0087f63e-3825-46d0-9de0-94c9ff1279e4">1,259</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i473c9cb95deb4ee889c81eb1819eea3d_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfMy02LTEtMS0w_e44d1c9a-1816-48e4-b8a0-19a64a123007">2,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amgen, Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Neulasta</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id516ba896043456c9bdbb51852afcdc0_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNC00LTEtMS0w_0c7573ac-963d-4365-b6f3-926529651e3c">1,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib2341951fc6949bb9192ad91d2f02f07_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNC02LTEtMS0w_4fbfafc2-3b61-467f-b8ce-3547cf377334">1,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iefc95f69692243d1831202814f3ecaef_D20200101-20200331" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNS00LTEtMS0w_52e29284-f028-4925-b1d3-a45b10193705">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i43f3a718f036485cabdfa41cfb7ef6b3_D20190101-20190331" decimals="-3" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNS02LTEtMS0w_cb774bd7-90df-4cbe-a2e1-c86b64b149bd">454</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">License, collaboration and other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNi00LTEtMS0w_8be81f43-9af7-40ee-855b-39971784dd2d">27,515</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="nktr:LicenseCollaborationOtherRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNi02LTEtMS0w_9681ff14-f720-4f47-b68b-bef4c5b35d77">4,204</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March&#160;31, 2020 and 2019, we recognized $<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjA5Nw_619675a5-cd2d-4a94-bcc6-0e4a78407d9a">44.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjExMg_da7a905b-6c53-4c46-82be-2d491338ce16">19.6</ix:nonFraction>&#160;million, respectively, of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue, as well as the $<ix:nonFraction unitRef="usd" contextRef="i64f7bf13694b434da50607cc92511ae6_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:SalesMilestoneRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjEyNw_54937233-f9ad-4176-938d-b33812383934">25.0</ix:nonFraction>&#160;million milestone received under our BMS Collaboration Agreement during the three months ended March&#160;31, 2020 described below, because we had previously completed our performance obligations of granting the licenses. </span></div><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTk3NTc_1bb2726c-6d9f-46dc-89df-175e61743308" escape="true"><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the three months ended March&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.712%;"><tr><td style="width:1.0%;"></td><td style="width:83.734%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.266%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue&#8212;December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOjE3ZWMzM2ZkNjU4ODRjMjViODQ1OGUwNmQzZmE3MWMwL3RhYmxlcmFuZ2U6MTdlYzMzZmQ2NTg4NGMyNWI4NDU4ZTA2ZDNmYTcxYzBfMS0xLTEtMS0w_106930cc-2521-4ecf-8cbd-8d412d0ccb0e">8,071</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recognition of previously unearned revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOjE3ZWMzM2ZkNjU4ODRjMjViODQ1OGUwNmQzZmE3MWMwL3RhYmxlcmFuZ2U6MTdlYzMzZmQ2NTg4NGMyNWI4NDU4ZTA2ZDNmYTcxYzBfMi0xLTEtMS0w_bd4e965b-ddd4-4eb2-823e-56fd0cd12b21">2,510</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue&#8212;March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOjE3ZWMzM2ZkNjU4ODRjMjViODQ1OGUwNmQzZmE3MWMwL3RhYmxlcmFuZ2U6MTdlYzMzZmQ2NTg4NGMyNWI4NDU4ZTA2ZDNmYTcxYzBfMy0xLTEtMS0w_83f8c132-7a14-44db-8207-48841144ab23">5,561</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $<ix:nonFraction unitRef="usd" contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331" decimals="-8" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMjYyNQ_72aec925-48f5-48d2-ba0c-b545fb289ae5">1.7</ix:nonFraction> billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material changes to our collaboration agreements in the three months ended March&#160;31, 2020, except as described below.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Bristol-Myers Squibb Company (BMS)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. The agreement replaced the Clinical Trial Agreement we had entered into in September 2016. Pursuant to these current agreements, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (nivolumab) and Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> plus Yervoy</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ipilimumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing <ix:nonFraction unitRef="number" contextRef="iba0f97bcb4b4439498c18a0cee8d7459_D20180212-20180213" decimals="INF" name="nktr:ProfitsAndLossesSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIwMg_0a312805-4159-4ecb-943c-2ada0267dd39">65</ix:nonFraction>% and BMS sharing <ix:nonFraction unitRef="number" contextRef="i9195970c9dc0457185dab641c8cb1b46_D20180212-20180213" decimals="INF" name="nktr:ProfitsAndLossesSharingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIwNw_d37f4528-3044-47a0-bd3d-aa93e7d8558f">35</ix:nonFraction>% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, <ix:nonFraction unitRef="number" contextRef="i7669b30a20914aa29e59f95f80c6ce1d_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIxMg_f93a12a4-ecb0-43f0-bfbd-df7fb670303a">67.5</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="i60c9630119f2431abfe04edb5e2fb3ed_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIxOQ_266f530a-57d0-44ee-beff-abc28b5c7673">32.5</ix:nonFraction>% to Nektar, and for bempegaldesleukin in a triplet combination with Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and Yervoy</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174; </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonFraction unitRef="number" contextRef="ifd93624e0fb543c2b0ac79d91fd72357_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIyNg_d66fe02f-3678-4e5e-a760-cb78ece9a954">78</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="i4279aa6d740d409f9971a4360326a569_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIzMQ_9f315392-e0e6-49f6-a1e4-aaf5fef12ec7">22</ix:nonFraction>% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, <ix:nonFraction unitRef="number" contextRef="i9195970c9dc0457185dab641c8cb1b46_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIzNg_238d5c9d-21e4-4981-acbb-65eef3776f31">35</ix:nonFraction>% of costs to BMS and <ix:nonFraction unitRef="number" contextRef="iba0f97bcb4b4439498c18a0cee8d7459_D20180212-20180213" decimals="INF" name="nktr:PercentageOfSharingInProductionCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjI0MQ_761de0a6-5308-4992-8621-eccf8b7cae36">65</ix:nonFraction>% to Nektar.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i78cc054f78e14454a10bbf7594a284a7_D20180401-20180430" decimals="-8" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNTI2OA_8cbd208f-c1d9-4b21-bf94-1986526fc198">1.0</ix:nonFraction> billion. We are eligible to receive additional cash payments up to a total of approximately $<ix:nonFraction unitRef="usd" contextRef="ife19b7e801a54e7aaa7298b8de21446d_D20200101-20200331" decimals="-7" format="ixt:numdotdecimal" name="nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNTM1NQ_1ecf336c-206b-4063-ba87-01f8e53f372e">1.45</ix:nonFraction> billion (including the milestones from Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones and up to a total of $<ix:nonFraction unitRef="usd" contextRef="i0111201aa93e4b82bb4611c26ba6b748_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNTQ0OQ_07d8edbc-118c-45f5-b302-c6e6be76d764">350.0</ix:nonFraction> million upon the achievement of certain sales milestones. In April 2018, BMS also </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><ix:continuation id="i2b72cb7664284f80844cdde4a061d979" continuedAt="i49531186dae146e6870ff9f40477623a"><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">purchased <ix:nonFraction unitRef="shares" contextRef="id3f27473571a48dd830b6f580001f835_I20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNTUzNg_39c5c95f-b244-4237-9020-b160a56be36f">8,284,600</ix:nonFraction> shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $<ix:nonFraction unitRef="usd" contextRef="if758da7137704b02aeb393bbd5f6d719_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="nktr:SaleOfStockConsiderationReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNTY1MA_242ec68d-46f9-4ea8-a06c-1ae11e54b149">850.0</ix:nonFraction> million.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. Additionally, we are eligible to receive an additional non-refundable, non-creditable milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ib5a5a0cd127f4c7bb5c3c685ed7d0af3_I20200109" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjE1Nw_93743b23-1bef-4c09-8d30-3881bcc7a8ad">25.0</ix:nonFraction>&#160;million following the achievement of the first patient, first visit in the registrational adjuvant melanoma trial, studying the combination of bempegaldesleukin and Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. We are also eligible to receive non-refundable, creditable milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ifc7fd90c5f154037a6e40bfef3b6fc10_I20200109" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjE3Mg_b9eb6ec9-3b65-47b1-b664-583767c11844">25.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idfbf1bae2fe14c92aa3559eb0012ec75_I20200109" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjE4Nw_cd793984-a516-4e2e-a59d-693d35244dda">75.0</ix:nonFraction>&#160;million following the achievement of the first patient, first visit in a registrational muscle-invasive bladder cancer trial and a registrational first-line non-small-cell lung cancer trial, respectively, in each case studying the combination of bempegaldesleukin and Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. For the two creditable milestones, BMS is entitled to deduct the amounts paid pursuant to these milestones from future development milestones due to us under the original agreement. On January 30, 2020, the milestone for the first patient, first visit milestone for the registrational muscle-invasive bladder cancer trial was achieved, and BMS paid us the $<ix:nonFraction unitRef="usd" contextRef="i013cfcd2f2bd4e028e742adb05277f94_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:SalesMilestoneRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjE0Mg_33ee616e-f490-45aa-840f-a1bc3e31514c">25.0</ix:nonFraction>&#160;million milestone in March 2020.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808, and we analogized to ASC 606 for the accounting for our performance obligation of the delivery of the licenses to develop and commercialize bempegaldesleukin.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2018, we aggregated the total consideration of $<ix:nonFraction unitRef="usd" contextRef="ic5a469ebee04424493829d25d002dafe_D20180401-20180430" decimals="-7" format="ixt:numdotdecimal" name="nktr:AggregateConsiderationReceivedFromAgreements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTM3NDM4OTUzNzk4MjM_00909da9-e911-4053-b766-01c5dcd96d0a">1.85</ix:nonFraction> billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $<ix:nonFraction unitRef="usd" contextRef="i6952cb9044694778b60945d87960f80d_I20180430" decimals="-5" format="ixt:numdotdecimal" name="nktr:EstimatedFairValueOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTM3NDM4OTUzODAxNzQ_fbc005a4-39fc-4aa7-b706-d2b995fca6b0">790.2</ix:nonFraction> million in stockholders&#8217; equity. We allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="ic5a469ebee04424493829d25d002dafe_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTM3NDM4OTUzODAyMjk_ff31b518-4c74-4ff8-96b2-41c7431927a2">1,059.8</ix:nonFraction> million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i6952cb9044694778b60945d87960f80d_I20180430" decimals="-8" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentRegulatoryAndSalesMilestones" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTM3NDM4OTUzODA0MTk_9882212f-0c94-4098-b1ab-9467e2b913d7">1.8</ix:nonFraction> billion to be variable consideration. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, we updated the transaction price by $<ix:nonFraction unitRef="usd" contextRef="i502169e6083e4ed8aadfa58300dc99f2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjI0Ng_defc4a78-4a70-4e7c-841e-73afdd0af90d">25.0</ix:nonFraction>&#160;million for the achievement of the first patient, first visit in the registrational muscle invasive bladder cancer trial. Since we had already completed our sole performance obligations of delivery of the licenses, we recognized this $<ix:nonFraction unitRef="usd" contextRef="i502169e6083e4ed8aadfa58300dc99f2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:RemainingAmountAllocatedToTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjI2MQ_c1698b4a-af6e-41e0-b964-b2d135474d44">25.0</ix:nonFraction>&#160;million in license, collaboration and other revenue during the three months ended March 31, 2020. We continue to exclude the other milestones from the transaction price as of March&#160;31, 2020 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#8217; costs as research and development expense. During the three months ended March&#160;31, 2020 and 2019, we recorded $<ix:nonFraction unitRef="usd" contextRef="i176a8a9518ea4b9299405db0af88f09a_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjI3Ng_bb174327-7440-41bb-92f6-39220b5d6546">30.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1bc208f913d540b49395ca3743b4185d_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="nktr:ReimbursementOfExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjI5MQ_dedbb675-f720-4acf-ab1d-8c8f17552091">28.8</ix:nonFraction>&#160;million, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses.&#160;As of March&#160;31, 2020, we have recorded an unbilled receivable of $<ix:nonFraction unitRef="usd" contextRef="ib630cc6da28d48d4b7c4878a9fd1f551_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjMwNg_57ed80ea-1454-4f96-ae25-a006c9ab5d4c">31.2</ix:nonFraction>&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Eli Lilly and Company (Lilly</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">): NKTR-358 </span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $<ix:nonFraction unitRef="usd" contextRef="i29f2903dd705405e9a99ce471b09643c_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfODY5Ng_c6529a33-de56-46c6-8c26-77fc841925e5">150.0</ix:nonFraction> million in September 2017 and are eligible for up to $<ix:nonFraction unitRef="usd" contextRef="i4abc773305a245a49879e92f7a2d8ec1_I20170823" decimals="INF" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentAndRegulatoryMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfODc0NA_be12512b-d066-473b-88c8-3cf45590fbe1">250.0</ix:nonFraction> million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and are responsible for certain drug product development and supply activities, (iii) will share with Lilly Phase 2 development costs with <ix:nonFraction unitRef="number" contextRef="ic6cffd33a538441793df552a4a634722_D20170822-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTAxOQ_bbc03c69-a4e5-4455-ac54-cfc87a3c79ab">75</ix:nonFraction>% of those costs borne by Lilly and <ix:nonFraction unitRef="number" contextRef="ib6ef8d2feff24382b89a963a955b7de1_D20170822-20170823" decimals="INF" name="nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTA1Ng_9570be7c-5ef1-4950-97b3-4766df723f36">25</ix:nonFraction>% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from <ix:nonFraction unitRef="number" contextRef="i8e09065b9a0547db82bcbd6ba0330136_D20170822-20170823" decimals="INF" format="ixt-sec:numwordsen" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTIwNg_a6cb46e1-c5e2-48ea-972e-b424c772a8d9">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="i7543f99a1365490685fe0784be6399be_D20170822-20170823" decimals="INF" name="nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTIxMg_23722024-3792-4b25-9452-6f70ea97250f">25</ix:nonFraction>% of development costs, and (v) will have the opportunity to receive up to double-digit sales royalty rates that escalate based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by <ix:nonFraction unitRef="number" contextRef="ie216ce51a8a24a0baa754fcee329ca73_D20170822-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTY0MA_f317f1ae-3164-4f3d-b041-6d871ba3f29b">50</ix:nonFraction>% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by <ix:nonFraction unitRef="number" contextRef="ie216ce51a8a24a0baa754fcee329ca73_D20170822-20170823" decimals="INF" name="nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTg3NQ_e759a889-90f2-467a-8832-2930489b7c3d">75</ix:nonFraction>% if both conditions occur.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><ix:continuation id="i49531186dae146e6870ff9f40477623a" continuedAt="i3f640ce31bb4478694faf41b42511f21"><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We identified our license grant to Lilly, our ongoing Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#8217;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we are entitled to significant development milestones under this arrangement, through March&#160;31, 2020, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i29f2903dd705405e9a99ce471b09643c_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE1ODQ_3b629264-a130-41b3-985b-42b83f5ffa36">150.0</ix:nonFraction> million in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $<ix:nonFraction unitRef="usd" contextRef="i29f2903dd705405e9a99ce471b09643c_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE3MTE_9de8eec9-7a52-4b1b-b6d7-37314a803782">150.0</ix:nonFraction> million upfront payment as $<ix:nonFraction unitRef="usd" contextRef="i3ca1ed110b144083ad7a0642944f0a64_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE3MzM_ceac2a10-b51f-4729-9a97-59067667825e">125.9</ix:nonFraction> million to the license, $<ix:nonFraction unitRef="usd" contextRef="i93c4b0f432a74b2e864cfce6498f7af2_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE3NTI_2073232d-1a6f-4054-ad15-cc199297ffe2">17.6</ix:nonFraction> million to our portion of the Phase 1 clinical development and $<ix:nonFraction unitRef="usd" contextRef="i69f7397d7d354dbca02775665425aeb3_D20170901-20170930" decimals="-5" format="ixt:numdotdecimal" name="nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE3OTU_dbf1f1d4-1f89-495b-9f99-fc79207e3df8">6.5</ix:nonFraction> million to the drug product development.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized the $<ix:nonFraction unitRef="usd" contextRef="ia7621d431c964328a7a71c7e9d1ac4bb_D20170801-20170831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE4NDk_fb4bdeeb-2d15-45a6-bf72-cd08e55916f5">125.9</ix:nonFraction> million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of March&#160;31, 2020, we completed our performance obligations and we have no deferred revenue related to this agreement.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Baxalta Inc. / Takeda Pharmaceutical Company Ltd</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">: Hemophilia</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Hemophilia A program includes ADYNOVATE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which was approved by the United States Food and Drug Administration (FDA) in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a $<ix:nonFraction unitRef="usd" contextRef="i7101cc04dec54a90adf4cbd5b102e5a2_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTM4MzI_0b0982db-15ff-4c3a-baee-d4bca19ebe61">10.0</ix:nonFraction> million development milestone, which we received in March 2018. During 2018, we earned an additional $<ix:nonFraction unitRef="usd" contextRef="i25fc7508773c488c99f151c7421c27ad_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTQzNDY_8ff41bfe-a35b-4906-af36-786e84dc9d2b">10.0</ix:nonFraction> million milestone for annual sales of ADYNOVATE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/ ADYNOVI</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#8482;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> reaching a certain specified amount.&#160;In addition, we are entitled to an additional sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.</span></div><div style="text-indent:31.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us $<ix:nonFraction unitRef="usd" contextRef="i444f981b5fcd4ae183f9670a94a6d5c7_D20171101-20171130" decimals="-5" format="ixt:numdotdecimal" name="nktr:PaymentsReceivedUnderRightsToSublicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTQ5NTQ_98f71ddb-ece8-45a1-8c1c-dbe37417d61b">12.0</ix:nonFraction> million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of March&#160;31, 2020, our deferred revenue from this arrangement is not significant.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><ix:continuation id="i3f640ce31bb4478694faf41b42511f21"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amgen, Inc</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.: Neulasta</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the Amended and Restated Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the Amended and Restated Agreement, we received a $<ix:nonFraction unitRef="usd" contextRef="ice87715efb8248b3aa2edabd0ba0a78d_D20101001-20101231" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTU3NzU_4204019a-77b1-4c2e-b588-264c7cac6478">50.0</ix:nonFraction> million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determined that our obligation to manufacture and supply our PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#8217;s right to require production of PEGylation materials at any time. As of March&#160;31, 2020, we have deferred revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i92df06331eee42a4bf5033fe820ebed9_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTY0MzQ_603817f7-b801-4e29-8e21-9d9d5df74200">2.9</ix:nonFraction> million related to this agreement, which we expect to recognize through October 2020, the estimated end of our obligations under this agreement.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">AstraZeneca AB</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">: MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(naloxegol oxalate), previously referred to as naloxegol and NKTR-118 </span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In September 2014 and December 2014, MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> /MOVENTIG</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was approved in the US and EU, respectively. As of March&#160;31, 2020, we have received a total of $<ix:nonFraction unitRef="usd" contextRef="i0aee212710ce422485f665ac0f228b73_D20090901-20151231" decimals="-5" format="ixt:numdotdecimal" name="nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTcxNzI_7a27b7d3-380f-4ea0-b0b5-fe4d0e1ab703">385.0</ix:nonFraction> million of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving <ix:nonFraction unitRef="number" contextRef="i99c7aa64c9624c1aafe571608dc6df48_D20160301-20160331" decimals="INF" name="nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTc5NDg_bb69232c-27d3-4d3a-8724-02e2800f5c6f">60</ix:nonFraction>% and Nektar receiving <ix:nonFraction unitRef="number" contextRef="i134e5ae7cfac48ccac7b40ae651a24b6_D20160301-20160331" decimals="INF" name="nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTc5NzI_596d83b5-be13-4642-8d4b-17f2690a159f">40</ix:nonFraction>%. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we do not have deferred revenue related to our agreement with AstraZeneca.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, excluding Europe, Canada and Israel, to RedHill Biopharma. This sublicense does not change our rights under the agreement with AstraZeneca and our royalty rate, royalty term and future potential sales milestones remain unchanged.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, as of March&#160;31, 2020, we have other collaboration agreements, including with our collaboration partner UCB Pharma, under which we are entitled to up to a total of $<ix:nonFraction unitRef="usd" contextRef="i3701e7bc10234eaba431f6c02eacf26f_I20200331" decimals="-5" format="ixt:numdotdecimal" name="nktr:PotentialDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTkxMjA_df41dc08-a775-402b-8499-d8d4fc13df35">40.0</ix:nonFraction> million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of March&#160;31, 2020, we have deferred revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i3701e7bc10234eaba431f6c02eacf26f_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTk3MDQ_68b0ee60-fa60-48cb-88d4-f93b0b96bf5f">2.0</ix:nonFraction> million related to these other collaboration agreements.</span></div></ix:continuation><div id="if0957f1cf80a4889940736b29ad56c63_76"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 7 &#8212; <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RleHRyZWdpb246MzI4YjFlNjNkZGFjNGNjOGI0NDhiNmEyNTAzNzk2MjRfMjg0_b69691d5-e9fc-42aa-8c0e-d7b9486b3d55" continuedAt="ia18366b19c9b47a29bc9d91b126e26f8" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ia18366b19c9b47a29bc9d91b126e26f8" continuedAt="iae35cbda5f1145db822a51d3e60eaf03"><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RleHRyZWdpb246MzI4YjFlNjNkZGFjNGNjOGI0NDhiNmEyNTAzNzk2MjRfMjg1_3a67c0bd-c4c7-42ff-aebf-9929f3c81c2e" escape="true"><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.994%;"><tr><td style="width:1.0%;"></td><td style="width:74.052%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.611%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.525%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.612%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i88cf58db52e049eab981ed11e7041d46_D20200101-20200331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfMi0xLTEtMS0w_516cc601-f14b-41cf-a084-13878b866f9a">761</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ied569ed2fa4643aabebcfeb1c89e3250_D20190101-20190331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfMi0zLTEtMS0w_9d72b4da-ff26-40ac-86db-74d1487e18f1">820</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic5081eafe45545ac99082fad3b96d97f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfMy0xLTEtMS0w_e7c200ac-77fc-40b0-83c3-99e98d0b652f">15,453</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i902932094c3b42388c75a5e0aea65f9b_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfMy0zLTEtMS0w_6de2884f-3ab8-4e9f-a0e4-c0bae2c8620e">16,623</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e337f5f20f943c6924b26a84f75f97c_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNC0xLTEtMS0w_20d3d1cc-a3c5-40da-b25c-165cccab4308">7,997</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if378fd08692e42a096dc6f036e090dde_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNC0zLTEtMS0w_2b153ca1-042c-42fe-bd33-7e43a5552270">7,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4abfc9f996224586a3e2de8b4adc9c6f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNS0xLTEtMS0xNjM5_82175c47-07db-44ea-96ee-136aa24f39d5">1,025</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5af1e965432744c6bcbe50332144c39c_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNS0zLTEtMS0xNjQy_4227ca30-3327-4f06-ab39-fe043e7edf30">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNS0xLTEtMS0w_b02ed49c-3bf9-40c9-b09a-4b19c4c0c1cf">25,236</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNS0zLTEtMS0w_ad56284e-0be6-4622-a02a-9cb8794e8043">25,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><ix:continuation id="iae35cbda5f1145db822a51d3e60eaf03"><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance, which we are currently accounting for as a liability award. However, we expect to settle this award in stock in the second quarter of 2020.</span></div><ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RleHRyZWdpb246MzI4YjFlNjNkZGFjNGNjOGI0NDhiNmEyNTAzNzk2MjRfMjgy_c25fe833-8c30-4c8a-94c3-3497394411dd" escape="true"><div style="text-indent:31.5pt;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.994%;"><tr><td style="width:1.0%;"></td><td style="width:74.052%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.611%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.525%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.612%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfMi0xLTEtMS0w_12435d0d-b891-4aeb-8b5c-b0c5325b752c">49</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfMi0zLTEtMS0w_9dbba0cc-1fd2-41cf-af76-4ed7125bd0be">20</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted-average grant-date fair value of options granted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i5f68d2ae466140aeb768fa1c116b8abb_D20200101-20200331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfMy0xLTEtMS0w_c5fbb1ee-aa98-4e5e-ab33-f99ca9c737f3">11.88</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ifa8cd256275e4cdfa9d8471075320759_D20190101-20190331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfMy0zLTEtMS0w_5fdf51a8-ae9b-47a0-bf10-8f72e3503232">25.51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RSUs granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f68d2ae466140aeb768fa1c116b8abb_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNC0xLTEtMS0w_4ee4a6df-4da6-4d1c-b628-ff6b1030a42c">245</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa8cd256275e4cdfa9d8471075320759_D20190101-20190331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNC0zLTEtMS0w_30691b34-c601-4c38-a17c-29f03365affd">133</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic56f9fb40dd94e43b2208c0ab8ecd6b1_D20200101-20200331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNS0xLTEtMS0w_174d22a5-2490-48d8-9795-9ebcf6efdb65">18.91</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8b46e908641040b989f8c417b89ce173_D20190101-20190331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNS0zLTEtMS0w_47a6259c-447d-45d0-b226-1807ed9278b0">40.95</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ic56f9fb40dd94e43b2208c0ab8ecd6b1_D20200101-20200331" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNi0xLTEtMS0w_df2c2c00-c664-49b3-87af-1bd645110c76">1,358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b46e908641040b989f8c417b89ce173_D20190101-20190331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNi0zLTEtMS0w_dd9bf32b-924c-4c82-873e-47b84d0286a5">698</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="if0957f1cf80a4889940736b29ad56c63_79"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 8 &#8212; <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183OS9mcmFnOjE2ZWI0ZjVlNmQyNzRiYjE5OWRiZmJhODgwNWJlNjI1L3RleHRyZWdpb246MTZlYjRmNWU2ZDI3NGJiMTk5ZGJmYmE4ODA1YmU2MjVfMTQwNw_7ce1ea58-a1b8-4948-9cdc-6e756e09d847" continuedAt="ie85cb8b9608243959cb27ec49f4054da" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie85cb8b9608243959cb27ec49f4054da" continuedAt="i9502b817d333478296306d93940cd4da">We calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. </ix:continuation></span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i9502b817d333478296306d93940cd4da">For the three months ended March&#160;31, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three months ended March&#160;31, 2020 and March 31, 2019, potentially dilutive securities consisted of the weighted-average common shares underlying outstanding stock options and RSUs, which totaled <ix:nonFraction unitRef="shares" contextRef="i432c6f2272a94bb69701de1fc16655e2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183OS9mcmFnOjE2ZWI0ZjVlNmQyNzRiYjE5OWRiZmJhODgwNWJlNjI1L3RleHRyZWdpb246MTZlYjRmNWU2ZDI3NGJiMTk5ZGJmYmE4ODA1YmU2MjVfMTM3NDM4OTUzNDkyMzg_9da9d946-11ce-4f13-907a-1c8e703f7c65">18.8</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ib127735d3b564c8089872b75e9382773_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183OS9mcmFnOjE2ZWI0ZjVlNmQyNzRiYjE5OWRiZmJhODgwNWJlNjI1L3RleHRyZWdpb246MTZlYjRmNWU2ZDI3NGJiMTk5ZGJmYmE4ODA1YmU2MjVfMTM3NDM4OTUzNDkyNzg_0ab37a4f-f831-4114-aca8-9a8f03c2e4b4">18.9</ix:nonFraction> million shares, respectively.</ix:continuation> </span></div><div id="if0957f1cf80a4889940736b29ad56c63_1254"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 9 &#8212; <ix:nonNumeric contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xMjU0L2ZyYWc6ZTM1NjYzY2RlNDVmNGI1YWIzOTFiZTJkYmZmMDRlN2YvdGV4dHJlZ2lvbjplMzU2NjNjZGU0NWY0YjVhYjM5MWJlMmRiZmYwNGU3Zl83MTQ2ODI1NTg5MDI5_a7be1e23-0e1e-4c2e-918e-2d8ee816aec7" continuedAt="i3a56d5a58e63481ab775610bac336bf8" escape="true">Subsequent Event</ix:nonNumeric></span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i3a56d5a58e63481ab775610bac336bf8" continuedAt="i6d823f5d36d3456999fcfd0112cfc58b">On October 5, 2015, we completed the sale and issuance of $<ix:nonFraction unitRef="usd" contextRef="idba37b08c6a74db5a4d1979fcb50d818_I20151005" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SeniorNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xMjU0L2ZyYWc6ZTM1NjYzY2RlNDVmNGI1YWIzOTFiZTJkYmZmMDRlN2YvdGV4dHJlZ2lvbjplMzU2NjNjZGU0NWY0YjVhYjM5MWJlMmRiZmYwNGU3Zl83MTQ2ODI1NTg5MDMx_b9acd0f1-5939-459e-92c4-4a0eb3579d0d">250.0</ix:nonFraction>&#160;million in aggregate principal amount of 7.75% senior secured notes due 2020 (the Notes). The Notes were secured by a first-priority lien on substantially all of our assets (except our right-of-use assets) and bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="idba37b08c6a74db5a4d1979fcb50d818_I20151005" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xMjU0L2ZyYWc6ZTM1NjYzY2RlNDVmNGI1YWIzOTFiZTJkYmZmMDRlN2YvdGV4dHJlZ2lvbjplMzU2NjNjZGU0NWY0YjVhYjM5MWJlMmRiZmYwNGU3Zl8xMDk5NTExNjI4NjMwNw_d646dd2c-7537-433f-9bbe-b3c9589814b1">7.75</ix:nonFraction>% per annum payable in cash quarterly in arrears on January 15, April 15, July 15, and October 15 of each year. Interest was calculated based on actual days outstanding over a 360 days year. The Notes were to mature on October 5, 2020, at which time the outstanding principal would be due and payable.</ix:continuation></span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i6d823f5d36d3456999fcfd0112cfc58b">On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $<ix:nonFraction unitRef="usd" contextRef="i617c906b489448d0a219e5d6dd99ee13_D20200413-20200413" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xMjU0L2ZyYWc6ZTM1NjYzY2RlNDVmNGI1YWIzOTFiZTJkYmZmMDRlN2YvdGV4dHJlZ2lvbjplMzU2NjNjZGU0NWY0YjVhYjM5MWJlMmRiZmYwNGU3Zl83MTQ2ODI1NTg5MDYx_5fccef9d-1ac3-42af-a125-2413861b7984">250.0</ix:nonFraction>&#160;million and accrued interest of $<ix:nonFraction unitRef="usd" contextRef="i08a1e29f68774a94850704062f4a83db_D20200413-20200413" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xMjU0L2ZyYWc6ZTM1NjYzY2RlNDVmNGI1YWIzOTFiZTJkYmZmMDRlN2YvdGV4dHJlZ2lvbjplMzU2NjNjZGU0NWY0YjVhYjM5MWJlMmRiZmYwNGU3Zl83MTQ2ODI1NTg5MDc3_0779b20e-3169-49c0-989a-54c56e383235">4.8</ix:nonFraction>&#160;million. As a result of the redemption and repayment, the liens discussed above were terminated.</ix:continuation> </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_82"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to those discussed in this section as well as factors described in Part II, Item&#160;1A &#8220;Risk Factors.&#8221;</span></div><div id="if0957f1cf80a4889940736b29ad56c63_85"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Strategic Direction of Our Business</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative new medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. We continue to make significant investments in building and advancing our pipeline of proprietary drug candidates as we believe that this is the best strategy to build long-term stockholder value.&#160;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In immuno-oncology (I-O), we are executing a clinical development program for bempegaldesleukin (previously referred to as NKTR-214), in collaboration with Bristol-Myers Squibb Company (BMS) as well as other independent development work evaluating bempegaldesleukin in combination with other agents with potential complementary mechanisms of action. We announced in August that the FDA granted a Breakthrough Therapy designation for bempegaldesleukin in combination with Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for the treatment of patients with untreated unresectable or metastatic melanoma. We expect our research and development expense to continue to grow over the next few years as we expand and execute our broad clinical development program for bempegaldesleukin. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 9, 2020, we and BMS entered into an Amendment No.&#160;1 (the Amendment) to the Collaboration Agreement. dated February 13, 2018 (the BMS Collaboration Agreement). Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. Specifically, pursuant to the updated Collaboration Development Plan, bempegaldesleukin in combination with Opdivo&#174; is currently being evaluated in ongoing registrational trials in first-line metastatic melanoma, first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer, first-line metastatic renal cell carcinoma (RCC), and muscle-invasive bladder cancer, and also includes an additional registrational trial in adjuvant melanoma, as well as a Phase 1/2 dose escalation and expansion study to evaluate bempegaldesleukin plus Opdivo&#174; in combination with axitinib in first line RCC in order to support a future Phase 3 registrational trial. Several other registrational-supporting pediatric and safety studies for the combination of bempegaldesleukin and Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> are either currently underway or planned to begin in 2020. Also, as specifically allowed under the BMS Collaboration Agreement, Nektar is independently studying bempegaldesleukin and pembrolizumab in a non-small cell lung cancer (NSCLC) Phase 1/2 trial, and BMS plans to independently study bempegaldesleukin and Opdivo&#174; in a NSCLC dose-optimization Phase 1/2 trial that BMS plans to begin in 2020.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Amendment did not alter the cost-sharing methodology under the BMS Collaboration Agreement.  The parties share development costs based on each party&#8217;s relative ownership interest in the compounds included in the regimen. For example, we share clinical development costs for bempegaldesleukin in combination with Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, BMS 67.5% and Nektar 32.5%. For costs of manufacturing bempegaldesleukin, however, BMS is responsible for 35% and Nektar is responsible for 65% of costs. BMS supplies Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> free of charge. We also share commercialization related costs, 35% BMS and 65% Nektar, which we present in general and administrative expense. Our share of development costs is limited to an annual cap of $125.0 million. To the extent this annual cap is exceeded, we will recognize our full share of the research and development expense and BMS will reimburse us for the amount over the annual cap which will be recorded as a contingent liability. This contingent liability will be paid to BMS only if bempegaldesleukin is approved and solely by reducing a portion of our share of net profits following the first commercial sale of bempegaldesleukin. The BMS Collaboration Agreement entitles Nektar to receive up to $1.455 billion of clinical, regulatory and commercial launch milestones, $650.0 million of which are associated with approval and launch of bempegaldesleukin in its first indication in the U.S., EU and Japan (subject to $100.0 million in creditable milestone payments). As a result, whether and when bempegaldesleukin is approved in any indication will have a significant impact on our future results of operations and financial condition.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, under the Amendment, we are entitled to an additional $25.0 million non-refundable, non-creditable milestone payment following the achievement of the first-patient, first-visit milestone in the registrational adjuvant melanoma trial studying bempegaldesleukin and Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. We are also eligible to receive non-refundable, creditable milestone payments of $25.0 million and $75.0 million following the achievement of the first-patient, first-visit milestone in the registrational muscle-</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">invasive bladder cancer trial (achieved in January 2020) and the first-patient, first-visit milestone in a registrational first-line non-small-cell lung cancer trial, respectively, in each case studying the combination of bempegaldesleukin and Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Outside of the collaboration development plan with BMS, we are conducting additional research and development activities evaluating bempegaldesleukin in combination with other agents that have potential complementary mechanisms of action. Our strategic objective is to establish bempegaldesleukin as a key component of many I-O combination regimens with the potential to enhance the standard of care in multiple oncology settings. On November 6, 2018, we entered into a clinical collaboration with Pfizer Inc. (Pfizer) to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer and squamous cell carcinoma of the head and neck.&#160;The combination regimens in this collaboration will evaluate bempegaldesleukin with avelumab, a human anti-PD-L1 antibody in development by Merck KGaA (Merck), and Pfizer; talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor developed by Pfizer; or enzalutamide, an androgen receptor inhibitor in development by Pfizer and Astellas Pharma Inc. We are planning a Phase 1 study this year in pancreatic cancer patients in collaboration with BioXcel Therapeutics Inc. (BioXcel) to evaluate a triplet combination of bempegaldesleukin, BXCL-701 (a small molecule immune-modulator, DPP 8/9), and avelumab being supplied to BioXcel by Pfizer and Merck. We are also working in collaboration with Vaccibody AS (Vaccibody) to evaluate in a Phase 1 proof-of-concept study combining bempegaldesleukin with Vaccibody&#8217;s personalized cancer neoantigen vaccine. With our non-BMS clinical collaborations for bempegaldesleukin, we generally share clinical development costs on a substantially pro-rata basis commensurate with our ownership interest in the underlying compounds. We expect to continue to make significant and increasing investments exploring the potential of bempegaldesleukin with mechanisms of action that we believe are synergistic with bempegaldesleukin based on emerging scientific findings in cancer biology and preclinical development work.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are also advancing other molecules, including NKTR-262 and NKTR-255, in our I-O portfolio. NKTR-262 is a small molecule agonist that targets toll-like receptors (TLRs) found on innate immune cells in the body. NKTR-262 is designed to stimulate the innate immune system and promote maturation and activation of antigen-presenting cells (APCs), such as dendritic cells, which are critical to induce the body&#8217;s adaptive immunity and create antigen-specific cytotoxic T cells. NKTR-262 is being developed as an intra-tumoral injection in combination with systemic bempegaldesleukin in order to induce an abscopal response and achieve the goal of tumor regression in cancer patients treated with both therapies. The Phase 1/2 dose-escalation and expansion trial of NKTR-262 in patients with solid tumors is currently ongoing. NKTR-255 is a biologic that targets the interleukin-15 (IL-15) pathway in order to activate the body&#8217;s innate and adaptive immunity. Activation of the IL-15 pathway enhances the survival and function of natural killer (NK) cells and induces survival of both effector and CD8 memory T cells. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody dependent cellular cytoxicity molecules as well as enhance CAR-T therapies. We have initiated a Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma. We are also designing other clinical trials in both liquid and solid tumor settings.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In immunology, we are developing NKTR-358, which is designed to correct the underlying immune system imbalance in the body that occurs in patients with autoimmune disease. NKTR-358 is designed to optimally target the IL-2 receptor complex in order to stimulate proliferation and growth of regulatory T cells. NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of autoimmune diseases. In 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to co-develop NKTR-358. We received an initial payment of $150.0 million in September 2017 and are eligible for up to an additional $250.0 million for development and regulatory milestones. We are responsible for completing Phase 1 clinical development and certain drug product development and supply activities. We also share Phase 2 development costs with Lilly, with Lilly responsible for 75% and Nektar responsible for 25% of these costs. We will have the option to contribute funding to Phase 3 development on an indication-by-indication basis, ranging from zero to 25% of the Phase 3 development costs. Lilly will be responsible for all costs of global commercialization and we will have an option to co-promote in the U.S. under certain conditions. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have completed a Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 100 healthy patients. Results from this study demonstrated a multiple-fold increase in regulatory T cells with no change in CD8 positive or natural killer cell levels and no dose-limiting toxicities were observed. We also completed treatment of a Phase 1 multiple-ascending dose trial to evaluate NKTR-358 in patients with systemic lupus erythematosus (SLE). Lilly is expected to initiate a Phase 2 study in SLE in mid-2020 and to start an additional Phase 2 study in another auto-immune disease in 2020. These clinical studies are in addition to the two Phase 1b studies in patients with psoriasis and atopic dermatitis being run by Lilly.&#160;</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ONZEALD&#174; (also known as NKTR-102, etirinotecan pegol) is a topoisomerase I inhibitor proprietary drug candidate. A Phase&#160;3 clinical study, which we called the BEACON study, evaluated ONZEALD</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> as a single-agent therapy for women with advanced metastatic breast cancer. In a top-line analysis of 852 patients from the trial, ONZEALD</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> provided a 2.1 month improvement in median overall survival over treatment of physician&#8217;s choice (TPC), which did not achieve statistical </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">significance. A significant overall survival benefit was observed in two pre-specified subgroup populations&#8212;patients with a history of brain metastases and patients with baseline liver metastases at study entry. We thereafter initiated the ATTAIN study, a Phase 3 study comparing overall survival in patients with advanced breast cancer and brain metastases who have been previously treated with an anthracycline, a taxane and capecitabine. On February 27, 2020, we announced that there was no improvement in overall survival between patients receiving ONZEALD</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and patients receiving TPC, and, as a result, we will wind down all development activities for ONZEALD</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were developing NKTR-181 for the treatment of chronic low back pain in adult patients and had submitted an NDA for NKTR-181. At the FDA advisory committee meeting held on January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of NKTR-181, and, as a result, we withdrew the NDA and decided to make no further investment commitments to this program.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The level of our future research and development investment will depend on a number of trends and uncertainties including clinical outcomes, future studies required to advance programs to regulatory approval, and the economics related to potential future collaborations that may include up-front payments, development funding, milestones, and royalties. Over the next several years, we plan to continue to make significant investments to advance our early drug candidate pipeline.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have historically derived all of our revenue and substantial amounts of operating capital from our collaboration agreements including the BMS Collaboration Agreement, pursuant to which we recognized $1.06 billion in revenue and recorded $790.2 million in additional paid in capital for shares of our common stock issued in the transaction. While in the near-term we continue to expect to generate substantially all of our revenue from collaboration arrangements, including the potential $1.43 billion in development and regulatory milestones under the BMS collaboration, in the medium- to long-term, our plan is to generate significant commercial revenue from proprietary products including bempegaldesleukin. Since we do not have experience commercializing products or an established commercialization organization, there will be substantial risks and uncertainties in future years as we build commercial, organizational, and operational capabilities.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We also receive royalties and milestones from two approved drugs. We have a collaboration with AstraZeneca for MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, an oral peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with non-cancer pain which was approved by the FDA and subsequently launched in March 2015 and MOVENTIG</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives, which was approved by health authorities in the European Union and many other countries beginning in 2014. We also have a collaboration with Baxalta Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd.) for ADYNOVATE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, that was approved by the FDA in late 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. ADYNOVI</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#8482;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was approved by health authorities in Europe in January 2018, and has also been approved in many other countries.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business is subject to significant risks, including the risks inherent in our development efforts, the results of our clinical trials, our dependence on the marketing efforts by our collaboration partners, uncertainties associated with obtaining and enforcing patents, the lengthy and expensive regulatory approval process and competition from other products. For a discussion of these and some of the other key risks and uncertainties affecting our business, see Item 1A. Risk Factors.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While the approved drugs and clinical development programs described above are key elements of our future success, we believe it is critically important that we continue to make substantial investments in our earlier-stage drug candidate pipeline. We have several drug candidates in earlier stage clinical development or being explored in research that we are preparing to advance into the clinic in future years. We are also advancing several other drug candidates in preclinical development in the areas of I-O, immunology, and other therapeutic indications. We believe that our substantial investment in research and development has the potential to create significant value if one or more of our drug candidates demonstrates positive clinical results, receives regulatory approval in one or more major markets and achieves commercial success. Drug research and development is an inherently uncertain process with a high risk of failure at every stage prior to approval. The timing and outcome of clinical trial results are extremely difficult to predict. Clinical development successes and failures can have a disproportionately positive or negative impact on our scientific and medical prospects, financial condition and prospects, results of operations and market value.</span></div><div style="text-indent:36pt;"><span><br/></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Effects of the COVID-19 Pandemic</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">During the first quarter of 2020, a novel strain of coronavirus (SARS-CoV-2) that was first identified in Wuhan, China spread to other countries. In March 2020, COVID-19, the disease resulting from coronavirus infection, was declared a global pandemic. Many countries, including the United States and India, have taken steps to slow or moderate the spread of the virus.  These steps include, among others, restricting travel, closing schools, and issuing shelter-in-place orders.  It remains unclear how long these measures will remain in place and whether these measures will be effective.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Currently, with respect to the operation of our facilities, we are closely adhering to applicable guidelines and orders.  Essential operations in research, manufacturing and maintenance that occur within our facilities are continuing in accordance with the permissions granted under government ordinances. Across all our locations, we have instituted a temporary work from home policy for all office personnel who do not need to work on site to maintain productivity. At this time, we have not identified a material change to our productivity as a result of these measures, but this could change, particularly if restricted travel, closed schools, and shelter-in-place orders are not removed or significantly eased.  </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">The safety and well-being of our employees, and the patients and healthcare providers in our clinical trial programs, are of first and foremost importance to us.  We believe that the safety measures we are taking and instructing our contractors to take in response to the COVID-19 pandemic meet or exceed the guidance and requirements issued from government and public health officials.   </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">We and our partners are currently engaged in the clinical testing of our proprietary drug candidates and the COVID-19 pandemic introduces significant challenges to our clinical development programs which are central to our business. The evolving situation around the COVID-19 pandemic, along with the resulting public health guidance measures that have been put into place, have thus far had varying impacts on the clinical testing of our proprietary drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the COVID-19 pandemic.  The rapid development and fluidity of the COVID-19 pandemic precludes any firm estimates as to the ultimate effect this disease will have on our clinical trials, our operations and our business.  As a result, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our specific clinical programs as discussed below, is difficult to predict and subject to change.  </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Specifically, for the ongoing registrational clinical trials studying the combination of bempegaldesleukin and Opdivo&#174; in cancer indications being led by Nektar (such as RCC and first-line cisplatin ineligible, PD-L1 low, locally advanced or metastatic urothelial cancer), although we have not seen evidence to date that the COVID-19 pandemic has had a significant impact on enrollment for these trials, the future impact of the COVID-19 pandemic on these trials is very difficult to predict and, with regard to individual clinical trial sites within these studies, will likely vary by the geographic region in which they are located.  </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">For Nektar&#8217;s Phase 1/2 trial studying bempegaldesleukin and pembrolizumab in NSCLC, the COVID-19 pandemic has delayed the initiation of certain investigator sites in Europe, which has been identified as an important location for enrollment in this trial.  Based on present estimates, we currently expect to have initial safety as well as preliminary overall response rate data for an initial set of patients in the dose-escalation and NSCLC cohorts of this study by the end of 2020 or the first quarter of 2021. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">With regard to Nektar&#8217;s ongoing clinical studies of NKTR-262 (the Phase 1/2 REVEAL study) and NKTR-255, these studies have thus far largely remained on track although we have experienced some challenges with new investigator site initiations. Nonetheless, the ongoing COVID-19 pandemic could still impact the timely completion of these studies by approximately three months.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">For clinical studies of our proprietary drug candidates being run by our partners, BMS has announced that, due to the COVID-19 pandemic, it has continued enrolling at existing investigator sites but paused initiation of new investigator sites for all of its studies, which include the first-line melanoma study and the muscle-invasive bladder cancer study, both evaluating the combination of bempegaldesleukin and Opdivo&#174;. As a result, we expect the COVID-19 pandemic to likely delay the projected study endpoints, study enrollment rates and study starts for these BMS-led studies by between three to six months if new investigator sites cannot be quickly initiated.  Our partner Lilly, which is running clinical trials of NKTR-358, temporarily suspended recruitment for clinical trials during the COVID-19 pandemic.  As a result, we also expect the timelines for projected study endpoints, study enrollment rates and study starts will have likely delays of between three to six months for ongoing and additional NKTR-358 clinical studies if mitigation strategies (e.g., initiating new trial sites in low or minimally impacted COVID-19 pandemic areas) are not successful.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">With regard to our IND-enabling research, although the COVID-19 pandemic has caused us to reduce the number of employees working at our sites, a subset of our research-based employees continues to conduct laboratory work in our research facilities (which is permitted under the applicable government ordinances). As a result, we continue to make progress in the identification of new drug candidates.  </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">In an effort to mitigate the negative effects of the COVID-19 pandemic on our clinical trials (both in terms of clinical trial timelines and integrity of clinical study data), we have taken steps to help our clinical trial investigators and their teams continue to provide care and uninterrupted access to their patients.  Particularly, in the context of our clinical trials directed to investigational cancer treatments, for example, we are actively working with our study sites to implement measures to prevent study protocol violations, to minimize any disruption of treatment visits, to accommodate for patient visit delays caused by limited access to healthcare facilities, to leverage alternative methods for maintaining clinical trial integrity, and to properly record patient event data that may be influenced by the COVID-19 pandemic.  </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">In this respect, we are also incorporating recent direction and flexibility provided by regulatory authorities, including the United States Food and Drug Administration in its March 18, 2020 Guidance (updated April 16, 2020) entitled &#8220;FDA Guidance on Conduct of Clinical Trials of Medicinal Products during COVID-19 Pandemic.&#8221; This Guidance is continually being updated by FDA and updates can be found on the FDA&#8217;s website at www.fda.gov. In addition, we may refer to guidance documents from </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">other regulatory agencies, such as, for example, the European Medicines Agency&#8217;s &#8220;Implications of coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials&#8221; found on www.ema.europa.eu, which are also continually being updated.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">With respect to financing our near-term business needs, as set forth below in &#8220;Key Developments and Trends in Liquidity and Capital Resources,&#8221; we estimate we have working capital to fund our current business plans through at least the next twelve months.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Key Developments and Trends in Liquidity and Capital Resources</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate that we have working capital to fund our current business plans through at least the next twelve months. As of March&#160;31, 2020, we had approximately $1.5 billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8 million. See Note 9 to our Condensed Consolidated Financial Statements for additional information.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Three Months Ended March 31, 2020 and 2019</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.568%;"><tr><td style="width:1.0%;"></td><td style="width:48.793%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.976%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.521%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.976%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.521%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.544%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.521%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.548%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product sales</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,444&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,398&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(954)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Royalty revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,719&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,390&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,671)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-cash royalty revenue related to sale of future royalties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,895&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">License, collaboration and other revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,204&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,311&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&gt;100%&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total revenue</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50,573&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,222&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, and license fees, as well as development and sales milestones and other contingent payments. We recognize revenue when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as development or manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of products and services expected to be required to fulfill our performance obligations. Given the uncertainties in research and development collaborations, significant judgment is required to make these estimates.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product Sales</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product sales include predominantly fixed price manufacturing and supply agreements with our collaboration partners and are the result of firm purchase orders from those partners. The timing of shipments is based solely on the demand and requirements of our collaboration partners and is not ratable throughout the year.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product sales decreased for the three months ended March 31, 2020 compared to the three months ended March&#160;31, 2019 primarily due to a decrease in product demand from our collaboration partners. We expect product sales for the full year of 2020 to be lower than 2019 due to this decrease in demand. At this time, we do not anticipate that effects of the COVID-19 pandemic will impact our product sales.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalty Revenue</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We receive royalty revenue from certain of our collaboration partners based on their net sales of commercial products. Royalty revenue for the three months ended March&#160;31, 2020 decreased as compared to the three months ended March&#160;31, 2019 due to a decrease in net sales by our collaboration patners. At this time, we cannot estimate the effects of the COVID-19 pandemic on the net sales of the commercial products of our collaboration partners and our resulting royalty revenues.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Non-cash Royalty Revenue Related to Sale of Future Royalties</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For a discussion of our Non-cash royalty revenue, please see our discussion below &#8220;Non-Cash Royalty Revenue and Non-Cash Interest Expense.&#8221;</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License, Collaboration and Other Revenue</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">License, collaboration and other revenue includes the recognition of upfront payments, milestone and other contingent payments received in connection with our license and collaboration agreements and certain research and development activities. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The level of license, collaboration and other revenue depends in part upon the achievement of milestones and other contingent events, the continuation of existing collaborations, the amount of our research and development services, and entering into new collaboration agreements, if any.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">License, collaboration and other revenue increased during the three months ended March&#160;31, 2020 compared to the three months ended March&#160;31, 2019 due to the recognition of the $25.0 million milestone for the first patient, first visit in the registrational muscle invasive bladder cancer trial under our BMS Collaboration Agreement. We expect that our license, collaboration and other revenue will increase significantly in the full year of 2020 compared to 2019 as a result of the recognition of this milestone and the potential recognition of the $25.0 million milestone for the first patient, first visit in the registrational adjuvant melanoma trial, both under our BMS Collaboration Agreement.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The timing and future success of our drug development programs and those of our collaboration partners are subject to a number of risks and uncertainties. See Item&#160;1A.&#160;Risk Factors for discussion of the risks associated with the complex nature of our collaboration agreements.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cost of Goods Sold and Product Gross Margin (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.712%;"><tr><td style="width:1.0%;"></td><td style="width:48.864%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.959%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.959%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.527%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.520%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.531%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,811&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,440&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,629)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product gross profit</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(367)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,042)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">675&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(65)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product gross margin</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our strategy is to manufacture and supply polymer reagents to support our proprietary drug candidates or our third-party collaborators where we have a strategic development and commercialization relationship or where we derive substantial economic benefit. We have elected to only enter into and maintain those manufacturing relationships associated with long-term collaboration agreements which include multiple sources of revenue, which we view holistically and in aggregate. We have a predominantly fixed cost base associated with our manufacturing activities. As a result, our product gross profit and margin are significantly impacted by the mix and volume of products sold in each period.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product gross margin was negative for the three months ended March 31, 2020 and March 31, 2019. We have a manufacturing arrangement with a partner that includes a fixed price which is less than the fully burdened manufacturing cost for the reagent, and we expect this situation to continue with this partner in future years. In addition to product sales from reagent materials supplied to the partner where our sales are less than our fully burdened manufacturing cost, we also receive royalty revenue from this collaboration. In the three months ended March 31, 2020 and 2019, the royalty revenue from this collaboration exceeded the related negative gross profit.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect product gross margin to continue to fluctuate in future periods depending on the level and mix of manufacturing orders from our customers. We currently expect product gross margin to be negative in 2020 as a result of the manufacturing arrangement described above.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.270%;"><tr><td style="width:1.0%;"></td><td style="width:47.630%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.259%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.259%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.816%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.822%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">108,987&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">118,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,476)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense consists primarily of clinical study costs, contract manufacturing costs, direct costs of outside research, materials, supplies, licenses and fees as well as personnel costs (including salaries, benefits, and stock-based compensation). Research and development expense also includes certain overhead allocations consisting of support and facilities-related costs. Where we perform research and development activities under a clinical joint development collaboration, such as our collaboration with BMS, we record the expense reimbursement from our partners as a reduction to research and development expense, and we record our share of our partners&#8217; expenses as an increase to research and development expense.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense decreased for the three months ended March&#160;31, 2020&#160;compared to the three months ended March&#160;31, 2019&#160;primarily due to pre-commercial manufacturing costs for NKTR-181 that we incurred during the three months ended March 31, 2019. Although we continued pre-commercial manufacturing activities for NKTR-181 during 2019 and early 2020, we present the costs of these activities for the three months ended March 31, 2020 in the Impairment of assets and other costs related to terminated program line in our Condensed Consolidated Statements of Operations as a result of our decision to withdraw our NDA for NKTR-181. The costs of our clinical development program, including bempegaldesleukin, NKTR-358, NKTR-262 and NKTR-255, were consistent between the three months ended March&#160;31, 2020 compared to the three months ended March&#160;31, 2019. During the three months ended March&#160;31, 2020 and 2019, we recorded net reductions to research and development expense for BMS&#8217;s reimbursements of our costs of&#160;$30.7 million and $28.8 million, respectively.&#160;Under the BMS Collaboration Agreement, BMS generally bears 67.5% of development costs for bempegaldesleukin in combination with Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and 35% of costs for manufacturing bempegaldesleukin. Please see Note 6 to our Condensed Consolidated Financial Statements for additional information regarding our BMS Collaboration Agreement.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect research and development expense to increase for 2020 compared to 2019 primarily as a result of advancing development of bempegaldesleukin under the BMS Collaboration Agreement. In addition, we are collaborating with Lilly to develop NKTR-358, and Lilly is planning additional studies, which are expected to begin in 2020, for which we are responsible for 25% of costs. We are continuing to enroll patients in a dose-escalation Phase 1/2 study for NKTR-262 in combination with bempegaldesleukin. We are also continuing our Phase 1 dose-escalation studies for NKTR-255 in multiple myeloma and non-Hodgkin lymphoma. The timing and amount of our future clinical investments will vary significantly based upon our evaluation of ongoing clinical results and the structure, timing, and scope of potential collaboration partnerships (if any) for these programs.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to our drug candidates that we plan to evaluate in clinical development during 2020 and beyond, we believe it is vitally important to continue our substantial investment in a pipeline of new drug candidates to continue to build the value of our drug candidate pipeline and our business. Our discovery research organization is identifying new drug candidates by applying our polymer conjugate technology platform to a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas. We plan to continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.</span></div><div><span><br/></span></div><div style="text-indent:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In order to advance our drug candidates through clinical development, each drug candidate must be tested in numerous preclinical safety, toxicology and efficacy studies. We then conduct clinical studies for our drug candidates that take several years to complete. The cost and time required to complete clinical trials may vary significantly over the life of a clinical development program as a result of a variety of factors, including but not limited to:</span></div><div style="text-indent:-36pt;padding-left:72pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the number of patients required for a given clinical study design;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the length of time required to enroll clinical study participants;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the number and location of sites included in the clinical studies;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the clinical study designs required by the health authorities (i.e. primary and secondary endpoints as well as the size of the study population needed to demonstrate efficacy and safety outcomes);</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the potential for changing standards of care for the target patient population;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the competition for patient recruitment from competitive drug candidates being studied in the same clinical setting;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the costs of producing supplies of the drug candidates needed for clinical trials and regulatory submissions;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the safety and efficacy profile of the drug candidate;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the use of clinical research organizations to assist with the management of the trials;&#160;and</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">the costs and timing of, and the ability to secure, approvals from government health authorities.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, our strategy includes the potential of entering into collaborations with third parties to participate in the development and commercialization of some of our drug candidates such as those collaborations that we have already completed for bempegaldesleukin, NKTR-358 and MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In certain situations, the clinical development program and process for a drug candidate and the estimated completion date will largely be under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our drug candidates will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As noted above, the evolving situation around the COVID-19 pandemic has had varying impacts on the clinical testing of our proprietary drug candidates depending on the therapeutic indication, geographic distribution of clinical trial sites, the clinical trial stage, and, in certain cases, our partners&#8217; general corporate approach to the pandemic. We currently believe that we could experience delays of approximately three months for earlier stage Nektar-run clinical studies (such as the Phase 1/2 trial studying </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">bempegaldesleukin and pembrolizumab in NSCLC). In addition, for clinical studies involving our proprietary drug candidates that are run by our partners, we currently expect adjustments of timelines for projected study endpoints, study enrollment rates and study starts will likely be delayed from three to six months. As a result of these delays and potential delays, we may incur additional costs associated with these clinical trials. At this time, we cannot estimate if such increases would have a material effect on our results of operations or financial position. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The risks and uncertainties associated with our research and development projects are discussed more fully in Item&#160;1A. Risk Factors. As a result of the uncertainties discussed above, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, anticipated completion dates or when and to what extent we will receive cash inflows from a collaboration arrangement or the commercialization of a drug candidate.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.568%;"><tr><td style="width:1.0%;"></td><td style="width:48.793%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.976%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.521%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.976%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.521%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.544%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.521%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.548%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,217&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,006&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,211&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expense includes the cost of administrative staffing, commercial, finance and legal activities. General and administrative expense increased marginally during the three months ended March&#160;31, 2020 compared with the three months ended March&#160;31, 2019. We expect general and administrative expenses in the full year of 2020 to increase compared to 2019, primarily due to increased personnel costs as we begin a stage appropriate build of our commercial capability to launch and co-commercialize bempegaldesleukin with BMS as early as 2021. At this time, we do not anticipate that the effects of the COVID-19 pandemic will materially affect our general and administrative expense.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Assets and Other Costs for Terminated Program (in thousands, except percentages)</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.137%;"><tr><td style="width:1.0%;"></td><td style="width:48.579%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.028%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.028%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.594%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.599%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impairment of assets and other costs for terminated program</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,189&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45,189&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result, in the three months ended March 31, 2020, we wrote off $19.7 million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5 million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Expense (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.137%;"><tr><td style="width:1.0%;"></td><td style="width:48.579%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.028%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.028%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.594%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.524%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.599%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,204&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,226&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">978&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest expense during the three months ended March&#160;31, 2020 and 2019 primarily consists of interest from our senior secured notes. In October 2015, we issued $250.0 million in aggregate principal amount of 7.75% senior secured notes due October 2020. Interest on the 7.75% senior secured notes is calculated based on actual days outstanding over a 360 day year. Interest expense for the three months ended March&#160;31, 2020 is consistent with interest expense for the three months ended March&#160;31, 2019. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8 million. As a result, we will incur no interest expense after the repayment date.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Non-Cash Royalty Revenue and Non-Cash Interest Expense</span></div><div style="text-align:center;margin-top:18pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:47.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.908%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.517%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.621%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.517%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.334%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.517%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.776%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash royalty revenue related to sale of future royalties</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,895&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,230&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Non-cash interest expense on liability related to sale of future royalties</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,968&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,065&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">903&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For a discussion of the sale of future royalties for CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, see Note 4 to our Condensed Consolidated Financial Statements.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed in Note 4, we continue to recognize non-cash royalty revenue, which increased for the three months ended March&#160;31, 2020 compared with the three months ended March&#160;31, 2019 due to increases in sales of CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Non-cash interest expense increased for the three months ended March&#160;31, 2020 compared with the three months ended March&#160;31, 2019 due to an increase in the estimated implicit interest rate over the life of the transaction. When forecasted future revenues rise, this results in an increase to the estimated implicit interest rate over the life of the transaction, which, in turn, increases the prospective effective interest rate in the current and future periods.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized non-cash interest expense at an effective rate of 29% for the three months ended March&#160;31, 2019, reflecting the estimated implicit interest rate over the life of the transaction of approximately 18.7%. During the fourth quarter of 2019, due to sustained increases in the forecasted sales of CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, we increased our estimated implicit interest rate over the life of the agreement from 18.7% to approximately 19.5%, which resulted in a prospective interest rate of 38%. The rate remained unchanged during the three months ended March&#160;31, 2020.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Over the term of this arrangement, the net proceeds of the transaction of $114.0 million, consisting of the original proceeds of $124.0 million, net of $10.0 million in payments from us to RPI, is amortized as the difference between the non-cash royalty revenue and the non-cash interest expense. To date, we have amortized $43.4 million of the net proceeds. We periodically assess future non-cash royalty revenues, and we may adjust the prospective effective interest rate based on our best estimates of future non-cash royalty revenue such that future non-cash interest expense will amortize the remaining $70.6 million of the net proceeds. There are a number of factors that could materially affect our estimated interest rate, in particular, the amount and timing of royalty payments from future net sales of CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. As a result, future interest rates could differ significantly, and we will adjust any such change in our estimated interest rate prospectively. At this time, we cannot estimate the effects of the COVID-19 pandemic on net sales of CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and the resulting effects on our non-cash royalty revenue and potential effects on our estimated implicit rate for non-cash interest expense.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Interest Income and Other Income (Expense), net (in thousands, except percentages)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.270%;"><tr><td style="width:1.0%;"></td><td style="width:47.630%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.259%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.259%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.816%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.822%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income and other income (expense), net</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,352&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,483&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,131)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interest income and other income (expense) decreased for the three months ended March&#160;31, 2020 compared to the three months ended March&#160;31, 2019 due to lower investment balances which have been utilized to fund our operations as well as decreases in market interest rates. We expect that our interest income and other income (expense), net will decrease for 2020 compared to 2019 for these same reasons, including lower investment balances due to our repayment of our senior notes on April 13, 2020. Additionally, due to the COVID-19 pandemic, the effective interest rate earned on new investments purchased as existing securities in our portfolio mature may be lower than historical interest rates.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Tax Expense</span></div><div style="text-align:center;margin-top:18pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.270%;"><tr><td style="width:1.0%;"></td><td style="width:47.630%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.259%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.259%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.816%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.538%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.822%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Percentage Increase/<br/>(Decrease)<br/>2020 vs. 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">200&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">137&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020 and 2019, our income tax expense primarily resulted from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><div id="if0957f1cf80a4889940736b29ad56c63_88"></div><div style="text-indent:2.25pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have financed our operations primarily through revenue from product sales, royalties and strategic collaboration agreements, as well as public offering and private placements of debt and equity securities. At March&#160;31, 2020, we had approximately $1.5 billion in cash and investments in marketable securities. As noted above, on April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8 million.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate that we have working capital to fund our current business plans for the next twelve months. We expect the clinical development of our proprietary drug candidates including bempegaldesleukin, NKTR-358, NKTR-262 and NKTR-255 will continue to require significant investment to continue to advance in clinical development with the objective of entering into a collaboration partnership or obtaining regulatory approval. In the past, we have received a number of significant payments from collaboration agreements and other significant transactions. In April 2018, we received a total of $1.85 billion from BMS including a $1.0 billion upfront payment and an $850.0 million premium investment in our common stock. In July 2017, we entered into a collaboration agreement for NKTR-358 with Lilly, under which we received a $150.0 million upfront payment. In the future, we expect to receive substantial payments from our collaboration agreements with BMS and Lilly and other existing and future collaboration transactions if drug candidates in our pipeline achieve positive clinical or regulatory outcomes. In particular, under the BMS Collaboration Agreement, we are entitled to $1.45 billion of clinical, regulatory and commercial launch milestones, $650.0 million of which are associated with approval and launch of bempegaldesleukin in its first indication in the U.S., EU and Japan (subject to $100.0 million in creditable payments based on clinical milestones that could occur prior to the approval and launch of bempegaldesleukin).&#160;As a result, whether and when bempegaldesleukin is approved in any indication will have a significant impact on our future liquidity and capital resources. We have no credit facility or any other sources of committed capital.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the short term, we do not anticipate that the effects of the COVID-19 pandemic will have a material effect on our results of operations or financial position since we do not generate significant cash flows from recurring revenues and our revenues are generally less affected by shelter-in place or similar orders. However, if the effects of the COVID-19 pandemic delay the commencement or enrollment of patients in our clinical trials, the completion of these trials may also be delayed, which in turn may delay our ability to file for regulatory approval and commercialize these products (if approved) or enter into collaboration agreements.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Due to the potential for adverse developments in the credit markets, we may experience reduced liquidity with respect to some of our investments in marketable securities. These investments are generally held to maturity, which, in accordance with our investment policy, is less than two years. However, if the need arises to liquidate such securities before maturity, we may experience losses on liquidation. At March&#160;31, 2020, the average time to maturity of the investments held in our portfolio was approximately six months. To date we have not experienced any liquidity issues with respect to these securities. We utilized proceeds of investments that had matured to repay $254.8 million for our senior notes and accrued interest on April 13, 2020. We believe that, even allowing for potential liquidity issues with respect to these securities and the effect of the COVID-19 pandemic on the financial markets, our remaining cash and investments in marketable securities will be sufficient to meet our anticipated cash needs for at least the next twelve months.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our current business plan is subject to significant uncertainties and risks as a result of, among other factors, clinical and regulatory outcomes for bempegaldesleukin, the sales levels of our products, if and when they are approved, the sales levels for those products for which we are entitled to royalties, clinical program outcomes, whether, when and on what terms we are able to enter into new collaboration transactions, expenses being higher than anticipated, unplanned expenses, cash receipts being lower than anticipated, and the need to satisfy contingent liabilities, including litigation matters and indemnification obligations.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The availability and terms of various financing alternatives, if required in the future, substantially depend on many factors including the success or failure of drug development programs in our pipeline. The availability and terms of financing alternatives and any future significant payments from existing or new collaborations depend on the positive outcome of ongoing or planned clinical studies, whether we or our partners are successful in obtaining regulatory authority approvals in major markets, and if approved, the commercial success of these drugs, as well as general capital market conditions. We may pursue various financing alternatives to fund the expansion of our business as appropriate.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash flows from operating activities</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash flows used in operating activities for the three months ended March&#160;31, 2020 totaled $78.1&#160;million, which includes $98.1 million of net operating cash uses as well as $5.0 million for interest payments on our senior secured notes, partially offset by the receipt of the $25.0 million milestone payment from BMS for the achievement of the first patient, first visit in the registrational muscle invasive bladder cancer trial. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash flows used in operating activities for the three months ended March 31, 2019 totaled $80.9 million, which includes $86.0 million of net operating cash uses as well as $4.9 million for interest payments on our senior secured notes, partially offset by the receipt of a $10.0 million sales milestone payment from our collaboration agreement with Baxalta. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that cash flows used in operating activities, excluding upfront, milestone and other contingent payments received, will increase in the full year of 2020 compared to 2019 primarily as a result of increased research and development expenses.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash flows from investing activities</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We paid $0.9&#160;million and $5.6&#160;million for the purchase or construction of property, plant and equipment in the three months ended March&#160;31, 2020 and 2019, respectively. The decrease for the three months ended March&#160;31, 2020 compared with 2019 resulted from the construction of leasehold improvements at our facilities lease on Third St. during 2019. We expect our capital expenditures in the full year of 2020 to decrease significantly compared with 2019, primarily due to the completion of the construction of these leasehold improvements. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash flows from financing activities</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We received proceeds from issuance of common stock related to our employee option and stock purchase plans of $11.1 million and $4.9&#160;million in the three months ended March&#160;31, 2020 and 2019, respectively.</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8 million. See Note 9 to our Condensed Consolidated Financial Statements for additional information.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contractual Obligations</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other than the repayment of our senior notes, there were no material changes outside the ordinary course of business during the three months ended March&#160;31, 2020 to the summary of contractual obligations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 on file with the SEC.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not utilize off-balance sheet financing arrangements as a source of liquidity or financing.</span></div><div id="if0957f1cf80a4889940736b29ad56c63_106"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1A.&#160;Risk Factors</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Investors in Nektar Therapeutics should carefully consider the risks described below before making an investment decision. The risks described below may not be the only ones relating to our company. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously disclosed in Item&#160;1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2019. Additional risks that we currently believe are immaterial may also impair our business operations. Our business, results of operations, financial condition, cash flows and future prospects and the trading price of our common stock and our ability to repay our senior secured notes could be harmed as a result of any of these risks, and investors may lose all or part of their investment. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for the year ended December&#160;31, 2019, including our consolidated financial statements and related notes, and our other filings made from time to time with the SEC.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are highly dependent on the success of bempegaldesleukin, our lead I-O candidate.&#160;We are executing a clinical development program for bempegaldesleukin and clinical and regulatory outcomes for bempegaldesleukin, if not successful, will significantly harm our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our future success is highly dependent on our ability to successfully develop, obtain regulatory approval for, and commercialize bempegaldesleukin. In general, most investigational drugs, including I-O drug candidates such as bempegaldesleukin, do not become approved drugs. Accordingly, there is a very meaningful risk that bempegaldesleukin will not succeed in one or more clinical trials sufficient to support one or more regulatory approvals.&#160;To date, reported clinical outcomes from bempegaldesleukin have had a significant impact on our market valuation, and business prospects and we expect this to continue in future periods.&#160;If one or more clinical studies of bempegaldesleukin are delayed (as a result of, for example, our collaboration partner causing a delay of the initiation of one or more clinical trials for reasons outside of our control) or not successful, it would materially harm our market valuation, prospects, financial condition and results of operations.&#160;For example, under the BMS Collaboration Agreement, we are entitled to up to $1.455 billion in development milestone payments that are based upon clinical and regulatory successes from the bempegaldesleukin development program. One or more failures in bempegaldesleukin studies could jeopardize such milestone payments, and any product sales or royalty revenue or commercial milestone payments that we would otherwise be entitled to receive could be reduced, delayed or eliminated.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our partners may experience delays in clinical trials of drug candidates. We have ongoing trials evaluating bempegaldesleukin, including trials evaluating bempegaldesleukin as a potential combination treatment with BMS&#8217;s Opdivo&#174; as well as other ongoing and planned combination trials. Our partner Lilly has initiated clinical Phase 1b studies of NKTR-358 for indications in systemic lupus erythematosus, psoriasis and atopic dermatitis. We also continue to enroll patients in a Phase 1/2 study evaluating bempegaldesleukin in combination with NKTR-262 in patients with solid tumors.&#160;&#160;In addition, we have initiated a Phase 1 clinical study of NKTR-255 in adults with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma. These and other clinical studies may not begin on time, enroll a sufficient number of patients or be completed on schedule, if at all. Clinical trials for any of our product candidates could be delayed for a variety of reasons, including:</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">delays in obtaining regulatory authorization to commence a clinical study;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">delays in reaching agreement with applicable regulatory authorities on a clinical study design;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">for product candidates (such as bempegaldesleukin and NKTR-358) partnered with other companies, delays caused by our partner; </span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">imposition of a clinical hold by the FDA or other health authorities, which may occur at any time including after any inspection of clinical trial operations or trial sites;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">suspension or termination of a clinical study by us, our partners, the FDA or foreign regulatory authorities due to adverse side effects of a drug on subjects in the trial;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">delays in recruiting suitable patients to participate in a trial;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">clinical sites dropping out of a trial to the detriment of enrollment rates;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">delays in manufacturing and delivery of sufficient supply of clinical trial materials;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">changes in regulatory authorities policies or guidance applicable to our drug candidates;</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">delays caused by changing standards of care or new treatment options; and</span></div><div style="text-indent:-36pt;padding-left:72pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt;">delays caused by the COVID-19 pandemic (See also the risk factor in this Item 1A titled &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;). </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the initiation or completion of any of the planned clinical studies for our drug candidates is delayed for any of the above or other reasons, the regulatory approval process would be delayed and the ability to commercialize and commence sales of these drug candidates could be materially harmed, which could have a material adverse effect on our business, financial condition and results of operations. Clinical study delays could also shorten any commercial periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies, could have a material and adverse impact on the value of our I-O research and development pipeline.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The research and development of I-O therapies is a very competitive global segment in the biopharmaceutical industry attracting billions of dollars of investment each year.&#160; Our clinical trial plans for bempegaldesleukin, NKTR-262, and NKTR-255 face substantial competition from other I-O combination regimens already approved, and many more combination therapies that are either ahead of or in parallel development in patient populations where we are studying our drug candidates. As I-O combination therapies are relatively new approaches in cancer treatment and few have successfully completed late stage development, I-O drug development entails substantial risks and uncertainties that include rapidly changing standards of care, patient enrollment competition, evolving regulatory frameworks to evaluate combination regimens, and varying risk-benefit profiles of competing therapies, any or all of which could have a material and adverse impact on the probability of success of I-O drug candidates.&#160;</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Drug development is a long and inherently uncertain process with a high risk of failure at every stage of development.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a number of proprietary drug candidates and partnered drug candidates in research and development ranging from the early discovery research phase through preclinical testing and clinical trials. Preclinical testing and clinical studies are long, expensive, difficult to design and implement and highly uncertain as to outcome. It will take us, or our collaborative partners, many years to conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparator drug or required prior therapy, clinical outcomes, or our and our partners&#8217; financial constraints.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Drug development is a highly uncertain scientific and medical endeavor, and failure can unexpectedly occur at any stage of preclinical and clinical development. Typically, there is a high rate of attrition for drug candidates in preclinical and clinical trials due to scientific feasibility, safety, efficacy, changing standards of medical care (including commercialization of a competing therapy in the same or similar indication for which our drug candidate is being studied) and other variables (such as commercial supply challenges). The risk of failure increases for our drug candidates that are based on new technologies, such as the application of our advanced polymer conjugate technology to bempegaldesleukin, NKTR-358, NKTR-262, NKTR-255, and other drug candidates currently in discovery research or preclinical development. The failure of one or more of our drug candidates could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="padding-left:22.5pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Our business could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and these health epidemics could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. For example, in December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including the United States, India and all European countries. In March 2020, the COVID-19 outbreak was declared a pandemic. Further, the President of the United States declared the COVID-19 pandemic a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response. Similarly, the State of California declared a state of emergency related to the spread of COVID-19, and the San Francisco Department of Public Health announced aggressive recommendations to reduce the spread of the disease. In addition, we have implemented work from home policies for most employees. The effects of the shelter-in-place order and our work from home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.  Although we have taken precautions to avoid the spread of the coronavirus among our employees, it is possible one or more members of our workforce will be diagnosed with COVID-19, which could adversely impact our operations. These and similar disruptions in our operations could negatively impact our business, operating results and financial condition.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Quarantines, shelter-in-place and similar government orders designed to slow or moderate the spread of the coronavirus or other infectious diseases, and even the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, could impact the availability and productivity of personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, any of which could disrupt our supply chain. For example, any manufacturing or supply chain interruptions of our proprietary drugs, or the comparator drugs used in our clinical trials, could adversely affect our ability to conduct ongoing and future clinical trials of our drug product candidates.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">In addition, our clinical trials may be affected by the COVID-19 pandemic. Clinical site initiation, patient screening and patient enrollment may be delayed due to, for example, prioritization of hospital resources toward the COVID-19 pandemic. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Some patients who are successfully enrolled in clinical trials involving our drug candidates may not be able to comply with clinical trial protocols due to, for example, shelter-in-place orders impeding movement, disrupted healthcare services, or health issues for suspected or confirmed COVID-19 status. Similarly, our ability to recruit and retain patients and principal investigators and site staff, all of whom may have heightened risk for COVID-19, could adversely impact our clinical trial operations.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Although we are implementing measures to maintain the integrity of our clinical trials, there is no guarantee that we will prevent all study protocol violations, missed study treatment visits, and other influences that jeopardize reliability and validity of our clinical trial data.  If a regulatory authority determines our clinical trial data lacks integrity, there is no guarantee that we will have a remedy to correct or otherwise address the deficiency.  Even if such a remedy is identified, the cost for implementing the remedy could be prohibitively expensive, time consuming, or both.  As a consequence, a clinical study of our proprietary drug candidate in which the integrity of the clinical study is questioned or doubted may require lengthy and costly remediation measures (such as, for example, repeating the study), thereby causing substantial harm to our business.  </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">Also, the COVID-19 pandemic could postpone necessary interactions with regulators regarding our drug candidates in development and could delay review or approval of our regulatory submissions. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">As a result of the increase of telehealth, work from home, and virtual meetings being necessitated by the COVID-19 pandemic, the risk for disruptions caused by cyber attacks is increased. Safeguards such as firewalls and other security measures that work well when employees are located within our facilities may not work as effectively when those employees are working remotely, and there is no guarantee that these and other cybersecurity safeguards will successfully prevent all cyber attacks.  If we, our partners, our suppliers, or our contractors experience a cyberattack, experience data accessibility issues, or encounter communication disruptions, our business may suffer as a result of the loss or theft of our important data, and we may be liable for compromising the protection of personal data.     </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">The rapid development and fluidity of the COVID-19 pandemic results in a substantial number of individual variables that could cause a negative impact on our operations and our business, thereby precluding useful predictions as to how this pandemic will ultimately affect us.  Thus, any current assessment of the effects of the COVID-19 pandemic, including the impact of this disease on our clinical trial timelines, is subject to change.  We do not yet know the full extent of potential impacts on our business, our clinical trials, healthcare systems or the global economy as a whole.  However, these effects could have a material negative impact on our operations and our business.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to product candidates granted breakthrough therapy by the FDA.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to evaluate and continue ongoing discussions with the FDA on regulatory strategies that could enable us to take advantage of expedited development pathways for certain of our drug candidates, although we cannot be certain that our drug candidates will qualify for any expedited development pathways or that regulatory authorities will grant, or allow us to maintain, the relevant qualifying designations. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Breakthrough therapy designation is intended to expedite the development and review of drug candidates that are designed to treat serious or life-threatening diseases when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation of a drug candidate as a breakthrough therapy provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the drug candidate and ensure collection of appropriate data needed to support approval; more frequent written correspondence from FDA about such things as the design of the proposed clinical trials and use of biomarkers; intensive guidance on an efficient drug development program, beginning as early as Phase 1; organizational commitment involving senior managers; and eligibility for rolling review and priority review.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although bempegaldesleukin in combination with Opdivo&#174; received breakthrough therapy designation for the treatment of patients with previously untreated unresectable or metastatic melanoma, we may elect not to pursue breakthrough therapy designation for our other drug candidates, and the FDA has broad discretion whether or not to grant these designations.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accordingly, even if we believe a particular drug candidate is eligible for breakthrough therapy, we cannot be assured that the FDA would decide to grant it. Breakthrough therapy designation does not change the standards for drug approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the breakthrough therapy designation. Thus, even though we have received breakthrough </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">therapy designation, we may not experience a faster development process or review, and, upon any filing seeking regulatory approval, we may not obtain an approval from the FDA.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The risk of clinical failure for any drug candidate remains high prior to regulatory approval.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A number of companies have suffered significant unforeseen failures in clinical studies due to factors such as inconclusive efficacy or safety, even after achieving preclinical proof-of-concept or positive results from earlier clinical studies that were satisfactory both to them and to reviewing regulatory authorities. Clinical study outcomes remain very unpredictable and it is possible that one or more of our clinical studies could fail at any time due to efficacy, safety or other important clinical findings or regulatory requirements. The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in later phase clinical trials of the product candidate. We, the FDA, an independent Institutional Review Board (IRB), an independent ethics committee (IEC), or other applicable regulatory authorities may suspend clinical trials of a product candidate at any time for various reasons, including a belief that patients participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or IEC may suspend a clinical trial at a particular trial site. If one or more of our drug candidates fail in clinical studies, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or our contract manufacturers are not able to manufacture and supply sufficient drug quantities meeting applicable quality standards required to support large clinical studies or commercial manufacturing in a timely manner, it could delay our or our collaboration partners&#8217; clinical studies or result in a breach of our contractual obligations, which could in turn reduce the potential commercial sales of our or our collaboration partners&#8217; products. As a result, we could incur substantial costs and damages and any product sales or royalty revenue that we would otherwise be entitled to receive could be reduced, delayed or eliminated. In most cases, we rely on contract manufacturing organizations to manufacture and supply drug product for our clinical studies and those of our collaboration partners. The manufacturing of drugs involves significant risks and uncertainties related to the demonstration of adequate stability, sufficient purification of the drug substance and drug product, the identification and elimination of impurities, optimal formulations, process and analytical methods validations, and challenges in controlling for all of these variables. These risks and uncertainties are compounded in the presence of the COVID-19 pandemic wherein the facilities and employees responsible for manufacturing drugs for use in clinical trials may be negatively impacted such that there is an insufficient supply of study treatment drugs. We have faced and may in the future face significant difficulties, delays and unexpected expenses as we validate third party contract manufacturers required for drug supply to support our clinical studies and the clinical studies and products of our collaboration partners. Failure by us or our contract manufacturers to supply API or drug products in sufficient quantities that meet all applicable quality requirements could result in supply shortages for our clinical studies or the clinical studies and commercial activities of our collaboration partners. Such failures could significantly and materially delay clinical trials and regulatory submissions or result in reduced sales, any of which could significantly harm our business prospects, results of operations and financial condition.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Building and validating large scale clinical or commercial-scale manufacturing facilities and processes, recruiting and training qualified personnel and obtaining necessary regulatory approvals is complex, expensive and time consuming. In the past, we have encountered challenges in scaling up manufacturing to meet the requirements of large scale clinical trials without making modifications to the drug formulation, which may cause significant delays in clinical development. There continues to be substantial and unpredictable risk and uncertainty related to manufacturing and supply until such time as the commercial supply chain is validated and proven.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We often face very limited supply of a critical raw material that can only be obtained from a single, or a limited number of, suppliers, which could cause production delays, clinical trial delays, substantial lost revenue opportunities or contract liabilities to third parties. For example, there are only a limited number of qualified suppliers, and in some cases single source suppliers, for the raw materials included in our PEGylation and advanced polymer conjugate drug formulations. Any interruption in supply, diminution in quality of raw materials supplied to us or failure to procure such raw materials on commercially feasible terms could harm our business by delaying our clinical trials, impeding commercialization of approved drugs or increasing our costs.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our contract manufacturers are required in certain cases to maintain compliance with current good manufacturing practices (cGMP), including cGMP guidelines applicable to active pharmaceutical ingredients, and drug products, and with laws and regulations governing manufacture and distribution of controlled substances, and are subject to inspections by the FDA, the Drug Enforcement Administration or comparable agencies in other jurisdictions administering such requirements. We anticipate periodic regulatory inspections of our drug manufacturing facilities and the manufacturing facilities of our contract manufacturers for compliance with applicable regulatory requirements. Any failure to follow and document our or our contract manufacturers&#8217; adherence to such cGMP and other laws and governmental regulations or satisfy other manufacturing and product release regulatory requirements may disrupt our ability to meet our manufacturing obligations to our customers, lead to significant delays in the availability of products for commercial use or clinical study, result in the termination or hold on a clinical study or delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable laws and regulations may also result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, license revocation, seizures, administrative detention, or recalls of products, operating restrictions and criminal prosecutions, any of which could harm our business. Regulatory inspections could result in costly manufacturing changes or facility or capital equipment upgrades to satisfy the FDA that our manufacturing and quality control procedures are in substantial compliance with cGMP. Manufacturing delays, for us or our contract manufacturers, pending resolution of regulatory deficiencies or suspensions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we or our partners do not obtain regulatory approval for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our partners may not obtain regulatory approval for drug candidates on a timely basis, or at all, or the terms of any approval (which in some countries includes pricing approval) may impose significant restrictions or limitations on use. Drug candidates must undergo rigorous animal and human testing and an extensive review process for safety and efficacy by the FDA and equivalent foreign regulatory authorities. The time required for obtaining regulatory decisions is uncertain and difficult to predict. For example, although the FDA granted a Breakthrough Therapy designation to bempegaldesleukin in combination with Opdivo&#174; for the treatment of patients with previously untreated unresectable or metastatic melanoma, there is no guarantee regulatory approval will follow, if at all, for this or any indication of bempegaldesleukin on a timely basis. The FDA and other U.S. and foreign regulatory authorities have substantial discretion, at any phase of development, to terminate clinical studies, require additional clinical development or other testing, delay or withhold registration and marketing approval and mandate product withdrawals, including recalls. Further, regulatory authorities have the discretion to analyze data using their own methodologies that may differ from those used by us or our partners, which could lead such authorities to arrive at different conclusions regarding the safety or efficacy of a drug candidate. In addition, undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restricted label or the delay or denial of regulatory approval by regulatory authorities. For example, AstraZeneca is&#160;conducting a post-marketing, observational epidemiological study comparing MOVANTIK&#174; to other treatments of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain and the results of this study could at some point in the future negatively impact the labeling, regulatory status, and commercial potential of MOVANTIK&#174;.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we or our partners receive regulatory approval of a product, the approval may limit the indicated uses for which the drug may be marketed. Our and our partnered drugs that have obtained regulatory approval, and the manufacturing processes for these products, are subject to continued review and periodic inspections by the FDA and other regulatory authorities. Discovery from such review and inspection of previously unknown problems may result in restrictions on marketed products or on us, including withdrawal or recall of such products from the market, suspension of related manufacturing operations or a more restricted label. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under our collaboration agreements with various pharmaceutical or biotechnology companies (other than Nektar-run trials under the BMS Collaboration Agreement), our collaboration partner is generally solely responsible for:</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">designing and conducting large scale clinical studies;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">preparing and filing documents necessary to obtain government approvals to sell a given drug candidate; and/or</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">marketing and selling the drugs when and if they are approved.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our reliance on collaboration partners poses a number of significant risks to our business, including risks that:</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we have very little control over the timing and level of resources that our collaboration partners dedicate to commercial marketing efforts such as the amount of investment in sales and marketing personnel, general marketing campaigns, direct-to-consumer advertising, product sampling, pricing agreements and rebate strategies with government and private payers, manufacturing and supply of drug product, and other marketing and selling activities that need to be undertaken and well executed for a drug to have the potential to achieve commercial success;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">collaboration partners with commercial rights may choose to devote fewer resources to the marketing of our partnered drugs than they devote to their own drugs or other drugs that they have in-licensed;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we have very little control over the timing and amount of resources our partners devote to development programs in one or more major markets;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">disagreements with partners could lead to delays in, or termination of, the research, development or commercialization of product candidates or to litigation or arbitration proceedings;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">disputes may arise or escalate in the future with respect to the ownership of rights to technology or intellectual property developed with partners;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">we do not have the ability to unilaterally terminate agreements (or partners may have extension or renewal rights) that we believe are not on commercially reasonable terms or consistent with our current business strategy;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">partners may be unable to pay us as expected;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">partners may terminate their agreements with us unilaterally for any or no reason, in some cases with the payment of a termination fee penalty and in other cases with no termination fee penalty; and</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">partners may respond to natural disasters, such as the COVID-19 pandemic, by ceasing all or some of their development responsibilities (including the responsibility to clinical develop our drug candidates).</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given these risks, the success of our current and future collaboration partnerships is highly unpredictable and can have a substantial negative impact on our business. If the approved drugs fail to achieve commercial success or the drugs in development fail to have positive late stage clinical outcomes sufficient to support regulatory approval in major markets, it could significantly impair our access to capital necessary to fund our research and development efforts for our proprietary drug candidates. If we are unable to obtain sufficient capital resources to advance our drug candidate pipeline, it would negatively impact the value of our business, results of operations and financial condition.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we had cash and investments in marketable securities valued at approximately $1.5 billion and had debt of $250.0 million in principal of senior secured notes. On April 13, 2020, we redeemed the notes at par and therefore repaid the principal of $250.0 million and accrued interest of $4.8 million. While we believe that our cash position will be sufficient to meet our liquidity requirements through at least the next 12 months, our future capital requirements will depend upon numerous unpredictable factors, including:</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the cost, timing and outcomes of clinical studies and regulatory reviews of our drug candidates &#8212;important examples include bempegaldesleukin and NKTR-358;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">if and when we receive potential milestone payments and royalties from our existing collaborations if the drug candidates subject to those collaborations achieve clinical, regulatory or commercial success;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the progress, timing, cost and results of our clinical development programs;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the success, progress, timing and costs of our efforts to implement new collaborations, licenses and other transactions that increase our current net cash, such as the sale of additional royalty interests held by us, term loan or other debt arrangements, and the issuance of securities;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the number of patients, enrollment criteria, primary and secondary endpoints, and the number of clinical studies required by the regulatory authorities in order to consider for approval our drug candidates and those of our collaboration partners;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our general and administrative expenses, capital expenditures and other uses of cash; </span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the sales levels of products marketed by our collaboration partners for which we are entitled to royalties and sales milestone payments &#8212; importantly, the levels of success in marketing and selling MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> by RedHill Biopharma pursuant to its sublicense from AstraZeneca in the U.S. and ADYNOVATE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> by Baxalta (a wholly </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">owned subsidiary of Takeda) globally, as well as MOVENTIG</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (the naloxegol brand name in the EU) by Kirin in the EU; and</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">disputes concerning patents, proprietary rights, or license and collaboration agreements that negatively impact our receipt of milestone payments or royalties or require us to make significant payments arising from licenses, settlements, adverse judgments or ongoing royalties.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A significant multi-year capital commitment is required to advance our drug candidates through the various stages of research and development in order to generate sufficient data to enable high value collaboration partnerships with significant upfront payments or to successfully achieve regulatory approval. In the event we do not enter into any new collaboration partnerships with significant upfront payments and we choose to continue our later stage research and development programs, we may need to pursue financing alternatives, including dilutive equity-based financings, such as an offering of convertible debt or common stock, which would dilute the percentage ownership of our current common stockholders and could significantly lower the market value of our common stock. If sufficient capital is not available to us or is not available on commercially reasonable terms, it could require us to delay or reduce one or more of our research and development programs. If we are unable to sufficiently advance our research and development programs, it could substantially impair the value of such programs and result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is very difficult to estimate the commercial potential of product candidates due to important factors such as safety and efficacy compared to other available treatments, including potential generic drug alternatives with similar efficacy profiles, changing standards of care, third party payer reimbursement standards, patient and physician preferences, drug scheduling status, the availability of competitive alternatives that may emerge either during the long drug development process or after commercial introduction, and the availability of generic versions of our product candidates following approval by regulatory authorities based on the expiration of regulatory exclusivity or our inability to prevent generic versions from coming to market by asserting our patents. If due to one or more of these risks the market potential for a drug candidate is lower than we anticipated, it could significantly and negatively impact the commercial potential of the drug candidate, the commercial terms of any collaboration partnership potential for such drug candidate, or if we have already entered into a collaboration for such drug candidate, the revenue potential from royalty and milestone payments could be significantly diminished and this would negatively impact our business, financial condition and results of operations. We also depend on our relationships with other companies for sales and marketing performance and the commercialization of product candidates. Poor performance by these companies, or disputes with these companies, could negatively impact our revenue and financial condition.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If government and private insurance programs do not provide payment or reimbursement for our partnered products or proprietary products, those products will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In both domestic and foreign markets, sales of our partnered and proprietary products that have received regulatory approval will depend in part on market acceptance among physicians and patients, pricing approvals by government authorities and the availability of coverage and payment or reimbursement from third-party payers, such as government programs, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. However, eligibility for coverage does not necessarily signify that a drug candidate will be adequately reimbursed in all cases or at a rate that covers costs related to research, development, manufacture, sale, and distribution. Third-party payers are increasingly challenging the price and cost effectiveness of medical products and services. Therefore, significant uncertainty exists as to the coverage and pricing approvals for, and the payment or reimbursement status of, newly approved healthcare products. Further, due to the COVID-19 pandemic, millions of individuals have lost or will be losing employer-based insurance coverage, which may adversely affect our ability to commercialize our product candidates even if there is adequate coverage and reimbursement from third-party payers. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Moreover, legislation and regulations affecting the pricing of pharmaceuticals may change before regulatory agencies approve our proposed products for marketing and could further limit coverage or pricing approvals for, and reimbursement of, our products from government authorities and third-party payers. For example, Congress passed the Affordable Care Act in 2010 which enacted a number of reforms to expand access to health insurance while also reducing or constraining the growth of healthcare spending, enhancing remedies against fraud and abuse, adding new transparency requirements for healthcare industries, and imposing new taxes on fees on healthcare industry participants, among other policy reforms. Federal agencies, Congress and state legislatures have continued to show interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">expenditures, and the Medicare and other healthcare programs are frequently identified as potential targets for spending cuts. New government legislation or regulations related to pricing or other fundamental changes to the healthcare delivery system as well as a government or third-party payer decision not to approve pricing for, or provide adequate coverage or reimbursement of, our products hold the potential to severely limit market opportunities of such products.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to continue to seek partnerships with pharmaceutical and biotechnology partners to fund a portion of our research and development capital requirements. The timing of new collaboration partnerships is difficult to predict due to availability of clinical data, the outcomes from our clinical studies, the number of potential partners that need to complete due diligence and approval processes, the definitive agreement negotiation process and numerous other unpredictable factors that can delay, impede or prevent significant transactions. If we are unable to find suitable partners or negotiate collaboration arrangements with favorable commercial terms with respect to our existing and future drug candidates or the licensing of our intellectual property, or if any arrangements we negotiate, or have negotiated, are terminated, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our revenue is exclusively derived from our collaboration agreements, from which we receive upfront fees, contract research payments, milestone and other contingent payments based on clinical progress, regulatory progress or net sales achievements, royalties and product sales. Significant variations in the timing of receipt of cash payments and our recognition of revenue can result from payments based on the execution of new collaboration agreements, the timing of clinical outcomes, regulatory approval, commercial launch or the achievement of certain annual sales thresholds. The amount of our revenue derived from collaboration agreements in any given period will depend on a number of unpredictable factors, including our ability to find and maintain suitable collaboration partners, the timing of the negotiation and conclusion of collaboration agreements with such partners, whether and when we or our collaboration partners achieve clinical, regulatory and sales milestones, the timing of regulatory approvals in one or more major markets, reimbursement levels by private and government payers, and the market introduction of new drugs or generic versions of the approved drug, as well as other factors. Our past revenue generated from collaboration agreements is not necessarily indicative of our future revenue. If any of our existing or future collaboration partners fails to develop, obtain regulatory approval for, manufacture or ultimately commercialize any product candidate under our collaboration agreement, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently derive, and expect to derive in the foreseeable future, substantially all of our revenue from collaboration agreements with biotechnology and pharmaceutical companies. These collaboration agreements contain complex commercial terms, including:</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">clinical development and commercialization obligations that are based on certain commercial reasonableness performance standards that can often be difficult to enforce if disputes arise as to adequacy of our partner&#8217;s performance;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">research and development performance and reimbursement obligations for our personnel and other resources allocated to partnered drug candidate development programs;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">clinical and commercial manufacturing agreements, some of which are priced on an actual cost basis for products supplied by us to our partners with complicated cost allocation formulas and methodologies;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">intellectual property ownership allocation between us and our partners for improvements and new inventions developed during the course of the collaboration;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">royalties on drug sales based on a number of complex variables, including net sales calculations, geography, scope of patent claim coverage, patent life, generic competitors, bundled pricing and other factors; and</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">indemnity obligations for intellectual property infringement, product liability and certain other claims.</span></div><div style="text-indent:36pt;margin-top:19pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to numerous significant collaboration agreements and other strategic transaction agreements (e.g., financings and asset divestitures) that contain complex representations and warranties, covenants and indemnification obligations. If we are found to have materially breached such agreements, it could subject us to substantial liabilities and harm our financial condition.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we are involved in litigation matters involving the interpretation and application of complex terms and conditions of our agreements. One or more disputes may arise or escalate in the future regarding our collaboration agreements, transaction documents, or third-party license agreements that may ultimately result in costly litigation and unfavorable interpretation of contract terms, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To the extent we rely on other pharmaceutical or biotechnology companies with established sales, marketing and distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenue we receive will depend upon the efforts of third parties, which may not be successful and over which we have little or no control&#8212;important examples of this risk include MOVANTIK&#174; partnered with AstraZeneca and ADYNOVATE&#174; (previously referred to as BAX 855) partnered with Baxalta (a wholly-owned subsidiary of Takeda). In the event that we market our products without a partner, we would be required to build, either internally or through third-party contracts, a sales and marketing organization and infrastructure, which would require a significant investment, and we may not be successful in building this organization and infrastructure in a timely or efficient manner.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we are unable to create robust sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have no sales or distribution capabilities. To commercialize any of our drugs that receive regulatory approval for commercialization, we must develop robust internal sales, marketing and distribution capabilities, and manage inventory, supply, labeling, storage, record keeping, and advertising and promotion capabilities, which would be expensive and time consuming, or enter into arrangements with third parties to perform these services. If we decide to market our products directly, we must commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution, administration and compliance capabilities. Factors that may inhibit our efforts to commercialize our products directly or through partnerships include:</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the inability of sales personnel to obtain access to or successfully educate adequate numbers of physicians about the potential benefits associated with the use of, and to subsequently prescribe, our products;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the lack of complementary products or multiple product pricing arrangements may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We depend on third parties to conduct the clinical trials for our proprietary product candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct clinical trials for our proprietary product candidates. We rely heavily on these parties for the successful execution of our clinical trials. Though we are ultimately responsible for the results of their activities, many aspects of their activities are beyond our control. For example, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trials, but the independent clinical investigators may prioritize other projects over ours or communicate issues regarding our products to us in an untimely manner. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The early termination of any of our clinical trial arrangements, the failure of third parties to comply with the regulations and requirements governing clinical trials or the failure of third parties to properly conduct our clinical trials could hinder or delay the development, approval and commercialization of our product candidates and would adversely affect our business, results of operations and financial condition.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March&#160;31, 2020, we reported net loss of $138.7 million. If and when we achieve profitability depends upon a number of factors, including the timing and recognition of milestone and other contingent payments and royalties </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">received, the timing of revenue under our collaboration agreements, the amount of investments we make in our proprietary product candidates and the regulatory approval and market success of our product candidates. We may not be able to achieve and sustain profitability.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other factors that will affect whether we achieve and sustain profitability include our ability, alone or together with our partners, to:</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">develop drugs utilizing our technologies, either independently or in collaboration with other pharmaceutical or biotechnology companies;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">effectively estimate and manage clinical development costs, particularly the cost of the clinical studies for bempegaldesleukin, NKTR-358, NKTR-262, and NKTR-255;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">receive necessary regulatory and marketing approvals;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">maintain or expand manufacturing at necessary levels;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">achieve market acceptance of our partnered products;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">receive royalties on products that have been approved, marketed or submitted for marketing approval with regulatory authorities; and</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">maintain sufficient funds to finance our activities.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary products and product candidates could make our technologies, products or product candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our advanced polymer conjugate chemistry platforms and our partnered and proprietary products and product candidates compete with various pharmaceutical and biotechnology companies. Competitors of our polymer conjugate chemistry technologies include Biogen Inc., Horizon Pharma, Dr.&#160;Reddy&#8217;s Laboratories Ltd., SunBio Corporation, Mountain View Pharmaceuticals, Inc., Novo Nordisk A/S (formerly assets held by Neose Technologies, Inc.), and NOF Corporation. Several other chemical, biotechnology and pharmaceutical companies may also be developing polymer conjugation technologies or technologies that have similar impact on target drug molecules. Some of these companies license or provide the technology to other companies, while others are developing the technology for internal use.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There are many competitors for our proprietary product candidates currently in development. For bempegaldesleukin, there are numerous companies engaged in developing immunotherapies to be used alone, or in combination, to treat a wide range of oncology indications targeting both solid and liquid tumors. In particular, we expect to compete with therapies with tumor infiltrating lymphocytes, or TILS, chimeric antigen receptor-expressing T cells, or CAR-T, cytokine-based therapies, and checkpoint inhibitors. Potential competitors in the TIL and CAR-T space include Gilead Sciences, Inc. (through its acquisition of Kite Pharma, Inc.)/NCI, Apeiron Biologics, Philogen S.p.A., Brooklyn ImmunoTherapeutics LLC, Anaveon AG, Adaptimmune LLC, and Novartis AG, Alkermes plc, Altor Bioscience, Roche, Sanofi SA (through its acquisition of Synthorx, Inc.), and Eli Lilly &amp; Co. (through its acquisition of Armo BioSciences) in the cytokine-based therapies space, and GlaxoSmithKline plc (through its acquisition of Tesaro, Inc.), Macrogenics, Inc., Merck, Bristol-Myers Squibb Company, and Roche in the checkpoint inhibitor space. For NKTR-358, there are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease. In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC, Janssen, AstraZeneca, and Tizona Therapeutics), regulatory T cell therapies (Targazyme, Inc., Caladrius BioSciences, Inc., and Tract Therapeutics, Inc.), or IL-2-based-therapies (Amgen Inc., Celgene Corporation, and ILTOO Pharma). For MOVANTIK&#174;, there are currently several alternative therapies used to address opioid-induced constipation (OIC) and opioid-induced bowel dysfunction (OBD), including RELISTOR&#174; (methylnaltrexone bromide), oral therapy AMITIZA&#174; (lubiprostone), and oral and rectal over-the-counter laxatives and stool softeners such as docusate sodium, senna and milk of magnesia. For ADYNOVATE&#174;, there is substantial competition from Sanofi&#8217;s Fc fusion protein ELOCTATE&#8482; for Hemophilia A treatment, JIVI&#174; (antihemophilic factor (recombinant) PEGylated-aucl), an extended half-life Factor VIII for Hemophilia A treatment, approved in the U.S. in August 2018, and marketed by Bayer Healthcare, and, more recently, an extended half-life product from Novo Nordisk. In addition, technologies other than those based on Fc fusion and polymer conjugation approaches (such as gene therapy approaches being developed by BioMarin Pharmaceutical Inc. and others) are being pursued to treat patients with Hemophilia A. There can be no assurance that we or our partners will successfully develop, obtain regulatory approvals for and commercialize next-generation or new products that will successfully compete with those of our competitors. Many of our competitors have greater financial, research and development, marketing and sales, manufacturing and managerial capabilities. We face competition from these companies not just in product development but also in areas such as recruiting employees, acquiring technologies that might enhance our ability to commercialize products, establishing relationships with certain research and academic institutions, enrolling patients in clinical trials and seeking program partnerships and collaborations with larger pharmaceutical companies. As a result, our competitors may succeed in developing competing technologies, obtaining regulatory approval or gaining market acceptance for products before we do. These developments could make our products or technologies uncompetitive or obsolete.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to manage our growth effectively, which could adversely affect our operations and financial performance.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ability to manage and operate our business as we execute our development and growth strategy will require effective planning. Significant rapid growth could strain our management and internal resources, and other problems may arise that could adversely affect our financial performance. We expect that our efforts to grow will place a significant strain on personnel, management systems, infrastructure and other resources. Our ability to effectively manage future growth will also require us to successfully attract, train, motivate, retain and manage new employees and continue to update and improve our operational, financial and management controls and procedures. If we do not manage our growth effectively, our operations and financial performance could be adversely affected.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our future depends on the proper management of our current and future business operations and their associated expenses.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business strategy requires us to manage our business to provide for the continued development and potential commercialization of our proprietary and partnered drug candidates. Our strategy also calls for us to undertake increased research and development activities and to manage an increasing number of relationships with partners and other third parties, while simultaneously managing the capital necessary to support this strategy. If we are unable to manage effectively our current operations and any growth we may experience, our business, financial condition and results of operations may be adversely affected. If we are unable to effectively manage our expenses, we may find it necessary to reduce our personnel-related costs through reductions in our workforce, which could harm our operations, employee morale and impair our ability to retain and recruit talent. Furthermore, if adequate funds are not available, we may be required to obtain funds through arrangements with partners or other sources that may require us to relinquish rights to certain of our technologies, products or future economic rights that we would not otherwise relinquish or require us to enter into other financing arrangements on unfavorable terms.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We must attract and retain experts in the areas of clinical testing, manufacturing, research, regulatory and finance, and may need to attract and retain commercial, marketing and distribution experts and develop additional expertise in our existing personnel. We face intense competition from other biopharmaceutical companies, research and academic institutions and other organizations for qualified personnel. Many of the organizations with which we compete for qualified personnel have greater resources than we have. Because competition for skilled personnel in our industry is intense, companies such as ours sometimes experience high attrition rates with regard to their skilled employees. Further, in making employment decisions, job candidates often consider the value of the stock awards they are to receive in connection with their employment. Our equity incentive plan and employee benefit plans may not be effective in motivating or retaining our employees or attracting new employees, and significant volatility in the price of our stock may adversely affect our ability to attract or retain qualified personnel. If we fail to attract new personnel or to retain and motivate our current personnel, our business and future growth prospects could be severely harmed.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our success largely depends on the continued services of our executive officers and other key personnel. The loss of one or more members of our management team or other key employees could seriously harm our business, operating results and financial condition. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are also dependent on the continued services of our technical personnel because of the highly technical nature of our products and the regulatory approval process. Because our executive officers and key employees are not obligated to provide us with continued services, they could terminate their employment with us at any time without penalty. We do not have any post-employment noncompetition agreements with any of our employees and do not maintain key person life insurance policies on any of our executive officers or key employees.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial losses for investors and securities class action and shareholder derivative litigation.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our stock price is volatile. During the three months ended March&#160;31, 2020, based on closing prices on the NASDAQ Global Select Market, the closing price of our common stock ranged from $14.47 to $27.96 per share. In response to volatility in the price of our common stock in the past, Plaintiffs&#8217; securities litigation firms have sought information from us and/or </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">shareholders as part of their investigation into potential securities violations and breaches of duties (among other corporate misconduct allegations). Following their investigations, Plaintiffs&#8217; securities litigation firms have often initiated legal action, including the filing of class action lawsuits, derivative lawsuits, and other forms of redress. We expect our stock price to remain volatile and we continue to expect the initiation of legal actions by Plaintiffs&#8217; securities litigation firms following share price fluctuations. </span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">A variety of factors may have a significant effect on the market price of our common stock, including the risks described in this section titled &#8220;Risk Factors&#8221; and the following:</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">announcements of data from, or material developments in, our clinical studies and those of our collaboration partners, including data regarding efficacy and safety, delays in clinical development, regulatory approval or commercial launch &#8211; in particular, data from clinical studies of bempegaldesleukin has had a significant impact on our stock price;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">announcements by collaboration partners as to their plans or expectations related to drug candidates and approved drugs in which we have a substantial economic interest;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">announcements regarding terminations or disputes under our collaboration agreements;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">fluctuations in our results of operations;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">developments in patent or other proprietary rights, including intellectual property litigation or entering into intellectual property license agreements and the costs associated with those arrangements;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">announcements of technological innovations or new therapeutic products that may compete with our approved products or products under development;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">announcements of changes in governmental regulation affecting us or our competitors;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">litigation brought against us or third parties to whom we have indemnification obligations;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">public concern as to the safety of drug formulations developed by us or others;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">our financing needs and activities; and</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">general market conditions.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At times, our stock price has been volatile even in the absence of significant news or developments. The stock prices of biotechnology companies and securities markets generally have been subject to dramatic price swings in recent years.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even though such acquisitions may be beneficial to our stockholders. These anti-takeover provisions include:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establishment of a classified board of directors such that not all members of the board may be elected at one time;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">lack of a provision for cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability of our board to authorize the issuance of &#8220;blank check&#8221; preferred stock to increase the number of outstanding shares and thwart a takeover attempt;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">prohibition on stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of stockholders;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">limitations on who may call a special meeting of stockholders.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, provisions of Delaware law relating to business combinations with interested stockholders may discourage, delay or prevent a third party from acquiring us. These provisions may also discourage, delay or prevent a third party from acquiring a large portion of our securities or initiating a tender offer or proxy contest, even if our stockholders might receive a premium for their shares in the acquisition over the then-current market prices. We also have a change of control severance benefit plan, which provides for certain cash severance, stock award acceleration and other benefits in the event our employees are terminated (or, in some cases, resign for specified reasons) following an acquisition. This severance plan could discourage a third party from acquiring us.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we publish preliminary or interim data from our clinical studies. Preliminary data remain subject to audit confirmation and verification procedures that may result in the final data being materially different from the preliminary </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">data we previously published. Interim data are also subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data could significantly harm our business prospects.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Numerous pending and issued U.S. and foreign patent rights and other proprietary rights owned by third parties relate to pharmaceutical compositions, methods of preparation and manufacturing, and methods of use and administration. We cannot predict with any certainty which, if any, patent rights will be considered relevant to our or our collaboration partners&#8217; technology or drug candidates by authorities in the various jurisdictions where such rights exist, nor can we predict with certainty which, if any, of these rights will or may be asserted against us by third parties. In certain cases, we have existing licenses or cross-licenses with third parties; however, the sufficiency of the scope and adequacy of these licenses is very uncertain in view of the long development and commercialization cycles for biotechnology and pharmaceutical products. There can be no assurance that we can obtain a license to any technology that we determine we need on reasonable terms, if at all, or that we could develop or otherwise obtain alternate technology to avoid a need to secure a license. If we are required to enter into a license with a third party, our potential economic benefit for the products subject to the license will be diminished. If a license is not available on commercially reasonable terms or at all, we may be prevented from developing and commercializing the drug, which could significantly harm our business, results of operations, and financial condition.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The patent positions of pharmaceutical and biotechnology companies, such as ours, are uncertain and involve complex legal and factual issues. We own more than 290 U.S. and 1000 foreign patents and have a number of pending patent applications that cover various aspects of our technologies. There can be no assurance that patents that have issued will be held valid and enforceable in a court of law. Even for patents that are held valid and enforceable, the legal process associated with obtaining such a judgment is time consuming and costly.&#160;Additionally, issued patents can be subject to opposition, inter partes review or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant and/or broad coverage).&#160;Further, our competitors may be able to circumvent and otherwise design around our patents. Even if a patent is issued and enforceable, because development and commercialization of pharmaceutical products can be subject to substantial delays, patents may expire prior to the commercialization of the drug. Moreover, even if a patent encompassing a drug has not expired prior to the drugs commercialization, the patent may only provide a short period of protection following the commercialization of products.&#160; In addition, our patents may be subject to post grant or inter partes review before the U.S. Patent and Trademark Office (or equivalent proceedings in other jurisdictions), which could result in a loss of the patent and/or substantial cost to us.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our proprietary product candidates.&#160;There can be no assurance that the patent applications for which we apply will actually issue as patents, or do so with commercially relevant and/or broad coverage. The coverage claimed in a patent application can be significantly reduced before the patent is issued.&#160;The scope of our claim coverage can be critical to our ability to enter into licensing transactions with third parties and our right to receive royalties from our collaboration partnerships. Since publication of discoveries in scientific or patent literature often lags behind the date of such discoveries, we cannot be certain that we were the first inventor of inventions covered by our patents or patent applications.&#160;In addition, there is no guarantee that we will be the first to file a patent application directed to an invention.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">An adverse outcome in any judicial proceeding involving intellectual property, including patents, could subject us to significant liabilities to third parties, require disputed rights to be licensed from or to third parties or require us to cease using the technology in dispute.&#160;In those instances where we seek an intellectual property license from another, we may not be able to obtain the license on a commercially reasonable basis, if at all, thereby raising concerns on our ability to freely commercialize our technologies or products.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on trade secret protection for our confidential and proprietary information. No assurance can be given that others will not independently develop substantially equivalent confidential and proprietary information or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. In addition, unpatented </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">proprietary rights, including trade secrets and know-how, can be difficult to protect and may lose their value if they are independently developed by a third party or if their secrecy is lost. Any loss of trade secret protection or other unpatented proprietary rights could harm our business, results of operations and financial condition.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If product liability lawsuits are brought against us, we may incur substantial liabilities.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The manufacture, clinical testing, marketing and sale of medical products involve inherent product liability risks. If product liability costs exceed our product liability insurance coverage (or if we cannot secure product liability insurance), we may incur substantial liabilities that could have a severe negative impact on our financial position. Whether or not we are ultimately successful in any product liability litigation, such litigation would consume substantial amounts of our financial and managerial resources and might result in adverse publicity, all of which would impair our business. Additionally, we may not be able to maintain our clinical trial insurance or product liability insurance at an acceptable cost, if at all, and this insurance may not provide adequate coverage against potential claims or losses.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we do not currently have any products on the market, once we begin commercializing our drug candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal and state governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payers play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our future arrangements with third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">federal civil and criminal false claims laws and civil monetary penalty laws, such as the U.S. federal False Claims Act (FCA), which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Ani-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">provisions of the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes, referred to as the &#8220;HIPAA All-Payer Fraud Prohibition,&#8221; that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">federal transparency laws, including the federal Physician Payment Sunshine Act, which require manufacturers of certain drugs and biologics to track and disclose payments and other transfers of value they make to U.S. physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals as well as physician ownership and investment interests in the manufacturer, and that such information is subsequently made publicly available in a searchable format on a CMS website, effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician assistants and nurse practitioners;</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></div><div style="text-indent:-27pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, state transparency reporting and compliance laws; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and which may not have the same effect, thus complicating compliance efforts.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including administrative, civil or criminal penalties, imprisonment, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely affect financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, third parties have asserted, and may in the future assert, that we or our partners infringe their proprietary rights, such as patents and trade secrets, or have otherwise breached our obligations to them. A third party often bases its assertions on a claim that its patents cover our technology platform or drug candidates or that we have misappropriated its confidential or proprietary information. Similar assertions of infringement could be based on future patents that may issue to third parties. In certain of our agreements with our partners, we are obligated to indemnify and hold harmless our collaboration partners from intellectual property infringement, product liability and certain other claims, which could cause us to incur substantial costs and liability if we are called upon to defend ourselves and our partners against any claims. If a third party obtains injunctive or other equitable relief against us or our partners, they could effectively prevent us, or our partners, from developing or commercializing, or deriving revenue from, certain drugs or drug candidates in the U.S. and abroad. Costs associated with litigation, substantial damage claims, indemnification claims or royalties paid for licenses from third parties could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are involved in legal proceedings where we or other third parties are enforcing or seeking intellectual property rights, invalidating or limiting patent rights that have already been allowed or issued, or otherwise asserting proprietary rights through one or more potential legal remedies. For example, we are currently involved in German litigation proceedings whereby we and Bayer Healthcare LLC are seeking at least co-ownership rights in certain of each other&#8217;s patent filings related to PEGylated Factor VIII products. We believe that Bayer&#8217;s claims to an ownership interest in these is without merit and we are vigorously defending our exclusive ownership rights to this intellectual property. These German litigation proceedings are currently stayed pending the outcome of ongoing mediation efforts. In the U.S., Bayer filed a complaint against Baxalta and Nektar alleging the ADYNOVATE&#174; product infringes a Bayer patent. Although the U.S. court dismissed all of Bayer&#8217;s claims against Nektar and Nektar was removed as a defendant, a jury found the Bayer patent was valid and infringed, and awarded Bayer damages, the responsibility of which are borne fully by Baxalta. This damages award does not impact our royalties from sales of ADYNOVATE&#174; under our collaboration with Baxalta and Baxalta is currently appealing the decision. In other U.S. proceedings, Nektar and Baxalta filed complaints against Bayer Healthcare alleging Bayer&#8217;s JIVI&#174; product infringes several Nektar patents. A jury trial in this proceeding is scheduled to being in the summer of 2020. In addition, in response to notices AstraZeneca and we received from the generic companies, Apotex (Apotex Inc. and Apotex Corp.), MSN Laboratories Pvt. Ltd., and Aurobindo Pharma USA INC. alerting us that they had filed abbreviated new drug applications (ANDAs) with the FDA to market a generic version of MOVANTIK&#174; (Paragraph IV Certifications), AstraZeneca and we together filed patent infringement suits against each of these generic companies. In these Paragraph IV Certifications, all three generic companies only alleged one patent, U.S. Patent No. 9,012,469, is invalid, unenforceable and/or not infringed by the manufacture, use or sale of their respective generic products. At this time, none of the other five Orange Book listed patents associated with MOVANTIK&#174; are being challenged by these generics companies. In addition, on March 18, 2020, Aether Therapeutics Inc. filed a complaint against AstraZeneca, Nektar and Daiichi-Sanko, Inc. alleging MOVANTIK&#174; infringes U.S. Patent Nos. 6,713,488, 8,748,448, 8,883,817 and 9,061,024. We are also regularly involved in opposition proceedings at the European Patent Office and in </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">inter partes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> review proceedings at the U.S. Patent and Trademark Office where third parties seek to invalidate or limit the scope of our allowed patent applications or issued patents covering (among other things) our drugs and platform technologies. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are involved in legal proceedings other than those related to intellectual property. For example, on October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on May 15, 2019.&#160;Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of Nektar&#8217;s board. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2020, shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California naming the CEO, CFO and certain members of Nektar's board. These class action and shareholder derivative actions assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The cost to us in initiating or defending any litigation or other proceeding, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts or result in financial implications either in terms of seeking license arrangements or payment of damages or royalties. There is no guarantee that our insurance coverage for damages resulting from a litigation or the settlement thereof (including the putative securities class action lawsuits and shareholder derivative lawsuits) is sufficient, thereby resulting in substantial financial risk to the Company.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our internal computer systems, or those of our partners, vendors, CROs, CMOs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs or the theft of our confidential information or patient confidential information.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Despite the implementation of security measures, our internal computer systems and those of our partners, vendors, contract research organizations (CROs), contract manufacturing organizations (CMOs) and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, business email compromise, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. For instance, the loss of preclinical data or data from any future clinical trial involving our product candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information of our company or clinical patients, we could suffer or be subject to reputational harm, monetary fines (such as those imposed by European Regulation 2016/679, known as the General Data Protection Regulation, or &#8220;GDPR&#8221; and, the California Consumer Privacy Act, or &#8220;CCPA&#8221;), civil suits, civil penalties or criminal sanctions and requirements to disclose the breach, and other forms of&#160;liability, and the development of our product candidates could be delayed. In addition, we continue to be subject to new and evolving data protection laws and regulations from a variety of jurisdictions, and there is a risk that our systems and processes for managing and protecting data may be found to be inadequate, which could expose us to fines and litigation. </span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The United Kingdom&#8217;s withdrawal from the European Union (EU) may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 31, 2020, the United Kingdom (UK) withdrew from the EU (Brexit), thereby triggering a transition period that is set to end on December 31, 2020, during which the UK and the EU will negotiate their future relationship. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">However, the terms of the withdrawal have yet to be fully negotiated. The implementation period began February 1, 2020 and will continue until December 31, 2020. During this 11-month period, the UK will continue to follow all of the EU&#8217;s rules and its trading relationship will remain the same. However, regulations (including financial laws and regulations, tax and free trade agreements, intellectual property rights, data protection laws, supply chain logistics, environmental, health and safety laws and regulations, medicine licensing and regulations, immigration laws and employment laws) have yet to be addressed. This lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations may negatively impact foreign direct investment in the UK, increase costs, depress economic activity, and restrict access to capital. The uncertainty concerning the UK&#8217;s legal, political, and economic relationship with the EU after Brexit may be a source of instability in the international markets, create significant currency fluctuations, and/or otherwise adversely affect trading agreements or similar cross-border co-operation arrangements (whether economic, tax, fiscal, legal, regulatory or otherwise) beyond the date of Brexit.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These developments, or the perception that any of them could occur, may have a significant adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and limit the ability of key market participants to operate in certain financial markets. In particular, it could also lead to a period of considerable uncertainty in relation to the UK financial and banking markets, as well as on the regulatory process in Europe. Asset valuations, currency exchange rates, and credit ratings may also be subject to increased market volatility. </span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If the UK and the EU are unable to negotiate acceptable agreements or if other EU Member States pursue withdrawal, barrier-free access between the UK and other EU Member States or among the European Economic Area overall could be diminished or eliminated. The long-term effects of Brexit will depend on any agreements (or lack thereof) between the UK and the EU and, in particular, any arrangements for the UK to retain access to EU markets either during a transitional period or more permanently.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is currently considerable uncertainty on regulatory processes in Europe and the European Economic Area. The lack of clarity about which EU rules and regulations the UK would replace or replicate, such as rules and regulations relating to trade (including the importation and exportation of pharmaceuticals), clinical research, and intellectual property, increases the risk that our clinical trials being carried out in UK are delayed or disrupted.&#160;Further, depending on which rules and regulations the UK ultimately adopts, our business could be negatively affected.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Global economic conditions may negatively affect us and may magnify certain risks that affect our business.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operations and performance have been, and may continue to be, affected by global economic conditions, including, for example, adverse global economic conditions resulting from the COVID-19 pandemic. See also the risk factor in this Item 1A titled &#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our business could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;  As a result of global economic conditions, some third-party payers may delay or be unable to satisfy their reimbursement obligations. Job losses or other economic hardships may also affect patients&#8217; ability to afford healthcare as a result of increased co-pay or deductible obligations, greater cost sensitivity to existing co-pay or deductible obligations, lost healthcare insurance coverage or for other reasons. We believe such conditions have led and could continue to lead to reduced demand for our and our collaboration partners&#8217; drug products, which could have a material adverse effect on our product sales, business and results of operations.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, with rising international trade tensions, our business may be adversely affected following new or increased tariffs that result in the increased global clinical trial costs as a result of international transportation of clinical drug supplies, as well as the costs of materials and products imported into the U.S. Tariffs, trade restrictions or sanctions imposed by the U.S. or other countries could increase the prices of our and our collaboration partners&#8217; drug products, affect our and our collaboration partners&#8217; ability to commercialize such drug products, or create adverse tax consequences in the U.S. or other countries. As a result, changes in international trade policy, changes in trade agreements and the imposition of tariffs or sanctions by the U.S. or other countries could materially adversely affect our results of operations and financial condition.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business could be negatively impacted by corporate citizenship and&#160;sustainability&#160;matters.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is an increased focus from certain investors, employees, and other stakeholders concerning corporate citizenship and&#160;sustainability&#160;matters, which include environmental concerns and social investments. We could fail to meet, or be perceived to fail to meet, the expectations of these certain investors, employees and other stakeholders concerning corporate citizenship and sustainability matters, thereby resulting in a negative impact to our business. </span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our operations may involve hazardous materials and are subject to environmental, health, and safety laws and regulations. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a research-based biopharmaceutical company with significant research and development and manufacturing operations, we are subject to extensive environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Our research and development and manufacturing activities involve the controlled use of chemicals, radioactive compounds, and other hazardous materials. The cost of compliance with environmental, health, and safety regulations is substantial. If an accident involving these materials or an environmental discharge were to occur, we could be held liable for any resulting damages, or face regulatory actions, which could exceed our resources or insurance coverage.</span></div><div style="padding-left:18pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If earthquakes or other catastrophic events strike, our business may be harmed.</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our corporate headquarters, including a substantial portion of our research and development operations, are located in the San Francisco Bay Area, a region known for seismic activity and a potential terrorist target. In addition, we own facilities for the manufacture of products using our advanced polymer conjugate technologies in Huntsville, Alabama and own and lease offices in Hyderabad, India. There are no backup facilities for our manufacturing operations located in Huntsville, Alabama. In the event of an earthquake or other natural disaster, political instability, or terrorist event in any of these locations, our ability to manufacture and supply materials for drug candidates in development and our ability to meet our manufacturing obligations to our customers would be significantly disrupted and our business, results of operations and financial condition would be harmed. Our collaboration partners and important vendors and suppliers to us or our collaboration partners may also be subject to catastrophic events, such as earthquakes, floods, hurricanes, tornadoes and pandemics any of which could harm our business (including, for example, by disrupting supply chains important to the success of our business), results of operations and financial condition. We have not undertaken a systematic analysis of the potential consequences to our business, results of operations and financial condition from a major earthquake or other catastrophic event, such as a fire, sustained loss of power, terrorist activity or other </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">disaster, and do not have a recovery plan for such disasters. In addition, our insurance coverage may not be sufficient to compensate us for actual losses from any interruption of our business that may occur.</span></div><div id="if0957f1cf80a4889940736b29ad56c63_91"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Estimates</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates on an ongoing basis. Actual results may differ from those estimates under different assumptions or conditions. Other than as the result of the adoption of the new credit impairment accounting guidance as described in Note 1 to our Condensed Consolidated Financial Statements, there have been no material changes to our critical accounting policies and estimates discussed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019.</span></div><div id="if0957f1cf80a4889940736b29ad56c63_1249"></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3.                Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our market risks at March&#160;31, 2020 have not changed materially from those discussed in Item 7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2019 on file with the SEC.</span></div><div id="if0957f1cf80a4889940736b29ad56c63_97"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4.&#160;Controls and Procedures</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Disclosure Controls and Procedures</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 (Exchange Act) reports is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon, and as of the date of, this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in Internal Control Over Financial Reporting</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We continuously seek to improve the efficiency and effectiveness of our internal controls. This results in refinements to processes throughout the Company. However, there was no change in our internal control over financial reporting that occurred in the three months ended March&#160;31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Specifically, despite the fact that most of our employees are working remotely due to the COVID-19 pandemic, we do not believe that our adjustments to how we work have materially impacted our internal controls over financial reporting. We continue to monitor and assess the potential impact of the COVID-19 pandemic, and the related shelter-in-place requirements, on our internal controls and strive to minimize the impact on our internal control design and operating effectiveness.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Limitations on the Effectiveness of Controls</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_100"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-align:center;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II: OTHER INFORMATION</span></div><div id="if0957f1cf80a4889940736b29ad56c63_103"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1.&#160;Legal Proceedings</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reference is hereby made to our disclosures in &#8220;Legal Matters&#8221; under Note 5 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q and the information under the heading &#8220;Legal Matters&#8221; is incorporated by reference herein.</span></div><div id="if0957f1cf80a4889940736b29ad56c63_109"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2.&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None, including no purchases of any class of our equity securities by us or any affiliate pursuant to any publicly announced repurchase plan in the three months ended March&#160;31, 2020.</span></div><div id="if0957f1cf80a4889940736b29ad56c63_112"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3.&#160;Defaults Upon Senior Securities</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="if0957f1cf80a4889940736b29ad56c63_115"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4.&#160;Mine Safety Disclosures</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="if0957f1cf80a4889940736b29ad56c63_118"></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;5.&#160;Other Information</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_121"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:18pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;6.&#160;Exhibits</span></div><div style="text-indent:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.856%;"><tr><td style="width:1.0%;"></td><td style="width:9.654%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.519%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:85.627%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit<br/>Number</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description of Documents</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.1(1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/906709/0001047469-98-031070.txt">Certificate of Incorporation of Inhale Therapeutic Systems (Delaware), Inc.</a></span></div></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.2(2)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="http://www.sec.gov/Archives/edgar/data/906709/000091205700037283/ex-3_3.txt">Certificate of Amendment of the Amended Certificate of Incorporation of Inhale Therapeutic Systems, Inc.</a></span></div></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.3(3)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/906709/000104746903002325/a2101294zex-3_1.htm">Certificate of Ownership and Merger of Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.4(4)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/906709/000114420410011093/v176023_ex3-6.htm">Certificate of Ownership and Merger of Nektar Therapeutics AL, Corporation with and into Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.5(5)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/906709/000119312519029550/d692256dex31.htm">Amended and Restated Bylaws of Nektar Therapeutics.</a></span></div></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10.1(6)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="nktr2020-03x31ex101.htm">Amended and Restated Compensation Plan for Non-Employee Directors</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="nktr2020-03x31ex101.htm"> ++</a></span></div></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31.1(6)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="nktr2020-03x31xexx311.htm">Certification of Nektar Therapeutics&#8217; principal executive officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31.2(6)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="nktr2020-03x31xexx312.htm">Certification of Nektar Therapeutics&#8217; principal financial officer required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32.1*</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="nktr2020-03x31xexx321.htm">Section 1350 Certifications.</a></span></div></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH(6)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL(6)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB(6)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE(6)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF(6)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:8pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104(6)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">_____________________</span></div><div style="text-indent:-36pt;padding-left:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended June 30, 1998.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Incorporated by reference to Exhibit 3.3 to Nektar Therapeutics&#8217; Quarterly Report on Form 10-Q, for the quarter ended June 30, 2000.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(3)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on January 23, 2003.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(4)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Incorporated by reference to Exhibit 3.6 to Nektar Therapeutics&#8217; Annual Report on Form 10-K, for the year ended December 31, 2009.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(5)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Incorporated by reference to Exhibit 3.1 to Nektar Therapeutics&#8217; Current Report on Form 8-K, filed with the SEC on February 6, 2019.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(6)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Filed herewith.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;Exhibit 32.1 is being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Securities Exchange Act, except as otherwise stated in such filing.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">++&#160;Management contract or compensatory plan or arrangement.</span></div><div style="text-indent:-36pt;padding-left:36pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><div id="if0957f1cf80a4889940736b29ad56c63_124"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Table o</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">f </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#if0957f1cf80a4889940736b29ad56c63_7">Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:54pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:right;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:41.534%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.741%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:49.725%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ GIL M. LABRUCHERIE</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gil M. Labrucherie<br/>Senior&#160;Vice&#160;President, Chief Operating Officer, and&#160;Chief&#160;Financial&#160;Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: May 7, 2020</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ JILLIAN B. THOMSEN</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Jillian B. Thomsen<br/>Senior&#160;Vice&#160;President,&#160;Finance&#160;and&#160;Chief&#160;Accounting&#160;Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: May 7, 2020</span></td></tr></table></div><div style="text-align:right;margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>nktr2020-03x31ex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i9d10f66792eb4b72b72b16e2a8ee87c6_1"></div><div style="height:72pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 10.1</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMENDED AND RESTATED </font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS</font></div><div style="text-indent:18pt;padding-left:18pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This is the Compensation Plan (the &#8220;Plan&#8221;) for Non-Employee Directors (each a &#8220;Non-Employee Director&#8221;) of Nektar Therapeutics (the &#8220;Company&#8221;). This Plan was most recently amended and restated by the Board of Directors on March 20, 2019, and made effective as of January 1, 2019 as to cash compensation, and effective as of September 26, 2018 as to equity compensation.  The terms and conditions of the Plan are described below&#58; </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">An annual retainer of $65,000 for serving on the Board of Directors, payable in equal quarterly installments (the &#8220;Annual Retainer&#8221;)&#59; </font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">An additional annual retainer of $50,000 for serving as the Chair or Lead Director of the Board of Directors, payable in equal quarterly installments&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">An additional annual retainer of $25,000 for serving as Independent Lead Director of the Board of Directors, payable in equal quarterly installments&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">An annual retainer of $33,000 for serving as the Chair of the Company&#8217;s Audit Committee, payable in equal quarterly installments&#59; </font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">An annual retainer of $26,000 for serving as Chair of the Company&#8217;s Compensation Committee, payable in equal quarterly installments&#59; </font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">An annual retainer of $20,000 for serving as Chair of the Company&#8217;s Nominating&#47;Governance Committee, payable in equal quarterly installments&#59; </font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">An annual retainer of $5,000 for serving as Chair of any other committee established by the Board of Directors, payable in equal quarterly installments&#59; </font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">An additional retainer of $13,000 for serving as a member (other than the Chair) of the Company&#8217;s Audit Committee, payable in equal quarterly installments&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">-</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">An additional retainer of $11,000 for serving as a member (other than the Chair) of the Company&#8217;s Compensation Committee, payable in equal quarterly installments&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">An additional retainer of $9,000 for serving as a member (other than the Chair) of the Company&#8217;s Nominating&#47;Governance Committee, payable in equal quarterly installments&#59; </font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">Beginning with the fourteenth (14</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) board meeting and each additional board meeting thereafter in a given calendar year, each Non-Employee Director shall receive $2,000 for attending each in-person or telephonic board meeting.  Beginning with the fourteenth (14</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) board meeting and each additional board meeting thereafter in a given calendar year, each Non-Employee Director shall receive $1,000 for each in-person board meeting attended via conference telephone.   </font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">For attending each &#8220;Added Committee Meeting,&#8221; each Non-Employee Director shall receive $1,750 for attending each in-person or telephonic committee meeting.  For attending each &#8220;Added Committee Meeting,&#8221; each Non-Employee Director shall receive $875 for each in-person committee meeting attended via conference telephone.  As used herein, an &#8220;Added Committee Meeting&#8221; shall have the following meanings&#58; for the Company&#8217;s Audit Committee, beginning with the tenth (10</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) Audit Committee meeting and each additional Audit Committee meeting thereafter in a calendar year&#59; for the Company&#8217;s Compensation Committee, beginning with the ninth (9</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) Compensation Committee meeting and each additional Compensation Committee meeting thereafter in a calendar year&#59; and for the Company&#8217;s Nominating&#47;Governance Committee, beginning with the seventh (7</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) Nominating&#47;Governance Committee meeting and each additional Nominating&#47;Governance Committee meeting thereafter in a calendar year.        </font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">Each Non-Employee Director shall be reimbursed for customary expenses for attending Board of Director, committee and stockholder meetings&#59; </font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">Upon initial appointment to the Board of Directors, each Non-Employee Director shall be awarded equity compensation composed of stock options and&#47;or restricted stock units under the Company&#8217;s equity incentive plans. This initial appointment equity compensation award will be based on approximately one hundred and eighty percent (180%) of the annual equity compensation grant, as determined annually by the Board of Directors in consultation with its professional advisors. For purposes of the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">-</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">foregoing, the value of stock options will be determined based on the Black-Scholes valuation methodology and the value of restricted stock units will be based on the value of the Company&#8217;s common stock on the grant date&#59;</font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">In September of each year, each Non-Employee Director shall be awarded equity compensation composed of stock options and&#47;or restricted stock units under the Company&#8217;s equity incentive plans. This annual equity compensation award will be based on a review of equity compensation for non-employee directors of comparable companies as determined by the Board of Directors in consultation with its professional advisors. For purposes of the foregoing, the value of stock options will be determined based on the Black-Scholes valuation methodology and the value of restricted stock units will be based on the value of the Company&#8217;s common stock on the grant date.  If any Non-Employee Director is appointed following the annual grant of equity compensation, he or she will also be entitled to a pro-rata portion of the most recent annual grant of equity compensation awarded by the Board of Directors &#59; and </font></div><div style="text-indent:-18pt;padding-left:54pt;padding-right:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt;">Non-Employee Directors are also eligible for discretionary grants of options or restricted stock units under the Company&#8217;s equity incentive plans.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Options granted to a Non-Employee Director for their annual service on the Board of Directors shall vest monthly over a period of one year. Restricted stock unit awards granted to a Non-Employee Director for their annual service shall vest over a period of one year.  Options granted to a Non-Employee Director for their initial appointment to the Board of Directors shall vest monthly over a period of three years. Restricted stock unit awards granted to a Non-Employee Director for their initial appointment shall vest on an annual basis over three years. The exercise price of options granted to Non-Employee Directors shall be equal to 100% of the fair market value of the Company&#8217;s common stock on the grant date. Following completion of a Non-Employee Director&#8217;s service on the Board of Directors, his or her stock options will remain exerciseable for a period of eighteen months.  The term of options granted to a Non-Employee Director is eight years.  All restricted stock units that are awarded under this Plan may only be delivered to the non-employee director upon either the earlier of (i) the completion of the entire vesting period to which the restricted stock unit award relates, or (ii) the termination of the Non-Employee Director&#8217;s service, and in no event at any earlier date or upon the election or request of a Non-Employee Director at any other alternative date.  In the event of a change of control, the vesting of each option or restricted stock unit award shall accelerate in full as of the closing of such transaction.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Ownership Guidelines</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">-</font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div style="text-align:justify;"><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The Board of Directors of the Company believes that Non-Employee Directors should own and hold common stock of the Company to further align their interests and actions with the interests of the Company&#8217;s stockholders. </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Non-Employee Directors of the Company should own shares of Nektar&#8217;s common stock equivalent to at least three times the value of the Annual Retainer.  The minimum stock ownership level should be achieved by each Non-Employee Director by January 1, 2015 or within five years of his or her first appointment to the Board of Directors.  Any change in the value of the stock (such as a stock split, stock dividend, recapitalization, etc.) will not affect the amount of stock Non-Employee Directors must hold.  Once achieved, ownership of the guideline amount should be maintained as long as the Non-Employee Director retains his or her seat on the Board.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Stock that counts towards satisfaction of these guidelines include&#58;</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9642;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24pt;">Stock purchased on the open market&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9642;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24pt;">Stock obtained through stock option exercises&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9642;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24pt;">Stock issued pursuant to the vesting of restricted stock units&#59;</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9642;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24pt;">Stock beneficially owned in a trust, by a spouse and&#47;or children&#59; and</font></div><div style="text-indent:-36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#9642;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24pt;">Other equity vehicles such as deferred stock units that may be implemented from time to time.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">These ownership guidelines are non-binding.  There may be rare instances where these guidelines would place a severe hardship on a Non-Employee Director.  In these cases, the Board will make the final decision as to developing an alternative stock ownership guideline for a Non-Employee Director that reflects the intention of these guidelines and his or her personal circumstances.</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">-</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">-</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>nktr2020-03x31xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if6b7e62e42e44347a0ccfcce6ef05ee6_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Howard W. Robin, certify that&#58;</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2020 of Nektar Therapeutics&#59;</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:54.661%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:40.607%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 7, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; HOWARD W. ROBIN</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Howard W. Robin<br>Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>nktr2020-03x31xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i6f11c06ff56449d3a5d7f5031c6a02fd_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Gil M. Labrucherie, certify that&#58;</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">I have reviewed this Quarterly Report on Form 10-Q for the period ended March&#160;31, 2020 of Nektar Therapeutics&#59;</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:81pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:54.661%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:40.607%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 7, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; GIL M. LABRUCHERIE</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gil M. Labrucherie<br>Senior Vice President, Chief Operating Officer,  and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>nktr2020-03x31xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i7610ef82b0ba4f569e2ce195f18aebc6_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 1350 CERTIFICATIONS*</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the &#8220;Company&#8221;), and Gil M. Labrucherie, Senior Vice President, Chief Operating Officer, and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">The Company&#8217;s Quarterly Report on Form 10-Q for the three months ended March&#160;31, 2020, to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Exchange Act&#59; and</font></div><div style="text-indent:-45pt;padding-left:45pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37.5pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:38.556%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.837%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.607%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 7, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; HOWARD W. ROBIN</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; GIL M. LABRUCHERIE</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Howard W. Robin</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Chief Executive Officer, President and Director</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Gil M. Labrucherie</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Senior Vice President, Chief Operating Officer,  and Chief Financial Officer</font></div></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;">___________________________________________</font></div><div style="text-indent:-45pt;padding-left:45pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>nktr-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:0794ac43-98cf-4d2f-9c7f-9f499c0d4858,g:07e3bb7c-ce78-4710-acc8-c80ed5139092-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nktr="http://www.nektar.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.nektar.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nktr-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.nektar.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecurities" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities">
        <link:definition>2104102 - Disclosure - Cash and Investments in Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesTables" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail">
        <link:definition>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
        <link:definition>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.nektar.com/role/Inventory">
        <link:definition>2109103 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.nektar.com/role/InventoryTables">
        <link:definition>2310302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.nektar.com/role/InventoryDetails">
        <link:definition>2411405 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyalties" roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties">
        <link:definition>2112104 - Disclosure - Liability Related to Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail">
        <link:definition>2413406 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.nektar.com/role/CommitmentsandContingencies">
        <link:definition>2114105 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2415407 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreements" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements">
        <link:definition>2116106 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsTables" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables">
        <link:definition>2317303 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail">
        <link:definition>2418408 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsAdditionalInformationDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail">
        <link:definition>2419409 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail">
        <link:definition>2420410 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.nektar.com/role/StockBasedCompensation">
        <link:definition>2121107 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.nektar.com/role/StockBasedCompensationTables">
        <link:definition>2322304 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2423411 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationActivityDetail" roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail">
        <link:definition>2424412 - Disclosure - Stock-Based Compensation - Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.nektar.com/role/NetLossPerShare">
        <link:definition>2125108 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAdditionalInformationDetail" roleURI="http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail">
        <link:definition>2426413 - Disclosure - Net Loss Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.nektar.com/role/SubsequentEvent">
        <link:definition>2127109 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.nektar.com/role/SubsequentEventDetails">
        <link:definition>2428414 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nktr_LongTermInvestmentMaturityPeriod" abstract="false" name="LongTermInvestmentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsTable" abstract="true" name="LicenseAndCollaborationAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" abstract="false" name="UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" abstract="false" name="ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_CollaborationPartnerMember" abstract="true" name="CollaborationPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_DebtInvestmentMaximumMaturityPeriod" abstract="false" name="DebtInvestmentMaximumMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OpdivoMember" abstract="true" name="OpdivoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_WriteOffOfPrepayment" abstract="false" name="WriteOffOfPrepayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ReimbursementOfExpenses" abstract="false" name="ReimbursementOfExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AstraZenecaAgreementWithKirinMember" abstract="true" name="AstraZenecaAgreementWithKirinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ImpairmentAndOtherMember" abstract="true" name="ImpairmentAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_SaleOfStockConsiderationReceived" abstract="false" name="SaleOfStockConsiderationReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OpdivoAndYervoyMember" abstract="true" name="OpdivoAndYervoyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" abstract="true" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsAbstract" abstract="true" name="LicenseAndCollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_EstimatedFairValueOfShares" abstract="false" name="EstimatedFairValueOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" abstract="false" name="PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_AmgenIncMember" abstract="true" name="AmgenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_AdvancePaymentsToContractManufacturers" abstract="false" name="AdvancePaymentsToContractManufacturers" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInProductionCosts" abstract="false" name="PercentageOfSharingInProductionCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" abstract="false" name="PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_RepaymentsOfLongTermDebtIncludingInterest" abstract="false" name="RepaymentsOfLongTermDebtIncludingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NeulastaMember" abstract="true" name="NeulastaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_NektarThreeFiveEightLicenseMember" abstract="true" name="NektarThreeFiveEightLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PhaseOneClinicalDevelopmentMember" abstract="true" name="PhaseOneClinicalDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" abstract="false" name="CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PercentageOfSharingInDevelopmentCosts" abstract="false" name="PercentageOfSharingInDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_NektarMember" abstract="true" name="NektarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" abstract="false" name="ProceedsFromSaleOfPotentialFutureRoyaltiesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PotentialDevelopmentAndRegulatoryMilestones" abstract="false" name="PotentialDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_LicenseCollaborationOtherRevenue" abstract="false" name="LicenseCollaborationOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AccruedClinicalTrialExpensesCurrent" abstract="false" name="AccruedClinicalTrialExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_DebtInvestmentMaturityTerm" abstract="false" name="DebtInvestmentMaturityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" abstract="false" name="PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" abstract="false" name="PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_AccruedContractManufacturingExpenseCurrent" abstract="false" name="AccruedContractManufacturingExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_AnnualSalesLevelMilestoneMember" abstract="true" name="AnnualSalesLevelMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" abstract="false" name="AmountOfTransactionPriceAllocatedToPerformanceObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_OrganizationPolicyTextBlock" abstract="false" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_NKTR181Member" abstract="true" name="NKTR181Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AggregateConsiderationReceivedFromAgreements" abstract="false" name="AggregateConsiderationReceivedFromAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" abstract="false" name="PercentageOfSharingInPhaseTwoDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_RemainingAmountAllocatedToTransactionPrice" abstract="false" name="RemainingAmountAllocatedToTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PotentialDevelopmentMilestones" abstract="false" name="PotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ProfitsAndLossesSharingPercentage" abstract="false" name="ProfitsAndLossesSharingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_PurchaseAndSaleAgreementMember" abstract="true" name="PurchaseAndSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_CashAndInvestmentsInMarketableSecuritiesTable" abstract="true" name="CashAndInvestmentsInMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_SalesMilestoneRevenue" abstract="false" name="SalesMilestoneRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" abstract="false" name="PaymentsReceivedUnderRightsToSublicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" abstract="false" name="UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" abstract="false" name="EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_LicenseAndCollaborationAgreementsLineItems" abstract="true" name="LicenseAndCollaborationAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" abstract="false" name="PotentialDevelopmentRegulatoryAndSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_BMSCollaborationAgreementMember" abstract="true" name="BMSCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_NektarThreeFiveEightMember" abstract="true" name="NektarThreeFiveEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" abstract="true" name="LiabilitiesAndStockholdersEquityDeficitAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nktr_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" abstract="false" name="CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_HemophiliaMember" abstract="true" name="HemophiliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_AstraZenecaAbMember" abstract="true" name="AstraZenecaAbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LicenseCollaborationAndOtherRevenueMember" abstract="true" name="LicenseCollaborationAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" abstract="false" name="EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_EliLillyAndCompanyMember" abstract="true" name="EliLillyAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_DrugProductDevelopmentMember" abstract="true" name="DrugProductDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_MOVANTIKAndMOVENTIGMember" abstract="true" name="MOVANTIKAndMOVENTIGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" abstract="false" name="LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nktr_ImpairmentOfEquipmentFromTerminatedProgram" abstract="false" name="ImpairmentOfEquipmentFromTerminatedProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_BaxaltaIncorporatedOrTakedaPLCMember" abstract="true" name="BaxaltaIncorporatedOrTakedaPLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nktr_BristolMyersSquibbCompanyMember" abstract="true" name="BristolMyersSquibbCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" abstract="true" name="SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nktr_ProspectiveInterestRatePercentage" abstract="false" name="ProspectiveInterestRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nktr_OtherPartnerMember" abstract="true" name="OtherPartnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_PreferredStockShareDesignated" abstract="false" name="PreferredStockShareDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nktr_NektarTwoOneFourMember" abstract="true" name="NektarTwoOneFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>nktr-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:0794ac43-98cf-4d2f-9c7f-9f499c0d4858,g:07e3bb7c-ce78-4710-acc8-c80ed5139092-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20200331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9414ef37-3620-42c4-8103-481df7956bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_39df65e1-7557-4f13-95ba-84acc152c8ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9414ef37-3620-42c4-8103-481df7956bd3" xlink:to="loc_us-gaap_AssetsCurrent_39df65e1-7557-4f13-95ba-84acc152c8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_27330578-fff7-4ac0-bbf6-4f4efdc67b17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9414ef37-3620-42c4-8103-481df7956bd3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_27330578-fff7-4ac0-bbf6-4f4efdc67b17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e10004a6-7e90-422f-a150-216f810709c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9414ef37-3620-42c4-8103-481df7956bd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e10004a6-7e90-422f-a150-216f810709c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_30883628-1fc4-43b8-abec-4e55e6016929" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9414ef37-3620-42c4-8103-481df7956bd3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_30883628-1fc4-43b8-abec-4e55e6016929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3d43c572-9573-4697-9bc0-8c05a7a12049" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9414ef37-3620-42c4-8103-481df7956bd3" xlink:to="loc_us-gaap_Goodwill_3d43c572-9573-4697-9bc0-8c05a7a12049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f7cff48a-8681-492d-b3c8-e11ee18c5908" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47aabdab-3288-40cf-9647-b494a382e628" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f7cff48a-8681-492d-b3c8-e11ee18c5908" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47aabdab-3288-40cf-9647-b494a382e628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_45f93503-9e84-4c18-9251-6c9db7fb0918" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f7cff48a-8681-492d-b3c8-e11ee18c5908" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_45f93503-9e84-4c18-9251-6c9db7fb0918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b07d07fa-d0fe-4e51-9a7c-3325552c22a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f7cff48a-8681-492d-b3c8-e11ee18c5908" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b07d07fa-d0fe-4e51-9a7c-3325552c22a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bf72835a-b4eb-4913-9a8e-42adb72f280f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f7cff48a-8681-492d-b3c8-e11ee18c5908" xlink:to="loc_us-gaap_InventoryNet_bf72835a-b4eb-4913-9a8e-42adb72f280f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers_95f957d7-34dc-4a7a-868b-73680d00167f" xlink:href="nktr-20200331.xsd#nktr_AdvancePaymentsToContractManufacturers"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f7cff48a-8681-492d-b3c8-e11ee18c5908" xlink:to="loc_nktr_AdvancePaymentsToContractManufacturers_95f957d7-34dc-4a7a-868b-73680d00167f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3df95391-bb93-42bd-9834-fdf5e4053b68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f7cff48a-8681-492d-b3c8-e11ee18c5908" xlink:to="loc_us-gaap_OtherAssetsCurrent_3df95391-bb93-42bd-9834-fdf5e4053b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5fa2bab6-6295-4930-b2e9-8c9c7e4d8e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fb7d45f4-962b-401b-889a-34c1d729637f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa2bab6-6295-4930-b2e9-8c9c7e4d8e4a" xlink:to="loc_us-gaap_AccountsPayableCurrent_fb7d45f4-962b-401b-889a-34c1d729637f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b96ac224-6d42-4a5f-8747-d1b8aaff90f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa2bab6-6295-4930-b2e9-8c9c7e4d8e4a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b96ac224-6d42-4a5f-8747-d1b8aaff90f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_dee59767-9283-4006-ae49-7836b89debd7" xlink:href="nktr-20200331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa2bab6-6295-4930-b2e9-8c9c7e4d8e4a" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_dee59767-9283-4006-ae49-7836b89debd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_a8123b75-b102-4697-a1b7-efedc69df8c0" xlink:href="nktr-20200331.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa2bab6-6295-4930-b2e9-8c9c7e4d8e4a" xlink:to="loc_nktr_AccruedContractManufacturingExpenseCurrent_a8123b75-b102-4697-a1b7-efedc69df8c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d4ecbdf5-936e-48fc-a833-9d74a374c7a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa2bab6-6295-4930-b2e9-8c9c7e4d8e4a" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d4ecbdf5-936e-48fc-a833-9d74a374c7a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesCurrent_48727fc6-8243-4726-a116-8cbd14d5ac65" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa2bab6-6295-4930-b2e9-8c9c7e4d8e4a" xlink:to="loc_us-gaap_SeniorNotesCurrent_48727fc6-8243-4726-a116-8cbd14d5ac65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_40566d74-7c33-4a2d-b3e1-e70d2cc2c36e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa2bab6-6295-4930-b2e9-8c9c7e4d8e4a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_40566d74-7c33-4a2d-b3e1-e70d2cc2c36e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6e0df46c-6d6e-448f-af3c-04e4a5452ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa2bab6-6295-4930-b2e9-8c9c7e4d8e4a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6e0df46c-6d6e-448f-af3c-04e4a5452ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_fdbb5198-e242-4bae-8fed-2efb4b1bfdb9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5fa2bab6-6295-4930-b2e9-8c9c7e4d8e4a" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_fdbb5198-e242-4bae-8fed-2efb4b1bfdb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e05e6d5-6709-40fd-b405-3f7b3117bce2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bcdd54f6-ae67-4063-80c5-a5c94d43d852" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e05e6d5-6709-40fd-b405-3f7b3117bce2" xlink:to="loc_us-gaap_Liabilities_bcdd54f6-ae67-4063-80c5-a5c94d43d852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5a27eda6-e4e9-409f-8cfb-ce1b0cea17aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e05e6d5-6709-40fd-b405-3f7b3117bce2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5a27eda6-e4e9-409f-8cfb-ce1b0cea17aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6e171a58-922c-4d1a-92ba-823aef1a6a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6e05e6d5-6709-40fd-b405-3f7b3117bce2" xlink:to="loc_us-gaap_StockholdersEquity_6e171a58-922c-4d1a-92ba-823aef1a6a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e9bb0cfc-a8b9-46d7-b53c-1424c688ce73" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9b099d7f-f69f-4ac4-ab64-c0a2c57f8060" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9bb0cfc-a8b9-46d7-b53c-1424c688ce73" xlink:to="loc_us-gaap_PreferredStockValue_9b099d7f-f69f-4ac4-ab64-c0a2c57f8060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c4fe62da-f507-456a-8283-9c75aa7a11aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9bb0cfc-a8b9-46d7-b53c-1424c688ce73" xlink:to="loc_us-gaap_CommonStockValue_c4fe62da-f507-456a-8283-9c75aa7a11aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_647b2800-c58e-496f-96b4-7ff9434e74b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9bb0cfc-a8b9-46d7-b53c-1424c688ce73" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_647b2800-c58e-496f-96b4-7ff9434e74b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5e654888-2ea8-4c1e-82c2-19d9b2e76d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9bb0cfc-a8b9-46d7-b53c-1424c688ce73" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5e654888-2ea8-4c1e-82c2-19d9b2e76d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0ecf829e-d80b-4ccc-8e6e-399b7c2129d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e9bb0cfc-a8b9-46d7-b53c-1424c688ce73" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0ecf829e-d80b-4ccc-8e6e-399b7c2129d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_235945bf-a278-4355-b2be-8e0f14a82c50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cc897d89-18e0-42c0-ae19-d3a3b501908a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_235945bf-a278-4355-b2be-8e0f14a82c50" xlink:to="loc_us-gaap_LiabilitiesCurrent_cc897d89-18e0-42c0-ae19-d3a3b501908a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_235eb839-3f0e-431e-9a71-db6c119f0051" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_235945bf-a278-4355-b2be-8e0f14a82c50" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_235eb839-3f0e-431e-9a71-db6c119f0051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0bf71a66-bff6-4ccf-826f-b3d1253ccdf9" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_235945bf-a278-4355-b2be-8e0f14a82c50" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_0bf71a66-bff6-4ccf-826f-b3d1253ccdf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7ca62ef8-1a01-4bbf-baeb-6168d4ec147a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_235945bf-a278-4355-b2be-8e0f14a82c50" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7ca62ef8-1a01-4bbf-baeb-6168d4ec147a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15c904d6-3ee0-433b-b3bd-d5c80fb70407" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88080b8b-a36a-4d48-81ca-74a779e0d908" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_15c904d6-3ee0-433b-b3bd-d5c80fb70407" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88080b8b-a36a-4d48-81ca-74a779e0d908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3394da8e-1c56-4d2f-a5b6-e81b68bd8db7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_15c904d6-3ee0-433b-b3bd-d5c80fb70407" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3394da8e-1c56-4d2f-a5b6-e81b68bd8db7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c634f0a6-1873-40fc-92d5-a783748222db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_337744e7-34f8-465f-b9d3-0e4b7a5c5e63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c634f0a6-1873-40fc-92d5-a783748222db" xlink:to="loc_us-gaap_OperatingIncomeLoss_337744e7-34f8-465f-b9d3-0e4b7a5c5e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e1943f9d-4bf5-4f57-be58-ecf5f5b97620" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c634f0a6-1873-40fc-92d5-a783748222db" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e1943f9d-4bf5-4f57-be58-ecf5f5b97620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_36ef1329-197b-45b9-8a53-a7f5fafc3eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aabd8b84-8538-4659-8ad6-26465010067d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_36ef1329-197b-45b9-8a53-a7f5fafc3eb9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aabd8b84-8538-4659-8ad6-26465010067d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2155beab-ed45-4601-abd6-23ed8f4e397c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_36ef1329-197b-45b9-8a53-a7f5fafc3eb9" xlink:to="loc_us-gaap_CostsAndExpenses_2155beab-ed45-4601-abd6-23ed8f4e397c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3b2d6c64-7716-44c4-9116-dbeca34e6500" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e8f82939-a147-4abe-9569-f977d596c3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3b2d6c64-7716-44c4-9116-dbeca34e6500" xlink:to="loc_us-gaap_InterestExpense_e8f82939-a147-4abe-9569-f977d596c3b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_5d27274c-abce-46b1-aeb6-a10e349cdcc6" xlink:href="nktr-20200331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3b2d6c64-7716-44c4-9116-dbeca34e6500" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_5d27274c-abce-46b1-aeb6-a10e349cdcc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ea0bc40b-a125-4c07-a097-b4eb4ec04742" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3b2d6c64-7716-44c4-9116-dbeca34e6500" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ea0bc40b-a125-4c07-a097-b4eb4ec04742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_62db5b47-83ea-4f77-a49a-cc76dca5b90d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3e68e99d-9432-4a84-9b4f-e4fb89cf0e82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_62db5b47-83ea-4f77-a49a-cc76dca5b90d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3e68e99d-9432-4a84-9b4f-e4fb89cf0e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ffb91a39-6012-4ae2-ace7-57318cf99dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_62db5b47-83ea-4f77-a49a-cc76dca5b90d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ffb91a39-6012-4ae2-ace7-57318cf99dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bc1edecd-e152-4665-80d9-81a61db80221" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_62db5b47-83ea-4f77-a49a-cc76dca5b90d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bc1edecd-e152-4665-80d9-81a61db80221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_246620bf-d3a8-431e-a770-b4622f0a95c1" xlink:href="nktr-20200331.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_62db5b47-83ea-4f77-a49a-cc76dca5b90d" xlink:to="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_246620bf-d3a8-431e-a770-b4622f0a95c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_85b30694-3a2d-4c3f-97fe-98768fefb156" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e9846765-e1fe-4e0f-b7e7-c286d1a0c97d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_85b30694-3a2d-4c3f-97fe-98768fefb156" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e9846765-e1fe-4e0f-b7e7-c286d1a0c97d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6b36760a-bc6d-49af-a2e5-6b9b4efb8b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_85b30694-3a2d-4c3f-97fe-98768fefb156" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6b36760a-bc6d-49af-a2e5-6b9b4efb8b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5d5d1df-7cce-4a80-ae2f-e908837392af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ec17bff-4cb3-452c-9ff5-0441c8227c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5d5d1df-7cce-4a80-ae2f-e908837392af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ec17bff-4cb3-452c-9ff5-0441c8227c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d319895a-d7c8-44bb-9c82-92f8971d3a22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5d5d1df-7cce-4a80-ae2f-e908837392af" xlink:to="loc_us-gaap_NetIncomeLoss_d319895a-d7c8-44bb-9c82-92f8971d3a22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_03961900-fe23-4c44-ac43-1d24178fd62e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_ff5f1150-4488-4f69-af87-4c2faf479d29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_03961900-fe23-4c44-ac43-1d24178fd62e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_ff5f1150-4488-4f69-af87-4c2faf479d29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd3ddaac-54ef-4de8-bbd1-6f7cac38b066" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_028e1635-803b-48c1-ad42-a458eec055c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd3ddaac-54ef-4de8-bbd1-6f7cac38b066" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_028e1635-803b-48c1-ad42-a458eec055c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_43ef805a-eb8c-41fd-b0f9-c438d7dba6be" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd3ddaac-54ef-4de8-bbd1-6f7cac38b066" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_43ef805a-eb8c-41fd-b0f9-c438d7dba6be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eec8b3ad-dacb-4c5d-99e2-9bb0d5d3a238" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd3ddaac-54ef-4de8-bbd1-6f7cac38b066" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eec8b3ad-dacb-4c5d-99e2-9bb0d5d3a238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2fe0430-ef51-4d9e-aabc-adb8820e1d00" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b2a23a7-c588-40ef-96ec-302dfb17e1ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2fe0430-ef51-4d9e-aabc-adb8820e1d00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2b2a23a7-c588-40ef-96ec-302dfb17e1ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4b9735b-20d3-4f35-8b4c-ab2d8f314dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2fe0430-ef51-4d9e-aabc-adb8820e1d00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4b9735b-20d3-4f35-8b4c-ab2d8f314dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51133efd-07b9-451e-8d9b-0d465ac7dad3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2fe0430-ef51-4d9e-aabc-adb8820e1d00" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_51133efd-07b9-451e-8d9b-0d465ac7dad3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1e4326e-ae84-406f-9015-a5530432b36c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2fe0430-ef51-4d9e-aabc-adb8820e1d00" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f1e4326e-ae84-406f-9015-a5530432b36c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_aeb9ff51-c71a-42f7-87ca-9d54005acb89" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_ProfitLoss_aeb9ff51-c71a-42f7-87ca-9d54005acb89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_59ed8124-c34b-489f-a619-5261852294ec" xlink:href="nktr-20200331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_59ed8124-c34b-489f-a619-5261852294ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_9f5033ba-4689-49c5-9287-4f3e15ea4adb" xlink:href="nktr-20200331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_9f5033ba-4689-49c5-9287-4f3e15ea4adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a6c9978a-7642-4be0-b334-e5ebbf2338e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a6c9978a-7642-4be0-b334-e5ebbf2338e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_cbeeeee6-4b2f-4e23-9c4d-5bff83bc8af0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_DepreciationAndAmortization_cbeeeee6-4b2f-4e23-9c4d-5bff83bc8af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_20a3f4b7-0d64-4158-84e3-2cd21ee6646b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_20a3f4b7-0d64-4158-84e3-2cd21ee6646b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5176640c-3f3d-4e5c-b240-ec7baee1a4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5176640c-3f3d-4e5c-b240-ec7baee1a4c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fa4072db-5237-4f9b-bdf4-d1d2a06f72cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fa4072db-5237-4f9b-bdf4-d1d2a06f72cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a8e73e2c-37ed-4759-a64e-468e75bfbf02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a8e73e2c-37ed-4759-a64e-468e75bfbf02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_94710705-8c8b-43e7-8bde-84c4b0e9cd33" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_94710705-8c8b-43e7-8bde-84c4b0e9cd33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ef9dcf45-0f83-4765-a753-b33d05d95a19" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ef9dcf45-0f83-4765-a753-b33d05d95a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_30523843-89c2-4aa2-9ead-588d59589c10" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_30523843-89c2-4aa2-9ead-588d59589c10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7858e5ca-1bf7-4141-a7ba-d7564bfa0b62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7858e5ca-1bf7-4141-a7ba-d7564bfa0b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fe129746-b347-40cc-b161-77819783eb80" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_fe129746-b347-40cc-b161-77819783eb80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_b3ab0f40-0b21-489a-9982-86e557f9609d" xlink:href="nktr-20200331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_b3ab0f40-0b21-489a-9982-86e557f9609d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_d6d5e756-9c3a-4942-a0c8-3b8c191a75fb" xlink:href="nktr-20200331.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d1143bb0-7ac2-41a7-9d4c-1ef0428a71d0" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_d6d5e756-9c3a-4942-a0c8-3b8c191a75fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20200331.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20200331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_952ea586-093e-4876-8d2d-f1a00f83129a" xlink:href="nktr-20200331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4748a794-ac91-4436-abcf-e495ff85b259" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_952ea586-093e-4876-8d2d-f1a00f83129a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4748a794-ac91-4436-abcf-e495ff85b259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_77725dc8-5aaf-4f2e-bb82-31837797edf2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_952ea586-093e-4876-8d2d-f1a00f83129a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_77725dc8-5aaf-4f2e-bb82-31837797edf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_70b8403c-53b7-4cb4-8de0-ba6ca74df99f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_952ea586-093e-4876-8d2d-f1a00f83129a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_70b8403c-53b7-4cb4-8de0-ba6ca74df99f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ec9559e9-2e0f-4100-858b-6c6aaaa281f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bfd0d195-95ba-4910-8a9c-6f2fa51653a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ec9559e9-2e0f-4100-858b-6c6aaaa281f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bfd0d195-95ba-4910-8a9c-6f2fa51653a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4e0005a5-49fb-40c5-ac49-765c6daafe3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ec9559e9-2e0f-4100-858b-6c6aaaa281f7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4e0005a5-49fb-40c5-ac49-765c6daafe3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8602d1f6-caf8-4016-b660-bd0dd38c850a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ec9559e9-2e0f-4100-858b-6c6aaaa281f7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8602d1f6-caf8-4016-b660-bd0dd38c850a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_79b65587-389b-41a0-b565-2cb84e8e07c4" xlink:href="nktr-20200331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f1c94ef1-c0a3-4769-b0ae-3b57d3661f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_79b65587-389b-41a0-b565-2cb84e8e07c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f1c94ef1-c0a3-4769-b0ae-3b57d3661f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_0bb56789-8e42-4e6f-b86a-4a43fddab474" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_79b65587-389b-41a0-b565-2cb84e8e07c4" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_0bb56789-8e42-4e6f-b86a-4a43fddab474" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_feae6150-52bb-442a-ad87-1b275595ba8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_79b65587-389b-41a0-b565-2cb84e8e07c4" xlink:to="loc_us-gaap_Cash_feae6150-52bb-442a-ad87-1b275595ba8f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20200331.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20200331.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e6ae83d1-47a3-47c8-bc53-1e10c2c215da" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1967a5a3-fb09-4c5a-92fa-5fc529b9fba4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e6ae83d1-47a3-47c8-bc53-1e10c2c215da" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1967a5a3-fb09-4c5a-92fa-5fc529b9fba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4c4bdb54-3efc-49ca-b1f8-2bd194dfce36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e6ae83d1-47a3-47c8-bc53-1e10c2c215da" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4c4bdb54-3efc-49ca-b1f8-2bd194dfce36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_29ed39e3-deb4-4b0f-a83c-72575a0bdd0a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e6ae83d1-47a3-47c8-bc53-1e10c2c215da" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_29ed39e3-deb4-4b0f-a83c-72575a0bdd0a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20200331.xsd#LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20200331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensationActivityDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20200331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#NetLossPerShareAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEvent" xlink:type="simple" xlink:href="nktr-20200331.xsd#SubsequentEvent"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SubsequentEvent" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="nktr-20200331.xsd#SubsequentEventDetails"/>
  <link:calculationLink xlink:role="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>nktr-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:0794ac43-98cf-4d2f-9c7f-9f499c0d4858,g:07e3bb7c-ce78-4710-acc8-c80ed5139092-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20200331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended" id="if3660b4b170f4a599af1a3035b375263_CoverPage"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i9c21fa59d1f74dcbab02e28757c4dd5a_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" id="ifa241bec2264480294a26cd6178ddd2c_CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i85788345566b4305935f45312746b491_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_29f363fd-d6f5-472f-bb0c-921dfabae60f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_RevenuesAbstract_29f363fd-d6f5-472f-bb0c-921dfabae60f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c301fc4-e9da-4f51-afac-d61851a86a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_29f363fd-d6f5-472f-bb0c-921dfabae60f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c301fc4-e9da-4f51-afac-d61851a86a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_88c08b61-e332-42ca-8f05-cf52c2f21586" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_88c08b61-e332-42ca-8f05-cf52c2f21586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bfb930d3-fb60-4a6b-8eae-d90f9d86dd20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bfb930d3-fb60-4a6b-8eae-d90f9d86dd20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1a8d566e-2313-4c3c-bda4-2527c80fa0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1a8d566e-2313-4c3c-bda4-2527c80fa0d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_ec46848e-3c9e-41da-af80-e2f870dbda85" xlink:href="nktr-20200331.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:to="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_ec46848e-3c9e-41da-af80-e2f870dbda85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3cb06224-dcd9-40cb-9708-c0226003aabd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:to="loc_us-gaap_CostsAndExpenses_3cb06224-dcd9-40cb-9708-c0226003aabd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0a03344e-c846-4869-8dbc-c7c42c36fbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_OperatingIncomeLoss_0a03344e-c846-4869-8dbc-c7c42c36fbf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_03f5bfec-8c84-481a-ba8e-c751bd695abe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:to="loc_us-gaap_InterestExpense_03f5bfec-8c84-481a-ba8e-c751bd695abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_0dd2bd83-8798-411d-b5d0-e0a2de64dc89" xlink:href="nktr-20200331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_0dd2bd83-8798-411d-b5d0-e0a2de64dc89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_29bad313-76f8-4517-95d8-a795dcf63303" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_29bad313-76f8-4517-95d8-a795dcf63303" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2d62d3b9-a78f-415e-a833-74e496ba8da7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2d62d3b9-a78f-415e-a833-74e496ba8da7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6de75913-2718-44b3-8880-54f3e141d8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6de75913-2718-44b3-8880-54f3e141d8bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a45d1447-664e-4515-b091-be93db8293ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a45d1447-664e-4515-b091-be93db8293ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0caaad42-db8e-471c-8cf0-189c75430359" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_NetIncomeLoss_0caaad42-db8e-471c-8cf0-189c75430359" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_92d4c2c8-8945-4454-bd75-9c1e8dbc8a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_92d4c2c8-8945-4454-bd75-9c1e8dbc8a7f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8a44c727-48ab-498e-a911-eeed0978fc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8a44c727-48ab-498e-a911-eeed0978fc1e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d91c9da6-5c47-4079-b930-8010499738f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_StatementTable_d91c9da6-5c47-4079-b930-8010499738f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0f4046ac-d6a3-41fc-8f13-c2b6f7d27a9b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d91c9da6-5c47-4079-b930-8010499738f0" xlink:to="loc_srt_ProductOrServiceAxis_0f4046ac-d6a3-41fc-8f13-c2b6f7d27a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0f4046ac-d6a3-41fc-8f13-c2b6f7d27a9b_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0f4046ac-d6a3-41fc-8f13-c2b6f7d27a9b" xlink:to="loc_srt_ProductsAndServicesDomain_0f4046ac-d6a3-41fc-8f13-c2b6f7d27a9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0f4046ac-d6a3-41fc-8f13-c2b6f7d27a9b" xlink:to="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_26a52779-d185-4fb2-88a3-ae6ecffd332a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:to="loc_us-gaap_ProductMember_26a52779-d185-4fb2-88a3-ae6ecffd332a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_e779c66c-be3a-4dda-a729-19f67d4f1563" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:to="loc_us-gaap_RoyaltyMember_e779c66c-be3a-4dda-a729-19f67d4f1563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_08b7409a-1b89-44c3-8dac-3020a726aa50" xlink:href="nktr-20200331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_08b7409a-1b89-44c3-8dac-3020a726aa50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_50c9d9b8-b23f-41ce-ac90-35bea3b54aff" xlink:href="nktr-20200331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_50c9d9b8-b23f-41ce-ac90-35bea3b54aff" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i4a2c8267b71f482ba963cb7bb4886450_CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ifc2513590bc44176953a7ce88afd6452_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_045fe11e-3ac8-488f-b453-5d6900affb93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_045fe11e-3ac8-488f-b453-5d6900affb93" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3ec2d244-eb86-4368-ad1b-4c6cee4a32cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_SharesOutstanding_3ec2d244-eb86-4368-ad1b-4c6cee4a32cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52e3080c-66eb-42b6-85d4-bc2ee60143c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_StockholdersEquity_52e3080c-66eb-42b6-85d4-bc2ee60143c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a1d8f49a-91a2-4aab-93d0-2255ff1268c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a1d8f49a-91a2-4aab-93d0-2255ff1268c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5759f85b-5199-43f3-9fea-bc21fc587a15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5759f85b-5199-43f3-9fea-bc21fc587a15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eea73038-c1e8-450f-af67-90965145a293" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eea73038-c1e8-450f-af67-90965145a293" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6cd3b399-1106-4452-b32f-adc38ceecb08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6cd3b399-1106-4452-b32f-adc38ceecb08" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ef474948-33d9-437e-8cbb-16cc72259bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5d5b76bd-d6f0-4a39-a9f6-23b72ec2c73a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0dde0aa-b5a7-4d78-a2f3-027d785da80d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_045fe11e-3ac8-488f-b453-5d6900affb93" xlink:to="loc_us-gaap_StatementTable_f0dde0aa-b5a7-4d78-a2f3-027d785da80d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_05463108-e112-49de-ac92-32922fbd2e45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f0dde0aa-b5a7-4d78-a2f3-027d785da80d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_05463108-e112-49de-ac92-32922fbd2e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_05463108-e112-49de-ac92-32922fbd2e45_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_05463108-e112-49de-ac92-32922fbd2e45" xlink:to="loc_us-gaap_EquityComponentDomain_05463108-e112-49de-ac92-32922fbd2e45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_05463108-e112-49de-ac92-32922fbd2e45" xlink:to="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8ebc8d7c-bdc8-4495-acf7-f6441db650f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:to="loc_us-gaap_CommonStockMember_8ebc8d7c-bdc8-4495-acf7-f6441db650f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3a180afa-8729-4e1e-ad50-065f4f3a7b87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3a180afa-8729-4e1e-ad50-065f4f3a7b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ec8abdf-aab2-4b0c-a792-bb1b2b9381d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ec8abdf-aab2-4b0c-a792-bb1b2b9381d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_84c3ace6-4ef6-4eca-b5d8-7a3678df3978" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:to="loc_us-gaap_RetainedEarningsMember_84c3ace6-4ef6-4eca-b5d8-7a3678df3978" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="ica5efaa0caf942c7a0f78a5f8a627669_CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20200331.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i0b3c19713a3844e3a0bd2e3f287b8e90_OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20200331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ia9e4800b5ecd455e98894abce97dc7ca_OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i9ca635efbbb54480a884ccf98953cc8e_OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:href="nktr-20200331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f40fdac7-b0b1-4c6e-b6ae-e0d562df10bb" xlink:href="nktr-20200331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f40fdac7-b0b1-4c6e-b6ae-e0d562df10bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_70c42e1b-28c0-41ef-b0d4-b948c1641ab5" xlink:href="nktr-20200331.xsd#nktr_RepaymentsOfLongTermDebtIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_70c42e1b-28c0-41ef-b0d4-b948c1641ab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_b205a970-0368-441d-bfc8-e1afd9e47390" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_SeniorNotes_b205a970-0368-441d-bfc8-e1afd9e47390" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_45be29bd-461f-4e0d-9980-87920142e26a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_45be29bd-461f-4e0d-9980-87920142e26a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a4f47f1a-2a10-4f17-97cc-27cff396241a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a4f47f1a-2a10-4f17-97cc-27cff396241a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a14fa2a2-79d5-4c7d-84f7-e634cf69d268" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a14fa2a2-79d5-4c7d-84f7-e634cf69d268" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0e53ab08-0625-4f3f-8f81-2005a9a9d4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0e53ab08-0625-4f3f-8f81-2005a9a9d4f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_3f3fd5e0-13a1-4f65-a3d4-710251c059b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment_de2c17d0-b05c-4fe2-a7c7-0d59c5237801" xlink:href="nktr-20200331.xsd#nktr_WriteOffOfPrepayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_nktr_WriteOffOfPrepayment_de2c17d0-b05c-4fe2-a7c7-0d59c5237801" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9a846409-62eb-443f-8cf4-28d5bac16d45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9a846409-62eb-443f-8cf4-28d5bac16d45" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:href="nktr-20200331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2717a5ed-1bc0-45e9-8abc-37cf4461d78e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_srt_CounterpartyNameAxis_2717a5ed-1bc0-45e9-8abc-37cf4461d78e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2717a5ed-1bc0-45e9-8abc-37cf4461d78e_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2717a5ed-1bc0-45e9-8abc-37cf4461d78e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2717a5ed-1bc0-45e9-8abc-37cf4461d78e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c85a938-c0c7-42df-b3e2-2ea15996f6cc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2717a5ed-1bc0-45e9-8abc-37cf4461d78e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c85a938-c0c7-42df-b3e2-2ea15996f6cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborationPartnerMember_4fb5330f-8311-4951-919e-4e6a351f3129" xlink:href="nktr-20200331.xsd#nktr_CollaborationPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c85a938-c0c7-42df-b3e2-2ea15996f6cc" xlink:to="loc_nktr_CollaborationPartnerMember_4fb5330f-8311-4951-919e-4e6a351f3129" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_11c326ef-470d-4c03-a36a-bf76972469d4" xlink:href="nktr-20200331.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c85a938-c0c7-42df-b3e2-2ea15996f6cc" xlink:to="loc_nktr_BMSCollaborationAgreementMember_11c326ef-470d-4c03-a36a-bf76972469d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_63cddfa1-917d-4b85-abb7-87ffa4463620" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_srt_ProductOrServiceAxis_63cddfa1-917d-4b85-abb7-87ffa4463620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_63cddfa1-917d-4b85-abb7-87ffa4463620_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_63cddfa1-917d-4b85-abb7-87ffa4463620" xlink:to="loc_srt_ProductsAndServicesDomain_63cddfa1-917d-4b85-abb7-87ffa4463620_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b2bac055-360a-4bd6-b13d-602e67f17bda" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_63cddfa1-917d-4b85-abb7-87ffa4463620" xlink:to="loc_srt_ProductsAndServicesDomain_b2bac055-360a-4bd6-b13d-602e67f17bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_dd977ff3-0269-4796-83b6-e34db9e228b5" xlink:href="nktr-20200331.xsd#nktr_NKTR181Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b2bac055-360a-4bd6-b13d-602e67f17bda" xlink:to="loc_nktr_NKTR181Member_dd977ff3-0269-4796-83b6-e34db9e228b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c5d667c8-53ef-4d42-920c-489480ee5fca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_us-gaap_DebtInstrumentAxis_c5d667c8-53ef-4d42-920c-489480ee5fca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c5d667c8-53ef-4d42-920c-489480ee5fca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c5d667c8-53ef-4d42-920c-489480ee5fca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c5d667c8-53ef-4d42-920c-489480ee5fca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a84627b-0948-4471-b2e5-c5e2a15547f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c5d667c8-53ef-4d42-920c-489480ee5fca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a84627b-0948-4471-b2e5-c5e2a15547f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_1c3ea05f-ac96-47de-9aa8-8d22b8622c52" xlink:href="nktr-20200331.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1a84627b-0948-4471-b2e5-c5e2a15547f9" xlink:to="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_1c3ea05f-ac96-47de-9aa8-8d22b8622c52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58fdb081-be5c-49a3-b4ae-bdd1fac6ffd7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_58fdb081-be5c-49a3-b4ae-bdd1fac6ffd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_58fdb081-be5c-49a3-b4ae-bdd1fac6ffd7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58fdb081-be5c-49a3-b4ae-bdd1fac6ffd7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_58fdb081-be5c-49a3-b4ae-bdd1fac6ffd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a756bc5f-ce80-485f-b22a-590983240ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58fdb081-be5c-49a3-b4ae-bdd1fac6ffd7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a756bc5f-ce80-485f-b22a-590983240ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3f1c0e1e-3a11-4049-b9d3-c46a0af7cab1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a756bc5f-ce80-485f-b22a-590983240ddc" xlink:to="loc_us-gaap_SeniorNotesMember_3f1c0e1e-3a11-4049-b9d3-c46a0af7cab1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3c6bb1ee-4257-48d4-97b8-bb6dfb35e01e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3c6bb1ee-4257-48d4-97b8-bb6dfb35e01e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3c6bb1ee-4257-48d4-97b8-bb6dfb35e01e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3c6bb1ee-4257-48d4-97b8-bb6dfb35e01e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3c6bb1ee-4257-48d4-97b8-bb6dfb35e01e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9c183747-b2c4-4c4a-8ed3-6bea49356f63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3c6bb1ee-4257-48d4-97b8-bb6dfb35e01e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9c183747-b2c4-4c4a-8ed3-6bea49356f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6ad68b4c-02ab-49ca-bb76-891898bff87f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9c183747-b2c4-4c4a-8ed3-6bea49356f63" xlink:to="loc_us-gaap_SubsequentEventMember_6ad68b4c-02ab-49ca-bb76-891898bff87f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended" id="i6ba159371230492d9b7da33c5388b05f_CashandInvestmentsinMarketableSecurities"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended" id="ie6bc9787e77e4f599c7ce888464977f8_CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended" id="i9fcd9d6db67242b7bd376a339b5b7fbf_CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" id="iec59b4a346e440b180d1205da88bb4a8_CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:href="nktr-20200331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_82c06e13-8a77-480c-afbf-9198e624c697" xlink:href="nktr-20200331.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_82c06e13-8a77-480c-afbf-9198e624c697" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_0eb3a1d4-2121-4084-859a-d76d8c58781d" xlink:href="nktr-20200331.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_0eb3a1d4-2121-4084-859a-d76d8c58781d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_9ccdc5fe-8eb6-4193-818b-c84b55385635" xlink:href="nktr-20200331.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_9ccdc5fe-8eb6-4193-818b-c84b55385635" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fdaa8d69-7246-4126-bfa8-6a39275bac06" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fdaa8d69-7246-4126-bfa8-6a39275bac06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_7227f360-c8e0-4658-a32d-905cc6277835" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_us-gaap_SeniorNotes_7227f360-c8e0-4658-a32d-905cc6277835" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_c04662f4-ee84-478f-b48e-132553d567db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_ed777a58-a04f-46bd-aab5-8dd6b1fb285e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_us-gaap_InterestReceivableCurrent_ed777a58-a04f-46bd-aab5-8dd6b1fb285e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_ebe2de27-4258-4c24-9d73-765ff899ad5e" xlink:href="nktr-20200331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_ebe2de27-4258-4c24-9d73-765ff899ad5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_01360d69-d174-4e02-827e-35b0f720af04" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_ebe2de27-4258-4c24-9d73-765ff899ad5e" xlink:to="loc_srt_RangeAxis_01360d69-d174-4e02-827e-35b0f720af04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01360d69-d174-4e02-827e-35b0f720af04_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_01360d69-d174-4e02-827e-35b0f720af04" xlink:to="loc_srt_RangeMember_01360d69-d174-4e02-827e-35b0f720af04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc99173a-c376-4190-a2d6-bfc8a54bfa10" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_01360d69-d174-4e02-827e-35b0f720af04" xlink:to="loc_srt_RangeMember_bc99173a-c376-4190-a2d6-bfc8a54bfa10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dae6ff14-cdcd-44ed-8d7c-5f78e6c53aba" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc99173a-c376-4190-a2d6-bfc8a54bfa10" xlink:to="loc_srt_MinimumMember_dae6ff14-cdcd-44ed-8d7c-5f78e6c53aba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a68bb8d9-aa53-4ddf-8af2-a8f881726f3d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bc99173a-c376-4190-a2d6-bfc8a54bfa10" xlink:to="loc_srt_MaximumMember_a68bb8d9-aa53-4ddf-8af2-a8f881726f3d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended" id="i6943bdd7fcfb44378b2ee288863efbdf_CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1acaff18-d3f4-4e77-b139-b4fc6b155560" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1acaff18-d3f4-4e77-b139-b4fc6b155560" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e60f5435-ed5a-47d8-8d0c-2cbaf036b675" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e60f5435-ed5a-47d8-8d0c-2cbaf036b675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9e49fa41-07f6-4fe3-95b7-935d814786b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9e49fa41-07f6-4fe3-95b7-935d814786b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3d43bb08-5140-4145-9bbf-7f5f3c3cffaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3d43bb08-5140-4145-9bbf-7f5f3c3cffaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_f71c6c09-54c5-45f7-a66c-26b7dd4cb5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_f71c6c09-54c5-45f7-a66c-26b7dd4cb5c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_bf024ada-c0ac-40df-8fe1-f67d3800e4af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_Cash_bf024ada-c0ac-40df-8fe1-f67d3800e4af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ef1aad3b-3b99-46db-9830-fea73c5bccf2" xlink:href="nktr-20200331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ef1aad3b-3b99-46db-9830-fea73c5bccf2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f8a251-58b4-4e61-b67a-adeecb6762a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f8a251-58b4-4e61-b67a-adeecb6762a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_36a5aed5-b623-4cc5-98d3-4fa342e8e9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f8a251-58b4-4e61-b67a-adeecb6762a4" xlink:to="loc_us-gaap_InvestmentTypeAxis_36a5aed5-b623-4cc5-98d3-4fa342e8e9ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_36a5aed5-b623-4cc5-98d3-4fa342e8e9ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_36a5aed5-b623-4cc5-98d3-4fa342e8e9ab" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_36a5aed5-b623-4cc5-98d3-4fa342e8e9ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_36a5aed5-b623-4cc5-98d3-4fa342e8e9ab" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ad3608d6-501a-4dcb-8d20-2151a1e9ac83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ad3608d6-501a-4dcb-8d20-2151a1e9ac83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1abbdb5d-1012-4124-bbeb-e772cad5129d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:to="loc_us-gaap_CommercialPaperMember_1abbdb5d-1012-4124-bbeb-e772cad5129d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_51da5b5a-4a3f-4305-aba6-43a780a56a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:to="loc_us-gaap_MoneyMarketFundsMember_51da5b5a-4a3f-4305-aba6-43a780a56a8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_49647eec-8046-49b8-a525-21c426f37537" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:to="loc_us-gaap_CertificatesOfDepositMember_49647eec-8046-49b8-a525-21c426f37537" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_947e9633-5123-4dfe-92c6-fcc7b90f77e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f8a251-58b4-4e61-b67a-adeecb6762a4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_947e9633-5123-4dfe-92c6-fcc7b90f77e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_947e9633-5123-4dfe-92c6-fcc7b90f77e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_947e9633-5123-4dfe-92c6-fcc7b90f77e3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_947e9633-5123-4dfe-92c6-fcc7b90f77e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2477ae67-d9b3-47ab-82d4-714776990afe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_947e9633-5123-4dfe-92c6-fcc7b90f77e3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2477ae67-d9b3-47ab-82d4-714776990afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ce1848b0-33ef-4955-9b0a-bc39f102b53a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2477ae67-d9b3-47ab-82d4-714776990afe" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ce1848b0-33ef-4955-9b0a-bc39f102b53a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4387e88f-d007-48e0-8dda-a081a223d230" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2477ae67-d9b3-47ab-82d4-714776990afe" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4387e88f-d007-48e0-8dda-a081a223d230" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20200331.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended" id="i90297c55f08544938dd76fffd9acb991_Inventory"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended" id="ief45de55b0d1409696c4680ff6b23d44_InventoryTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20200331.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended" id="iddfcb77063144d66b7dd123b513e6317_InventoryDetails"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20200331.xsd#LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended" id="i3622e31b248e415eb55633577956bb3f_LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended" id="i99cf21dc81dd43308f50c15ff4dfeab7_LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_4ef0070d-b4ac-4519-9d03-b7ba5b417e0c" xlink:href="nktr-20200331.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_4ef0070d-b4ac-4519-9d03-b7ba5b417e0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_60fdd166-09d4-43de-9ddf-484c3f843561" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_60fdd166-09d4-43de-9ddf-484c3f843561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_f284b39c-ce23-41aa-9650-4ebac688f0dc" xlink:href="nktr-20200331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_f284b39c-ce23-41aa-9650-4ebac688f0dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_508ddd2f-c688-4d24-88d5-52248b8f04c0" xlink:href="nktr-20200331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_508ddd2f-c688-4d24-88d5-52248b8f04c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_122ecf4d-c6b5-4ed5-9f5b-266947777ac7" xlink:href="nktr-20200331.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_122ecf4d-c6b5-4ed5-9f5b-266947777ac7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_5df4e6a3-8817-4000-9da4-bfdfd1b74f91" xlink:href="nktr-20200331.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_ProspectiveInterestRatePercentage_5df4e6a3-8817-4000-9da4-bfdfd1b74f91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_340ba853-8c9a-453a-b5fc-29a116db4bce" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_340ba853-8c9a-453a-b5fc-29a116db4bce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f89c4faa-a990-44a1-ba8a-3587a3532a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_340ba853-8c9a-453a-b5fc-29a116db4bce" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f89c4faa-a990-44a1-ba8a-3587a3532a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f89c4faa-a990-44a1-ba8a-3587a3532a9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f89c4faa-a990-44a1-ba8a-3587a3532a9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f89c4faa-a990-44a1-ba8a-3587a3532a9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_274ac47b-7122-4457-a28f-c3fb5a175ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f89c4faa-a990-44a1-ba8a-3587a3532a9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_274ac47b-7122-4457-a28f-c3fb5a175ad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_1c2177d7-3460-46a0-a4a7-ccbfda2777d5" xlink:href="nktr-20200331.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_274ac47b-7122-4457-a28f-c3fb5a175ad4" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_1c2177d7-3460-46a0-a4a7-ccbfda2777d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20200331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended" id="i2d206311600242809551e3fd1e07220f_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="ifa4e413ff222499e98a476216cce731d_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e8aff778-184b-401a-89fe-5a77a98e15ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_561ecbf5-38de-4079-85e6-86586835184d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e8aff778-184b-401a-89fe-5a77a98e15ee" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_561ecbf5-38de-4079-85e6-86586835184d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_98b16bd5-99aa-4a25-b126-37a0118cec64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_e8aff778-184b-401a-89fe-5a77a98e15ee" xlink:to="loc_us-gaap_LossContingenciesTable_98b16bd5-99aa-4a25-b126-37a0118cec64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_c2b23294-68d0-4901-97a0-39dbf112af17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_98b16bd5-99aa-4a25-b126-37a0118cec64" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_c2b23294-68d0-4901-97a0-39dbf112af17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_c2b23294-68d0-4901-97a0-39dbf112af17_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_c2b23294-68d0-4901-97a0-39dbf112af17" xlink:to="loc_us-gaap_LossContingencyNatureDomain_c2b23294-68d0-4901-97a0-39dbf112af17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_923b52ef-5dda-4b8c-a56a-dc8bd83fcc87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_c2b23294-68d0-4901-97a0-39dbf112af17" xlink:to="loc_us-gaap_LossContingencyNatureDomain_923b52ef-5dda-4b8c-a56a-dc8bd83fcc87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_de5aa4aa-0b31-4b7e-b446-0f53b322ae95" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_923b52ef-5dda-4b8c-a56a-dc8bd83fcc87" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_de5aa4aa-0b31-4b7e-b446-0f53b322ae95" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended" id="i72d88ca565e24469ad290366bac35c1d_LicenseandCollaborationAgreements"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended" id="ia2c639f1e1704cddaaf06de64fdf35ff_LicenseandCollaborationAgreementsTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended" id="i80afa5893bfe41deaf49958dff5ff402_LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail">
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_096ed4d1-3975-4787-80a6-b0a3790bc445" xlink:href="nktr-20200331.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_ef98a91e-a156-47f1-b8e6-c9016c0bcda8" xlink:href="nktr-20200331.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_096ed4d1-3975-4787-80a6-b0a3790bc445" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_ef98a91e-a156-47f1-b8e6-c9016c0bcda8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_6bfcddd1-d06c-4544-9e82-651f2b80cdcc" xlink:href="nktr-20200331.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_096ed4d1-3975-4787-80a6-b0a3790bc445" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_6bfcddd1-d06c-4544-9e82-651f2b80cdcc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_edaf8078-b702-4af8-aa46-ca3afd880b04" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_6bfcddd1-d06c-4544-9e82-651f2b80cdcc" xlink:to="loc_dei_LegalEntityAxis_edaf8078-b702-4af8-aa46-ca3afd880b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_edaf8078-b702-4af8-aa46-ca3afd880b04_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_edaf8078-b702-4af8-aa46-ca3afd880b04" xlink:to="loc_dei_EntityDomain_edaf8078-b702-4af8-aa46-ca3afd880b04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_edaf8078-b702-4af8-aa46-ca3afd880b04" xlink:to="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_3eeaee02-71d4-44ca-bec8-736f4d97d1bb" xlink:href="nktr-20200331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_3eeaee02-71d4-44ca-bec8-736f4d97d1bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_dbd3e2b8-8944-40be-981a-fd2b2a2a1c78" xlink:href="nktr-20200331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:to="loc_nktr_EliLillyAndCompanyMember_dbd3e2b8-8944-40be-981a-fd2b2a2a1c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_0e375c15-d560-4d27-b1b7-c3b8e70375a4" xlink:href="nktr-20200331.xsd#nktr_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:to="loc_nktr_AmgenIncMember_0e375c15-d560-4d27-b1b7-c3b8e70375a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_a9ddda2c-78b2-4d70-9b46-927bcdc44f98" xlink:href="nktr-20200331.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:to="loc_nktr_OtherPartnerMember_a9ddda2c-78b2-4d70-9b46-927bcdc44f98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_873f3883-160e-4fba-b4c7-7c6b0069dc69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_6bfcddd1-d06c-4544-9e82-651f2b80cdcc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_873f3883-160e-4fba-b4c7-7c6b0069dc69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_873f3883-160e-4fba-b4c7-7c6b0069dc69_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_873f3883-160e-4fba-b4c7-7c6b0069dc69" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_873f3883-160e-4fba-b4c7-7c6b0069dc69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65368cf8-ff55-4f8e-800f-98fb2060eed0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_873f3883-160e-4fba-b4c7-7c6b0069dc69" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65368cf8-ff55-4f8e-800f-98fb2060eed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarTwoOneFourMember_d3b7e7fb-2431-469d-a45e-61c066719187" xlink:href="nktr-20200331.xsd#nktr_NektarTwoOneFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65368cf8-ff55-4f8e-800f-98fb2060eed0" xlink:to="loc_nktr_NektarTwoOneFourMember_d3b7e7fb-2431-469d-a45e-61c066719187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_796adaff-83e6-4347-a509-b48450da71fd" xlink:href="nktr-20200331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65368cf8-ff55-4f8e-800f-98fb2060eed0" xlink:to="loc_nktr_NektarThreeFiveEightMember_796adaff-83e6-4347-a509-b48450da71fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember_6ef22cc5-3ff2-424a-9400-b1ab78b400c8" xlink:href="nktr-20200331.xsd#nktr_NeulastaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65368cf8-ff55-4f8e-800f-98fb2060eed0" xlink:to="loc_nktr_NeulastaMember_6ef22cc5-3ff2-424a-9400-b1ab78b400c8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended" id="id36d47b76e224dd699eb5d9978fcd33b_LicenseandCollaborationAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9db887d4-3be3-4d1e-b0c7-dceefa32e943" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9db887d4-3be3-4d1e-b0c7-dceefa32e943" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_6c6040f3-2d29-4a16-a57a-fe4f3e707762" xlink:href="nktr-20200331.xsd#nktr_SalesMilestoneRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_SalesMilestoneRevenue_6c6040f3-2d29-4a16-a57a-fe4f3e707762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_72a3cf9e-a0eb-4cd6-ad7e-f41126d5ba46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_72a3cf9e-a0eb-4cd6-ad7e-f41126d5ba46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_64dd0eff-b093-4906-89bf-4cc87b903fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_64dd0eff-b093-4906-89bf-4cc87b903fb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_1323938a-849e-4de5-92ac-bba7e5b46630" xlink:href="nktr-20200331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_1323938a-849e-4de5-92ac-bba7e5b46630" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_bd59d09d-a465-4b63-805a-e21ecfcc3fc3" xlink:href="nktr-20200331.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_bd59d09d-a465-4b63-805a-e21ecfcc3fc3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_e9c96637-0c55-47a1-ab15-9ba928721750" xlink:href="nktr-20200331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_e9c96637-0c55-47a1-ab15-9ba928721750" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_70a39440-a5af-48b4-92fd-c6f074fb1d96" xlink:href="nktr-20200331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_70a39440-a5af-48b4-92fd-c6f074fb1d96" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_1dafcdae-131c-4230-9349-e31ad99180e7" xlink:href="nktr-20200331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_1dafcdae-131c-4230-9349-e31ad99180e7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_7587f75c-31c5-4c2f-a59b-57c8e54451a8" xlink:href="nktr-20200331.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_7587f75c-31c5-4c2f-a59b-57c8e54451a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_e7106c91-63af-4262-87fc-f19d4719aa66" xlink:href="nktr-20200331.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_e7106c91-63af-4262-87fc-f19d4719aa66" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6dfd338d-9d48-4706-82e4-4ac8f68d38d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_SharesIssued_6dfd338d-9d48-4706-82e4-4ac8f68d38d3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_32633438-8092-4204-9d5f-e10cbb1aa7b3" xlink:href="nktr-20200331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_32633438-8092-4204-9d5f-e10cbb1aa7b3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_852b2870-7e71-48f3-9256-a1ea6645cbf9" xlink:href="nktr-20200331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_ReimbursementOfExpenses_852b2870-7e71-48f3-9256-a1ea6645cbf9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_904d5ae1-1f6c-40cb-875d-bf5ef144b8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_904d5ae1-1f6c-40cb-875d-bf5ef144b8dc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_c2526b06-1430-4345-893e-d629ce0e8771" xlink:href="nktr-20200331.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_c2526b06-1430-4345-893e-d629ce0e8771" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_680760e8-b6c5-4cc6-9d88-c114723fbb92" xlink:href="nktr-20200331.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_EstimatedFairValueOfShares_680760e8-b6c5-4cc6-9d88-c114723fbb92" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_b4886cd4-79a5-42a3-8edb-28a1d38e9df2" xlink:href="nktr-20200331.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_b4886cd4-79a5-42a3-8edb-28a1d38e9df2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_f723383d-eb40-42af-99fc-989e9ebdd5c7" xlink:href="nktr-20200331.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_f723383d-eb40-42af-99fc-989e9ebdd5c7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_be55436a-7e88-4f47-a853-731c4fa4f650" xlink:href="nktr-20200331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_be55436a-7e88-4f47-a853-731c4fa4f650" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_ae3d59a8-3d69-4a37-9e3e-0401a9d9f7ff" xlink:href="nktr-20200331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_ae3d59a8-3d69-4a37-9e3e-0401a9d9f7ff" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_a1a8ddb7-982f-42d0-8249-45101365344b" xlink:href="nktr-20200331.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_a1a8ddb7-982f-42d0-8249-45101365344b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_ae12a416-8bd9-467d-a674-84793be2f353" xlink:href="nktr-20200331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_ae12a416-8bd9-467d-a674-84793be2f353" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_a2035ea9-bb9e-4af5-a1be-7fa6c1216f54" xlink:href="nktr-20200331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_a2035ea9-bb9e-4af5-a1be-7fa6c1216f54" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_9d696131-b8a4-4a7f-adcc-0bc579b16eb3" xlink:href="nktr-20200331.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_9d696131-b8a4-4a7f-adcc-0bc579b16eb3" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ebe6271-5d7b-4b71-b681-f2356973a97d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ebe6271-5d7b-4b71-b681-f2356973a97d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f250c71e-a6f2-4b5d-b4c1-a048aabbaabb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f250c71e-a6f2-4b5d-b4c1-a048aabbaabb" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_b2c59957-a050-4204-868c-871323a970b9" xlink:href="nktr-20200331.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_b2c59957-a050-4204-868c-871323a970b9" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_f0253a4b-dcd8-4636-a9bc-b1c70bf92aea" xlink:href="nktr-20200331.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_f0253a4b-dcd8-4636-a9bc-b1c70bf92aea" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_0795a09c-f1a3-4434-a869-3c377fde2a8a" xlink:href="nktr-20200331.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_0795a09c-f1a3-4434-a869-3c377fde2a8a" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_333375f2-9e21-46c3-9b1a-147f48f23547" xlink:href="nktr-20200331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PotentialDevelopmentMilestones_333375f2-9e21-46c3-9b1a-147f48f23547" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cbbf4504-c8a5-4e14-bfd6-47d56b1fa324" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_dei_LegalEntityAxis_cbbf4504-c8a5-4e14-bfd6-47d56b1fa324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cbbf4504-c8a5-4e14-bfd6-47d56b1fa324_default" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cbbf4504-c8a5-4e14-bfd6-47d56b1fa324" xlink:to="loc_dei_EntityDomain_cbbf4504-c8a5-4e14-bfd6-47d56b1fa324_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cbbf4504-c8a5-4e14-bfd6-47d56b1fa324" xlink:to="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_733bec95-3d53-41b1-bbd3-18d2d83d1d0d" xlink:href="nktr-20200331.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_733bec95-3d53-41b1-bbd3-18d2d83d1d0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_31f243eb-6e01-419e-998d-03fa77dc8869" xlink:href="nktr-20200331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_31f243eb-6e01-419e-998d-03fa77dc8869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_8598a61d-b026-42ef-bb16-268f4170ef4c" xlink:href="nktr-20200331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_EliLillyAndCompanyMember_8598a61d-b026-42ef-bb16-268f4170ef4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_9f093ffc-9a24-43e9-9124-8cf5897a42c2" xlink:href="nktr-20200331.xsd#nktr_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_EliLillyMember_9f093ffc-9a24-43e9-9124-8cf5897a42c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_889e5678-c68f-4cc0-8aa9-ac86390894f0" xlink:href="nktr-20200331.xsd#nktr_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_AmgenIncMember_889e5678-c68f-4cc0-8aa9-ac86390894f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_a52fecde-e629-4f54-9fa4-2f3d01803e3f" xlink:href="nktr-20200331.xsd#nktr_AstraZenecaAbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_AstraZenecaAbMember_a52fecde-e629-4f54-9fa4-2f3d01803e3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_1eb5d9e2-bc41-4bb5-a094-7bb177f6efe9" xlink:href="nktr-20200331.xsd#nktr_OtherPartnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_OtherPartnerMember_1eb5d9e2-bc41-4bb5-a094-7bb177f6efe9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a7cae4b4-3e3c-4c95-b82b-275137914fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a7cae4b4-3e3c-4c95-b82b-275137914fe1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7cae4b4-3e3c-4c95-b82b-275137914fe1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a7cae4b4-3e3c-4c95-b82b-275137914fe1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7cae4b4-3e3c-4c95-b82b-275137914fe1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a7cae4b4-3e3c-4c95-b82b-275137914fe1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaMember_78164fd2-80e0-4920-97be-e754037fb095" xlink:href="nktr-20200331.xsd#nktr_HemophiliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_HemophiliaMember_78164fd2-80e0-4920-97be-e754037fb095" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_4ac0c6ff-7feb-4638-9d8d-a0eee9e7a8b3" xlink:href="nktr-20200331.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_BMSCollaborationAgreementMember_4ac0c6ff-7feb-4638-9d8d-a0eee9e7a8b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_801024a1-2a8c-4348-89cd-ac22d6779832" xlink:href="nktr-20200331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_NektarThreeFiveEightMember_801024a1-2a8c-4348-89cd-ac22d6779832" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_da5b360f-ac20-44ba-8855-bb2d4e03c262" xlink:href="nktr-20200331.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_da5b360f-ac20-44ba-8855-bb2d4e03c262" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_362d289e-3dfe-4acc-8f8b-f41d68cec546" xlink:href="nktr-20200331.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_DrugProductDevelopmentMember_362d289e-3dfe-4acc-8f8b-f41d68cec546" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember_6ec06f2d-f64e-49f7-9dea-f3cf9a35f4e2" xlink:href="nktr-20200331.xsd#nktr_MOVANTIKAndMOVENTIGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_MOVANTIKAndMOVENTIGMember_6ec06f2d-f64e-49f7-9dea-f3cf9a35f4e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember_83914806-ed8e-475a-b7b9-92d207eae2ac" xlink:href="nktr-20200331.xsd#nktr_AstraZenecaAgreementWithKirinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_AstraZenecaAgreementWithKirinMember_83914806-ed8e-475a-b7b9-92d207eae2ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember_ea6ece71-1db9-4276-aead-39ed2d32d7f0" xlink:href="nktr-20200331.xsd#nktr_NektarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_NektarMember_ea6ece71-1db9-4276-aead-39ed2d32d7f0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cf531b15-d10c-407d-8de2-d24188521fec" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_srt_StatementGeographicalAxis_cf531b15-d10c-407d-8de2-d24188521fec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cf531b15-d10c-407d-8de2-d24188521fec_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cf531b15-d10c-407d-8de2-d24188521fec" xlink:to="loc_srt_SegmentGeographicalDomain_cf531b15-d10c-407d-8de2-d24188521fec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c8eb6ccb-6be9-49a9-ba97-dfde7f3db68d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cf531b15-d10c-407d-8de2-d24188521fec" xlink:to="loc_srt_SegmentGeographicalDomain_c8eb6ccb-6be9-49a9-ba97-dfde7f3db68d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_a674a446-1e44-4fae-b437-790e68d4ad09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c8eb6ccb-6be9-49a9-ba97-dfde7f3db68d" xlink:to="loc_us-gaap_EuropeanUnionMember_a674a446-1e44-4fae-b437-790e68d4ad09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_23e4efbf-3ffc-48fa-8b37-a595d0346242" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_srt_ProductOrServiceAxis_23e4efbf-3ffc-48fa-8b37-a595d0346242" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_23e4efbf-3ffc-48fa-8b37-a595d0346242_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_23e4efbf-3ffc-48fa-8b37-a595d0346242" xlink:to="loc_srt_ProductsAndServicesDomain_23e4efbf-3ffc-48fa-8b37-a595d0346242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abdf3672-bfb7-4768-a937-8f1d420d8158" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_23e4efbf-3ffc-48fa-8b37-a595d0346242" xlink:to="loc_srt_ProductsAndServicesDomain_abdf3672-bfb7-4768-a937-8f1d420d8158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarTwoOneFourMember_ce6306ce-3248-4c5b-b4d8-631456af34ef" xlink:href="nktr-20200331.xsd#nktr_NektarTwoOneFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abdf3672-bfb7-4768-a937-8f1d420d8158" xlink:to="loc_nktr_NektarTwoOneFourMember_ce6306ce-3248-4c5b-b4d8-631456af34ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_45d0b0e1-547c-4d39-979d-53e5738c7635" xlink:href="nktr-20200331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abdf3672-bfb7-4768-a937-8f1d420d8158" xlink:to="loc_nktr_NektarThreeFiveEightMember_45d0b0e1-547c-4d39-979d-53e5738c7635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightLicenseMember_3beef703-41fb-4d39-895b-c1669ce2e5fd" xlink:href="nktr-20200331.xsd#nktr_NektarThreeFiveEightLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abdf3672-bfb7-4768-a937-8f1d420d8158" xlink:to="loc_nktr_NektarThreeFiveEightLicenseMember_3beef703-41fb-4d39-895b-c1669ce2e5fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_4fae054e-01aa-4e56-905f-ab965f1311c1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_4fae054e-01aa-4e56-905f-ab965f1311c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_4fae054e-01aa-4e56-905f-ab965f1311c1_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4fae054e-01aa-4e56-905f-ab965f1311c1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_4fae054e-01aa-4e56-905f-ab965f1311c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0df08376-ca75-4a1e-90e2-a132e7336db3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4fae054e-01aa-4e56-905f-ab965f1311c1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0df08376-ca75-4a1e-90e2-a132e7336db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_ff6422ba-387e-475e-bef7-676cb3d89c77" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0df08376-ca75-4a1e-90e2-a132e7336db3" xlink:to="loc_srt_ParentCompanyMember_ff6422ba-387e-475e-bef7-676cb3d89c77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d5c65a5b-6d83-49c1-a190-a9402439ebca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d5c65a5b-6d83-49c1-a190-a9402439ebca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d5c65a5b-6d83-49c1-a190-a9402439ebca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d5c65a5b-6d83-49c1-a190-a9402439ebca" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d5c65a5b-6d83-49c1-a190-a9402439ebca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1040fd84-2543-4fbf-8afd-7c288b885e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d5c65a5b-6d83-49c1-a190-a9402439ebca" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1040fd84-2543-4fbf-8afd-7c288b885e0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_a974c1a2-08f3-4177-a146-cd976bf59c28" xlink:href="nktr-20200331.xsd#nktr_OpdivoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1040fd84-2543-4fbf-8afd-7c288b885e0d" xlink:to="loc_nktr_OpdivoMember_a974c1a2-08f3-4177-a146-cd976bf59c28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoAndYervoyMember_64f286b2-da84-4f8e-a7d9-256c08e78a56" xlink:href="nktr-20200331.xsd#nktr_OpdivoAndYervoyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1040fd84-2543-4fbf-8afd-7c288b885e0d" xlink:to="loc_nktr_OpdivoAndYervoyMember_64f286b2-da84-4f8e-a7d9-256c08e78a56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8fd56795-f1d1-4e37-923d-39517198c268" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_srt_RangeAxis_8fd56795-f1d1-4e37-923d-39517198c268" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8fd56795-f1d1-4e37-923d-39517198c268_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8fd56795-f1d1-4e37-923d-39517198c268" xlink:to="loc_srt_RangeMember_8fd56795-f1d1-4e37-923d-39517198c268_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56602155-fcf4-4d79-ac9f-3db539835d4c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8fd56795-f1d1-4e37-923d-39517198c268" xlink:to="loc_srt_RangeMember_56602155-fcf4-4d79-ac9f-3db539835d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e13a36b0-1af2-4b98-aa6b-ed75e9c186b4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56602155-fcf4-4d79-ac9f-3db539835d4c" xlink:to="loc_srt_MaximumMember_e13a36b0-1af2-4b98-aa6b-ed75e9c186b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ba733e4a-62e3-4326-b30e-1651bb1a983b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56602155-fcf4-4d79-ac9f-3db539835d4c" xlink:to="loc_srt_MinimumMember_ba733e4a-62e3-4326-b30e-1651bb1a983b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f8715549-b947-4775-b39f-9d572b395dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f8715549-b947-4775-b39f-9d572b395dd7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f8715549-b947-4775-b39f-9d572b395dd7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f8715549-b947-4775-b39f-9d572b395dd7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f8715549-b947-4775-b39f-9d572b395dd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a3ad46c0-6fc7-45ac-95ad-08279add131d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f8715549-b947-4775-b39f-9d572b395dd7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a3ad46c0-6fc7-45ac-95ad-08279add131d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_f85e0eda-51d6-4b9d-beb0-0c6fc6240940" xlink:href="nktr-20200331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a3ad46c0-6fc7-45ac-95ad-08279add131d" xlink:to="loc_nktr_SharePurchaseAgreementMember_f85e0eda-51d6-4b9d-beb0-0c6fc6240940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c3060bcb-b60e-4b26-8f9a-661c8f203253" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c3060bcb-b60e-4b26-8f9a-661c8f203253" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c3060bcb-b60e-4b26-8f9a-661c8f203253_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c3060bcb-b60e-4b26-8f9a-661c8f203253" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c3060bcb-b60e-4b26-8f9a-661c8f203253_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2e53cf22-0300-482b-8366-59b2d36f5a67" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c3060bcb-b60e-4b26-8f9a-661c8f203253" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2e53cf22-0300-482b-8366-59b2d36f5a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c2c955a7-2189-44b1-9d3a-84b6b42182f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2e53cf22-0300-482b-8366-59b2d36f5a67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c2c955a7-2189-44b1-9d3a-84b6b42182f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a6c7ed39-5818-4f0b-a7a8-8d30acd363f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a6c7ed39-5818-4f0b-a7a8-8d30acd363f0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a6c7ed39-5818-4f0b-a7a8-8d30acd363f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a6c7ed39-5818-4f0b-a7a8-8d30acd363f0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a6c7ed39-5818-4f0b-a7a8-8d30acd363f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_f7f53a21-20fe-4839-a812-e69996a81288" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a6c7ed39-5818-4f0b-a7a8-8d30acd363f0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_f7f53a21-20fe-4839-a812-e69996a81288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_47986eb3-1c58-468a-922f-a9e9bb426a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_f7f53a21-20fe-4839-a812-e69996a81288" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_47986eb3-1c58-468a-922f-a9e9bb426a2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_6fff5b2a-52d2-4fcc-b285-bfe98f6726ba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_6fff5b2a-52d2-4fcc-b285-bfe98f6726ba" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_6fff5b2a-52d2-4fcc-b285-bfe98f6726ba_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_6fff5b2a-52d2-4fcc-b285-bfe98f6726ba" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_6fff5b2a-52d2-4fcc-b285-bfe98f6726ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_8b8baaef-c55a-4668-b731-ce46b35d3222" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_6fff5b2a-52d2-4fcc-b285-bfe98f6726ba" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_8b8baaef-c55a-4668-b731-ce46b35d3222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember_a5403e48-072c-4936-b648-64e7a7a2d508" xlink:href="nktr-20200331.xsd#nktr_AnnualSalesLevelMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_8b8baaef-c55a-4668-b731-ce46b35d3222" xlink:to="loc_nktr_AnnualSalesLevelMilestoneMember_a5403e48-072c-4936-b648-64e7a7a2d508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_fac540d2-d93e-4ca0-9fc8-396639fa319f" xlink:href="nktr-20200331.xsd#nktr_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_nktr_MilestoneAxis_fac540d2-d93e-4ca0-9fc8-396639fa319f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_fac540d2-d93e-4ca0-9fc8-396639fa319f_default" xlink:href="nktr-20200331.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nktr_MilestoneAxis_fac540d2-d93e-4ca0-9fc8-396639fa319f" xlink:to="loc_nktr_MilestoneDomain_fac540d2-d93e-4ca0-9fc8-396639fa319f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_5e5c113d-19b2-40d5-a9de-8817f34ad7fe" xlink:href="nktr-20200331.xsd#nktr_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nktr_MilestoneAxis_fac540d2-d93e-4ca0-9fc8-396639fa319f" xlink:to="loc_nktr_MilestoneDomain_5e5c113d-19b2-40d5-a9de-8817f34ad7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_232df5d5-8059-4799-876a-cc76eb2cab78" xlink:href="nktr-20200331.xsd#nktr_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_5e5c113d-19b2-40d5-a9de-8817f34ad7fe" xlink:to="loc_nktr_MilestoneOneMember_232df5d5-8059-4799-876a-cc76eb2cab78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneTwoMember_9f3045c0-6151-4bd0-881e-0d234a05d596" xlink:href="nktr-20200331.xsd#nktr_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_5e5c113d-19b2-40d5-a9de-8817f34ad7fe" xlink:to="loc_nktr_MilestoneTwoMember_9f3045c0-6151-4bd0-881e-0d234a05d596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneThreeMember_eec0b039-b3c1-4d4b-932f-07a0b8973457" xlink:href="nktr-20200331.xsd#nktr_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nktr_MilestoneDomain_5e5c113d-19b2-40d5-a9de-8817f34ad7fe" xlink:to="loc_nktr_MilestoneThreeMember_eec0b039-b3c1-4d4b-932f-07a0b8973457" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="extended" id="iab8fa69ade964cca918d2e83aba8ca06_LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended" id="ia16c0e09ac6a4dfb9608be8219b42222_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended" id="i65036f03e58e4bb59a1578c9454b45c5_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" id="i3208d630280c45ef8c693e1b0d16fc23_StockBasedCompensationStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2262d610-b44f-4333-8241-b482cb9851b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_db9c4007-bf1a-48f1-ba5f-5451c804b2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2262d610-b44f-4333-8241-b482cb9851b4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_db9c4007-bf1a-48f1-ba5f-5451c804b2c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79134265-9da5-4e3d-a370-7fb04cc6a218" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2262d610-b44f-4333-8241-b482cb9851b4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79134265-9da5-4e3d-a370-7fb04cc6a218" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6ede7ccc-4a9d-4767-b7c3-dc716bc1e980" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79134265-9da5-4e3d-a370-7fb04cc6a218" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6ede7ccc-4a9d-4767-b7c3-dc716bc1e980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6ede7ccc-4a9d-4767-b7c3-dc716bc1e980_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6ede7ccc-4a9d-4767-b7c3-dc716bc1e980" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6ede7ccc-4a9d-4767-b7c3-dc716bc1e980_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6ede7ccc-4a9d-4767-b7c3-dc716bc1e980" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3d17f954-cae6-42fa-9bcf-7228589f29d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:to="loc_us-gaap_CostOfSalesMember_3d17f954-cae6-42fa-9bcf-7228589f29d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4233d8ef-e440-40bf-b75b-211a2fac2940" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4233d8ef-e440-40bf-b75b-211a2fac2940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_97ef9feb-0dfc-4834-b8d1-7280fa1c487b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_97ef9feb-0dfc-4834-b8d1-7280fa1c487b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentAndOtherMember_c96ff22d-170c-4789-b232-fd37a15603d7" xlink:href="nktr-20200331.xsd#nktr_ImpairmentAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:to="loc_nktr_ImpairmentAndOtherMember_c96ff22d-170c-4789-b232-fd37a15603d7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensationActivityDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended" id="id8b603389d91472891f664f7fe830aa5_StockBasedCompensationActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6af20fcd-bf6d-447a-a042-ee3ba38559ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6af20fcd-bf6d-447a-a042-ee3ba38559ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da4a9089-6953-47ed-a25d-4afe4c1893c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da4a9089-6953-47ed-a25d-4afe4c1893c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ffbda399-c3c3-4288-955a-da3c6011465f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ffbda399-c3c3-4288-955a-da3c6011465f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6ca98cf-78f2-4936-8883-ac1096b0d207" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6ca98cf-78f2-4936-8883-ac1096b0d207" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54f0394c-c013-4e4f-af4e-9d6e684e3d35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54f0394c-c013-4e4f-af4e-9d6e684e3d35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bdf786a-4a19-420e-8453-c656606ec84b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bdf786a-4a19-420e-8453-c656606ec84b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd616bb0-b8be-42e8-a95d-0dac1f96a75f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bdf786a-4a19-420e-8453-c656606ec84b" xlink:to="loc_us-gaap_AwardTypeAxis_cd616bb0-b8be-42e8-a95d-0dac1f96a75f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd616bb0-b8be-42e8-a95d-0dac1f96a75f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cd616bb0-b8be-42e8-a95d-0dac1f96a75f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd616bb0-b8be-42e8-a95d-0dac1f96a75f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d56af436-cf0e-4611-ac5e-cf9d51e08bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cd616bb0-b8be-42e8-a95d-0dac1f96a75f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d56af436-cf0e-4611-ac5e-cf9d51e08bd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_719b7028-cd3b-406a-a7cd-2f1c785f59b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d56af436-cf0e-4611-ac5e-cf9d51e08bd6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_719b7028-cd3b-406a-a7cd-2f1c785f59b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_83013f50-1258-4cdc-a1e1-8baad54d8c09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d56af436-cf0e-4611-ac5e-cf9d51e08bd6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_83013f50-1258-4cdc-a1e1-8baad54d8c09" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20200331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended" id="ia854b7c00f404cab91b98b4def2da069_NetLossPerShare"/>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#NetLossPerShareAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail" xlink:type="extended" id="i444c072752994392b65e4d1cf276777f_NetLossPerShareAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_121a75eb-6e2b-4c2a-9479-0c762f7c96e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_30f8d14e-dc97-404d-a188-237bc38cea02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_121a75eb-6e2b-4c2a-9479-0c762f7c96e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_30f8d14e-dc97-404d-a188-237bc38cea02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97b276f4-1efd-431c-94e1-f6c3a11438cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_121a75eb-6e2b-4c2a-9479-0c762f7c96e2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97b276f4-1efd-431c-94e1-f6c3a11438cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e0d8f14-1041-4cf3-b290-53960416070c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97b276f4-1efd-431c-94e1-f6c3a11438cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e0d8f14-1041-4cf3-b290-53960416070c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2e0d8f14-1041-4cf3-b290-53960416070c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e0d8f14-1041-4cf3-b290-53960416070c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2e0d8f14-1041-4cf3-b290-53960416070c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_590a6735-8b38-45f8-b037-6c13d74bc079" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e0d8f14-1041-4cf3-b290-53960416070c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_590a6735-8b38-45f8-b037-6c13d74bc079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_1ab40306-3958-4144-9fd7-86dd9e639e98" xlink:href="nktr-20200331.xsd#nktr_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_590a6735-8b38-45f8-b037-6c13d74bc079" xlink:to="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_1ab40306-3958-4144-9fd7-86dd9e639e98" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEvent" xlink:type="simple" xlink:href="nktr-20200331.xsd#SubsequentEvent"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SubsequentEvent" xlink:type="extended" id="i913c3cff834b4f1d8173169c65d76f99_SubsequentEvent"/>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="nktr-20200331.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="extended" id="iee07f7fd65ec4d57965350bb2c36af13_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_88e1ad67-0811-4e59-9733-997540e14d34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:to="loc_us-gaap_SeniorNotes_88e1ad67-0811-4e59-9733-997540e14d34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6af50ebe-645e-4bce-ba8f-1b7c5ed4c8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6af50ebe-645e-4bce-ba8f-1b7c5ed4c8ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d9ae4384-1858-4c33-9bcc-99d78b935198" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d9ae4384-1858-4c33-9bcc-99d78b935198" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_dc8529fe-9de3-4ed8-bab5-441944c7f9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_dc8529fe-9de3-4ed8-bab5-441944c7f9f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:to="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_31c418b2-694b-430d-84c0-7c72cf699a61" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_31c418b2-694b-430d-84c0-7c72cf699a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_31c418b2-694b-430d-84c0-7c72cf699a61_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_31c418b2-694b-430d-84c0-7c72cf699a61" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_31c418b2-694b-430d-84c0-7c72cf699a61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fcf858cc-d913-4271-9f27-de39fe98556b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_31c418b2-694b-430d-84c0-7c72cf699a61" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fcf858cc-d913-4271-9f27-de39fe98556b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5525bac0-6bf6-4b3b-a3a7-f0311776ce59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fcf858cc-d913-4271-9f27-de39fe98556b" xlink:to="loc_us-gaap_SubsequentEventMember_5525bac0-6bf6-4b3b-a3a7-f0311776ce59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d5fb30e6-2350-46da-81af-b1b0d14664af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:to="loc_us-gaap_DebtInstrumentAxis_d5fb30e6-2350-46da-81af-b1b0d14664af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d5fb30e6-2350-46da-81af-b1b0d14664af_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d5fb30e6-2350-46da-81af-b1b0d14664af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d5fb30e6-2350-46da-81af-b1b0d14664af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9f3b6c2b-985f-440f-8747-02b9ed43c0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d5fb30e6-2350-46da-81af-b1b0d14664af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9f3b6c2b-985f-440f-8747-02b9ed43c0e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_3173f0d6-83d5-4fe0-8724-831888e4748c" xlink:href="nktr-20200331.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9f3b6c2b-985f-440f-8747-02b9ed43c0e6" xlink:to="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_3173f0d6-83d5-4fe0-8724-831888e4748c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_037eb12e-67cd-4365-9797-e488dcf05faa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_037eb12e-67cd-4365-9797-e488dcf05faa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_037eb12e-67cd-4365-9797-e488dcf05faa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_037eb12e-67cd-4365-9797-e488dcf05faa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_037eb12e-67cd-4365-9797-e488dcf05faa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_92eafe54-4a14-4e56-818a-b2068e8fc9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_037eb12e-67cd-4365-9797-e488dcf05faa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_92eafe54-4a14-4e56-818a-b2068e8fc9c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_fdfe4189-5e56-461c-b30e-ef66f05c50a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_92eafe54-4a14-4e56-818a-b2068e8fc9c6" xlink:to="loc_us-gaap_SeniorNotesMember_fdfe4189-5e56-461c-b30e-ef66f05c50a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>nktr-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:0794ac43-98cf-4d2f-9c7f-9f499c0d4858,g:07e3bb7c-ce78-4710-acc8-c80ed5139092-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_6040b515-9cdf-491f-bdfa-f62db6d1f809_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_e6aae40a-c1d1-4d17-b17a-b4633b941a5d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 606</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_0f7dfbc4-6edd-4088-bd51-d7ec2a384018_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f4e89453-b1f5-401c-93a7-2fc02c8397f8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_e716eca7-cdde-45b2-9d13-991a65de2a6a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7cf4a2c7-b8d1-47f6-b4cd-f2d645e73d7d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82d0c9c2-20b8-4ce9-8780-dd26d5a2746c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7f867fe0-9b88-4dc8-8b71-3c20032e0d01_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_74672eee-7910-4eff-8a87-c13e69aba29c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_3b5be9de-6413-4bfa-aa32-cd08263459de_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum maturity term for debt securities investment</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Investment Maximum Maturity Period</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaximumMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt investment maximum maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:href="nktr-20200331.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:to="lab_nktr_DebtInvestmentMaximumMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d907fa9b-2cdd-40d3-b15c-fc7381dd0905_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6042eb03-e6b0-4599-b2b6-9e23af877b04_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3fa628a0-e490-4252-a28a-5b62ee093e5d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesCurrent_cca1ab19-2481-4c54-bfd0-b5477dac9728_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes, net and interest payable</link:label>
    <link:label id="lab_us-gaap_SeniorNotesCurrent_label_en-US" xlink:label="lab_us-gaap_SeniorNotesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesCurrent" xlink:to="lab_us-gaap_SeniorNotesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_721ae533-35a1-48b8-a722-78d815cb3376_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bfa8c7d-d0f9-4086-9631-870a83be57b8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_92d0edcb-ff82-426f-a969-4f0e3d4fef18_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_cc1c30fe-6781-4668-9b3c-dd8c17d6e371_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_3cfb61b8-f61e-4903-97d0-2f3bce4d1a12_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8f6ddad1-cebf-41df-87b1-a3ae98ca44da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarMember_6ee41bf9-359b-424f-9dfd-aea1d94381da_terseLabel_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar</link:label>
    <link:label id="lab_nktr_NektarMember_label_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar [Member]</link:label>
    <link:label id="lab_nktr_NektarMember_documentation_en-US" xlink:label="lab_nktr_NektarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember" xlink:href="nktr-20200331.xsd#nktr_NektarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarMember" xlink:to="lab_nktr_NektarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_c953a423-60c0-46da-b8db-085c7f557b10_terseLabel_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing expenses</link:label>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_label_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Contract Manufacturing Expense Current</link:label>
    <link:label id="lab_nktr_AccruedContractManufacturingExpenseCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract manufacturing expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent" xlink:href="nktr-20200331.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedContractManufacturingExpenseCurrent" xlink:to="lab_nktr_AccruedContractManufacturingExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_4976f4c8-a4ad-4e23-9fd4-e5ef6141d298_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a474f757-1d13-480e-a893-cae9dfde7103_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c3d5d877-9410-4e20-a318-31a1c9d9995d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_87b3bdb8-6311-4e10-91b2-33bd3e867d93_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional development and regulatory milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20200331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_PotentialDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_812462a4-7b39-408a-aa07-7677a1052b71_terseLabel_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global commercialization profits and losses sharing percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_label_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits And Losses Sharing Percentage</link:label>
    <link:label id="lab_nktr_ProfitsAndLossesSharingPercentage_documentation_en-US" xlink:label="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits and losses sharing percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage" xlink:href="nktr-20200331.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProfitsAndLossesSharingPercentage" xlink:to="lab_nktr_ProfitsAndLossesSharingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_8dd19175-5384-48f7-8340-39ff8ce37a3c_terseLabel_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration received under agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_label_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Consideration Received From Agreements</link:label>
    <link:label id="lab_nktr_AggregateConsiderationReceivedFromAgreements_documentation_en-US" xlink:label="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate consideration received from agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements" xlink:href="nktr-20200331.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AggregateConsiderationReceivedFromAgreements" xlink:to="lab_nktr_AggregateConsiderationReceivedFromAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_653909f5-afcc-4efc-97d5-ca3654917ff2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a664defe-6969-4934-8400-57490db71b74_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneDomain_961e5ced-01b2-4c56-94c3-61eb36c09143_terseLabel_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_label_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_nktr_MilestoneDomain_documentation_en-US" xlink:label="lab_nktr_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain" xlink:href="nktr-20200331.xsd#nktr_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneDomain" xlink:to="lab_nktr_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d41d60af-596c-477f-89ec-4dbc4af654db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4deb2e71-87c8-4f0e-bed9-d1e7b6593248_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9bf871a2-449a-4f57-a9f0-ec02b6a0edc6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_af57c19d-e593-4dcf-ac04-e7424c6d9bad_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_b511cacc-fa7c-4503-9274-9ee1109394aa_terseLabel_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_label_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly And Company [Member]</link:label>
    <link:label id="lab_nktr_EliLillyAndCompanyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly and Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember" xlink:href="nktr-20200331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyAndCompanyMember" xlink:to="lab_nktr_EliLillyAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_8d7c353d-14d3-46af-bed9-adae93080cb5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmgenIncMember_81dccd47-4c39-4c7f-bea9-f2726d8a8d7a_terseLabel_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen, Inc.</link:label>
    <link:label id="lab_nktr_AmgenIncMember_label_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Inc [Member]</link:label>
    <link:label id="lab_nktr_AmgenIncMember_documentation_en-US" xlink:label="lab_nktr_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember" xlink:href="nktr-20200331.xsd#nktr_AmgenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmgenIncMember" xlink:to="lab_nktr_AmgenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d8159915-473a-4a22-b368-5ad7b83a4b2c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_050e32ad-ed75-4c90-967f-cafa10906c9c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_95271bcd-1df8-4b5b-a756-af6dbb23a1a2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9a7b8b21-f53c-4f26-a5d3-37265bccf207_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_778a116d-1dec-439c-b69f-f57286f9a8aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b7f4e8e-e62d-49a5-bc62-d222c6be3dcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OpdivoMember_44bf3593-8223-4840-b694-12eaf58a215b_terseLabel_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo</link:label>
    <link:label id="lab_nktr_OpdivoMember_label_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo [Member]</link:label>
    <link:label id="lab_nktr_OpdivoMember_documentation_en-US" xlink:label="lab_nktr_OpdivoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember" xlink:href="nktr-20200331.xsd#nktr_OpdivoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoMember" xlink:to="lab_nktr_OpdivoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_eefbc45c-3878-4420-b02b-d00bcc82d402_terseLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_0ad694ed-337f-46f0-9026-f4d84f51b548_totalLabel_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and investments in marketable securities</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_label_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Restricted Cash Cash Equivalents And Available For Sale Investments</link:label>
    <link:label id="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_documentation_en-US" xlink:label="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, restricted cash, cash equivalents, and available for sale investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:href="nktr-20200331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:to="lab_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_8c0172e3-43b1-4af7-b13c-6054b2a1599f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_7fd0c116-b305-4ae8-8685-7061d6cb51b7_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets and other costs for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment And Other Costs For Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment And Other Costs For Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:href="nktr-20200331.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_315510b7-20aa-4c13-be30-b2ce4f967a39_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f8c03f88-0686-4739-a623-30c2b26b5d30_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_badda2d3-47cb-43d5-bbc5-56cb6036c360_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_53e0bdd0-2fc9-41d4-b61d-1ac0a4656749_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_de556024-544f-45ec-b5f3-c3f382df3d7c_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_dd6e774e-71b5-40a6-b697-c8f1bd40dd2b_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_label_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration And Other Revenue [Member]</link:label>
    <link:label id="lab_nktr_LicenseCollaborationAndOtherRevenueMember_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License collaboration and other revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:href="nktr-20200331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:to="lab_nktr_LicenseCollaborationAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_63ccdd9e-765f-4aa5-a77a-637025b9c9c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_32d2a5ba-6d2e-4080-99a6-f6ba2b377bc4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized in period related to performance in prior periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_0ede5232-33c3-4784-b3b3-462a8ff73d64_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecf60d52-bc1d-4e5a-85db-08f4086a936e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f245d853-a3f7-4c76-93ba-a78ccc2efebd_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_9068038a-18e8-4215-b29b-7a49b1670042_terseLabel_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_label_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones</link:label>
    <link:label id="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_documentation_en-US" xlink:label="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible additional cash payments receivable upon achievement of certain sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:href="nktr-20200331.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:to="lab_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_37eac72f-48dc-46f6-9633-d97f26d8ad17_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_33eca1a0-07ba-43ac-b9c9-6f6ba6b248f2_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar's</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_b5d694b7-a2f9-4b20-9e72-a7af2a888e47_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_085649c8-3faa-49ba-a1de-7358b9493bfc_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Table]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:href="nktr-20200331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_cd216db8-7f4c-4864-83e8-9db3bfcce618_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segment</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_76305255-e981-4ed8-a16d-092974f7fd15_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_b1b53e96-0e40-4d90-87ba-7745f150b598_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_6e297ea5-ed6b-4a27-8733-0dea3f8006c0_terseLabel_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Sales Level Milestone</link:label>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_label_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Sales Level Milestone [Member]</link:label>
    <link:label id="lab_nktr_AnnualSalesLevelMilestoneMember_documentation_en-US" xlink:label="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual sales level milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember" xlink:href="nktr-20200331.xsd#nktr_AnnualSalesLevelMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AnnualSalesLevelMilestoneMember" xlink:to="lab_nktr_AnnualSalesLevelMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ace4ec99-a389-46c5-89b1-4315dee852ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_56ee0d65-15e1-4b0f-ad34-372c55d1dd84_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision on unrealized gain on available-for-sale securities, offset by benefit in continuing operations</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_d69c765c-fd6f-46cf-8597-f95aeec19490_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of premiums (discounts), net and other non-cash transactions</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_af4f8ad1-8edd-4e87-b8dc-0e2feb74ede3_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Phase Two Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in Phase 2 development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:href="nktr-20200331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5ce0be0e-12a5-425d-a8b7-86a2ced8f4c3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6f9fd57f-1502-4818-9118-00836ddb1847_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6eed6921-7103-48ab-93ab-fa19a8f6cf8e_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_49d25d4a-4e48-4193-812a-4e5cb9683cdc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_998ea9fc-9012-4b3f-a4ea-1b8e6ccd59f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_060db564-4645-4370-a76a-3b20deff681b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4cb05e9b-6c28-4e55-86f1-55dcdd9a3e78_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6bcada7e-f5c9-44cb-84ec-132f0b3f412d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f8ad3b2c-f603-4762-9942-89d1c6c78e43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4ccc82aa-3c93-487d-9403-79246794bd0b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_98bccce7-0e02-404a-b6e3-f194796121a8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_7a2591b4-b200-4515-afec-d64a43bf4e21_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3d36e362-5a8b-4b20-87d2-041c020470dd_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_403b86d5-63cf-4817-bc54-f162ee2f7f94_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_5133afc6-0838-4b6c-b8b4-07590dc1a1e7_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing production costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Production Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInProductionCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInProductionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in production costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts" xlink:href="nktr-20200331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInProductionCosts" xlink:to="lab_nktr_PercentageOfSharingInProductionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_86dcb366-fff0-4ab1-a0e1-c90d1741cdfa_terseLabel_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Collaboration Agreement</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_label_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B M S Collaboration Agreement [Member]</link:label>
    <link:label id="lab_nktr_BMSCollaborationAgreementMember_documentation_en-US" xlink:label="lab_nktr_BMSCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember" xlink:href="nktr-20200331.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BMSCollaborationAgreementMember" xlink:to="lab_nktr_BMSCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_6cf0a32c-9381-4cb1-8b6e-06d5aabc2646_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced under certain conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received Under Certain Conditions</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received under certain conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:href="nktr-20200331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OtherPartnerMember_bf9fe6a9-e7ac-416c-982d-d8b43c315572_terseLabel_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_label_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Partner [Member]</link:label>
    <link:label id="lab_nktr_OtherPartnerMember_documentation_en-US" xlink:label="lab_nktr_OtherPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember" xlink:href="nktr-20200331.xsd#nktr_OtherPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OtherPartnerMember" xlink:to="lab_nktr_OtherPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2763f083-b06c-4216-a688-2ba51570f655_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_bfd24f72-e1fc-4feb-a465-ba255176ced8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_1adc6ae4-095b-46db-8685-00ff4df62235_negatedLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_3de9dc5f-7959-461a-9daf-b24f7607ddce_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash royalty revenue related to sale future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:href="nktr-20200331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7105ab15-cf94-464f-b2ed-5a6e42bde221_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_9a16d637-0bad-4326-a6d4-62782c5685fe_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_49f42ce3-83e5-46cb-a8c8-5daf834662d4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_698f095d-3cc9-476c-b10f-5784cb9065c8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net foreign currency translation gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_dedc0dbb-e5fe-48db-a351-6a2ae1c7dd89_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_8cc0172c-b4dc-4936-8d09-0fee202fa284_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6c9f4e27-82d5-42e5-b234-f291efb9b069_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9e14b83e-a43f-414c-81b6-72a12eeed275_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4e2cea70-9ca8-44a7-89ae-b9d0fb12a6e6_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of previously unearned revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_553d1634-11ed-4499-9085-da39d65d7745_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8ccb06ef-b8a6-45aa-a0a0-da0da391bc9e_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_82191908-39ae-456f-b6e9-5c722ec7908c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f9d442ea-5800-4eac-9562-f759e718ea69_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_405986e4-91fd-4edb-bac3-b9ac81cf4fbf_terseLabel_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.75% Senior Secured Notes Due October 2020</link:label>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_label_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seven Point Seven Five Percent Senior Secured Notes Due October Two Thousand And Twenty [Member]</link:label>
    <link:label id="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_documentation_en-US" xlink:label="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seven point seven five percent senior secured notes due October two thousand and twenty.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:href="nktr-20200331.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:to="lab_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_51e45813-e814-4e3b-af07-95360a9d3a2d_terseLabel_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_label_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investment Maturity Period</link:label>
    <link:label id="lab_nktr_LongTermInvestmentMaturityPeriod_documentation_en-US" xlink:label="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term investment maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:href="nktr-20200331.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LongTermInvestmentMaturityPeriod" xlink:to="lab_nktr_LongTermInvestmentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_28e2b266-1aae-4502-96aa-c0f88bee48b8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6973ff23-be08-443b-a870-9e0a114c7f3f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_e70d47d8-42c7-4587-af2d-05b45cd5305c_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c74ac3e6-8a5d-436a-a6d8-608d569b83d4_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_197a2489-12d4-43da-bcfd-dcc945cbfd33_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_78a34f3b-ccd5-41e3-ab4c-4e7ce3159415_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_24896d6f-744b-428a-b432-c011cf1e32e0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_252fd352-2bcd-4c81-996d-1f0790e7d369_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000 shares authorized; 177,863 shares and 176,505 shares outstanding at March 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_c1be38cd-32a4-4f8b-826e-9ee4d9499233_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="nktr-20200331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_82d97def-7ffe-47b9-a97d-434ecb5cebe9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9b074762-ecbc-4fa9-811c-6b78bd5403e4_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c23e061d-26b2-492f-8662-76b8e69cebfa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8dbe73a2-d65f-4d11-b312-288391b52a61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c47dd7fb-0014-4949-a213-0d10b2ae54fb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, accumulated gross unrealized gain, before tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e632fdb6-6069-4b31-a551-688b4161f2b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a32385ef-3a4f-408d-a86d-7201aee030b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6abd47e8-2670-4f28-a4e4-c609518ee903_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_4c8c7857-2164-4acb-a23d-e69fc7711e5e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_c7840625-65c0-4eb1-a416-f885984ae552_terseLabel_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Investments In Marketable Securities [Line Items]</link:label>
    <link:label id="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:href="nktr-20200331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:to="lab_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_bd0c54c6-3a98-4fce-84c1-3e32e33a55f6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_da6e1fea-aec6-4ace-866e-4e6f098d1104_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_85d4871a-b5bb-4208-b964-cde0b3bbc6f2_negatedLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_6fe35640-262b-49a5-bde0-f549e1955a91_terseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_2439f384-0dae-4382-b144-55f07984a271_negatedTerseLabel_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_label_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Royalties</link:label>
    <link:label id="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_documentation_en-US" xlink:label="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to sale of royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:href="nktr-20200331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:to="lab_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ae19dda6-5959-4d61-afa5-f15d1b76c396_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_7c2bbdfb-2998-4974-b4ad-0ccb9d7fdd63_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future additional payments for development milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones" xlink:href="nktr-20200331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentMilestones" xlink:to="lab_nktr_PotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_fbc64595-e1cf-49a4-afe2-ae90d7b334a5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b5983159-a21c-45cd-b226-937fd0fb1ac4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_9fe98dac-323b-48a0-900b-0d0096de9658_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_b091f15f-9e26-48b5-b2ce-b709dab614a4_terseLabel_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 Clinical Development</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_label_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase One Clinical Development [Member]</link:label>
    <link:label id="lab_nktr_PhaseOneClinicalDevelopmentMember_documentation_en-US" xlink:label="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 1 clinical development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember" xlink:href="nktr-20200331.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PhaseOneClinicalDevelopmentMember" xlink:to="lab_nktr_PhaseOneClinicalDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6f0413b1-270a-4a31-b1bc-cf87460f5cf5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value, RSUs (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4aa13d85-53d4-46f4-88e7-0473699e4936_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_ddfb963a-b61b-48d7-9adf-d6c722726166_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties, net</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties non current net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2aa8b83c-c8da-4b97-8c36-1e8253c4c164_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2fc2856d-7f3f-4d1e-832b-b12bec28463f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_516df6d7-d24b-450e-a849-e13d6491a160_verboseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received From License Agreements</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received from license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:href="nktr-20200331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_8b418208-4a15-460a-a0ea-ac0c515323af_terseLabel_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_label_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb Company [Member]</link:label>
    <link:label id="lab_nktr_BristolMyersSquibbCompanyMember_documentation_en-US" xlink:label="lab_nktr_BristolMyersSquibbCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol-Myers Squibb Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember" xlink:href="nktr-20200331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BristolMyersSquibbCompanyMember" xlink:to="lab_nktr_BristolMyersSquibbCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6564a309-2ae3-42fa-bb79-d25b570c6ec1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_bdbc7884-0da2-4e6f-9ccd-9bcc70b2cb52_terseLabel_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future development, regulatory and sales milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_label_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Development Regulatory And Sales Milestones</link:label>
    <link:label id="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_documentation_en-US" xlink:label="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development regulatory and sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:href="nktr-20200331.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:to="lab_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_6098d375-e87f-4f76-ae01-ee57b0aec634_terseLabel_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MOVANTIK and MOVENTIG</link:label>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_label_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">M O V A N T I K And M O V E N T I G [Member]</link:label>
    <link:label id="lab_nktr_MOVANTIKAndMOVENTIGMember_documentation_en-US" xlink:label="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MOVANTIK and MOVENTIG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember" xlink:href="nktr-20200331.xsd#nktr_MOVANTIKAndMOVENTIGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MOVANTIKAndMOVENTIGMember" xlink:to="lab_nktr_MOVANTIKAndMOVENTIGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_c9697951-4fe8-4e5e-b556-7954da8b3f0a_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing development costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_label_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Sharing In Development Costs</link:label>
    <link:label id="lab_nktr_PercentageOfSharingInDevelopmentCosts_documentation_en-US" xlink:label="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sharing in development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:href="nktr-20200331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfSharingInDevelopmentCosts" xlink:to="lab_nktr_PercentageOfSharingInDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborationPartnerMember_3307d15c-28b7-4317-bb8b-fd16996b2409_terseLabel_en-US" xlink:label="lab_nktr_CollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Partner</link:label>
    <link:label id="lab_nktr_CollaborationPartnerMember_label_en-US" xlink:label="lab_nktr_CollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Partner [Member]</link:label>
    <link:label id="lab_nktr_CollaborationPartnerMember_documentation_en-US" xlink:label="lab_nktr_CollaborationPartnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborationPartnerMember" xlink:href="nktr-20200331.xsd#nktr_CollaborationPartnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborationPartnerMember" xlink:to="lab_nktr_CollaborationPartnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_68a62065-7713-427f-84cf-ef21515b8f8c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_abaaacf9-e305-49cf-8bcd-fb3b89594549_terseLabel_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_nktr_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_nktr_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember" xlink:href="nktr-20200331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SharePurchaseAgreementMember" xlink:to="lab_nktr_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_71fd2120-2692-4d8e-823f-33afbe7447d0_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsTable_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:href="nktr-20200331.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NeulastaMember_c3558474-8218-4e1f-832f-107146a0b053_terseLabel_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta</link:label>
    <link:label id="lab_nktr_NeulastaMember_label_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta [Member]</link:label>
    <link:label id="lab_nktr_NeulastaMember_documentation_en-US" xlink:label="lab_nktr_NeulastaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neulasta.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember" xlink:href="nktr-20200331.xsd#nktr_NeulastaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NeulastaMember" xlink:to="lab_nktr_NeulastaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0808c868-aeb5-4547-a61f-b004b2b019b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_fd75c8e8-fce1-40d9-b569-75504c7f904e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_4f72e025-d545-446c-ae76-32f6d58debd2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a08553a9-181a-4ce0-8aaa-5f3d54b1b8c8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_efdb5b1d-8076-43de-a4c8-2aeb65c9ddcc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2897d1e0-4099-4f5b-ae45-e125eb5fcb80_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_f3915ae5-6d6c-4608-95ef-6a45adfe4b9d_terseLabel_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received under right to sublicense agreement</link:label>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_label_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Received Under Rights To Sublicense Agreement</link:label>
    <link:label id="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_documentation_en-US" xlink:label="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received under rights to sublicense agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:href="nktr-20200331.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:to="lab_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_6d652810-66ba-4344-b76f-197fe878d50f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9a0af264-f6bb-424d-a503-2ec326dde0e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_cff574d2-87a4-43c2-9d82-f5987d5930af_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a6cdd811-5dd6-4d2d-afa5-7eb8e3e8d0d1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_57a1c66d-86d2-4ba3-8caf-b7295889ce7f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneTwoMember_c584b825-7429-4d44-ae0d-2e12e484c09b_terseLabel_en-US" xlink:label="lab_nktr_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_nktr_MilestoneTwoMember_label_en-US" xlink:label="lab_nktr_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_nktr_MilestoneTwoMember_documentation_en-US" xlink:label="lab_nktr_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneTwoMember" xlink:href="nktr-20200331.xsd#nktr_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneTwoMember" xlink:to="lab_nktr_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_5d10fe29-277e-4368-bcd9-3a97bea3f02d_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Potential Future Royalties [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of potential future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:to="lab_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_WriteOffOfPrepayment_2f26d873-acce-4e5a-835d-820c0f3c9d28_terseLabel_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of prepayment</link:label>
    <link:label id="lab_nktr_WriteOffOfPrepayment_label_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Prepayment</link:label>
    <link:label id="lab_nktr_WriteOffOfPrepayment_documentation_en-US" xlink:label="lab_nktr_WriteOffOfPrepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Prepayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment" xlink:href="nktr-20200331.xsd#nktr_WriteOffOfPrepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_WriteOffOfPrepayment" xlink:to="lab_nktr_WriteOffOfPrepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_ea2d8920-caae-43f2-9d48-e548f98e0e83_terseLabel_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_label_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Policy [Text Block]</link:label>
    <link:label id="lab_nktr_OrganizationPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_OrganizationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock" xlink:href="nktr-20200331.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationPolicyTextBlock" xlink:to="lab_nktr_OrganizationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_955c4bf3-7405-4c69-aaf1-dfbcf3bcb9c0_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_82b93803-ff4e-4aa3-aed4-cc7d36638db3_terseLabel_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and Sale Agreement with RPI</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_label_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase And Sale Agreement [Member]</link:label>
    <link:label id="lab_nktr_PurchaseAndSaleAgreementMember_documentation_en-US" xlink:label="lab_nktr_PurchaseAndSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase and sale agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember" xlink:href="nktr-20200331.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PurchaseAndSaleAgreementMember" xlink:to="lab_nktr_PurchaseAndSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8e670d3c-bc68-4580-98c3-220c60b14b93_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cf99b0cb-821f-4547-a767-6237ab9c8cf4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3bf026bd-87db-4056-b4ff-c7ea587f15d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ce370241-16c6-4e8f-879b-ec6e6730030f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AstraZenecaAbMember_ecd04efe-ec6f-4343-af3c-c1a48a482868_terseLabel_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca AB</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_label_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Ab [Member]</link:label>
    <link:label id="lab_nktr_AstraZenecaAbMember_documentation_en-US" xlink:label="lab_nktr_AstraZenecaAbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca AB.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember" xlink:href="nktr-20200331.xsd#nktr_AstraZenecaAbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AstraZenecaAbMember" xlink:to="lab_nktr_AstraZenecaAbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_afb4809e-44c8-4ca8-af7d-5e10d1093bcc_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_c7bdad1c-86cb-4018-bf67-e1bcdddc8d99_terseLabel_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_label_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock Consideration Received</link:label>
    <link:label id="lab_nktr_SaleOfStockConsiderationReceived_documentation_en-US" xlink:label="lab_nktr_SaleOfStockConsiderationReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived" xlink:href="nktr-20200331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SaleOfStockConsiderationReceived" xlink:to="lab_nktr_SaleOfStockConsiderationReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3e545a99-aa80-458c-9c05-d2de3044255b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_b64cb6b8-3d15-4b35-9153-964902b49a19_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ae6cb8c0-8559-4139-9ed5-f2e80d0c7cfa_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset recognized in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_ca9e9bd4-4091-4ae5-93dc-8060746a0fdc_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_53bfbb6f-6182-485b-8d59-231a8241a6f0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_03241f9f-f1b2-4286-bd34-7230f8989602_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_48dd1f22-9eeb-442a-965a-193b45a5c301_terseLabel_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Received upfront and milestone payment</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_label_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Received Under License Agreement</link:label>
    <link:label id="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments received under license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:href="nktr-20200331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:to="lab_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PreferredStockShareDesignated_d5d6a477-52d1-4583-a9bb-d9d560ecec5a_terseLabel_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated (in shares)</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_label_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Share Designated</link:label>
    <link:label id="lab_nktr_PreferredStockShareDesignated_documentation_en-US" xlink:label="lab_nktr_PreferredStockShareDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated" xlink:href="nktr-20200331.xsd#nktr_PreferredStockShareDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PreferredStockShareDesignated" xlink:to="lab_nktr_PreferredStockShareDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_bf3aaf5c-d33f-4b14-afef-8648e86594b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_44a4afa9-21d9-45b1-9505-3ad958aaec5c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_09a24a5e-f592-4114-8145-dae453e42871_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_5c1ea9b4-6828-4dd3-bf9d-fb19e84a8e8f_terseLabel_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_label_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses Current</link:label>
    <link:label id="lab_nktr_AccruedClinicalTrialExpensesCurrent_documentation_en-US" xlink:label="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:href="nktr-20200331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AccruedClinicalTrialExpensesCurrent" xlink:to="lab_nktr_AccruedClinicalTrialExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_13297a20-b1cc-4497-bdfe-9fc4557a814e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_029e3f34-bb17-4f8e-b4ab-637a08643a75_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8405cadb-1efa-44fd-9d7f-a1867c213e29_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_eaba9d99-0a45-45ae-8eda-1141de8bb665_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_1335fb63-b056-4db8-bc36-89be783099ec_terseLabel_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca-Kirin</link:label>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_label_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astra Zeneca Agreement With Kirin [Member]</link:label>
    <link:label id="lab_nktr_AstraZenecaAgreementWithKirinMember_documentation_en-US" xlink:label="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca agreement with Kirin.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember" xlink:href="nktr-20200331.xsd#nktr_AstraZenecaAgreementWithKirinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AstraZenecaAgreementWithKirinMember" xlink:to="lab_nktr_AstraZenecaAgreementWithKirinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_4c4aed99-2114-4d5f-82f2-eaa3f47abee6_terseLabel_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount allocated to transaction price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_label_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Amount Allocated To Transaction Price</link:label>
    <link:label id="lab_nktr_RemainingAmountAllocatedToTransactionPrice_documentation_en-US" xlink:label="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amount allocated to transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:href="nktr-20200331.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:to="lab_nktr_RemainingAmountAllocatedToTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d70289c5-75f9-413b-98ea-8ee3d4cba8ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portfolio of Cash and Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_884ffde6-35c7-4cae-b14b-dbb452c381c1_terseLabel_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average maturity term for debt securities investment (or less)</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_label_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Investment Maturity Term</link:label>
    <link:label id="lab_nktr_DebtInvestmentMaturityTerm_documentation_en-US" xlink:label="lab_nktr_DebtInvestmentMaturityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt investment maturity date description.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm" xlink:href="nktr-20200331.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DebtInvestmentMaturityTerm" xlink:to="lab_nktr_DebtInvestmentMaturityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2cffd152-478b-4d3b-8b68-c28e3f46a024_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_673eaef5-6865-4963-8bfc-72894567f4ee_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_56d17cce-ec97-4eea-9710-98a70b9bf051_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_2258d641-3c68-4d17-ab34-89ab5222895f_terseLabel_en-US" xlink:label="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_label_en-US" xlink:label="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities And Stockholders Equity Deficit [Abstract]</link:label>
    <link:label id="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_documentation_en-US" xlink:label="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stock holders equity (deficit) abstract..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:href="nktr-20200331.xsd#nktr_LiabilitiesAndStockholdersEquityDeficitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:to="lab_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2534ed0-494d-4f52-82e6-9b277e36cd51_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3eea5d13-3dde-447a-bdf6-871c3513ab96_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NKTR181Member_a5ba5403-84e4-4ddc-80c9-b6fd17233e9f_terseLabel_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181</link:label>
    <link:label id="lab_nktr_NKTR181Member_label_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:label id="lab_nktr_NKTR181Member_documentation_en-US" xlink:label="lab_nktr_NKTR181Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR - 181 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member" xlink:href="nktr-20200331.xsd#nktr_NKTR181Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NKTR181Member" xlink:to="lab_nktr_NKTR181Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ffb3a50d-76e6-404c-b1e6-8ee56e74f613_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_4559ecad-7e66-44ab-a63a-aee3b452f606_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a4e94775-d5b8-4dd1-b9fa-2ea46826c755_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ab7902ea-eb1b-46a9-ba4b-6828e31a118c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cd9928d2-6d9d-4d2d-94ca-4b0a5b9f1b0f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable for expense reimbursements from collaboration partner</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b62f3cca-cabf-48bd-b606-23d498c33f4b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9a9db1c8-6086-4630-b7dd-825de96fa91a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneAxis_1dfdf1af-d6ef-4d09-87c1-05776a95c439_terseLabel_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_label_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_nktr_MilestoneAxis_documentation_en-US" xlink:label="lab_nktr_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis" xlink:href="nktr-20200331.xsd#nktr_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneAxis" xlink:to="lab_nktr_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9369ff6a-9d60-4c1b-a97c-a40bbcf0a660_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_ab2fe0da-3224-4aae-9984-614df608a1a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_1923f9b8-74ee-46e3-9b79-deae74863d38_terseLabel_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Development</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_label_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Product Development [Member]</link:label>
    <link:label id="lab_nktr_DrugProductDevelopmentMember_documentation_en-US" xlink:label="lab_nktr_DrugProductDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug product development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember" xlink:href="nktr-20200331.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_DrugProductDevelopmentMember" xlink:to="lab_nktr_DrugProductDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_27b2b566-5974-48ef-b316-5f87c363005e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc5d49ac-5615-4f60-bd47-622b8d63b828_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c9c28987-a6da-4af5-913c-becfaee70677_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_dd9add03-041d-45b2-be4a-91ce9e35acf6_negatedLabel_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, net</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_label_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:label id="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:href="nktr-20200331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:to="lab_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_d3d1f351-e8ac-4099-8cc3-2b77c9f08c2b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, less current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_06b43227-46c5-4411-a7a5-1d5c3463cb24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22f3df45-2e4c-4a4f-ac9b-b5a4eac2638c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_bf247f27-d644-4105-bea3-940a6c7bbbaa_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_b9be4f75-72ea-4650-b51d-d7741d4f6c20_terseLabel_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual interest rate</link:label>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_label_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Annual Interest Rate Over Life Of Royalty Liability</link:label>
    <link:label id="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_documentation_en-US" xlink:label="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual interest rate over life of royalty liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:href="nktr-20200331.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:to="lab_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8d725c69-84f7-4f10-bc3e-152224690142_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_69865fac-a61c-451f-8101-f99355dd3af4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ca80db31-cef3-428a-8207-e42087fee363_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7cf4281f-4515-4252-b31a-1eb56d2ee7e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a06a3d16-f9c3-4303-9608-14b7502b1ee5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_8f95cc2e-d4fa-461d-85ff-4a3aab16534d_terseLabel_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_label_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones</link:label>
    <link:label id="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_documentation_en-US" xlink:label="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:href="nktr-20200331.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:to="lab_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c1476c9f-8c70-439d-b16a-560efccd4805_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_be8c2a40-004b-4062-be90-b59fa9c0417e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5f2c425d-de74-452d-9e7a-48d92e118c5a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_HemophiliaMember_a911553f-14ba-443f-84b8-e393bf30f3b9_terseLabel_en-US" xlink:label="lab_nktr_HemophiliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia</link:label>
    <link:label id="lab_nktr_HemophiliaMember_label_en-US" xlink:label="lab_nktr_HemophiliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia [Member]</link:label>
    <link:label id="lab_nktr_HemophiliaMember_documentation_en-US" xlink:label="lab_nktr_HemophiliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hemophilia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaMember" xlink:href="nktr-20200331.xsd#nktr_HemophiliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_HemophiliaMember" xlink:to="lab_nktr_HemophiliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4fcca8c7-5a09-4106-a320-7c9167ae3524_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e5aca229-2b0a-4e6f-84d3-5d5318d3257e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_bac9f8e7-a335-4b0c-bf43-17ea6e434376_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_62ac1ddb-7208-4a17-a1eb-94ea2935d9f7_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Notes and Bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_783fbea3-6a8c-4b11-95ef-f05bcec57844_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_df71ceca-613a-406e-aa56-abe1d79864ae_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5e0cd789-ed19-4d19-b8ba-fc704b61f541_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_cc535729-4de9-4cc1-8c7a-4e94970bdc34_terseLabel_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of royalty rights</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_label_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Potential Future Royalties Gross</link:label>
    <link:label id="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_documentation_en-US" xlink:label="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of potential future royalties gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:href="nktr-20200331.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:to="lab_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_0133fd7b-4dae-40c7-87d7-9a46af6ebc66_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_87428a91-ba8e-42e5-9049-7c5a1205d61e_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_32225202-4038-4a0e-8c97-c40f387a8cb0_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestones, royalties and sales milestones</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_label_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_documentation_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:href="nktr-20200331.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:to="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e66c0a3e-4a24-44c1-8188-df7d27924b53_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1b0381c4-6f81-40c5-b6ec-f41fd615daac_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2b1d1c55-502c-4f1b-8199-9d8349967d53_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_241180f3-3155-46be-b227-9affde60419a_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of advance payments to contract manufacturers and equipment for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_label_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment From Terminated Program</link:label>
    <link:label id="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram_documentation_en-US" xlink:label="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Equipment From Terminated Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:href="nktr-20200331.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:to="lab_nktr_ImpairmentOfEquipmentFromTerminatedProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_773696da-de9d-4ed4-b1cd-40e64f786308_terseLabel_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price allocated to performance obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_label_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Transaction Price Allocated To Performance Obligation</link:label>
    <link:label id="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_documentation_en-US" xlink:label="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price allocated to performance obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:href="nktr-20200331.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:to="lab_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_bd99d9ea-5e7a-41ec-820e-ef7ebef524ca_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6fb26fc7-14c4-4f4c-b8ba-05542f1d69ea_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a326f55f-bb1e-46be-b6c4-2ac1ad578628_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_fb645af7-2005-4dea-b813-74bff4865ee5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_3c55222a-fd25-44f4-aa2d-be7360562cf2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_68f87617-0a79-4b2a-9c10-644289f96d3b_terseLabel_en-US" xlink:label="lab_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and Restricted Stock Units</link:label>
    <link:label id="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_nktr_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:href="nktr-20200331.xsd#nktr_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_nktr_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_71b9c8d8-8e94-40dd-8089-9d32d0af2f0b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8c58579f-3e44-423a-9ced-78beae1fa58b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_88995c7e-2824-4bf3-b402-9e0b500fb968_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarTwoOneFourMember_2b789f21-843d-4fea-a97c-7354b5f35b6d_terseLabel_en-US" xlink:label="lab_nktr_NektarTwoOneFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bempegaldesleukin</link:label>
    <link:label id="lab_nktr_NektarTwoOneFourMember_label_en-US" xlink:label="lab_nktr_NektarTwoOneFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar Two One Four [Member]</link:label>
    <link:label id="lab_nktr_NektarTwoOneFourMember_documentation_en-US" xlink:label="lab_nktr_NektarTwoOneFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar two one four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarTwoOneFourMember" xlink:href="nktr-20200331.xsd#nktr_NektarTwoOneFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarTwoOneFourMember" xlink:to="lab_nktr_NektarTwoOneFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_82430b37-2f32-4d89-a838-ecc6eddda405_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5f4f37af-df3d-4efb-bd9a-4488771af9e8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Deferred Revenue Balance from Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79a0919a-d0eb-4e14-8aae-c18e08237242_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value, options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_784efd5c-464c-4d2e-b1a3-8b98cf290c3c_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_17dc668e-3b4a-4fdb-befa-9ecf7fc31a56_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_92a42898-14e6-41f8-84ee-529cf4333dfe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_b34fd20c-186e-48c0-95fb-86cb13880a7b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_08af68d0-0879-4ffe-93ec-a6d8bf8b929f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1248b643-ed34-4d01-9bc3-b2a4f9a3ccce_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d73d7aad-2f1d-4d2c-803c-5761710661e7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9d31b0c3-5088-4d7d-90ee-63813e8e7e2a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a59ab00a-2862-4fa1-8eae-632a4b960a3f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_e8095c3e-860e-4c2f-b119-f751b4f28d22_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Table]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_f35bddad-7353-4956-afe1-14e101bbab4c_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_label_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments From Sublicense Agreement Retained By Our Collaboration Partner</link:label>
    <link:label id="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_documentation_en-US" xlink:label="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:href="nktr-20200331.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:to="lab_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_58cde670-2d7d-460b-be27-40f14118d140_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c081383b-9845-451a-a11e-301074d54985_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_ec9e17f2-2bad-46f4-96e4-d46d60e2de95_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_060ddbbd-3373-430c-9aaa-cea69d94c14a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_35e6459a-d541-4805-b6ec-23faef9e2122_terseLabel_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_label_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value Of Shares</link:label>
    <link:label id="lab_nktr_EstimatedFairValueOfShares_documentation_en-US" xlink:label="lab_nktr_EstimatedFairValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares" xlink:href="nktr-20200331.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EstimatedFairValueOfShares" xlink:to="lab_nktr_EstimatedFairValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_48f3b1b6-3a97-4869-8c51-a369b61645c8_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Line Items]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e5f6c3da-cbdf-42d8-bc98-837c9e664f66_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_327b30b4-4f90-4359-8165-7011b3d8a417_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2724f6bd-4430-4222-8ec7-e68a018cfa0e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_EliLillyMember_346f7170-efb1-43aa-b61d-b447ee2b723e_terseLabel_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_nktr_EliLillyMember_label_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_nktr_EliLillyMember_documentation_en-US" xlink:label="lab_nktr_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember" xlink:href="nktr-20200331.xsd#nktr_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_EliLillyMember" xlink:to="lab_nktr_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_59ddc87f-9119-4055-a6d3-2f92f6708100_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_376721a9-bf8c-4e3a-ac5c-1fd189866b89_terseLabel_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="nktr-20200331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67b5ce2f-104d-4027-afe8-46364f41cc20_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_99a4f952-42aa-4583-b233-bf358679dcd1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4292e165-824d-44ab-88d7-99e22efaf976_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_440cd8cc-3d93-4bcb-934f-856ee0fa8519_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_728429d5-a3f2-4431-a3e4-70a7fcbd592a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under equity compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_8e06058f-3177-4254-9e07-feacc99e8a3b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_OpdivoAndYervoyMember_f2cce26e-086b-4365-ac3f-eab7df75efd1_terseLabel_en-US" xlink:label="lab_nktr_OpdivoAndYervoyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo and Yervoy</link:label>
    <link:label id="lab_nktr_OpdivoAndYervoyMember_label_en-US" xlink:label="lab_nktr_OpdivoAndYervoyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo And Yervoy [Member]</link:label>
    <link:label id="lab_nktr_OpdivoAndYervoyMember_documentation_en-US" xlink:label="lab_nktr_OpdivoAndYervoyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opdivo and yervoy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoAndYervoyMember" xlink:href="nktr-20200331.xsd#nktr_OpdivoAndYervoyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_OpdivoAndYervoyMember" xlink:to="lab_nktr_OpdivoAndYervoyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_05f91ea3-ded9-419e-a65e-b3c497de913a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_297607b7-d4f1-4ea0-a64b-36a818053cb4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_e826f0fb-aac5-442c-a98f-fb5da3eb6f6f_terseLabel_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR-358</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_label_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar Three Five Eight [Member]</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightMember_documentation_en-US" xlink:label="lab_nktr_NektarThreeFiveEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar three five eight.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember" xlink:href="nktr-20200331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarThreeFiveEightMember" xlink:to="lab_nktr_NektarThreeFiveEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest_473ea977-3fdd-4dbe-b815-3b52f2b39fab_terseLabel_en-US" xlink:label="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long term debt, including interest</link:label>
    <link:label id="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest_label_en-US" xlink:label="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long Term Debt, Including Interest</link:label>
    <link:label id="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest_documentation_en-US" xlink:label="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Long Term Debt, Including Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:href="nktr-20200331.xsd#nktr_RepaymentsOfLongTermDebtIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:to="lab_nktr_RepaymentsOfLongTermDebtIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a7ecef7b-d14f-480c-bef3-59b2cccbbf8a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_cddfa198-ddc8-436c-abac-325f48613c1d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ad2f212a-c255-43c4-8aa4-199b47bc244d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, sold</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_f0f0b3f7-e9e5-4a4e-8b77-cbd4379517a7_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of regulatory milestones payments will be reduced if conditions occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_label_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Milestones Payments To Be Received If Conditions Occur</link:label>
    <link:label id="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_documentation_en-US" xlink:label="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development milestones payments, to be received, if conditions occur.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:href="nktr-20200331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:to="lab_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4f9ef31c-4a61-4971-a4d6-dde4f4c38b2f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_451167d4-0d0e-4d19-81c8-f3e8efe7539a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c1116a0-0707-422b-a577-cf5109225fb3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_cf969ffa-4cda-4c39-93ff-c67afe4a8fca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes, interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_2197487f-1550-47c3-9300-1bfdb9dbce76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, Collaboration and Other Revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneOneMember_b5e18fe9-ab2d-4919-b1a0-efd99e7b9636_terseLabel_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_label_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_nktr_MilestoneOneMember_documentation_en-US" xlink:label="lab_nktr_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember" xlink:href="nktr-20200331.xsd#nktr_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneOneMember" xlink:to="lab_nktr_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1fe7181d-7bb4-415b-bc45-c10ba0eedc7b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6e140cf3-0660-4e6f-877b-88af98633ce3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_36f1a687-bab5-4c93-89d3-976a35715f40_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding used in computing basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b871d324-72b3-4459-8d8b-b86056148bc9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a967cc92-385a-4456-9abb-8fb87673c45f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8154632d-57ad-43b2-8d25-fd3cc2f4acd6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_b7ab9609-0105-47ff-99a5-f544415bf703_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_80601743-a188-4d67-9fcc-331bf087c096_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1fd97476-b9b8-48ce-a655-09e8988f3d7f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c9444593-a814-4eeb-aace-d464018308a2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_6e635e26-9d48-47bc-ac41-1aea7ad6ee96_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Abstract]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:href="nktr-20200331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_a8b1611f-048c-4a95-9ea1-54a3047b1358_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_91f3b9b3-6ac0-44ab-bbc1-2ebebc55aa6c_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment, remaining minimum amount committed</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ImpairmentAndOtherMember_894156fa-cc9d-4053-8daf-c4f88e5ac7c4_terseLabel_en-US" xlink:label="lab_nktr_ImpairmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of assets and other costs for terminated program</link:label>
    <link:label id="lab_nktr_ImpairmentAndOtherMember_label_en-US" xlink:label="lab_nktr_ImpairmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment And Other [Member]</link:label>
    <link:label id="lab_nktr_ImpairmentAndOtherMember_documentation_en-US" xlink:label="lab_nktr_ImpairmentAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentAndOtherMember" xlink:href="nktr-20200331.xsd#nktr_ImpairmentAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ImpairmentAndOtherMember" xlink:to="lab_nktr_ImpairmentAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_13057e21-f3a6-4bf2-adf0-590d15e9db46_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_2fce01d3-aaff-4f70-9513-2cee152c28b6_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b381d64b-d42e-4954-9869-245155736faa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ReimbursementOfExpenses_fc790efe-620d-4e25-9db9-8e1468d026e6_terseLabel_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_label_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement Of Expenses</link:label>
    <link:label id="lab_nktr_ReimbursementOfExpenses_documentation_en-US" xlink:label="lab_nktr_ReimbursementOfExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement of expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses" xlink:href="nktr-20200331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ReimbursementOfExpenses" xlink:to="lab_nktr_ReimbursementOfExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c805f42d-64ff-43a8-80c6-ca7a5b09d95e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7ec5261f-d891-4ad9-8eb5-43ef454d093e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_aff1f940-0b82-4c4c-9064-0e8af2afa53a_terseLabel_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_label_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Line Items]</link:label>
    <link:label id="lab_nktr_LicenseAndCollaborationAgreementsLineItems_documentation_en-US" xlink:label="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:href="nktr-20200331.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:to="lab_nktr_LicenseAndCollaborationAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fb3d4e84-de9a-4015-b49b-b27bac78d000_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_SalesMilestoneRevenue_3f44a41f-e3a1-4c8c-85f2-a39c83511386_terseLabel_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_label_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Revenue</link:label>
    <link:label id="lab_nktr_SalesMilestoneRevenue_documentation_en-US" xlink:label="lab_nktr_SalesMilestoneRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue" xlink:href="nktr-20200331.xsd#nktr_SalesMilestoneRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_SalesMilestoneRevenue" xlink:to="lab_nktr_SalesMilestoneRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d6831560-aa0a-4acc-a2f1-93252775524e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_465b44a8-1e9a-409b-80db-0fc2b06c9d8f_terseLabel_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_label_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]</link:label>
    <link:label id="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_documentation_en-US" xlink:label="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:href="nktr-20200331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:to="lab_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_3fd13a16-9d76-4507-9a84-d1a980d4d902_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Investments in Marketable Securities, Including Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_c77c9fdb-43c7-415a-ae9a-ea303554d1cf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_676c6bf9-ad97-41ec-8658-a7bb6bec6797_terseLabel_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License, collaboration and other revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_label_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Collaboration Other Revenue</link:label>
    <link:label id="lab_nktr_LicenseCollaborationOtherRevenue_documentation_en-US" xlink:label="lab_nktr_LicenseCollaborationOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue" xlink:href="nktr-20200331.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LicenseCollaborationOtherRevenue" xlink:to="lab_nktr_LicenseCollaborationOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_104ff666-8f68-4b7a-981a-82dd7e97aa35_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EuropeanUnionMember_afc93ae6-b509-45f2-ac1d-4aeaf0a8e4e3_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember" xlink:to="lab_us-gaap_EuropeanUnionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a3b9810c-42e2-4b8c-af23-530f593a8412_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a3e176c-0773-4371-8318-c22c217e9205_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_5f8eb2bf-f0ed-4c70-a9cf-b5aea6065544_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3517f5d5-1619-4d31-b1fd-361cce45a597_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_24c318da-5804-4238-9c63-da2c767a75ce_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_709779f9-dc3d-49b7-b77a-f58da56473ea_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_c1f93644-8fab-4820-9e9e-53350081913e_terseLabel_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Obligation</link:label>
    <link:label id="lab_us-gaap_IndemnificationGuaranteeMember_label_en-US" xlink:label="lab_us-gaap_IndemnificationGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndemnificationGuaranteeMember" xlink:to="lab_us-gaap_IndemnificationGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_07ee0085-0c1e-42c3-a15f-9526d1aefe3c_terseLabel_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective interest rate</link:label>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_label_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective Interest Rate Percentage</link:label>
    <link:label id="lab_nktr_ProspectiveInterestRatePercentage_documentation_en-US" xlink:label="lab_nktr_ProspectiveInterestRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospective interest rate percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage" xlink:href="nktr-20200331.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_ProspectiveInterestRatePercentage" xlink:to="lab_nktr_ProspectiveInterestRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0aaee246-fced-49d7-97c9-037bec2f0a3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_22bc4b51-1ed5-4459-9cb4-c7f3e26bb766_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_95f9613f-baa1-4738-83b6-1cf74814877f_terseLabel_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance payments to contract manufacturers</link:label>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_label_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Payments To Contract Manufacturers</link:label>
    <link:label id="lab_nktr_AdvancePaymentsToContractManufacturers_documentation_en-US" xlink:label="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of advance payments to contract manufacturers, net of amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers" xlink:href="nktr-20200331.xsd#nktr_AdvancePaymentsToContractManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_AdvancePaymentsToContractManufacturers" xlink:to="lab_nktr_AdvancePaymentsToContractManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_9d4edba3-a751-4d42-94d4-9c74daa9cc94_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation matters, liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_90fe3185-92d1-4254-8f41-6779cc89341d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_00fa8fd9-c079-48ea-818a-117593781ffc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2020 or December 31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4a98b748-96eb-4ffd-86fe-8cba354b563f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1ad9b90d-6965-46d6-85d5-d5987cfbcd25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_684bd52b-230c-44c1-b733-335d1a0e4285_terseLabel_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding phase 3 development costs on an indication by indication basis borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_label_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne</link:label>
    <link:label id="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_documentation_en-US" xlink:label="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of funding Phase three development costs on an indication by indication basis borne.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:href="nktr-20200331.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:to="lab_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_5c5bee00-719e-449f-9077-db9d70433e07_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_426f78ba-e87f-4f45-ae99-199f7fab4576_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_f8c6fb30-140a-4477-894e-484b76ac228a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_0d36fe8c-2060-445d-93b8-acd094e850da_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_704c6edc-f137-4bdb-a7f8-72b14664fee5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_21f6a339-a6fc-4a71-80a5-c65bf10c8a6b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_ea6ca5e0-e053-4f6a-b7d4-f7cb680ea2c4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs related to sale of potential future royalties</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2d013b9c-5f75-4985-8669-78992a534fd1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_94c89a50-5e68-4a63-b884-5950e293ba88_terseLabel_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_label_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties Policy [Text Block]</link:label>
    <link:label id="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_documentation_en-US" xlink:label="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:to="lab_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_79508e8c-53fe-41ec-a756-8bd59b80dbf5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_MilestoneThreeMember_ff41b7b1-b3af-4aab-b899-c49815619f52_terseLabel_en-US" xlink:label="lab_nktr_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_nktr_MilestoneThreeMember_label_en-US" xlink:label="lab_nktr_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_nktr_MilestoneThreeMember_documentation_en-US" xlink:label="lab_nktr_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneThreeMember" xlink:href="nktr-20200331.xsd#nktr_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_MilestoneThreeMember" xlink:to="lab_nktr_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotes_affbc56b-ff7f-42ae-9908-fcd6dbc3ec74_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_83fa966c-31d3-45ec-822e-746608d67862_verboseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured notes, principal amount</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_label_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_56728368-5e1f-4c67-a465-4e316f26fe85_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_165d423b-89cf-4545-a17f-0e749e21fe14_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6c126ee2-3393-41ef-8830-82f851e10992_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d2c4d83c-e1c8-43c6-ae45-ba04c2d88b46_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_96634e1b-b52c-4b8f-97d4-12bf48a3ce7d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_df48c913-0a19-48b8-8ace-8e7c1198102d_terseLabel_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated/Takeda</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_label_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated Or Takeda P L C [Member]</link:label>
    <link:label id="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember_documentation_en-US" xlink:label="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baxalta Incorporated or takeda PLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:href="nktr-20200331.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:to="lab_nktr_BaxaltaIncorporatedOrTakedaPLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_a24ca414-4596-4b82-9eb0-f78fb660ebe0_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_513dba5a-66e2-4a42-bc1b-6bcd44de5b46_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a2352035-1dff-4a6f-9713-64f2f2494d80_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_71a4f344-0b43-456d-842e-facf1c03bbec_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_3e5c3e36-ba23-4548-b4f4-e269f96cc8ea_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nktr_NektarThreeFiveEightLicenseMember_a866a638-5866-43aa-afa5-3143c848ed93_terseLabel_en-US" xlink:label="lab_nktr_NektarThreeFiveEightLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NKTR-358 License</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightLicenseMember_label_en-US" xlink:label="lab_nktr_NektarThreeFiveEightLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar Three Five Eight License [Member]</link:label>
    <link:label id="lab_nktr_NektarThreeFiveEightLicenseMember_documentation_en-US" xlink:label="lab_nktr_NektarThreeFiveEightLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nektar three five eight license.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightLicenseMember" xlink:href="nktr-20200331.xsd#nktr_NektarThreeFiveEightLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nktr_NektarThreeFiveEightLicenseMember" xlink:to="lab_nktr_NektarThreeFiveEightLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a7610024-ad6b-4a74-99e4-960d83b19218_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_35dbe8d9-dbd2-4d22-b70b-08c534f5a780_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_ac9f9aff-fa45-4081-82af-cc233b6a3eba_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7cb1030e-ec9f-4619-a93c-b5d09511cb3e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_88b2ac4d-954b-49cd-9612-a014f47d41f3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_d307fb7b-9b14-495d-b1b3-1fb8c9d60c19_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>nktr-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:0794ac43-98cf-4d2f-9c7f-9f499c0d4858,g:07e3bb7c-ce78-4710-acc8-c80ed5139092-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.nektar.com/role/CoverPage" xlink:type="simple" xlink:href="nktr-20200331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8daa20bd-a5d3-406f-9da8-8b362561e359" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_DocumentType_8daa20bd-a5d3-406f-9da8-8b362561e359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_681fbe97-2140-4f22-8eb2-920121d1b400" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_DocumentQuarterlyReport_681fbe97-2140-4f22-8eb2-920121d1b400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4cbfc042-7321-4920-aacc-7e7328ff8d2a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_DocumentPeriodEndDate_4cbfc042-7321-4920-aacc-7e7328ff8d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9a611542-3b60-4e45-90aa-65343e03bed2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_DocumentTransitionReport_9a611542-3b60-4e45-90aa-65343e03bed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5632a88d-5426-4896-b60d-c7d0e3bbb2b6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityFileNumber_5632a88d-5426-4896-b60d-c7d0e3bbb2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_31bac7c3-041d-4c03-a0df-ac0fb93b32d9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityRegistrantName_31bac7c3-041d-4c03-a0df-ac0fb93b32d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e866bf7f-231e-4597-9df9-69381362de97" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e866bf7f-231e-4597-9df9-69381362de97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a03fdd89-c1d2-495a-a23a-a7c6a865650d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityTaxIdentificationNumber_a03fdd89-c1d2-495a-a23a-a7c6a865650d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_58823413-3f2e-488c-a2c0-74d11b11d6b9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityAddressAddressLine1_58823413-3f2e-488c-a2c0-74d11b11d6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6345429d-1943-4c7e-a70a-d01d7ed63b88" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityAddressCityOrTown_6345429d-1943-4c7e-a70a-d01d7ed63b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_65d46be5-6215-449b-b2c5-e91743520482" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityAddressStateOrProvince_65d46be5-6215-449b-b2c5-e91743520482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7b409f39-b6fd-41d1-ac75-13fc266d3cc0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityAddressPostalZipCode_7b409f39-b6fd-41d1-ac75-13fc266d3cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c8879bce-4870-4732-8b14-4d94b441a18b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_CityAreaCode_c8879bce-4870-4732-8b14-4d94b441a18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c51293b7-8124-4db6-9f4f-934e54d6f77c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_LocalPhoneNumber_c51293b7-8124-4db6-9f4f-934e54d6f77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0799e2d1-3817-45ba-9f84-cda124017700" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_Security12bTitle_0799e2d1-3817-45ba-9f84-cda124017700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_05000140-73df-4863-b1f0-5032acc5ed9b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_TradingSymbol_05000140-73df-4863-b1f0-5032acc5ed9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_34332bdb-2d5d-4293-b002-46966b4d93ca" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_SecurityExchangeName_34332bdb-2d5d-4293-b002-46966b4d93ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_965609f3-3748-41cf-be04-c0f4658de00d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityCurrentReportingStatus_965609f3-3748-41cf-be04-c0f4658de00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b2c157c8-04eb-4ac3-9e19-1ecd86000eed" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityInteractiveDataCurrent_b2c157c8-04eb-4ac3-9e19-1ecd86000eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_359e8e89-6804-4182-835f-fb339586c553" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityFilerCategory_359e8e89-6804-4182-835f-fb339586c553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b7584c36-d4a6-442f-9842-ec7ccffade3d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntitySmallBusiness_b7584c36-d4a6-442f-9842-ec7ccffade3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_31bb667c-23da-4f08-ada3-c9ff160a40a7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityEmergingGrowthCompany_31bb667c-23da-4f08-ada3-c9ff160a40a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5b93fc7c-4844-44f9-a48d-25c9f4543b77" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityShellCompany_5b93fc7c-4844-44f9-a48d-25c9f4543b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_57332588-6003-47e3-905f-e7aa2782ece2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_57332588-6003-47e3-905f-e7aa2782ece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_295a4530-70b1-443f-94c1-7adcf2856cd7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_AmendmentFlag_295a4530-70b1-443f-94c1-7adcf2856cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ebec7d98-768f-40d1-916b-bc107280c7cc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_DocumentFiscalYearFocus_ebec7d98-768f-40d1-916b-bc107280c7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_de5adb5e-ae4b-4722-8a3b-9c20a34236f7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_de5adb5e-ae4b-4722-8a3b-9c20a34236f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_84070c68-b7f6-4388-9809-bdf5e642e7fe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_EntityCentralIndexKey_84070c68-b7f6-4388-9809-bdf5e642e7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_726ad21b-5ae8-4a43-a0be-30c3f9b66f70" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60783647-7c2e-4c62-a118-b50dfc458f0e" xlink:to="loc_dei_CurrentFiscalYearEndDate_726ad21b-5ae8-4a43-a0be-30c3f9b66f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_6179457a-3eb9-4e79-b725-9ae13e410ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_fafd4fcd-790f-422d-8e08-ffa4c836f153" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6179457a-3eb9-4e79-b725-9ae13e410ee6" xlink:to="loc_us-gaap_AssetsAbstract_fafd4fcd-790f-422d-8e08-ffa4c836f153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f6e31238-4eb5-4fd6-8346-81bdd8839e6c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fafd4fcd-790f-422d-8e08-ffa4c836f153" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f6e31238-4eb5-4fd6-8346-81bdd8839e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ff6fad8-d50a-4ccd-a922-e32947b6ee31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e31238-4eb5-4fd6-8346-81bdd8839e6c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9ff6fad8-d50a-4ccd-a922-e32947b6ee31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ba54cabf-a8dd-4f66-97de-6e7d1b401329" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e31238-4eb5-4fd6-8346-81bdd8839e6c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ba54cabf-a8dd-4f66-97de-6e7d1b401329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e0a5cb99-dbd3-4944-b2aa-66d96ca87159" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e31238-4eb5-4fd6-8346-81bdd8839e6c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e0a5cb99-dbd3-4944-b2aa-66d96ca87159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e9b90310-f122-4b31-b981-9c8802882cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e31238-4eb5-4fd6-8346-81bdd8839e6c" xlink:to="loc_us-gaap_InventoryNet_e9b90310-f122-4b31-b981-9c8802882cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AdvancePaymentsToContractManufacturers_e25e0326-9a70-460f-b2a4-fd6967392096" xlink:href="nktr-20200331.xsd#nktr_AdvancePaymentsToContractManufacturers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e31238-4eb5-4fd6-8346-81bdd8839e6c" xlink:to="loc_nktr_AdvancePaymentsToContractManufacturers_e25e0326-9a70-460f-b2a4-fd6967392096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e812d786-3e32-4c96-98a4-2ebc2ef20d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e31238-4eb5-4fd6-8346-81bdd8839e6c" xlink:to="loc_us-gaap_OtherAssetsCurrent_e812d786-3e32-4c96-98a4-2ebc2ef20d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_15b30318-329d-419e-a8f1-3967eb31e580" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e31238-4eb5-4fd6-8346-81bdd8839e6c" xlink:to="loc_us-gaap_AssetsCurrent_15b30318-329d-419e-a8f1-3967eb31e580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5b302e91-7bed-486c-b811-a8ab8aac00aa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fafd4fcd-790f-422d-8e08-ffa4c836f153" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5b302e91-7bed-486c-b811-a8ab8aac00aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3747ee2e-0a19-4318-9776-fa63b1f63e54" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fafd4fcd-790f-422d-8e08-ffa4c836f153" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3747ee2e-0a19-4318-9776-fa63b1f63e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_88c6b45c-4e51-4d17-89c3-03bbdbba4eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fafd4fcd-790f-422d-8e08-ffa4c836f153" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_88c6b45c-4e51-4d17-89c3-03bbdbba4eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_07da80ec-5e0f-4821-af69-2a5e8953a3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fafd4fcd-790f-422d-8e08-ffa4c836f153" xlink:to="loc_us-gaap_Goodwill_07da80ec-5e0f-4821-af69-2a5e8953a3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1dc33293-be06-4e49-a6df-3f34f336bc80" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_fafd4fcd-790f-422d-8e08-ffa4c836f153" xlink:to="loc_us-gaap_Assets_1dc33293-be06-4e49-a6df-3f34f336bc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_0e20ef5e-ed65-49e4-afee-20d0b94e90bf" xlink:href="nktr-20200331.xsd#nktr_LiabilitiesAndStockholdersEquityDeficitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_6179457a-3eb9-4e79-b725-9ae13e410ee6" xlink:to="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_0e20ef5e-ed65-49e4-afee-20d0b94e90bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_0e20ef5e-ed65-49e4-afee-20d0b94e90bf" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesCurrent_1cd94e46-b4fd-4030-a731-cb43e5631bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:to="loc_us-gaap_SeniorNotesCurrent_1cd94e46-b4fd-4030-a731-cb43e5631bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_846f53c9-dbc4-49c7-9988-8f907f5d3543" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:to="loc_us-gaap_AccountsPayableCurrent_846f53c9-dbc4-49c7-9988-8f907f5d3543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d865b56b-d2d8-47e5-9ebb-119df919d8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d865b56b-d2d8-47e5-9ebb-119df919d8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedClinicalTrialExpensesCurrent_e295b282-66bf-49ed-893b-f70f5f2337e0" xlink:href="nktr-20200331.xsd#nktr_AccruedClinicalTrialExpensesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:to="loc_nktr_AccruedClinicalTrialExpensesCurrent_e295b282-66bf-49ed-893b-f70f5f2337e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AccruedContractManufacturingExpenseCurrent_9c39bc4d-46e8-432b-bcb7-37662a2fa68d" xlink:href="nktr-20200331.xsd#nktr_AccruedContractManufacturingExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:to="loc_nktr_AccruedContractManufacturingExpenseCurrent_9c39bc4d-46e8-432b-bcb7-37662a2fa68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_20fefa2a-5b45-47cf-9d16-0c5bd1611b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_20fefa2a-5b45-47cf-9d16-0c5bd1611b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4ccbdbef-f01b-42ff-bd27-f3bd0ac3c90d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4ccbdbef-f01b-42ff-bd27-f3bd0ac3c90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f04af08b-ee74-46a9-93c4-9bf0c1ca9bae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f04af08b-ee74-46a9-93c4-9bf0c1ca9bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_155fa002-8d44-474a-9974-ff170aa42d82" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_155fa002-8d44-474a-9974-ff170aa42d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f037e4ad-35c0-47db-9d34-e13779888108" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_07b52f4d-bda5-4608-ae21-955fb2235ab4" xlink:to="loc_us-gaap_LiabilitiesCurrent_f037e4ad-35c0-47db-9d34-e13779888108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5c9529d0-9f95-4ff0-a045-f6ed393819c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_0e20ef5e-ed65-49e4-afee-20d0b94e90bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5c9529d0-9f95-4ff0-a045-f6ed393819c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_6dbb34ac-8630-4484-9a34-69aaa9db1951" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_0e20ef5e-ed65-49e4-afee-20d0b94e90bf" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts_6dbb34ac-8630-4484-9a34-69aaa9db1951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_67b82734-c58c-4966-a3fb-fb57d1953702" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_0e20ef5e-ed65-49e4-afee-20d0b94e90bf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_67b82734-c58c-4966-a3fb-fb57d1953702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a3ea274e-bac0-42eb-bf46-95cbb19de680" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_0e20ef5e-ed65-49e4-afee-20d0b94e90bf" xlink:to="loc_us-gaap_Liabilities_a3ea274e-bac0-42eb-bf46-95cbb19de680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_101e7211-276c-4358-a016-ff4ecee4db1c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_0e20ef5e-ed65-49e4-afee-20d0b94e90bf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_101e7211-276c-4358-a016-ff4ecee4db1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d7243dc9-567c-4412-ab80-4759233d19af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_0e20ef5e-ed65-49e4-afee-20d0b94e90bf" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d7243dc9-567c-4412-ab80-4759233d19af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3b86abad-e500-4c59-bbd4-fe0ecbe1e706" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d7243dc9-567c-4412-ab80-4759233d19af" xlink:to="loc_us-gaap_PreferredStockValue_3b86abad-e500-4c59-bbd4-fe0ecbe1e706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ca26e3c7-3ad6-4934-83db-d2b562da0f80" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d7243dc9-567c-4412-ab80-4759233d19af" xlink:to="loc_us-gaap_CommonStockValue_ca26e3c7-3ad6-4934-83db-d2b562da0f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3b67f649-8645-4ad2-b34a-2917a0fa2b72" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d7243dc9-567c-4412-ab80-4759233d19af" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3b67f649-8645-4ad2-b34a-2917a0fa2b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_23288107-bf1f-4df7-8e6d-be14dc10337b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d7243dc9-567c-4412-ab80-4759233d19af" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_23288107-bf1f-4df7-8e6d-be14dc10337b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d140e1cc-ad45-4792-a574-ca5777e4a64f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d7243dc9-567c-4412-ab80-4759233d19af" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d140e1cc-ad45-4792-a574-ca5777e4a64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e5c125a4-0053-4f44-b27b-68903c9fc442" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d7243dc9-567c-4412-ab80-4759233d19af" xlink:to="loc_us-gaap_StockholdersEquity_e5c125a4-0053-4f44-b27b-68903c9fc442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f11694ff-9bac-4e38-b1b4-ec10a3d2e4ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilitiesAndStockholdersEquityDeficitAbstract_0e20ef5e-ed65-49e4-afee-20d0b94e90bf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f11694ff-9bac-4e38-b1b4-ec10a3d2e4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4f35ab9b-ca23-458a-a32b-d1d16ac76106" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_eecdd52b-d1fa-429a-b637-7f75fc6c6e62" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f35ab9b-ca23-458a-a32b-d1d16ac76106" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_eecdd52b-d1fa-429a-b637-7f75fc6c6e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_62258dda-a4cb-4e18-a3e8-c7c70b86445e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f35ab9b-ca23-458a-a32b-d1d16ac76106" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_62258dda-a4cb-4e18-a3e8-c7c70b86445e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PreferredStockShareDesignated_2c840872-82d7-4c4b-a199-1228f65de9f9" xlink:href="nktr-20200331.xsd#nktr_PreferredStockShareDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f35ab9b-ca23-458a-a32b-d1d16ac76106" xlink:to="loc_nktr_PreferredStockShareDesignated_2c840872-82d7-4c4b-a199-1228f65de9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2d735889-ffe8-4c9e-bee7-5b2a63e9abd2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f35ab9b-ca23-458a-a32b-d1d16ac76106" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2d735889-ffe8-4c9e-bee7-5b2a63e9abd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4adf6e9a-a207-424e-844b-86f4e5c16ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f35ab9b-ca23-458a-a32b-d1d16ac76106" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4adf6e9a-a207-424e-844b-86f4e5c16ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a18b9184-a55e-4525-9405-bd23b45e3d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f35ab9b-ca23-458a-a32b-d1d16ac76106" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a18b9184-a55e-4525-9405-bd23b45e3d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0a4f5382-441c-4b49-80d2-d0e642b595ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4f35ab9b-ca23-458a-a32b-d1d16ac76106" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0a4f5382-441c-4b49-80d2-d0e642b595ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_38abf5bf-d641-48ce-8d98-5d525f6ab8a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d91c9da6-5c47-4079-b930-8010499738f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_38abf5bf-d641-48ce-8d98-5d525f6ab8a6" xlink:to="loc_us-gaap_StatementTable_d91c9da6-5c47-4079-b930-8010499738f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0f4046ac-d6a3-41fc-8f13-c2b6f7d27a9b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d91c9da6-5c47-4079-b930-8010499738f0" xlink:to="loc_srt_ProductOrServiceAxis_0f4046ac-d6a3-41fc-8f13-c2b6f7d27a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0f4046ac-d6a3-41fc-8f13-c2b6f7d27a9b" xlink:to="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_26a52779-d185-4fb2-88a3-ae6ecffd332a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:to="loc_us-gaap_ProductMember_26a52779-d185-4fb2-88a3-ae6ecffd332a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_e779c66c-be3a-4dda-a729-19f67d4f1563" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:to="loc_us-gaap_RoyaltyMember_e779c66c-be3a-4dda-a729-19f67d4f1563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_08b7409a-1b89-44c3-8dac-3020a726aa50" xlink:href="nktr-20200331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember_08b7409a-1b89-44c3-8dac-3020a726aa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationAndOtherRevenueMember_50c9d9b8-b23f-41ce-ac90-35bea3b54aff" xlink:href="nktr-20200331.xsd#nktr_LicenseCollaborationAndOtherRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7dde2d20-64d8-485e-9ff6-735c312b64e6" xlink:to="loc_nktr_LicenseCollaborationAndOtherRevenueMember_50c9d9b8-b23f-41ce-ac90-35bea3b54aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d91c9da6-5c47-4079-b930-8010499738f0" xlink:to="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_29f363fd-d6f5-472f-bb0c-921dfabae60f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_RevenuesAbstract_29f363fd-d6f5-472f-bb0c-921dfabae60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c301fc4-e9da-4f51-afac-d61851a86a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_29f363fd-d6f5-472f-bb0c-921dfabae60f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5c301fc4-e9da-4f51-afac-d61851a86a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_88c08b61-e332-42ca-8f05-cf52c2f21586" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_88c08b61-e332-42ca-8f05-cf52c2f21586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bfb930d3-fb60-4a6b-8eae-d90f9d86dd20" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bfb930d3-fb60-4a6b-8eae-d90f9d86dd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1a8d566e-2313-4c3c-bda4-2527c80fa0d7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1a8d566e-2313-4c3c-bda4-2527c80fa0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_ec46848e-3c9e-41da-af80-e2f870dbda85" xlink:href="nktr-20200331.xsd#nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:to="loc_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram_ec46848e-3c9e-41da-af80-e2f870dbda85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3cb06224-dcd9-40cb-9708-c0226003aabd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3a530745-6e0a-477a-a361-a2ffe8493e2c" xlink:to="loc_us-gaap_CostsAndExpenses_3cb06224-dcd9-40cb-9708-c0226003aabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0a03344e-c846-4869-8dbc-c7c42c36fbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_OperatingIncomeLoss_0a03344e-c846-4869-8dbc-c7c42c36fbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_03f5bfec-8c84-481a-ba8e-c751bd695abe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:to="loc_us-gaap_InterestExpense_03f5bfec-8c84-481a-ba8e-c751bd695abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_0dd2bd83-8798-411d-b5d0-e0a2de64dc89" xlink:href="nktr-20200331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_0dd2bd83-8798-411d-b5d0-e0a2de64dc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_29bad313-76f8-4517-95d8-a795dcf63303" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_29bad313-76f8-4517-95d8-a795dcf63303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_2d62d3b9-a78f-415e-a833-74e496ba8da7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_5dbbf190-e533-4bbb-9a88-aeb48bc1967c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_2d62d3b9-a78f-415e-a833-74e496ba8da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6de75913-2718-44b3-8880-54f3e141d8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6de75913-2718-44b3-8880-54f3e141d8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a45d1447-664e-4515-b091-be93db8293ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a45d1447-664e-4515-b091-be93db8293ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0caaad42-db8e-471c-8cf0-189c75430359" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_NetIncomeLoss_0caaad42-db8e-471c-8cf0-189c75430359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_92d4c2c8-8945-4454-bd75-9c1e8dbc8a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_92d4c2c8-8945-4454-bd75-9c1e8dbc8a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8a44c727-48ab-498e-a911-eeed0978fc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_577aee07-692d-42be-a643-b4fb214fc0dd" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8a44c727-48ab-498e-a911-eeed0978fc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_47ad198f-b382-4718-acf1-6180b9685607" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7b8ce808-de08-4637-bf61-0aea18d8d8cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_47ad198f-b382-4718-acf1-6180b9685607" xlink:to="loc_us-gaap_NetIncomeLoss_7b8ce808-de08-4637-bf61-0aea18d8d8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e83a193-1dd4-4e97-bd87-4be9d2510305" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_47ad198f-b382-4718-acf1-6180b9685607" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e83a193-1dd4-4e97-bd87-4be9d2510305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0d8fada2-f43e-4beb-ad48-a778b88a19c1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e83a193-1dd4-4e97-bd87-4be9d2510305" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0d8fada2-f43e-4beb-ad48-a778b88a19c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f36fbe70-42e7-4307-8001-64e313e27c87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e83a193-1dd4-4e97-bd87-4be9d2510305" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f36fbe70-42e7-4307-8001-64e313e27c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5f766403-3827-4757-9126-e995fad22e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_4e83a193-1dd4-4e97-bd87-4be9d2510305" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5f766403-3827-4757-9126-e995fad22e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_531e309b-823b-4580-9aab-00df9e7cc297" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_47ad198f-b382-4718-acf1-6180b9685607" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_531e309b-823b-4580-9aab-00df9e7cc297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_03d461c8-bce0-4245-9f74-cf302b862d85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0dde0aa-b5a7-4d78-a2f3-027d785da80d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_03d461c8-bce0-4245-9f74-cf302b862d85" xlink:to="loc_us-gaap_StatementTable_f0dde0aa-b5a7-4d78-a2f3-027d785da80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_05463108-e112-49de-ac92-32922fbd2e45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0dde0aa-b5a7-4d78-a2f3-027d785da80d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_05463108-e112-49de-ac92-32922fbd2e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_05463108-e112-49de-ac92-32922fbd2e45" xlink:to="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8ebc8d7c-bdc8-4495-acf7-f6441db650f3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:to="loc_us-gaap_CommonStockMember_8ebc8d7c-bdc8-4495-acf7-f6441db650f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3a180afa-8729-4e1e-ad50-065f4f3a7b87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3a180afa-8729-4e1e-ad50-065f4f3a7b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ec8abdf-aab2-4b0c-a792-bb1b2b9381d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6ec8abdf-aab2-4b0c-a792-bb1b2b9381d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_84c3ace6-4ef6-4eca-b5d8-7a3678df3978" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_66a26a2c-91e1-4375-8e7f-71be97c0cefd" xlink:to="loc_us-gaap_RetainedEarningsMember_84c3ace6-4ef6-4eca-b5d8-7a3678df3978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_045fe11e-3ac8-488f-b453-5d6900affb93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0dde0aa-b5a7-4d78-a2f3-027d785da80d" xlink:to="loc_us-gaap_StatementLineItems_045fe11e-3ac8-488f-b453-5d6900affb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_045fe11e-3ac8-488f-b453-5d6900affb93" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3ec2d244-eb86-4368-ad1b-4c6cee4a32cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_SharesOutstanding_3ec2d244-eb86-4368-ad1b-4c6cee4a32cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_52e3080c-66eb-42b6-85d4-bc2ee60143c9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_StockholdersEquity_52e3080c-66eb-42b6-85d4-bc2ee60143c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a1d8f49a-91a2-4aab-93d0-2255ff1268c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a1d8f49a-91a2-4aab-93d0-2255ff1268c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5759f85b-5199-43f3-9fea-bc21fc587a15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5759f85b-5199-43f3-9fea-bc21fc587a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eea73038-c1e8-450f-af67-90965145a293" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eea73038-c1e8-450f-af67-90965145a293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6cd3b399-1106-4452-b32f-adc38ceecb08" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6cd3b399-1106-4452-b32f-adc38ceecb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ef474948-33d9-437e-8cbb-16cc72259bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_SharesOutstanding_ef474948-33d9-437e-8cbb-16cc72259bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5d5b76bd-d6f0-4a39-a9f6-23b72ec2c73a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c8379fb-7452-499a-8bf5-0ac9565cfab6" xlink:to="loc_us-gaap_StockholdersEquity_5d5b76bd-d6f0-4a39-a9f6-23b72ec2c73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="nktr-20200331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_4a00c82d-022b-492e-8a79-f14a7250139a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4a5383-9f93-4e1d-9e55-8ec72c43a5f2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a00c82d-022b-492e-8a79-f14a7250139a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4a5383-9f93-4e1d-9e55-8ec72c43a5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c8462810-fa80-47b0-a5be-2f985ceed079" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4a5383-9f93-4e1d-9e55-8ec72c43a5f2" xlink:to="loc_us-gaap_ProfitLoss_c8462810-fa80-47b0-a5be-2f985ceed079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7c99ac7-03ae-4327-9242-0434e30e57ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4a5383-9f93-4e1d-9e55-8ec72c43a5f2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7c99ac7-03ae-4327-9242-0434e30e57ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_56ef5d8f-868f-4861-be04-ee6fb826d489" xlink:href="nktr-20200331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7c99ac7-03ae-4327-9242-0434e30e57ed" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_56ef5d8f-868f-4861-be04-ee6fb826d489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_588be85d-f949-479e-9d42-e725dd91e91d" xlink:href="nktr-20200331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7c99ac7-03ae-4327-9242-0434e30e57ed" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_588be85d-f949-479e-9d42-e725dd91e91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_205f1006-fc98-4b59-93fe-ba7f766608a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7c99ac7-03ae-4327-9242-0434e30e57ed" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_205f1006-fc98-4b59-93fe-ba7f766608a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_242a7f8d-0bf1-4538-b128-c8e251759a18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7c99ac7-03ae-4327-9242-0434e30e57ed" xlink:to="loc_us-gaap_DepreciationAndAmortization_242a7f8d-0bf1-4538-b128-c8e251759a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_ff0cbb27-f670-474f-a225-a40909552ca0" xlink:href="nktr-20200331.xsd#nktr_ImpairmentOfEquipmentFromTerminatedProgram"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7c99ac7-03ae-4327-9242-0434e30e57ed" xlink:to="loc_nktr_ImpairmentOfEquipmentFromTerminatedProgram_ff0cbb27-f670-474f-a225-a40909552ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9e218233-aac0-4780-89b0-f9a3f21cd867" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7c99ac7-03ae-4327-9242-0434e30e57ed" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9e218233-aac0-4780-89b0-f9a3f21cd867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7c99ac7-03ae-4327-9242-0434e30e57ed" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_06f807e7-a976-4d81-95dd-8e06c8de242b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_06f807e7-a976-4d81-95dd-8e06c8de242b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f150e893-bc41-4ccc-8cf4-6926980b350b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f150e893-bc41-4ccc-8cf4-6926980b350b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_2fb6657a-6653-46b0-94f8-7d47e2e5c2d6" xlink:href="nktr-20200331.xsd#nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:to="loc_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities_2fb6657a-6653-46b0-94f8-7d47e2e5c2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b8f81e82-1e00-4979-957b-1a01a5a4b23c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b8f81e82-1e00-4979-957b-1a01a5a4b23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_01e8fef5-38ab-4863-ba51-fb29bc929e64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_01e8fef5-38ab-4863-ba51-fb29bc929e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2fd452d1-7330-4f8d-842f-d346370d5419" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2fd452d1-7330-4f8d-842f-d346370d5419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_38ba0a8e-dfbb-4494-baea-f74f4ee12bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_38ba0a8e-dfbb-4494-baea-f74f4ee12bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c4256013-c5a9-4177-8c42-99e1f19e6d47" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c4256013-c5a9-4177-8c42-99e1f19e6d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_80869767-25dc-40f5-a3e7-0286d6bfa018" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c4444b6a-1821-4ac7-9584-fe875546d64b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_80869767-25dc-40f5-a3e7-0286d6bfa018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e99ac0b-5338-4659-92d6-7f9a2b971b18" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c4a5383-9f93-4e1d-9e55-8ec72c43a5f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e99ac0b-5338-4659-92d6-7f9a2b971b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29a023fd-6528-47ee-a0c3-73782db441b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a00c82d-022b-492e-8a79-f14a7250139a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29a023fd-6528-47ee-a0c3-73782db441b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c5d3115f-28c6-4962-9bd1-43ff0a4e6614" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29a023fd-6528-47ee-a0c3-73782db441b9" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c5d3115f-28c6-4962-9bd1-43ff0a4e6614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6cb1d0e8-5064-4375-aa4f-5b0f484df020" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29a023fd-6528-47ee-a0c3-73782db441b9" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6cb1d0e8-5064-4375-aa4f-5b0f484df020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b73c4779-8fff-40a2-b370-9520a004a2df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29a023fd-6528-47ee-a0c3-73782db441b9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b73c4779-8fff-40a2-b370-9520a004a2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_271cfad5-3986-49b3-aabe-ece4d6765cfc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29a023fd-6528-47ee-a0c3-73782db441b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_271cfad5-3986-49b3-aabe-ece4d6765cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4c51f084-90eb-479d-b4cf-3fde715f8f29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a00c82d-022b-492e-8a79-f14a7250139a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4c51f084-90eb-479d-b4cf-3fde715f8f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2fbf43fa-8546-4ab6-92f3-afe4936147e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4c51f084-90eb-479d-b4cf-3fde715f8f29" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2fbf43fa-8546-4ab6-92f3-afe4936147e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_06e1bd59-f89e-4e4c-85b2-df5fc900ef0a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4c51f084-90eb-479d-b4cf-3fde715f8f29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_06e1bd59-f89e-4e4c-85b2-df5fc900ef0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c990ff42-4bb3-450e-8367-6a2fa465794e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a00c82d-022b-492e-8a79-f14a7250139a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c990ff42-4bb3-450e-8367-6a2fa465794e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cd4e2ac3-f52c-4c41-a72f-54993f578f03" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a00c82d-022b-492e-8a79-f14a7250139a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cd4e2ac3-f52c-4c41-a72f-54993f578f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7595abc6-74ef-495a-89be-f16dc77c392d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a00c82d-022b-492e-8a79-f14a7250139a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7595abc6-74ef-495a-89be-f16dc77c392d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_efdafe43-cc70-4ca7-a96e-2aaec696d935" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a00c82d-022b-492e-8a79-f14a7250139a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_efdafe43-cc70-4ca7-a96e-2aaec696d935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_89978937-f73f-46fc-a93b-0eabe24d2e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_4a00c82d-022b-492e-8a79-f14a7250139a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_89978937-f73f-46fc-a93b-0eabe24d2e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_fc21bd92-a88c-40e5-adfe-adc315ce0d29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_89978937-f73f-46fc-a93b-0eabe24d2e7e" xlink:to="loc_us-gaap_InterestPaidNet_fc21bd92-a88c-40e5-adfe-adc315ce0d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8c6661f2-ce25-4b6d-9db6-880e1bd741df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_89978937-f73f-46fc-a93b-0eabe24d2e7e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8c6661f2-ce25-4b6d-9db6-880e1bd741df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="nktr-20200331.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d1c825f-6f38-4642-8d08-6b23b5d6d4dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f7d039d7-1bab-49d3-b159-cacc816ae14e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d1c825f-6f38-4642-8d08-6b23b5d6d4dd" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f7d039d7-1bab-49d3-b159-cacc816ae14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nktr-20200331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationPolicyTextBlock_0f361f98-6f25-47a9-887a-2d1dbd344a29" xlink:href="nktr-20200331.xsd#nktr_OrganizationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_nktr_OrganizationPolicyTextBlock_0f361f98-6f25-47a9-887a-2d1dbd344a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_aec680d9-30a6-4cf5-b636-3cabb4a829e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_aec680d9-30a6-4cf5-b636-3cabb4a829e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5281a690-c1ca-44f2-aaf9-26a56bd9ec48" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_UseOfEstimates_5281a690-c1ca-44f2-aaf9-26a56bd9ec48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_13a7a8ba-42e0-4a97-a7da-6dc74d868e86" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_13a7a8ba-42e0-4a97-a7da-6dc74d868e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_eda54fe8-2791-4aa4-96cf-4e9d14ee62d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_eda54fe8-2791-4aa4-96cf-4e9d14ee62d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_f891b132-1d3e-44af-8dd9-1a57a6f31ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_f891b132-1d3e-44af-8dd9-1a57a6f31ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_cbc32590-bf81-48bb-adc5-acd2bb31a4a6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_cbc32590-bf81-48bb-adc5-acd2bb31a4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a8dab010-b012-42c0-8db6-dade5c56d5b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a8dab010-b012-42c0-8db6-dade5c56d5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fa3a24a3-e4e1-4a5d-8a9e-28f4d89d3f77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fa3a24a3-e4e1-4a5d-8a9e-28f4d89d3f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_936d72b1-5e41-421e-bfef-133e0f5dfc26" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_936d72b1-5e41-421e-bfef-133e0f5dfc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b3376270-bde0-4dec-b2ce-68e56876483a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b3376270-bde0-4dec-b2ce-68e56876483a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_d2028836-4718-4277-a63b-0f63408212cb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_d2028836-4718-4277-a63b-0f63408212cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_9736f693-338f-4da7-8a89-07a0987a5817" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f3de7cba-70a4-4a1b-b54c-fad52d22316a" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock_9736f693-338f-4da7-8a89-07a0987a5817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f9d02d8-4c46-4caf-aad5-562b09ceeafc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:href="nktr-20200331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f9d02d8-4c46-4caf-aad5-562b09ceeafc" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2717a5ed-1bc0-45e9-8abc-37cf4461d78e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_srt_CounterpartyNameAxis_2717a5ed-1bc0-45e9-8abc-37cf4461d78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c85a938-c0c7-42df-b3e2-2ea15996f6cc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2717a5ed-1bc0-45e9-8abc-37cf4461d78e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c85a938-c0c7-42df-b3e2-2ea15996f6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborationPartnerMember_4fb5330f-8311-4951-919e-4e6a351f3129" xlink:href="nktr-20200331.xsd#nktr_CollaborationPartnerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c85a938-c0c7-42df-b3e2-2ea15996f6cc" xlink:to="loc_nktr_CollaborationPartnerMember_4fb5330f-8311-4951-919e-4e6a351f3129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_11c326ef-470d-4c03-a36a-bf76972469d4" xlink:href="nktr-20200331.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2c85a938-c0c7-42df-b3e2-2ea15996f6cc" xlink:to="loc_nktr_BMSCollaborationAgreementMember_11c326ef-470d-4c03-a36a-bf76972469d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_63cddfa1-917d-4b85-abb7-87ffa4463620" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_srt_ProductOrServiceAxis_63cddfa1-917d-4b85-abb7-87ffa4463620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b2bac055-360a-4bd6-b13d-602e67f17bda" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_63cddfa1-917d-4b85-abb7-87ffa4463620" xlink:to="loc_srt_ProductsAndServicesDomain_b2bac055-360a-4bd6-b13d-602e67f17bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NKTR181Member_dd977ff3-0269-4796-83b6-e34db9e228b5" xlink:href="nktr-20200331.xsd#nktr_NKTR181Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b2bac055-360a-4bd6-b13d-602e67f17bda" xlink:to="loc_nktr_NKTR181Member_dd977ff3-0269-4796-83b6-e34db9e228b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c5d667c8-53ef-4d42-920c-489480ee5fca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_us-gaap_DebtInstrumentAxis_c5d667c8-53ef-4d42-920c-489480ee5fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a84627b-0948-4471-b2e5-c5e2a15547f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c5d667c8-53ef-4d42-920c-489480ee5fca" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a84627b-0948-4471-b2e5-c5e2a15547f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_1c3ea05f-ac96-47de-9aa8-8d22b8622c52" xlink:href="nktr-20200331.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1a84627b-0948-4471-b2e5-c5e2a15547f9" xlink:to="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_1c3ea05f-ac96-47de-9aa8-8d22b8622c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_58fdb081-be5c-49a3-b4ae-bdd1fac6ffd7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_58fdb081-be5c-49a3-b4ae-bdd1fac6ffd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a756bc5f-ce80-485f-b22a-590983240ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_58fdb081-be5c-49a3-b4ae-bdd1fac6ffd7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a756bc5f-ce80-485f-b22a-590983240ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3f1c0e1e-3a11-4049-b9d3-c46a0af7cab1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a756bc5f-ce80-485f-b22a-590983240ddc" xlink:to="loc_us-gaap_SeniorNotesMember_3f1c0e1e-3a11-4049-b9d3-c46a0af7cab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3c6bb1ee-4257-48d4-97b8-bb6dfb35e01e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3c6bb1ee-4257-48d4-97b8-bb6dfb35e01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9c183747-b2c4-4c4a-8ed3-6bea49356f63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3c6bb1ee-4257-48d4-97b8-bb6dfb35e01e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9c183747-b2c4-4c4a-8ed3-6bea49356f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6ad68b4c-02ab-49ca-bb76-891898bff87f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9c183747-b2c4-4c4a-8ed3-6bea49356f63" xlink:to="loc_us-gaap_SubsequentEventMember_6ad68b4c-02ab-49ca-bb76-891898bff87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:href="nktr-20200331.xsd#nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_9541eb6a-185c-4747-a1d5-dce7802da120" xlink:to="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f40fdac7-b0b1-4c6e-b6ae-e0d562df10bb" xlink:href="nktr-20200331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_f40fdac7-b0b1-4c6e-b6ae-e0d562df10bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_70c42e1b-28c0-41ef-b0d4-b948c1641ab5" xlink:href="nktr-20200331.xsd#nktr_RepaymentsOfLongTermDebtIncludingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_nktr_RepaymentsOfLongTermDebtIncludingInterest_70c42e1b-28c0-41ef-b0d4-b948c1641ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_b205a970-0368-441d-bfc8-e1afd9e47390" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_SeniorNotes_b205a970-0368-441d-bfc8-e1afd9e47390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_45be29bd-461f-4e0d-9980-87920142e26a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_45be29bd-461f-4e0d-9980-87920142e26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a4f47f1a-2a10-4f17-97cc-27cff396241a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a4f47f1a-2a10-4f17-97cc-27cff396241a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a14fa2a2-79d5-4c7d-84f7-e634cf69d268" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a14fa2a2-79d5-4c7d-84f7-e634cf69d268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0e53ab08-0625-4f3f-8f81-2005a9a9d4f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0e53ab08-0625-4f3f-8f81-2005a9a9d4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_3f3fd5e0-13a1-4f65-a3d4-710251c059b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_WriteOffOfPrepayment_de2c17d0-b05c-4fe2-a7c7-0d59c5237801" xlink:href="nktr-20200331.xsd#nktr_WriteOffOfPrepayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_nktr_WriteOffOfPrepayment_de2c17d0-b05c-4fe2-a7c7-0d59c5237801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9a846409-62eb-443f-8cf4-28d5bac16d45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_514f5bdc-20b5-4b42-86cc-5e379a02549f" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_9a846409-62eb-443f-8cf4-28d5bac16d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5e540953-65a3-4dfe-8f65-ac77fa4ead6b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b00aa6ff-91ef-4292-9cef-789c69264900" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e540953-65a3-4dfe-8f65-ac77fa4ead6b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b00aa6ff-91ef-4292-9cef-789c69264900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fbf09e93-5dc0-471c-b6a0-a6a82d915233" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_d0f81236-a1b6-43d8-9654-7ce45e308aaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fbf09e93-5dc0-471c-b6a0-a6a82d915233" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_d0f81236-a1b6-43d8-9654-7ce45e308aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_211267ed-6831-43e2-ade9-5fec4f33f44b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fbf09e93-5dc0-471c-b6a0-a6a82d915233" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_211267ed-6831-43e2-ade9-5fec4f33f44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bc5145a3-76bd-44fe-a7db-4a85debcd9db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b4edeb9e-1a79-4492-9812-f4200f8f303f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bc5145a3-76bd-44fe-a7db-4a85debcd9db" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b4edeb9e-1a79-4492-9812-f4200f8f303f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13b02af1-b00c-4aca-9e2d-17cff4396d6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b4edeb9e-1a79-4492-9812-f4200f8f303f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13b02af1-b00c-4aca-9e2d-17cff4396d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fd2ee4d9-da91-48b1-b5fc-edeb7708dd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b4edeb9e-1a79-4492-9812-f4200f8f303f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fd2ee4d9-da91-48b1-b5fc-edeb7708dd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7a5f3021-12a3-4e0a-870b-af0237edfb34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b4edeb9e-1a79-4492-9812-f4200f8f303f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_7a5f3021-12a3-4e0a-870b-af0237edfb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_17442846-4d03-4952-9bca-5aa1123ba06f" xlink:href="nktr-20200331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_b4edeb9e-1a79-4492-9812-f4200f8f303f" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_17442846-4d03-4952-9bca-5aa1123ba06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_84d9f8fe-b61e-40bd-91f1-679cb8468dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_ebe2de27-4258-4c24-9d73-765ff899ad5e" xlink:href="nktr-20200331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_84d9f8fe-b61e-40bd-91f1-679cb8468dd1" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_ebe2de27-4258-4c24-9d73-765ff899ad5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_01360d69-d174-4e02-827e-35b0f720af04" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_ebe2de27-4258-4c24-9d73-765ff899ad5e" xlink:to="loc_srt_RangeAxis_01360d69-d174-4e02-827e-35b0f720af04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc99173a-c376-4190-a2d6-bfc8a54bfa10" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_01360d69-d174-4e02-827e-35b0f720af04" xlink:to="loc_srt_RangeMember_bc99173a-c376-4190-a2d6-bfc8a54bfa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dae6ff14-cdcd-44ed-8d7c-5f78e6c53aba" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc99173a-c376-4190-a2d6-bfc8a54bfa10" xlink:to="loc_srt_MinimumMember_dae6ff14-cdcd-44ed-8d7c-5f78e6c53aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a68bb8d9-aa53-4ddf-8af2-a8f881726f3d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bc99173a-c376-4190-a2d6-bfc8a54bfa10" xlink:to="loc_srt_MaximumMember_a68bb8d9-aa53-4ddf-8af2-a8f881726f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:href="nktr-20200331.xsd#nktr_CashAndInvestmentsInMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesTable_ebe2de27-4258-4c24-9d73-765ff899ad5e" xlink:to="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaximumMaturityPeriod_82c06e13-8a77-480c-afbf-9198e624c697" xlink:href="nktr-20200331.xsd#nktr_DebtInvestmentMaximumMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_nktr_DebtInvestmentMaximumMaturityPeriod_82c06e13-8a77-480c-afbf-9198e624c697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DebtInvestmentMaturityTerm_0eb3a1d4-2121-4084-859a-d76d8c58781d" xlink:href="nktr-20200331.xsd#nktr_DebtInvestmentMaturityTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_nktr_DebtInvestmentMaturityTerm_0eb3a1d4-2121-4084-859a-d76d8c58781d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LongTermInvestmentMaturityPeriod_9ccdc5fe-8eb6-4193-818b-c84b55385635" xlink:href="nktr-20200331.xsd#nktr_LongTermInvestmentMaturityPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_nktr_LongTermInvestmentMaturityPeriod_9ccdc5fe-8eb6-4193-818b-c84b55385635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fdaa8d69-7246-4126-bfa8-6a39275bac06" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fdaa8d69-7246-4126-bfa8-6a39275bac06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_7227f360-c8e0-4658-a32d-905cc6277835" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_us-gaap_SeniorNotes_7227f360-c8e0-4658-a32d-905cc6277835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_c04662f4-ee84-478f-b48e-132553d567db" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_us-gaap_SeniorNotes_c04662f4-ee84-478f-b48e-132553d567db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_ed777a58-a04f-46bd-aab5-8dd6b1fb285e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems_53861159-1f7d-420a-82bb-39bee81aa737" xlink:to="loc_us-gaap_InterestReceivableCurrent_ed777a58-a04f-46bd-aab5-8dd6b1fb285e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_72dfba06-cf24-420e-963c-f57ce961c5b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f8a251-58b4-4e61-b67a-adeecb6762a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_72dfba06-cf24-420e-963c-f57ce961c5b5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f8a251-58b4-4e61-b67a-adeecb6762a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_36a5aed5-b623-4cc5-98d3-4fa342e8e9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f8a251-58b4-4e61-b67a-adeecb6762a4" xlink:to="loc_us-gaap_InvestmentTypeAxis_36a5aed5-b623-4cc5-98d3-4fa342e8e9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_36a5aed5-b623-4cc5-98d3-4fa342e8e9ab" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_ad3608d6-501a-4dcb-8d20-2151a1e9ac83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_ad3608d6-501a-4dcb-8d20-2151a1e9ac83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1abbdb5d-1012-4124-bbeb-e772cad5129d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:to="loc_us-gaap_CommercialPaperMember_1abbdb5d-1012-4124-bbeb-e772cad5129d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_51da5b5a-4a3f-4305-aba6-43a780a56a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:to="loc_us-gaap_MoneyMarketFundsMember_51da5b5a-4a3f-4305-aba6-43a780a56a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_49647eec-8046-49b8-a525-21c426f37537" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_705c4cc7-7b2d-445b-8bc4-db374718e6ed" xlink:to="loc_us-gaap_CertificatesOfDepositMember_49647eec-8046-49b8-a525-21c426f37537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_947e9633-5123-4dfe-92c6-fcc7b90f77e3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f8a251-58b4-4e61-b67a-adeecb6762a4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_947e9633-5123-4dfe-92c6-fcc7b90f77e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2477ae67-d9b3-47ab-82d4-714776990afe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_947e9633-5123-4dfe-92c6-fcc7b90f77e3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2477ae67-d9b3-47ab-82d4-714776990afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ce1848b0-33ef-4955-9b0a-bc39f102b53a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2477ae67-d9b3-47ab-82d4-714776990afe" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ce1848b0-33ef-4955-9b0a-bc39f102b53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4387e88f-d007-48e0-8dda-a081a223d230" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2477ae67-d9b3-47ab-82d4-714776990afe" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4387e88f-d007-48e0-8dda-a081a223d230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f8a251-58b4-4e61-b67a-adeecb6762a4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1acaff18-d3f4-4e77-b139-b4fc6b155560" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1acaff18-d3f4-4e77-b139-b4fc6b155560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e60f5435-ed5a-47d8-8d0c-2cbaf036b675" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e60f5435-ed5a-47d8-8d0c-2cbaf036b675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9e49fa41-07f6-4fe3-95b7-935d814786b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9e49fa41-07f6-4fe3-95b7-935d814786b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3d43bb08-5140-4145-9bbf-7f5f3c3cffaf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3d43bb08-5140-4145-9bbf-7f5f3c3cffaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_f71c6c09-54c5-45f7-a66c-26b7dd4cb5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_f71c6c09-54c5-45f7-a66c-26b7dd4cb5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_bf024ada-c0ac-40df-8fe1-f67d3800e4af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_us-gaap_Cash_bf024ada-c0ac-40df-8fe1-f67d3800e4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ef1aad3b-3b99-46db-9830-fea73c5bccf2" xlink:href="nktr-20200331.xsd#nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_129b4076-44f1-4da6-b1c4-61078b85e3d0" xlink:to="loc_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments_ef1aad3b-3b99-46db-9830-fea73c5bccf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/Inventory" xlink:type="simple" xlink:href="nktr-20200331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f517fe59-2a58-4dd0-8b4d-c2b92e5de578" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_0d6f8fb3-51c4-47cf-90fa-a65ee6fd8b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f517fe59-2a58-4dd0-8b4d-c2b92e5de578" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_0d6f8fb3-51c4-47cf-90fa-a65ee6fd8b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b128699b-751e-42da-b08e-a72df3ad2358" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_af4c4437-4304-4d5c-8e4c-4cf44d474d63" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b128699b-751e-42da-b08e-a72df3ad2358" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_af4c4437-4304-4d5c-8e4c-4cf44d474d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/InventoryDetails" xlink:type="simple" xlink:href="nktr-20200331.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7aff8687-6be1-4404-9105-dbb799d4226a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_acd6009a-fb40-4a82-a0e4-6b44bcd41b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7aff8687-6be1-4404-9105-dbb799d4226a" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_acd6009a-fb40-4a82-a0e4-6b44bcd41b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_062790bd-0416-41ad-9bb0-88e8ca2207b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7aff8687-6be1-4404-9105-dbb799d4226a" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_062790bd-0416-41ad-9bb0-88e8ca2207b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2c59c8d8-a454-4ae3-8122-6d1c60f73572" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7aff8687-6be1-4404-9105-dbb799d4226a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2c59c8d8-a454-4ae3-8122-6d1c60f73572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8ec9b989-25a1-4348-a70e-0a5896f7494d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7aff8687-6be1-4404-9105-dbb799d4226a" xlink:to="loc_us-gaap_InventoryNet_8ec9b989-25a1-4348-a70e-0a5896f7494d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="simple" xlink:href="nktr-20200331.xsd#LiabilityRelatedtoSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1b707f5a-3a8c-4b4d-8a69-7f785e7ed9df" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_237aebef-c0a8-482e-9255-0376c0ddd57b" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1b707f5a-3a8c-4b4d-8a69-7f785e7ed9df" xlink:to="loc_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock_237aebef-c0a8-482e-9255-0376c0ddd57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_dacf4b28-6a6c-4a47-826f-caf55165b8af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_340ba853-8c9a-453a-b5fc-29a116db4bce" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_dacf4b28-6a6c-4a47-826f-caf55165b8af" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_340ba853-8c9a-453a-b5fc-29a116db4bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f89c4faa-a990-44a1-ba8a-3587a3532a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_340ba853-8c9a-453a-b5fc-29a116db4bce" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f89c4faa-a990-44a1-ba8a-3587a3532a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_274ac47b-7122-4457-a28f-c3fb5a175ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f89c4faa-a990-44a1-ba8a-3587a3532a9e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_274ac47b-7122-4457-a28f-c3fb5a175ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PurchaseAndSaleAgreementMember_1c2177d7-3460-46a0-a4a7-ccbfda2777d5" xlink:href="nktr-20200331.xsd#nktr_PurchaseAndSaleAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_274ac47b-7122-4457-a28f-c3fb5a175ad4" xlink:to="loc_nktr_PurchaseAndSaleAgreementMember_1c2177d7-3460-46a0-a4a7-ccbfda2777d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:href="nktr-20200331.xsd#nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable_340ba853-8c9a-453a-b5fc-29a116db4bce" xlink:to="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_4ef0070d-b4ac-4519-9d03-b7ba5b417e0c" xlink:href="nktr-20200331.xsd#nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross_4ef0070d-b4ac-4519-9d03-b7ba5b417e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_60fdd166-09d4-43de-9ddf-484c3f843561" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_60fdd166-09d4-43de-9ddf-484c3f843561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_f284b39c-ce23-41aa-9650-4ebac688f0dc" xlink:href="nktr-20200331.xsd#nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_f284b39c-ce23-41aa-9650-4ebac688f0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_508ddd2f-c688-4d24-88d5-52248b8f04c0" xlink:href="nktr-20200331.xsd#nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties_508ddd2f-c688-4d24-88d5-52248b8f04c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_122ecf4d-c6b5-4ed5-9f5b-266947777ac7" xlink:href="nktr-20200331.xsd#nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability_122ecf4d-c6b5-4ed5-9f5b-266947777ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProspectiveInterestRatePercentage_5df4e6a3-8817-4000-9da4-bfdfd1b74f91" xlink:href="nktr-20200331.xsd#nktr_ProspectiveInterestRatePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems_0b27dbd9-0f5b-42b1-9ba5-cec53b2fe3a2" xlink:to="loc_nktr_ProspectiveInterestRatePercentage_5df4e6a3-8817-4000-9da4-bfdfd1b74f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="nktr-20200331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b36516ea-7491-4c5e-8e34-202a1234213b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1c6535c6-8973-4bd0-b284-57fe60061e0e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b36516ea-7491-4c5e-8e34-202a1234213b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1c6535c6-8973-4bd0-b284-57fe60061e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94da09e8-6577-4c3e-b174-56f863ce4138" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_98b16bd5-99aa-4a25-b126-37a0118cec64" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_94da09e8-6577-4c3e-b174-56f863ce4138" xlink:to="loc_us-gaap_LossContingenciesTable_98b16bd5-99aa-4a25-b126-37a0118cec64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_c2b23294-68d0-4901-97a0-39dbf112af17" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_98b16bd5-99aa-4a25-b126-37a0118cec64" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_c2b23294-68d0-4901-97a0-39dbf112af17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_923b52ef-5dda-4b8c-a56a-dc8bd83fcc87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_c2b23294-68d0-4901-97a0-39dbf112af17" xlink:to="loc_us-gaap_LossContingencyNatureDomain_923b52ef-5dda-4b8c-a56a-dc8bd83fcc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndemnificationGuaranteeMember_de5aa4aa-0b31-4b7e-b446-0f53b322ae95" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndemnificationGuaranteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_923b52ef-5dda-4b8c-a56a-dc8bd83fcc87" xlink:to="loc_us-gaap_IndemnificationGuaranteeMember_de5aa4aa-0b31-4b7e-b446-0f53b322ae95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e8aff778-184b-401a-89fe-5a77a98e15ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_98b16bd5-99aa-4a25-b126-37a0118cec64" xlink:to="loc_us-gaap_LossContingenciesLineItems_e8aff778-184b-401a-89fe-5a77a98e15ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_561ecbf5-38de-4079-85e6-86586835184d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e8aff778-184b-401a-89fe-5a77a98e15ee" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_561ecbf5-38de-4079-85e6-86586835184d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67b0a8ab-9b5b-45c3-a660-12331552e61b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e9d88b56-956b-4676-a123-4df6394b72cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67b0a8ab-9b5b-45c3-a660-12331552e61b" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e9d88b56-956b-4676-a123-4df6394b72cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c54cb849-cb56-41ef-b1d5-d03f90ec4260" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_30aeae4e-aa56-4440-b18a-84f46e0c0480" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c54cb849-cb56-41ef-b1d5-d03f90ec4260" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_30aeae4e-aa56-4440-b18a-84f46e0c0480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_348fe849-0d4f-4a93-92f4-f5790ee68927" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c54cb849-cb56-41ef-b1d5-d03f90ec4260" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_348fe849-0d4f-4a93-92f4-f5790ee68927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aa0433ec-110c-49cd-9e01-18999156f0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsTable_6bfcddd1-d06c-4544-9e82-651f2b80cdcc" xlink:href="nktr-20200331.xsd#nktr_LicenseAndCollaborationAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aa0433ec-110c-49cd-9e01-18999156f0e4" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsTable_6bfcddd1-d06c-4544-9e82-651f2b80cdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_edaf8078-b702-4af8-aa46-ca3afd880b04" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_6bfcddd1-d06c-4544-9e82-651f2b80cdcc" xlink:to="loc_dei_LegalEntityAxis_edaf8078-b702-4af8-aa46-ca3afd880b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_edaf8078-b702-4af8-aa46-ca3afd880b04" xlink:to="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_3eeaee02-71d4-44ca-bec8-736f4d97d1bb" xlink:href="nktr-20200331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_3eeaee02-71d4-44ca-bec8-736f4d97d1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_dbd3e2b8-8944-40be-981a-fd2b2a2a1c78" xlink:href="nktr-20200331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:to="loc_nktr_EliLillyAndCompanyMember_dbd3e2b8-8944-40be-981a-fd2b2a2a1c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_0e375c15-d560-4d27-b1b7-c3b8e70375a4" xlink:href="nktr-20200331.xsd#nktr_AmgenIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:to="loc_nktr_AmgenIncMember_0e375c15-d560-4d27-b1b7-c3b8e70375a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_a9ddda2c-78b2-4d70-9b46-927bcdc44f98" xlink:href="nktr-20200331.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b99f983c-a20d-4d44-8d1e-06ed7eb42339" xlink:to="loc_nktr_OtherPartnerMember_a9ddda2c-78b2-4d70-9b46-927bcdc44f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_873f3883-160e-4fba-b4c7-7c6b0069dc69" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_6bfcddd1-d06c-4544-9e82-651f2b80cdcc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_873f3883-160e-4fba-b4c7-7c6b0069dc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65368cf8-ff55-4f8e-800f-98fb2060eed0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_873f3883-160e-4fba-b4c7-7c6b0069dc69" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65368cf8-ff55-4f8e-800f-98fb2060eed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarTwoOneFourMember_d3b7e7fb-2431-469d-a45e-61c066719187" xlink:href="nktr-20200331.xsd#nktr_NektarTwoOneFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65368cf8-ff55-4f8e-800f-98fb2060eed0" xlink:to="loc_nktr_NektarTwoOneFourMember_d3b7e7fb-2431-469d-a45e-61c066719187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_796adaff-83e6-4347-a509-b48450da71fd" xlink:href="nktr-20200331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65368cf8-ff55-4f8e-800f-98fb2060eed0" xlink:to="loc_nktr_NektarThreeFiveEightMember_796adaff-83e6-4347-a509-b48450da71fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NeulastaMember_6ef22cc5-3ff2-424a-9400-b1ab78b400c8" xlink:href="nktr-20200331.xsd#nktr_NeulastaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65368cf8-ff55-4f8e-800f-98fb2060eed0" xlink:to="loc_nktr_NeulastaMember_6ef22cc5-3ff2-424a-9400-b1ab78b400c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsLineItems_096ed4d1-3975-4787-80a6-b0a3790bc445" xlink:href="nktr-20200331.xsd#nktr_LicenseAndCollaborationAgreementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsTable_6bfcddd1-d06c-4544-9e82-651f2b80cdcc" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsLineItems_096ed4d1-3975-4787-80a6-b0a3790bc445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseCollaborationOtherRevenue_ef98a91e-a156-47f1-b8e6-c9016c0bcda8" xlink:href="nktr-20200331.xsd#nktr_LicenseCollaborationOtherRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsLineItems_096ed4d1-3975-4787-80a6-b0a3790bc445" xlink:to="loc_nktr_LicenseCollaborationOtherRevenue_ef98a91e-a156-47f1-b8e6-c9016c0bcda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad761d49-b920-4b5b-a203-f617f08392d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_LicenseAndCollaborationAgreementsAbstract_3f9a1476-64bf-432f-ab51-13f425b660bc" xlink:href="nktr-20200331.xsd#nktr_LicenseAndCollaborationAgreementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad761d49-b920-4b5b-a203-f617f08392d6" xlink:to="loc_nktr_LicenseAndCollaborationAgreementsAbstract_3f9a1476-64bf-432f-ab51-13f425b660bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_LicenseAndCollaborationAgreementsAbstract_3f9a1476-64bf-432f-ab51-13f425b660bc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cbbf4504-c8a5-4e14-bfd6-47d56b1fa324" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_dei_LegalEntityAxis_cbbf4504-c8a5-4e14-bfd6-47d56b1fa324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cbbf4504-c8a5-4e14-bfd6-47d56b1fa324" xlink:to="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_733bec95-3d53-41b1-bbd3-18d2d83d1d0d" xlink:href="nktr-20200331.xsd#nktr_BaxaltaIncorporatedOrTakedaPLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_BaxaltaIncorporatedOrTakedaPLCMember_733bec95-3d53-41b1-bbd3-18d2d83d1d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BristolMyersSquibbCompanyMember_31f243eb-6e01-419e-998d-03fa77dc8869" xlink:href="nktr-20200331.xsd#nktr_BristolMyersSquibbCompanyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_BristolMyersSquibbCompanyMember_31f243eb-6e01-419e-998d-03fa77dc8869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyAndCompanyMember_8598a61d-b026-42ef-bb16-268f4170ef4c" xlink:href="nktr-20200331.xsd#nktr_EliLillyAndCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_EliLillyAndCompanyMember_8598a61d-b026-42ef-bb16-268f4170ef4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EliLillyMember_9f093ffc-9a24-43e9-9124-8cf5897a42c2" xlink:href="nktr-20200331.xsd#nktr_EliLillyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_EliLillyMember_9f093ffc-9a24-43e9-9124-8cf5897a42c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmgenIncMember_889e5678-c68f-4cc0-8aa9-ac86390894f0" xlink:href="nktr-20200331.xsd#nktr_AmgenIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_AmgenIncMember_889e5678-c68f-4cc0-8aa9-ac86390894f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAbMember_a52fecde-e629-4f54-9fa4-2f3d01803e3f" xlink:href="nktr-20200331.xsd#nktr_AstraZenecaAbMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_AstraZenecaAbMember_a52fecde-e629-4f54-9fa4-2f3d01803e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OtherPartnerMember_1eb5d9e2-bc41-4bb5-a094-7bb177f6efe9" xlink:href="nktr-20200331.xsd#nktr_OtherPartnerMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_f8690981-225e-47f4-a519-3c8d6bc5a15c" xlink:to="loc_nktr_OtherPartnerMember_1eb5d9e2-bc41-4bb5-a094-7bb177f6efe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a7cae4b4-3e3c-4c95-b82b-275137914fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a7cae4b4-3e3c-4c95-b82b-275137914fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a7cae4b4-3e3c-4c95-b82b-275137914fe1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_HemophiliaMember_78164fd2-80e0-4920-97be-e754037fb095" xlink:href="nktr-20200331.xsd#nktr_HemophiliaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_HemophiliaMember_78164fd2-80e0-4920-97be-e754037fb095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_BMSCollaborationAgreementMember_4ac0c6ff-7feb-4638-9d8d-a0eee9e7a8b3" xlink:href="nktr-20200331.xsd#nktr_BMSCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_BMSCollaborationAgreementMember_4ac0c6ff-7feb-4638-9d8d-a0eee9e7a8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_801024a1-2a8c-4348-89cd-ac22d6779832" xlink:href="nktr-20200331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_NektarThreeFiveEightMember_801024a1-2a8c-4348-89cd-ac22d6779832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PhaseOneClinicalDevelopmentMember_da5b360f-ac20-44ba-8855-bb2d4e03c262" xlink:href="nktr-20200331.xsd#nktr_PhaseOneClinicalDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_PhaseOneClinicalDevelopmentMember_da5b360f-ac20-44ba-8855-bb2d4e03c262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_DrugProductDevelopmentMember_362d289e-3dfe-4acc-8f8b-f41d68cec546" xlink:href="nktr-20200331.xsd#nktr_DrugProductDevelopmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_DrugProductDevelopmentMember_362d289e-3dfe-4acc-8f8b-f41d68cec546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MOVANTIKAndMOVENTIGMember_6ec06f2d-f64e-49f7-9dea-f3cf9a35f4e2" xlink:href="nktr-20200331.xsd#nktr_MOVANTIKAndMOVENTIGMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_MOVANTIKAndMOVENTIGMember_6ec06f2d-f64e-49f7-9dea-f3cf9a35f4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AstraZenecaAgreementWithKirinMember_83914806-ed8e-475a-b7b9-92d207eae2ac" xlink:href="nktr-20200331.xsd#nktr_AstraZenecaAgreementWithKirinMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_AstraZenecaAgreementWithKirinMember_83914806-ed8e-475a-b7b9-92d207eae2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarMember_ea6ece71-1db9-4276-aead-39ed2d32d7f0" xlink:href="nktr-20200331.xsd#nktr_NektarMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f08b5c2a-1da4-4688-becb-f69802e2d3f4" xlink:to="loc_nktr_NektarMember_ea6ece71-1db9-4276-aead-39ed2d32d7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cf531b15-d10c-407d-8de2-d24188521fec" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_srt_StatementGeographicalAxis_cf531b15-d10c-407d-8de2-d24188521fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c8eb6ccb-6be9-49a9-ba97-dfde7f3db68d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cf531b15-d10c-407d-8de2-d24188521fec" xlink:to="loc_srt_SegmentGeographicalDomain_c8eb6ccb-6be9-49a9-ba97-dfde7f3db68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EuropeanUnionMember_a674a446-1e44-4fae-b437-790e68d4ad09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c8eb6ccb-6be9-49a9-ba97-dfde7f3db68d" xlink:to="loc_us-gaap_EuropeanUnionMember_a674a446-1e44-4fae-b437-790e68d4ad09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_23e4efbf-3ffc-48fa-8b37-a595d0346242" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_srt_ProductOrServiceAxis_23e4efbf-3ffc-48fa-8b37-a595d0346242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abdf3672-bfb7-4768-a937-8f1d420d8158" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_23e4efbf-3ffc-48fa-8b37-a595d0346242" xlink:to="loc_srt_ProductsAndServicesDomain_abdf3672-bfb7-4768-a937-8f1d420d8158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarTwoOneFourMember_ce6306ce-3248-4c5b-b4d8-631456af34ef" xlink:href="nktr-20200331.xsd#nktr_NektarTwoOneFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_abdf3672-bfb7-4768-a937-8f1d420d8158" xlink:to="loc_nktr_NektarTwoOneFourMember_ce6306ce-3248-4c5b-b4d8-631456af34ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightMember_45d0b0e1-547c-4d39-979d-53e5738c7635" xlink:href="nktr-20200331.xsd#nktr_NektarThreeFiveEightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_abdf3672-bfb7-4768-a937-8f1d420d8158" xlink:to="loc_nktr_NektarThreeFiveEightMember_45d0b0e1-547c-4d39-979d-53e5738c7635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_NektarThreeFiveEightLicenseMember_3beef703-41fb-4d39-895b-c1669ce2e5fd" xlink:href="nktr-20200331.xsd#nktr_NektarThreeFiveEightLicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_abdf3672-bfb7-4768-a937-8f1d420d8158" xlink:to="loc_nktr_NektarThreeFiveEightLicenseMember_3beef703-41fb-4d39-895b-c1669ce2e5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_4fae054e-01aa-4e56-905f-ab965f1311c1" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_4fae054e-01aa-4e56-905f-ab965f1311c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0df08376-ca75-4a1e-90e2-a132e7336db3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4fae054e-01aa-4e56-905f-ab965f1311c1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0df08376-ca75-4a1e-90e2-a132e7336db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_ff6422ba-387e-475e-bef7-676cb3d89c77" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_0df08376-ca75-4a1e-90e2-a132e7336db3" xlink:to="loc_srt_ParentCompanyMember_ff6422ba-387e-475e-bef7-676cb3d89c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d5c65a5b-6d83-49c1-a190-a9402439ebca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d5c65a5b-6d83-49c1-a190-a9402439ebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1040fd84-2543-4fbf-8afd-7c288b885e0d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d5c65a5b-6d83-49c1-a190-a9402439ebca" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1040fd84-2543-4fbf-8afd-7c288b885e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoMember_a974c1a2-08f3-4177-a146-cd976bf59c28" xlink:href="nktr-20200331.xsd#nktr_OpdivoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1040fd84-2543-4fbf-8afd-7c288b885e0d" xlink:to="loc_nktr_OpdivoMember_a974c1a2-08f3-4177-a146-cd976bf59c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_OpdivoAndYervoyMember_64f286b2-da84-4f8e-a7d9-256c08e78a56" xlink:href="nktr-20200331.xsd#nktr_OpdivoAndYervoyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1040fd84-2543-4fbf-8afd-7c288b885e0d" xlink:to="loc_nktr_OpdivoAndYervoyMember_64f286b2-da84-4f8e-a7d9-256c08e78a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8fd56795-f1d1-4e37-923d-39517198c268" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_srt_RangeAxis_8fd56795-f1d1-4e37-923d-39517198c268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56602155-fcf4-4d79-ac9f-3db539835d4c" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8fd56795-f1d1-4e37-923d-39517198c268" xlink:to="loc_srt_RangeMember_56602155-fcf4-4d79-ac9f-3db539835d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e13a36b0-1af2-4b98-aa6b-ed75e9c186b4" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56602155-fcf4-4d79-ac9f-3db539835d4c" xlink:to="loc_srt_MaximumMember_e13a36b0-1af2-4b98-aa6b-ed75e9c186b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ba733e4a-62e3-4326-b30e-1651bb1a983b" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56602155-fcf4-4d79-ac9f-3db539835d4c" xlink:to="loc_srt_MinimumMember_ba733e4a-62e3-4326-b30e-1651bb1a983b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f8715549-b947-4775-b39f-9d572b395dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f8715549-b947-4775-b39f-9d572b395dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a3ad46c0-6fc7-45ac-95ad-08279add131d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f8715549-b947-4775-b39f-9d572b395dd7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a3ad46c0-6fc7-45ac-95ad-08279add131d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SharePurchaseAgreementMember_f85e0eda-51d6-4b9d-beb0-0c6fc6240940" xlink:href="nktr-20200331.xsd#nktr_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a3ad46c0-6fc7-45ac-95ad-08279add131d" xlink:to="loc_nktr_SharePurchaseAgreementMember_f85e0eda-51d6-4b9d-beb0-0c6fc6240940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c3060bcb-b60e-4b26-8f9a-661c8f203253" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c3060bcb-b60e-4b26-8f9a-661c8f203253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2e53cf22-0300-482b-8366-59b2d36f5a67" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c3060bcb-b60e-4b26-8f9a-661c8f203253" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2e53cf22-0300-482b-8366-59b2d36f5a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c2c955a7-2189-44b1-9d3a-84b6b42182f1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2e53cf22-0300-482b-8366-59b2d36f5a67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c2c955a7-2189-44b1-9d3a-84b6b42182f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a6c7ed39-5818-4f0b-a7a8-8d30acd363f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a6c7ed39-5818-4f0b-a7a8-8d30acd363f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_f7f53a21-20fe-4839-a812-e69996a81288" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a6c7ed39-5818-4f0b-a7a8-8d30acd363f0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_f7f53a21-20fe-4839-a812-e69996a81288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_47986eb3-1c58-468a-922f-a9e9bb426a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_f7f53a21-20fe-4839-a812-e69996a81288" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_47986eb3-1c58-468a-922f-a9e9bb426a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_6fff5b2a-52d2-4fcc-b285-bfe98f6726ba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_6fff5b2a-52d2-4fcc-b285-bfe98f6726ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_8b8baaef-c55a-4668-b731-ce46b35d3222" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_6fff5b2a-52d2-4fcc-b285-bfe98f6726ba" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_8b8baaef-c55a-4668-b731-ce46b35d3222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AnnualSalesLevelMilestoneMember_a5403e48-072c-4936-b648-64e7a7a2d508" xlink:href="nktr-20200331.xsd#nktr_AnnualSalesLevelMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_8b8baaef-c55a-4668-b731-ce46b35d3222" xlink:to="loc_nktr_AnnualSalesLevelMilestoneMember_a5403e48-072c-4936-b648-64e7a7a2d508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneAxis_fac540d2-d93e-4ca0-9fc8-396639fa319f" xlink:href="nktr-20200331.xsd#nktr_MilestoneAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_nktr_MilestoneAxis_fac540d2-d93e-4ca0-9fc8-396639fa319f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneDomain_5e5c113d-19b2-40d5-a9de-8817f34ad7fe" xlink:href="nktr-20200331.xsd#nktr_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneAxis_fac540d2-d93e-4ca0-9fc8-396639fa319f" xlink:to="loc_nktr_MilestoneDomain_5e5c113d-19b2-40d5-a9de-8817f34ad7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneOneMember_232df5d5-8059-4799-876a-cc76eb2cab78" xlink:href="nktr-20200331.xsd#nktr_MilestoneOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_5e5c113d-19b2-40d5-a9de-8817f34ad7fe" xlink:to="loc_nktr_MilestoneOneMember_232df5d5-8059-4799-876a-cc76eb2cab78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneTwoMember_9f3045c0-6151-4bd0-881e-0d234a05d596" xlink:href="nktr-20200331.xsd#nktr_MilestoneTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_5e5c113d-19b2-40d5-a9de-8817f34ad7fe" xlink:to="loc_nktr_MilestoneTwoMember_9f3045c0-6151-4bd0-881e-0d234a05d596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_MilestoneThreeMember_eec0b039-b3c1-4d4b-932f-07a0b8973457" xlink:href="nktr-20200331.xsd#nktr_MilestoneThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nktr_MilestoneDomain_5e5c113d-19b2-40d5-a9de-8817f34ad7fe" xlink:to="loc_nktr_MilestoneThreeMember_eec0b039-b3c1-4d4b-932f-07a0b8973457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e7b2ef23-b732-435f-ae19-43a04f74ca8f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9db887d4-3be3-4d1e-b0c7-dceefa32e943" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9db887d4-3be3-4d1e-b0c7-dceefa32e943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SalesMilestoneRevenue_6c6040f3-2d29-4a16-a57a-fe4f3e707762" xlink:href="nktr-20200331.xsd#nktr_SalesMilestoneRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_SalesMilestoneRevenue_6c6040f3-2d29-4a16-a57a-fe4f3e707762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_72a3cf9e-a0eb-4cd6-ad7e-f41126d5ba46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_72a3cf9e-a0eb-4cd6-ad7e-f41126d5ba46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_64dd0eff-b093-4906-89bf-4cc87b903fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_64dd0eff-b093-4906-89bf-4cc87b903fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_1323938a-849e-4de5-92ac-bba7e5b46630" xlink:href="nktr-20200331.xsd#nktr_PotentialDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PotentialDevelopmentAndRegulatoryMilestones_1323938a-849e-4de5-92ac-bba7e5b46630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ProfitsAndLossesSharingPercentage_bd59d09d-a465-4b63-805a-e21ecfcc3fc3" xlink:href="nktr-20200331.xsd#nktr_ProfitsAndLossesSharingPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_ProfitsAndLossesSharingPercentage_bd59d09d-a465-4b63-805a-e21ecfcc3fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInDevelopmentCosts_e9c96637-0c55-47a1-ab15-9ba928721750" xlink:href="nktr-20200331.xsd#nktr_PercentageOfSharingInDevelopmentCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfSharingInDevelopmentCosts_e9c96637-0c55-47a1-ab15-9ba928721750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInProductionCosts_70a39440-a5af-48b4-92fd-c6f074fb1d96" xlink:href="nktr-20200331.xsd#nktr_PercentageOfSharingInProductionCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfSharingInProductionCosts_70a39440-a5af-48b4-92fd-c6f074fb1d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_1dafcdae-131c-4230-9349-e31ad99180e7" xlink:href="nktr-20200331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements_1dafcdae-131c-4230-9349-e31ad99180e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_7587f75c-31c5-4c2f-a59b-57c8e54451a8" xlink:href="nktr-20200331.xsd#nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones_7587f75c-31c5-4c2f-a59b-57c8e54451a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_e7106c91-63af-4262-87fc-f19d4719aa66" xlink:href="nktr-20200331.xsd#nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones_e7106c91-63af-4262-87fc-f19d4719aa66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6dfd338d-9d48-4706-82e4-4ac8f68d38d3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_SharesIssued_6dfd338d-9d48-4706-82e4-4ac8f68d38d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SaleOfStockConsiderationReceived_32633438-8092-4204-9d5f-e10cbb1aa7b3" xlink:href="nktr-20200331.xsd#nktr_SaleOfStockConsiderationReceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_SaleOfStockConsiderationReceived_32633438-8092-4204-9d5f-e10cbb1aa7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ReimbursementOfExpenses_852b2870-7e71-48f3-9256-a1ea6645cbf9" xlink:href="nktr-20200331.xsd#nktr_ReimbursementOfExpenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_ReimbursementOfExpenses_852b2870-7e71-48f3-9256-a1ea6645cbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_904d5ae1-1f6c-40cb-875d-bf5ef144b8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_904d5ae1-1f6c-40cb-875d-bf5ef144b8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AggregateConsiderationReceivedFromAgreements_c2526b06-1430-4345-893e-d629ce0e8771" xlink:href="nktr-20200331.xsd#nktr_AggregateConsiderationReceivedFromAgreements"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_AggregateConsiderationReceivedFromAgreements_c2526b06-1430-4345-893e-d629ce0e8771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_EstimatedFairValueOfShares_680760e8-b6c5-4cc6-9d88-c114723fbb92" xlink:href="nktr-20200331.xsd#nktr_EstimatedFairValueOfShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_EstimatedFairValueOfShares_680760e8-b6c5-4cc6-9d88-c114723fbb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_RemainingAmountAllocatedToTransactionPrice_b4886cd4-79a5-42a3-8edb-28a1d38e9df2" xlink:href="nktr-20200331.xsd#nktr_RemainingAmountAllocatedToTransactionPrice"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_RemainingAmountAllocatedToTransactionPrice_b4886cd4-79a5-42a3-8edb-28a1d38e9df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_f723383d-eb40-42af-99fc-989e9ebdd5c7" xlink:href="nktr-20200331.xsd#nktr_PotentialDevelopmentRegulatoryAndSalesMilestones"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones_f723383d-eb40-42af-99fc-989e9ebdd5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_be55436a-7e88-4f47-a853-731c4fa4f650" xlink:href="nktr-20200331.xsd#nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement_be55436a-7e88-4f47-a853-731c4fa4f650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_ae3d59a8-3d69-4a37-9e3e-0401a9d9f7ff" xlink:href="nktr-20200331.xsd#nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts_ae3d59a8-3d69-4a37-9e3e-0401a9d9f7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_a1a8ddb7-982f-42d0-8249-45101365344b" xlink:href="nktr-20200331.xsd#nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne_a1a8ddb7-982f-42d0-8249-45101365344b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_ae12a416-8bd9-467d-a674-84793be2f353" xlink:href="nktr-20200331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions_ae12a416-8bd9-467d-a674-84793be2f353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_a2035ea9-bb9e-4af5-a1be-7fa6c1216f54" xlink:href="nktr-20200331.xsd#nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur_a2035ea9-bb9e-4af5-a1be-7fa6c1216f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_9d696131-b8a4-4a7f-adcc-0bc579b16eb3" xlink:href="nktr-20200331.xsd#nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation_9d696131-b8a4-4a7f-adcc-0bc579b16eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ebe6271-5d7b-4b71-b681-f2356973a97d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6ebe6271-5d7b-4b71-b681-f2356973a97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f250c71e-a6f2-4b5d-b4c1-a048aabbaabb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f250c71e-a6f2-4b5d-b4c1-a048aabbaabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_b2c59957-a050-4204-868c-871323a970b9" xlink:href="nktr-20200331.xsd#nktr_PaymentsReceivedUnderRightsToSublicenseAgreement"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement_b2c59957-a050-4204-868c-871323a970b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_f0253a4b-dcd8-4636-a9bc-b1c70bf92aea" xlink:href="nktr-20200331.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner_f0253a4b-dcd8-4636-a9bc-b1c70bf92aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_0795a09c-f1a3-4434-a869-3c377fde2a8a" xlink:href="nktr-20200331.xsd#nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments_0795a09c-f1a3-4434-a869-3c377fde2a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_PotentialDevelopmentMilestones_333375f2-9e21-46c3-9b1a-147f48f23547" xlink:href="nktr-20200331.xsd#nktr_PotentialDevelopmentMilestones"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0754b3da-7b6c-479c-a1c8-a236f8268c68" xlink:to="loc_nktr_PotentialDevelopmentMilestones_333375f2-9e21-46c3-9b1a-147f48f23547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_217e8547-d40c-4d29-a37b-91640801a3d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1314af11-2978-44e8-b786-6eddad5213dd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_217e8547-d40c-4d29-a37b-91640801a3d6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1314af11-2978-44e8-b786-6eddad5213dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dc78334e-b855-4538-aff7-b8e296a23585" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_217e8547-d40c-4d29-a37b-91640801a3d6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_dc78334e-b855-4538-aff7-b8e296a23585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_85e0541f-5020-44e0-9f80-036994cfcbd4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_217e8547-d40c-4d29-a37b-91640801a3d6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_85e0541f-5020-44e0-9f80-036994cfcbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f72b25f-e324-4bc7-83a3-566463768a75" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7cf91491-0d86-4d5e-9e67-20b506b82df5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f72b25f-e324-4bc7-83a3-566463768a75" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7cf91491-0d86-4d5e-9e67-20b506b82df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13f9f1f0-3939-469c-8d86-e5f253ff8721" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_763c28bd-d3b4-4c27-ab48-3d3cc08831c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13f9f1f0-3939-469c-8d86-e5f253ff8721" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_763c28bd-d3b4-4c27-ab48-3d3cc08831c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_63813230-8a60-47a4-9dc7-59340740fa46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13f9f1f0-3939-469c-8d86-e5f253ff8721" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_63813230-8a60-47a4-9dc7-59340740fa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c47c57c-0950-4d6b-a49e-c09d8676c85f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79134265-9da5-4e3d-a370-7fb04cc6a218" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6c47c57c-0950-4d6b-a49e-c09d8676c85f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79134265-9da5-4e3d-a370-7fb04cc6a218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6ede7ccc-4a9d-4767-b7c3-dc716bc1e980" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79134265-9da5-4e3d-a370-7fb04cc6a218" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6ede7ccc-4a9d-4767-b7c3-dc716bc1e980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6ede7ccc-4a9d-4767-b7c3-dc716bc1e980" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_3d17f954-cae6-42fa-9bcf-7228589f29d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:to="loc_us-gaap_CostOfSalesMember_3d17f954-cae6-42fa-9bcf-7228589f29d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4233d8ef-e440-40bf-b75b-211a2fac2940" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4233d8ef-e440-40bf-b75b-211a2fac2940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_97ef9feb-0dfc-4834-b8d1-7280fa1c487b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_97ef9feb-0dfc-4834-b8d1-7280fa1c487b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_ImpairmentAndOtherMember_c96ff22d-170c-4789-b232-fd37a15603d7" xlink:href="nktr-20200331.xsd#nktr_ImpairmentAndOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e898e1b0-78a8-4241-adc6-9fa3b931c908" xlink:to="loc_nktr_ImpairmentAndOtherMember_c96ff22d-170c-4789-b232-fd37a15603d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2262d610-b44f-4333-8241-b482cb9851b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79134265-9da5-4e3d-a370-7fb04cc6a218" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2262d610-b44f-4333-8241-b482cb9851b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_db9c4007-bf1a-48f1-ba5f-5451c804b2c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2262d610-b44f-4333-8241-b482cb9851b4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_db9c4007-bf1a-48f1-ba5f-5451c804b2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#StockBasedCompensationActivityDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/StockBasedCompensationActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_900376cf-030a-4056-95af-a27974037174" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bdf786a-4a19-420e-8453-c656606ec84b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_900376cf-030a-4056-95af-a27974037174" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bdf786a-4a19-420e-8453-c656606ec84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd616bb0-b8be-42e8-a95d-0dac1f96a75f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bdf786a-4a19-420e-8453-c656606ec84b" xlink:to="loc_us-gaap_AwardTypeAxis_cd616bb0-b8be-42e8-a95d-0dac1f96a75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d56af436-cf0e-4611-ac5e-cf9d51e08bd6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cd616bb0-b8be-42e8-a95d-0dac1f96a75f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d56af436-cf0e-4611-ac5e-cf9d51e08bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_719b7028-cd3b-406a-a7cd-2f1c785f59b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d56af436-cf0e-4611-ac5e-cf9d51e08bd6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_719b7028-cd3b-406a-a7cd-2f1c785f59b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_83013f50-1258-4cdc-a1e1-8baad54d8c09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d56af436-cf0e-4611-ac5e-cf9d51e08bd6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_83013f50-1258-4cdc-a1e1-8baad54d8c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8bdf786a-4a19-420e-8453-c656606ec84b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6af20fcd-bf6d-447a-a042-ee3ba38559ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_6af20fcd-bf6d-447a-a042-ee3ba38559ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da4a9089-6953-47ed-a25d-4afe4c1893c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da4a9089-6953-47ed-a25d-4afe4c1893c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ffbda399-c3c3-4288-955a-da3c6011465f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ffbda399-c3c3-4288-955a-da3c6011465f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6ca98cf-78f2-4936-8883-ac1096b0d207" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e6ca98cf-78f2-4936-8883-ac1096b0d207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54f0394c-c013-4e4f-af4e-9d6e684e3d35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24d88cd3-06f7-4873-9ced-91775b4fee44" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_54f0394c-c013-4e4f-af4e-9d6e684e3d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShare" xlink:type="simple" xlink:href="nktr-20200331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_04d8cef2-80b5-49cb-88f2-83e844a45542" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6ffbe5b9-056b-4a73-94c7-db1642347746" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_04d8cef2-80b5-49cb-88f2-83e844a45542" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6ffbe5b9-056b-4a73-94c7-db1642347746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail" xlink:type="simple" xlink:href="nktr-20200331.xsd#NetLossPerShareAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fd7f7148-9165-4775-9430-e41e3606e635" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97b276f4-1efd-431c-94e1-f6c3a11438cc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fd7f7148-9165-4775-9430-e41e3606e635" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97b276f4-1efd-431c-94e1-f6c3a11438cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e0d8f14-1041-4cf3-b290-53960416070c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97b276f4-1efd-431c-94e1-f6c3a11438cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e0d8f14-1041-4cf3-b290-53960416070c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_590a6735-8b38-45f8-b037-6c13d74bc079" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2e0d8f14-1041-4cf3-b290-53960416070c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_590a6735-8b38-45f8-b037-6c13d74bc079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_1ab40306-3958-4144-9fd7-86dd9e639e98" xlink:href="nktr-20200331.xsd#nktr_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_590a6735-8b38-45f8-b037-6c13d74bc079" xlink:to="loc_nktr_StockOptionsAndRestrictedStockUnitsMember_1ab40306-3958-4144-9fd7-86dd9e639e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_121a75eb-6e2b-4c2a-9479-0c762f7c96e2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_97b276f4-1efd-431c-94e1-f6c3a11438cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_121a75eb-6e2b-4c2a-9479-0c762f7c96e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_30f8d14e-dc97-404d-a188-237bc38cea02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_121a75eb-6e2b-4c2a-9479-0c762f7c96e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_30f8d14e-dc97-404d-a188-237bc38cea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEvent" xlink:type="simple" xlink:href="nktr-20200331.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_21b98474-9a83-47ad-9c77-6b6a9c597145" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1c419ffe-af84-4f08-8525-971242c516f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_21b98474-9a83-47ad-9c77-6b6a9c597145" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1c419ffe-af84-4f08-8525-971242c516f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="nktr-20200331.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.nektar.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9526a4de-76f7-4974-b4af-eca540c2c8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9526a4de-76f7-4974-b4af-eca540c2c8a7" xlink:to="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_31c418b2-694b-430d-84c0-7c72cf699a61" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_31c418b2-694b-430d-84c0-7c72cf699a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fcf858cc-d913-4271-9f27-de39fe98556b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_31c418b2-694b-430d-84c0-7c72cf699a61" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fcf858cc-d913-4271-9f27-de39fe98556b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5525bac0-6bf6-4b3b-a3a7-f0311776ce59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fcf858cc-d913-4271-9f27-de39fe98556b" xlink:to="loc_us-gaap_SubsequentEventMember_5525bac0-6bf6-4b3b-a3a7-f0311776ce59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d5fb30e6-2350-46da-81af-b1b0d14664af" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:to="loc_us-gaap_DebtInstrumentAxis_d5fb30e6-2350-46da-81af-b1b0d14664af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9f3b6c2b-985f-440f-8747-02b9ed43c0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d5fb30e6-2350-46da-81af-b1b0d14664af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9f3b6c2b-985f-440f-8747-02b9ed43c0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_3173f0d6-83d5-4fe0-8724-831888e4748c" xlink:href="nktr-20200331.xsd#nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9f3b6c2b-985f-440f-8747-02b9ed43c0e6" xlink:to="loc_nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember_3173f0d6-83d5-4fe0-8724-831888e4748c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_037eb12e-67cd-4365-9797-e488dcf05faa" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_037eb12e-67cd-4365-9797-e488dcf05faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_92eafe54-4a14-4e56-818a-b2068e8fc9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_037eb12e-67cd-4365-9797-e488dcf05faa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_92eafe54-4a14-4e56-818a-b2068e8fc9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_fdfe4189-5e56-461c-b30e-ef66f05c50a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_92eafe54-4a14-4e56-818a-b2068e8fc9c6" xlink:to="loc_us-gaap_SeniorNotesMember_fdfe4189-5e56-461c-b30e-ef66f05c50a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b0b30355-818a-4bb5-b565-ae3e2f905f09" xlink:to="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_88e1ad67-0811-4e59-9733-997540e14d34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:to="loc_us-gaap_SeniorNotes_88e1ad67-0811-4e59-9733-997540e14d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6af50ebe-645e-4bce-ba8f-1b7c5ed4c8ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6af50ebe-645e-4bce-ba8f-1b7c5ed4c8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d9ae4384-1858-4c33-9bcc-99d78b935198" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d9ae4384-1858-4c33-9bcc-99d78b935198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_dc8529fe-9de3-4ed8-bab5-441944c7f9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9647ffc5-403b-43a5-a426-da22e84911e8" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_dc8529fe-9de3-4ed8-bab5-441944c7f9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6608372112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Detail) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsAndRestrictedStockUnitsMember', window );">Stock Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">18.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nktr_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6835282560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">76 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2018</div></th>
<th class="th"><div>Aug. 23, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jan. 09, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized in period related to performance in prior periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,600,000<span></span>
</td>
<td class="nump">$ 19,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,517,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,554,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,554,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,554,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,802,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,573,000<span></span>
</td>
<td class="nump">28,222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,071,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SalesMilestoneRevenue', window );">Sales Milestone Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements', window );">Upfront and milestone payments received from license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones', window );">Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones', window );">Eligible additional cash payments receivable upon achievement of certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Opdivo and Yervoy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember', window );">NKTR-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_NektarMember', window );">Nektar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments', window );">Percentage of upfront payment, market access milestones, royalties and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated/Takeda | Hemophilia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement', window );">Received under right to sublicense agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated/Takeda | Hemophilia | Annual Sales Level Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember', window );">Baxalta Incorporated/Takeda | Hemophilia | European Union</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,284,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_SaleOfStockConsiderationReceived', window );">Sale of stock consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Bempegaldesleukin | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ReimbursementOfExpenses', window );">Reimbursement of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,700,000<span></span>
</td>
<td class="nump">$ 28,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AggregateConsiderationReceivedFromAgreements', window );">Total consideration received under agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedFairValueOfShares', window );">Estimated fair value of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RemainingAmountAllocatedToTransactionPrice', window );">Remaining amount allocated to transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones', window );">Potential future development, regulatory and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | Bempegaldesleukin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProfitsAndLossesSharingPercentage', window );">Global commercialization profits and losses sharing percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInProductionCosts', window );">Percentage of sharing production costs</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | Bempegaldesleukin | Opdivo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">67.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | BMS Collaboration Agreement | Bempegaldesleukin | Opdivo and Yervoy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInDevelopmentCosts', window );">Percentage of sharing development costs</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentAndRegulatoryMilestones', window );">Potential future additional development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Nektar's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions', window );">Percentage of regulatory milestones payments will be reduced under certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur', window );">Percentage of regulatory milestones payments will be reduced if conditions occur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Nektar's | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358 | Nektar's | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne', window );">Percentage of funding phase 3 development costs on an indication by indication basis borne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Phase 1 Clinical Development | NKTR-358 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | Drug Product Development | NKTR-358 License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation', window );">Amount of transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyMember', window );">Eli Lilly | NKTR-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts', window );">Percentage of sharing in Phase 2 development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB | MOVANTIK and MOVENTIG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement', window );">Received upfront and milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember', window );">AstraZeneca AB | AstraZeneca-Kirin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner', window );">Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PotentialDevelopmentMilestones', window );">Potential future additional payments for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AggregateConsiderationReceivedFromAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate consideration received from agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AggregateConsiderationReceivedFromAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible additional cash payments receivable upon achievement of certain sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PaymentsReceivedUnderRightsToSublicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments received under rights to sublicense agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PaymentsReceivedUnderRightsToSublicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received, if conditions occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development milestones payments, to be received under certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of funding Phase three development costs on an indication by indication basis borne.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in Phase 2 development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfSharingInProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sharing in production costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfSharingInProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PotentialDevelopmentRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development regulatory and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PotentialDevelopmentRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProfitsAndLossesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profits and losses sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProfitsAndLossesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ReimbursementOfExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ReimbursementOfExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RemainingAmountAllocatedToTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amount allocated to transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RemainingAmountAllocatedToTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SaleOfStockConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SaleOfStockConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_SalesMilestoneRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_SalesMilestoneRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received from license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and milestone payments received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NektarTwoOneFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NektarTwoOneFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_MilestoneAxis=nktr_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_MilestoneAxis=nktr_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoAndYervoyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoAndYervoyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrTakedaPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=nktr_AnnualSalesLevelMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=nktr_AnnualSalesLevelMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NektarThreeFiveEightLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NektarThreeFiveEightLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PhaseOneClinicalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_DrugProductDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AstraZenecaAbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AstraZenecaAbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVENTIGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVENTIGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6633912208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">License and Collaboration AgreementsWe have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. <div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. </span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.856%;"><tr><td style="width:1.0%;"/><td style="width:41.597%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.519%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:29.223%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.519%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.510%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.519%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.513%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Partner</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Drug or Drug Candidate</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Bristol-Myers Squibb Company</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Eli Lilly and Company</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NKTR-358</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amgen, Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Neulasta</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">454&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">License, collaboration and other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,204&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March&#160;31, 2020 and 2019, we recognized $44.6&#160;million and $19.6&#160;million, respectively, of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue, as well as the $25.0&#160;million milestone received under our BMS Collaboration Agreement during the three months ended March&#160;31, 2020 described below, because we had previously completed our performance obligations of granting the licenses. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the three months ended March&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.712%;"><tr><td style="width:1.0%;"/><td style="width:83.734%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.266%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue&#8212;December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,071&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recognition of previously unearned revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,510)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue&#8212;March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,561&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $1.7 billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no material changes to our collaboration agreements in the three months ended March&#160;31, 2020, except as described below.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Bristol-Myers Squibb Company (BMS)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">: Bempegaldesleukin, also referred to as NKTR-214 </span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. The agreement replaced the Clinical Trial Agreement we had entered into in September 2016. Pursuant to these current agreements, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#8217;s Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (nivolumab) and Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> plus Yervoy</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ipilimumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#8217;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, 67.5% of costs to BMS and 32.5% to Nektar, and for bempegaldesleukin in a triplet combination with Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and Yervoy</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174; </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">78% of costs to BMS and 22% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, 35% of costs to BMS and 65% to Nektar.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0 billion. We are eligible to receive additional cash payments up to a total of approximately $1.45 billion (including the milestones from Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones and up to a total of $350.0 million upon the achievement of certain sales milestones. In April 2018, BMS also </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0 million.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. Additionally, we are eligible to receive an additional non-refundable, non-creditable milestone payment of $25.0&#160;million following the achievement of the first patient, first visit in the registrational adjuvant melanoma trial, studying the combination of bempegaldesleukin and Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. We are also eligible to receive non-refundable, creditable milestone payments of $25.0&#160;million and $75.0&#160;million following the achievement of the first patient, first visit in a registrational muscle-invasive bladder cancer trial and a registrational first-line non-small-cell lung cancer trial, respectively, in each case studying the combination of bempegaldesleukin and Opdivo</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. For the two creditable milestones, BMS is entitled to deduct the amounts paid pursuant to these milestones from future development milestones due to us under the original agreement. On January 30, 2020, the milestone for the first patient, first visit milestone for the registrational muscle-invasive bladder cancer trial was achieved, and BMS paid us the $25.0&#160;million milestone in March 2020.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determined that the BMS Collaboration Agreement falls within the scope of ASC 808, and we analogized to ASC 606 for the accounting for our performance obligation of the delivery of the licenses to develop and commercialize bempegaldesleukin.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2018, we aggregated the total consideration of $1.85 billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $790.2 million in stockholders&#8217; equity. We allocated the remaining $1,059.8 million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones of up to approximately $1.8 billion to be variable consideration. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, we updated the transaction price by $25.0&#160;million for the achievement of the first patient, first visit in the registrational muscle invasive bladder cancer trial. Since we had already completed our sole performance obligations of delivery of the licenses, we recognized this $25.0&#160;million in license, collaboration and other revenue during the three months ended March 31, 2020. We continue to exclude the other milestones from the transaction price as of March&#160;31, 2020 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#8217; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#8217; costs as research and development expense. During the three months ended March&#160;31, 2020 and 2019, we recorded $30.7&#160;million and $28.8&#160;million, respectively, as a reduction of research and development expense for BMS&#8217; share of our expenses, net of our share of BMS&#8217; expenses.&#160;As of March&#160;31, 2020, we have recorded an unbilled receivable of $31.2&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Eli Lilly and Company (Lilly</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">): NKTR-358 </span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $150.0 million in September 2017 and are eligible for up to $250.0 million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and are responsible for certain drug product development and supply activities, (iii) will share with Lilly Phase 2 development costs with 75% of those costs borne by Lilly and 25% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from zero to 25% of development costs, and (v) will have the opportunity to receive up to double-digit sales royalty rates that escalate based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We identified our license grant to Lilly, our ongoing Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#8217;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we are entitled to significant development milestones under this arrangement, through March&#160;31, 2020, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of $150.0 million in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $150.0 million upfront payment as $125.9 million to the license, $17.6 million to our portion of the Phase 1 clinical development and $6.5 million to the drug product development.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized the $125.9 million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of March&#160;31, 2020, we completed our performance obligations and we have no deferred revenue related to this agreement.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Baxalta Inc. / Takeda Pharmaceutical Company Ltd</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">: Hemophilia</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Hemophilia A program includes ADYNOVATE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which was approved by the United States Food and Drug Administration (FDA) in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a $10.0 million development milestone, which we received in March 2018. During 2018, we earned an additional $10.0 million milestone for annual sales of ADYNOVATE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">/ ADYNOVI</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#8482;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> reaching a certain specified amount.&#160;In addition, we are entitled to an additional sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.</span></div><div style="text-indent:31.5pt;text-align:justify;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us $12.0 million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of March&#160;31, 2020, our deferred revenue from this arrangement is not significant.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Amgen, Inc</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">.: Neulasta</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the Amended and Restated Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the Amended and Restated Agreement, we received a $50.0 million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We determined that our obligation to manufacture and supply our PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#8217;s right to require production of PEGylation materials at any time. As of March&#160;31, 2020, we have deferred revenue of approximately $2.9 million related to this agreement, which we expect to recognize through October 2020, the estimated end of our obligations under this agreement.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">AstraZeneca AB</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">: MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(naloxegol oxalate), previously referred to as naloxegol and NKTR-118 </span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In September 2014 and December 2014, MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> /MOVENTIG</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was approved in the US and EU, respectively. As of March&#160;31, 2020, we have received a total of $385.0 million of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving 60% and Nektar receiving 40%. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we do not have deferred revenue related to our agreement with AstraZeneca.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, excluding Europe, Canada and Israel, to RedHill Biopharma. This sublicense does not change our rights under the agreement with AstraZeneca and our royalty rate, royalty term and future potential sales milestones remain unchanged.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, as of March&#160;31, 2020, we have other collaboration agreements, including with our collaboration partner UCB Pharma, under which we are entitled to up to a total of $40.0 million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of March&#160;31, 2020, we have deferred revenue of approximately $2.0 million related to these other collaboration agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813706896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Organization</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer and autoimmune disease.</span></div>Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Principles of Consolidation</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2020 and 2019.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2019 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 filed with the SEC on February 28, 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassifications</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss), which totaled $1.1&#160;million for the three months ended March 31, 2019. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment Information</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Significant Concentrations</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Concentrations</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of March 31, 2020, our accounts receivable includes $10.9&#160;million under customer contracts from our collaboration partners and $31.2 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $12.8&#160;million from customer contracts and $24.0 million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable. We have not recorded a reserve for credit losses at March 31, 2020 or December 31, 2019.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services, automotive and food and beverage industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been </span></div>downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaborative Arrangements</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product Sales</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalty Revenue</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License, Collaboration and other Revenue</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">License Grants</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone Payments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. Our partners generally pay development milestones</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">subsequent to</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">achievement of the triggering event.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Services</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expense</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div>As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821586736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_PreferredStockShareDesignated', window );">Preferred stock, shares designated (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">177,863,000<span></span>
</td>
<td class="nump">176,505,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801582064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (138,651)<span></span>
</td>
<td class="num">$ (119,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="num">(9,895)<span></span>
</td>
<td class="num">(8,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="nump">6,968<span></span>
</td>
<td class="nump">6,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">25,236<span></span>
</td>
<td class="nump">25,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,502<span></span>
</td>
<td class="nump">3,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram', window );">Impairment of advance payments to contract manufacturers and equipment for terminated program</a></td>
<td class="nump">20,351<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Accretion of premiums (discounts), net and other non-cash transactions</a></td>
<td class="num">(1,289)<span></span>
</td>
<td class="num">(3,183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(5,229)<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,655)<span></span>
</td>
<td class="num">(397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities', window );">Operating leases, net</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="nump">1,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">4,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,687<span></span>
</td>
<td class="nump">5,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">9,920<span></span>
</td>
<td class="nump">8,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="nump">7,716<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(2,510)<span></span>
</td>
<td class="num">(4,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(233)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(78,075)<span></span>
</td>
<td class="num">(80,895)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(241,068)<span></span>
</td>
<td class="num">(368,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">439,735<span></span>
</td>
<td class="nump">362,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(900)<span></span>
</td>
<td class="num">(5,648)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">197,767<span></span>
</td>
<td class="num">(12,138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued under equity compensation plans</a></td>
<td class="nump">11,077<span></span>
</td>
<td class="nump">4,894<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">11,077<span></span>
</td>
<td class="nump">4,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">130,672<span></span>
</td>
<td class="num">(88,153)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">96,363<span></span>
</td>
<td class="nump">194,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">227,035<span></span>
</td>
<td class="nump">106,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4,951<span></span>
</td>
<td class="nump">4,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset recognized in exchange for lease liabilities</a></td>
<td class="nump">$ 2,133<span></span>
</td>
<td class="nump">$ 1,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfEquipmentFromTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Equipment From Terminated Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfEquipmentFromTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based compensation arrangement, excluding stock option exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809090528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.994%;"><tr><td style="width:1.0%;"/><td style="width:74.052%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.611%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.612%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">761&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,453&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,997&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,942&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-based Compensation, Activity</a></td>
<td class="text"><div style="text-indent:31.5pt;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.994%;"><tr><td style="width:1.0%;"/><td style="width:74.052%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.611%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.612%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted-average grant-date fair value of options granted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.88&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RSUs granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,358&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">698&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801498896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, available-for-sale, accumulated gross unrealized gain, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 5,994<span></span>
</td>
<td class="nump">5,829<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">1,531,782<span></span>
</td>
<td class="nump">1,603,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, available-for-sale, amortized cost</a></td>
<td class="nump">1,362,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, available-for-sale, accumulated gross unrealized gain, before tax</a></td>
<td class="nump">830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</a></td>
<td class="nump">4,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">1,359,460<span></span>
</td>
<td class="nump">1,507,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Notes and Bonds | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, available-for-sale, amortized cost</a></td>
<td class="nump">989,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, available-for-sale, accumulated gross unrealized gain, before tax</a></td>
<td class="nump">736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</a></td>
<td class="nump">4,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">986,237<span></span>
</td>
<td class="nump">1,132,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Corporate Commercial Paper | Fair Value Hierarchy Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, available-for-sale, amortized cost</a></td>
<td class="nump">373,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, available-for-sale, accumulated gross unrealized gain, before tax</a></td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, available-for-sale accumulated gross unrealized loss, before tax</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale investments</a></td>
<td class="nump">373,223<span></span>
</td>
<td class="nump">375,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Fair Value Hierarchy Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">158,080<span></span>
</td>
<td class="nump">83,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments in marketable securities</a></td>
<td class="nump">$ 8,248<span></span>
</td>
<td class="nump">$ 6,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6824025072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 27,515<span></span>
</td>
<td class="nump">$ 4,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember', window );">Bristol-Myers Squibb Company | Bempegaldesleukin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember', window );">Eli Lilly and Company | NKTR-358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_AmgenIncMember', window );">Amgen, Inc. | Neulasta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=nktr_OtherPartnerMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LicenseCollaborationOtherRevenue', window );">License, collaboration and other revenue</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseAndCollaborationAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseAndCollaborationAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LicenseCollaborationOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LicenseCollaborationOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarTwoOneFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarTwoOneFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_NeulastaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=nktr_OtherPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=nktr_OtherPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821272928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 227,035<span></span>
</td>
<td class="nump">$ 96,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">1,118,847<span></span>
</td>
<td class="nump">1,228,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">42,031<span></span>
</td>
<td class="nump">36,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">14,320<span></span>
</td>
<td class="nump">12,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AdvancePaymentsToContractManufacturers', window );">Advance payments to contract manufacturers</a></td>
<td class="nump">13,280<span></span>
</td>
<td class="nump">31,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">13,811<span></span>
</td>
<td class="nump">15,731<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,429,324<span></span>
</td>
<td class="nump">1,421,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">185,900<span></span>
</td>
<td class="nump">279,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">62,307<span></span>
</td>
<td class="nump">65,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">133,901<span></span>
</td>
<td class="nump">134,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,501<span></span>
</td>
<td class="nump">76,501<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,887,933<span></span>
</td>
<td class="nump">1,977,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotesCurrent', window );">Senior secured notes, net and interest payable</a></td>
<td class="nump">254,144<span></span>
</td>
<td class="nump">252,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">21,789<span></span>
</td>
<td class="nump">19,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">22,412<span></span>
</td>
<td class="nump">11,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedClinicalTrialExpensesCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">38,624<span></span>
</td>
<td class="nump">32,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_AccruedContractManufacturingExpenseCurrent', window );">Accrued contract manufacturing expenses</a></td>
<td class="nump">8,579<span></span>
</td>
<td class="nump">7,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">11,844<span></span>
</td>
<td class="nump">11,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">15,613<span></span>
</td>
<td class="nump">12,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">3,007<span></span>
</td>
<td class="nump">5,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="nump">1,692<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">377,471<span></span>
</td>
<td class="nump">354,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">142,297<span></span>
</td>
<td class="nump">142,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts', window );">Liability related to the sale of future royalties, net</a></td>
<td class="nump">69,185<span></span>
</td>
<td class="nump">72,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, less current portion</a></td>
<td class="nump">2,554<span></span>
</td>
<td class="nump">2,554<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">591,507<span></span>
</td>
<td class="nump">571,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2020 or December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000 shares authorized; 177,863 shares and 176,505 shares outstanding at March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,306,655<span></span>
</td>
<td class="nump">3,271,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,877)<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,003,369)<span></span>
</td>
<td class="num">(1,864,718)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,296,426<span></span>
</td>
<td class="nump">1,405,391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,887,933<span></span>
</td>
<td class="nump">$ 1,977,356<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedClinicalTrialExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedClinicalTrialExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AccruedContractManufacturingExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AccruedContractManufacturingExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_AdvancePaymentsToContractManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of advance payments to contract manufacturers, net of amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_AdvancePaymentsToContractManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties non current net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821833376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,717,575<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 3,147,925<span></span>
</td>
<td class="num">$ (6,316)<span></span>
</td>
<td class="num">$ (1,424,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 5,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">25,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(114,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,720<span></span>
</td>
<td class="num">(119,632)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">1,633,511<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,178,773<span></span>
</td>
<td class="num">(1,596)<span></span>
</td>
<td class="num">(1,543,683)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,405,391<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">3,271,097<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
<td class="num">(1,864,718)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">1,358,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares issued under equity compensation plans</a></td>
<td class="nump">$ 11,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">24,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(144,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,872)<span></span>
</td>
<td class="num">(138,651)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 1,296,426<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 3,306,655<span></span>
</td>
<td class="num">$ (6,877)<span></span>
</td>
<td class="num">$ (2,003,369)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805320080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember', window );">Indemnification Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Litigation matters, liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_IndemnificationGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809105040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">License, Collaboration and Other Revenue</a></td>
<td class="text"><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.856%;"><tr><td style="width:1.0%;"/><td style="width:41.597%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.519%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:29.223%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.519%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.510%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.519%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.513%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Partner</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Drug or Drug Candidate</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Bristol-Myers Squibb Company</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Bempegaldesleukin</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Eli Lilly and Company</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">NKTR-358</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,259&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amgen, Inc.</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Neulasta</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,250&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">454&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">License, collaboration and other revenue</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,204&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Changes in Deferred Revenue Balance from Collaboration Agreements</a></td>
<td class="text"><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in our deferred revenue balance from our collaboration agreements during the three months ended March&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.712%;"><tr><td style="width:1.0%;"/><td style="width:83.734%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.266%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue&#8212;December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,071&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recognition of previously unearned revenue</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,510)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred revenue&#8212;March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,561&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6822636624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaximumMaturityPeriod', window );">Maximum maturity term for debt securities investment</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_DebtInvestmentMaturityTerm', window );">Weighted average maturity term for debt securities investment (or less)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Available-for-sale securities, sold</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes</a></td>
<td class="nump">254,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes, principal amount</a></td>
<td class="nump">254,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivable</a></td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems', window );"><strong>Cash and Investments in Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LongTermInvestmentMaturityPeriod', window );">Long term investment maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashAndInvestmentsInMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Investments in Marketable Securities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashAndInvestmentsInMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maturity date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_DebtInvestmentMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt investment maximum maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_DebtInvestmentMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LongTermInvestmentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term investment maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LongTermInvestmentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>nktr-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nktr="http://www.nektar.com/20200331"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nktr-20200331.xsd" xlink:type="simple"/>
    <context id="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0d9e59819bcb48b9afca31437d7dd506_I20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-05-01</instant>
        </period>
    </context>
    <context id="ifbb4be8e78984f9b982e39128071667a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i92b3ad4ac67b4455a3c9802320152891_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i206c822e44844e6d8c9a8878d54cdb82_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5a678b6b3e864f2eb9b2e381794c4da8_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0efadd0052274204bbd4eee79288b4ea_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i579879be3d9d4e9ba231135652799fc0_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i019e7c29ebdc411b8f4ab036df57ab24_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5fbbd193f91f4e33836cd1cc651690b0_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ia710b16c060f49b094bdb84fe9f40c6d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic5bc0b330b3b43cd89330149bc3a1b21_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:LicenseCollaborationAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie5fdaed97d5a4bbd8922f30a1bd1e928_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i241a6ffe64d345b9b815f1b853ee9a79_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6be903b189ea47d2b3464ca31dbef069_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8fbb869dd6324f779968528868504d9f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8a0d62a4e534478a8f3dbd0b9c4a9d82_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0c2a3f7bdb424534b926f3598ed9653a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0ab56b00693644e9a5c6ff7f3dc0c0b3_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id49c1db014fc497d8472960ad4070a17_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i768ed2c4850c48f6a6500688f1a016e3_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ibc5d122cc68f41fc93209ede839c32a7_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ic9b47f5237864755aefc5562482c7fbd_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8547a8cca34a4758b81996732bc8f2f1_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia1121ec1c4f3499a8e410586cc1cbf3d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i941b5c3651924990ab68ad8cb3e8b2de_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i86ea8909183e4a519a2620f8ba50b115_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic76656708b514c009c3d779f4b128f64_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i15e5dfd53d9c4e07acc0e26501a67651_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifaabcaf066d24b2686f0349b89851a2e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7873bda1e2354f1ab9d6905b20c6b9e4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iea1dfe0226d44464a9003812ad216e56_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia9377ff38abc4416a7a66a775c05241e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0278c7d606b04e5eba2f454a342be177_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6500865a65a8437f8ee292f8fd4d7655_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ida2d9e34320a44d7aa3415f6dd51c7fd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie78ccec663024b2cb3701efac4a6e73c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2052866c6650444f9b65d63e1fe916eb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i617c906b489448d0a219e5d6dd99ee13_D20200413-20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <context id="ie5764993ab504d65aacd5098dfb7222c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i657f08c144a940829954faa0eeb0ad80_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i25dac032704d462cb271e24170497260_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:CollaborationPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ec364a7590642378be3d04fe71fb93b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i68abed833c9c4661bbe068761870699a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NKTR181Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i632345d08db6484894d70ab3ce958364_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib5116a61e3b14a5f838ca99d6f39919b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9c8f5c54957945ab9e0c8833712982bb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id43bdc0f960a40e680fd02bc07f10995_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i51acd3b95c4149dc8cd83ecdfa9b12b1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id7f7eb1f87944780a02ca9ee1d9db1bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5afc4a43bd794ef8adb57279613cc1dd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i938a9e31f4a64af492d8c31056483e3f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i07085c452e9e46fe9f8b9074ea3df31a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia82602267fa24e74b8fe2c74cf36b690_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib1849ac1a92f46c5ae1b8a55162ddd3c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i392410be9f884e3dba660113995bcb25_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c61034529c24a02ad03caceb320bacc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i848f5b28c13943a9a8360104ac654571_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i55ebaedb84964cd4b5712ade47ad52d9_D20120223-20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-02-23</startDate>
            <endDate>2012-02-24</endDate>
        </period>
    </context>
    <context id="i420c7f47313d4e2793bf297d5ef97ff1_I20120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-02-24</instant>
        </period>
    </context>
    <context id="ia994984450184042ba5fc3190eb272a1_D20120223-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2012-02-23</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ife966253eae849efaf2c94d1e31949be_D20171001-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i39de4441ca0e49f2a86c258e4f2b6611_D20181001-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia10a44927680469a914aaa3781e9e7dd_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i428e2157a70c43f3a299cacec891a04c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8757df3c4b9949b5a56ec0f462c39d45_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:IndemnificationGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1492124b62b94996a7f0d95f8f8f292c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4c8b3e65156e43079d5d07536ba9b742_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie32189417fc6405184490d6c99a30561_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i473c9cb95deb4ee889c81eb1819eea3d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id516ba896043456c9bdbb51852afcdc0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib2341951fc6949bb9192ad91d2f02f07_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NeulastaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iefc95f69692243d1831202814f3ecaef_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i43f3a718f036485cabdfa41cfb7ef6b3_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i64f7bf13694b434da50607cc92511ae6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iba0f97bcb4b4439498c18a0cee8d7459_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i9195970c9dc0457185dab641c8cb1b46_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i7669b30a20914aa29e59f95f80c6ce1d_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i60c9630119f2431abfe04edb5e2fb3ed_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="ifd93624e0fb543c2b0ac79d91fd72357_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoAndYervoyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i4279aa6d740d409f9971a4360326a569_D20180212-20180213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">nktr:OpdivoAndYervoyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-12</startDate>
            <endDate>2018-02-13</endDate>
        </period>
    </context>
    <context id="i78cc054f78e14454a10bbf7594a284a7_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ife19b7e801a54e7aaa7298b8de21446d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0111201aa93e4b82bb4611c26ba6b748_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="id3f27473571a48dd830b6f580001f835_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="if758da7137704b02aeb393bbd5f6d719_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ib5a5a0cd127f4c7bb5c3c685ed7d0af3_I20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="ifc7fd90c5f154037a6e40bfef3b6fc10_I20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="idfbf1bae2fe14c92aa3559eb0012ec75_I20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nktr:MilestoneAxis">nktr:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="i013cfcd2f2bd4e028e742adb05277f94_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic5a469ebee04424493829d25d002dafe_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i6952cb9044694778b60945d87960f80d_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i502169e6083e4ed8aadfa58300dc99f2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nktr:SharePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i176a8a9518ea4b9299405db0af88f09a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1bc208f913d540b49395ca3743b4185d_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarTwoOneFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib630cc6da28d48d4b7c4878a9fd1f551_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:BMSCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i29f2903dd705405e9a99ce471b09643c_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i4abc773305a245a49879e92f7a2d8ec1_I20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-23</instant>
        </period>
    </context>
    <context id="ic6cffd33a538441793df552a4a634722_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="ib6ef8d2feff24382b89a963a955b7de1_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i8e09065b9a0547db82bcbd6ba0330136_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i7543f99a1365490685fe0784be6399be_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="ie216ce51a8a24a0baa754fcee329ca73_D20170822-20170823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-22</startDate>
            <endDate>2017-08-23</endDate>
        </period>
    </context>
    <context id="i3ca1ed110b144083ad7a0642944f0a64_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i93c4b0f432a74b2e864cfce6498f7af2_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:PhaseOneClinicalDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="i69f7397d7d354dbca02775665425aeb3_D20170901-20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:DrugProductDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="ia7621d431c964328a7a71c7e9d1ac4bb_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nktr:NektarThreeFiveEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:EliLillyAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i7101cc04dec54a90adf4cbd5b102e5a2_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i25fc7508773c488c99f151c7421c27ad_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">nktr:AnnualSalesLevelMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i444f981b5fcd4ae183f9670a94a6d5c7_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:HemophiliaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:BaxaltaIncorporatedOrTakedaPLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="ice87715efb8248b3aa2edabd0ba0a78d_D20101001-20101231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-10-01</startDate>
            <endDate>2010-12-31</endDate>
        </period>
    </context>
    <context id="i92df06331eee42a4bf5033fe820ebed9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0aee212710ce422485f665ac0f228b73_D20090901-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:MOVANTIKAndMOVENTIGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-09-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i99c7aa64c9624c1aafe571608dc6df48_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i134e5ae7cfac48ccac7b40ae651a24b6_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:NektarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i3701e7bc10234eaba431f6c02eacf26f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:OtherPartnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i94931dcc4c3342aaab0d9fa72b183bd4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nktr:AstraZenecaAgreementWithKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">nktr:AstraZenecaAbMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i88cf58db52e049eab981ed11e7041d46_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ied569ed2fa4643aabebcfeb1c89e3250_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic5081eafe45545ac99082fad3b96d97f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i902932094c3b42388c75a5e0aea65f9b_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i6e337f5f20f943c6924b26a84f75f97c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if378fd08692e42a096dc6f036e090dde_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4abfc9f996224586a3e2de8b4adc9c6f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5af1e965432744c6bcbe50332144c39c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">nktr:ImpairmentAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5f68d2ae466140aeb768fa1c116b8abb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifa8cd256275e4cdfa9d8471075320759_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic56f9fb40dd94e43b2208c0ab8ecd6b1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8b46e908641040b989f8c417b89ce173_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i432c6f2272a94bb69701de1fc16655e2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib127735d3b564c8089872b75e9382773_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nktr:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="idba37b08c6a74db5a4d1979fcb50d818_I20151005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nktr:SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-05</instant>
        </period>
    </context>
    <context id="i08a1e29f68774a94850704062f4a83db_D20200413-20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000906709</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>nktr:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180L2ZyYWc6MTgxYzY4ZWRkMWQxNDQxMWI0YmVhMmIzODU1YjAzZWEvdGFibGU6MDAyOTg1M2U0M2M2NDU0OGE4ZmYyY2ZjY2U3MzhhNWIvdGFibGVyYW5nZTowMDI5ODUzZTQzYzY0NTQ4YThmZjJjZmNjZTczOGE1Yl8yLTEtMS0xLTA_045bf8b0-37a3-4bd8-bfbc-49f92897fe13">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180L2ZyYWc6MTgxYzY4ZWRkMWQxNDQxMWI0YmVhMmIzODU1YjAzZWEvdGFibGU6MDAyOTg1M2U0M2M2NDU0OGE4ZmYyY2ZjY2U3MzhhNWIvdGFibGVyYW5nZTowMDI5ODUzZTQzYzY0NTQ4YThmZjJjZmNjZTczOGE1Yl80LTEtMS0xLTA_45a2c005-ac0c-476e-9445-f8dd42227f78">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180L2ZyYWc6MTgxYzY4ZWRkMWQxNDQxMWI0YmVhMmIzODU1YjAzZWEvdGFibGU6MDAyOTg1M2U0M2M2NDU0OGE4ZmYyY2ZjY2U3MzhhNWIvdGFibGVyYW5nZTowMDI5ODUzZTQzYzY0NTQ4YThmZjJjZmNjZTczOGE1Yl81LTEtMS0xLTA_a0e5f5f6-8562-4e58-afa0-679020ee5680">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180L2ZyYWc6MTgxYzY4ZWRkMWQxNDQxMWI0YmVhMmIzODU1YjAzZWEvdGFibGU6MDAyOTg1M2U0M2M2NDU0OGE4ZmYyY2ZjY2U3MzhhNWIvdGFibGVyYW5nZTowMDI5ODUzZTQzYzY0NTQ4YThmZjJjZmNjZTczOGE1Yl84LTEtMS0xLTA_7b72853b-5794-46fb-9b66-5e28176d979c">0000906709</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180L2ZyYWc6MTgxYzY4ZWRkMWQxNDQxMWI0YmVhMmIzODU1YjAzZWEvdGFibGU6MDAyOTg1M2U0M2M2NDU0OGE4ZmYyY2ZjY2U3MzhhNWIvdGFibGVyYW5nZTowMDI5ODUzZTQzYzY0NTQ4YThmZjJjZmNjZTczOGE1Yl85LTEtMS0xLTA_751823af-2dee-4728-bfc0-790c0ddbd13e">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMS0xLTEtMS0w_b3c032fc-d829-4864-aa9b-adadcaf24dab"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMS0xLTEtMS0w_bb06fa5a-3a0d-4bce-af96-4ea1d339f698"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMy0xLTEtMS0w_169b6dc8-dcda-4a13-93e5-9ecaf36d9a2b"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMy0xLTEtMS0w_c82d90cf-1382-4ac0-a597-61c11fd7dbb7"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfNS0xLTEtMS0w_15d2710d-51b2-40cb-9c21-9eb95f21d5cc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfNS0xLTEtMS0w_7e185be8-d6de-44d5-b8da-39a4b9541bf2"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <nktr:PreferredStockShareDesignated
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfNS0xLTEtMS0w_b3a6f2c0-ee5e-4159-8560-6f737523cfda"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfNS0xLTEtMS0w_ee53525d-82a9-422e-a9ad-8f72d3df92ca"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfOS0xLTEtMS0w_5fc6c4fc-0fa3-40ee-ac26-6031e7999888"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfOS0xLTEtMS0w_ebd08346-db55-4be8-8874-4e78242ed29a"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMTEtMS0xLTEtMA_31c9c414-dfae-47f7-850c-66eab1b8d3b9"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMTEtMS0xLTEtMA_48ddbc38-7457-46bd-97e3-755a409b3c68"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMTMtMS0xLTEtMA_bce84bdc-a1a7-45cd-8065-dc7a41c4a1c2"
      unitRef="shares">177863000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yMi9mcmFnOmU4ODk4NTE4NmE2ZjQ5YTE4ZTA2NTMzYjlhYTU4ODJlL3RhYmxlOmVlMTJhMTUwMDM1ZDQ0ODk5YmRhZDM5YTczYjhkOTY3L3RhYmxlcmFuZ2U6ZWUxMmExNTAwMzVkNDQ4OTliZGFkMzlhNzNiOGQ5NjdfMTMtMi0xLTEtMA_52ba1a00-4416-4898-b42c-c43ea67c7c59"
      unitRef="shares">176505000</us-gaap:CommonStockSharesOutstanding>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i632345d08db6484894d70ab3ce958364_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTUz_40a91577-8b0a-499f-ace6-b778d1948c9f">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="ib5116a61e3b14a5f838ca99d6f39919b_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTUz_d3c2600b-5a29-4044-88bc-bc0629d86f53">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i632345d08db6484894d70ab3ce958364_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180OS9mcmFnOjA5YWVmZTE2NzI1ODQ4NDVhNjI5YTkwN2ZmMDkxYjY3L3RleHRyZWdpb246MDlhZWZlMTY3MjU4NDg0NWE2MjlhOTA3ZmYwOTFiNjdfODU_40a91577-8b0a-499f-ace6-b778d1948c9f">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="ib5116a61e3b14a5f838ca99d6f39919b_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180OS9mcmFnOjA5YWVmZTE2NzI1ODQ4NDVhNjI5YTkwN2ZmMDkxYjY3L3RleHRyZWdpb246MDlhZWZlMTY3MjU4NDg0NWE2MjlhOTA3ZmYwOTFiNjdfODU_d3c2600b-5a29-4044-88bc-bc0629d86f53">P1Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i9c8f5c54957945ab9e0c8833712982bb_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180OS9mcmFnOjA5YWVmZTE2NzI1ODQ4NDVhNjI5YTkwN2ZmMDkxYjY3L3RleHRyZWdpb246MDlhZWZlMTY3MjU4NDg0NWE2MjlhOTA3ZmYwOTFiNjdfOTI_807909cc-ac55-4f36-a902-7ae5c98fcc10">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="id43bdc0f960a40e680fd02bc07f10995_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180OS9mcmFnOjA5YWVmZTE2NzI1ODQ4NDVhNjI5YTkwN2ZmMDkxYjY3L3RleHRyZWdpb246MDlhZWZlMTY3MjU4NDg0NWE2MjlhOTA3ZmYwOTFiNjdfOTI_838bd4e0-3e1e-4f1e-99e0-afe09f21c067">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i94931dcc4c3342aaab0d9fa72b183bd4_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183My9mcmFnOmIxNDU4MTFhOWIwNzQ5YjI5Y2E2NTYxYTdhMjM1MWYyL3RhYmxlOjVhNjYxM2I2MDlhYzRhZjk4YzI2NDBlZDZhNDdkMGQwL3RhYmxlcmFuZ2U6NWE2NjEzYjYwOWFjNGFmOThjMjY0MGVkNmE0N2QwZDBfNC0xLTEtMS0w_4494ca6b-5d1a-4796-94d6-25f11257e555"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <dei:DocumentType
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY2_667ef543-0afd-4cc5-a194-6f771a59e894">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6MmQyZjYzZGM3MTBlNGQxMThjMzM3ZjllZjdjNWZjYzgvdGFibGVyYW5nZToyZDJmNjNkYzcxMGU0ZDExOGMzMzdmOWVmN2M1ZmNjOF8wLTAtMS0xLTA_c97c9c5c-8b3c-468e-8fb7-c88ca45d31d7">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8xNDg0MzQwNjk3NzM2NQ_a2db98ea-ef11-400f-8e77-1bad09680af5">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6MmExMWNjNWEyYjRmNDNkMjg0YTdhYzZhNjRkMWFiOWUvdGFibGVyYW5nZToyYTExY2M1YTJiNGY0M2QyODRhN2FjNmE2NGQxYWI5ZV8wLTAtMS0xLTA_416bbfc2-b4ae-4528-8ab9-44350a626c1b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjc0_e6dcf6e7-0e76-413c-bc6f-388ffa44e0ae">0-24006</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY3_36a653b6-24af-4c04-a267-2f7a346e5685">NEKTAR THERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZThlMDZlOTU4ZWVlNGMzOWJmOWIxYWU3MjI0OWY5ZGQvdGFibGVyYW5nZTplOGUwNmU5NThlZWU0YzM5YmY5YjFhZTcyMjQ5ZjlkZF8wLTAtMS0xLTA_2740b605-11d0-4c96-bdd6-1fab4cdd45ac">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZThlMDZlOTU4ZWVlNGMzOWJmOWIxYWU3MjI0OWY5ZGQvdGFibGVyYW5nZTplOGUwNmU5NThlZWU0YzM5YmY5YjFhZTcyMjQ5ZjlkZF8wLTItMS0xLTA_2de5f720-2d12-4939-a078-6597c6d4c571">94-3134940</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY4_a5cc07f8-b9f4-4ee9-9c05-01ae74f7416d">455 Mission Bay Boulevard South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY5_acf30b5f-9ed4-4734-9ef3-49781f4a3086">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjcw_b1704ab6-2c62-4c7b-9d10-d36653d8692c">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjcx_0fa11a27-e6af-4c2f-8eaa-56fde14fdbba">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjcy_c3851416-816b-4aaf-b4d9-01214c5f48e4">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjcz_6e1fa01d-27cb-4af6-98e4-6aa9e0dd51f8">482-5300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZjI4ZmNjZjJjODJiNGI1Y2FjZjk5MWJmOWIwNDNhMTUvdGFibGVyYW5nZTpmMjhmY2NmMmM4MmI0YjVjYWNmOTkxYmY5YjA0M2ExNV8yLTEtMS0xLTA_f57c6f22-7ca8-452d-8140-ce886c9aab9c">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZjI4ZmNjZjJjODJiNGI1Y2FjZjk5MWJmOWIwNDNhMTUvdGFibGVyYW5nZTpmMjhmY2NmMmM4MmI0YjVjYWNmOTkxYmY5YjA0M2ExNV8yLTItMS0xLTA_ca717d52-218b-4eb7-80f0-89bb76398377">NKTR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZjI4ZmNjZjJjODJiNGI1Y2FjZjk5MWJmOWIwNDNhMTUvdGFibGVyYW5nZTpmMjhmY2NmMmM4MmI0YjVjYWNmOTkxYmY5YjA0M2ExNV8yLTMtMS0xLTA_d7ef98ef-6982-40de-b194-552a11445fdd">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjYz_2e0274d1-d518-42ca-870f-744ef26e9b35">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY0_9d562f42-0733-4fd2-b4c7-bbfe5b5ac016">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZDAzNWE0NjhjNzQwNGE5Njk2Y2JjOTc0ZWNlOTg2YzAvdGFibGVyYW5nZTpkMDM1YTQ2OGM3NDA0YTk2OTZjYmM5NzRlY2U5ODZjMF8wLTAtMS0xLTA_c4496b77-0ff1-4448-874a-944756d1cc3c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZDAzNWE0NjhjNzQwNGE5Njk2Y2JjOTc0ZWNlOTg2YzAvdGFibGVyYW5nZTpkMDM1YTQ2OGM3NDA0YTk2OTZjYmM5NzRlY2U5ODZjMF8yLTYtMS0xLTA_9157f0bb-0d21-4ecd-b7de-01f9919393eb">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGFibGU6ZDAzNWE0NjhjNzQwNGE5Njk2Y2JjOTc0ZWNlOTg2YzAvdGFibGVyYW5nZTpkMDM1YTQ2OGM3NDA0YTk2OTZjYmM5NzRlY2U5ODZjMF80LTItMS0xLTA_f8a9a104-8b8d-435a-85dd-13dae87f1fc1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF8yMjY1_9968a968-d9e0-4e5c-9acd-6985bb3f47dd">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0d9e59819bcb48b9afca31437d7dd506_I20200501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xL2ZyYWc6YzUwY2RiMGUzY2RkNGI2MzhlZGRlYjQ4YmU4Zjg3NjgvdGV4dHJlZ2lvbjpjNTBjZGIwZTNjZGQ0YjYzOGVkZGViNDhiZThmODc2OF83MTQ2ODI1NTgyOTE5_fe184798-d501-45bc-9bd5-f40208aa4cc6"
      unitRef="shares">177989857</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMy0xLTEtMS0w_78d23329-4657-44bd-aff9-6e6468149c5f"
      unitRef="usd">227035000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMy0zLTEtMS0w_591d0a48-79ce-4fbd-9868-17050863f3a5"
      unitRef="usd">96363000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNC0xLTEtMS0w_9857e3de-f527-49d5-8c4b-f29ec9218561"
      unitRef="usd">1118847000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNC0zLTEtMS0w_081c994b-f44a-46c5-963a-016660cc2858"
      unitRef="usd">1228499000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNS0xLTEtMS0w_edfed25e-904c-49dd-a3d0-4eec3aeca577"
      unitRef="usd">42031000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNS0zLTEtMS0w_de75bd51-8311-4696-9c89-1e9b1e102953"
      unitRef="usd">36802000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNi0xLTEtMS0w_a2c4036e-7671-490e-840e-a02a300f72d8"
      unitRef="usd">14320000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNi0zLTEtMS0w_f2d0a471-b323-410b-89ea-8387cc766f74"
      unitRef="usd">12665000</us-gaap:InventoryNet>
    <nktr:AdvancePaymentsToContractManufacturers
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNy0xLTEtMS0w_c914dea3-de39-4aee-8c84-a26606d2c872"
      unitRef="usd">13280000</nktr:AdvancePaymentsToContractManufacturers>
    <nktr:AdvancePaymentsToContractManufacturers
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNy0zLTEtMS0w_e49854ed-0483-418d-a9f3-de316453464a"
      unitRef="usd">31834000</nktr:AdvancePaymentsToContractManufacturers>
    <us-gaap:OtherAssetsCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfOC0xLTEtMS0w_b491c13f-0366-440f-9ec0-c9df76a7c555"
      unitRef="usd">13811000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfOC0zLTEtMS0w_91446030-a792-4af9-b8a2-3e89488fa811"
      unitRef="usd">15731000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfOS0xLTEtMS0w_a89c0a9e-96a6-49a9-8344-50a2b8283dda"
      unitRef="usd">1429324000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfOS0zLTEtMS0w_7b2fda26-c28f-456b-a166-320eb9a4bb8b"
      unitRef="usd">1421894000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTAtMS0xLTEtMA_96c2e485-b9c6-44ad-9470-c2e17e6c491a"
      unitRef="usd">185900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTAtMy0xLTEtMA_55d1ba21-bf98-41c4-884d-1109a0bd1f85"
      unitRef="usd">279119000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTEtMS0xLTEtMA_edb978a0-a84c-4b21-b7ad-3e2df1c8c8f2"
      unitRef="usd">62307000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTEtMy0xLTEtMA_c4c137b3-0baa-4ad6-9ad2-52f08d99f8f2"
      unitRef="usd">65665000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTItMS0xLTEtMA_e54311d3-f5bb-4f6b-8b41-1de21a226c3e"
      unitRef="usd">133901000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTItMy0xLTEtMA_14cd3f39-2f79-4522-bf68-90dca6fdb621"
      unitRef="usd">134177000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTMtMS0xLTEtMA_144fa8d1-dcb6-4eee-ba24-6a22a61c33d7"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTMtMy0xLTEtMA_410ebf21-4e47-4874-9733-c8b39cc488c1"
      unitRef="usd">76501000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTUtMS0xLTEtMA_c58d3543-c016-493e-8183-fce3cce7f905"
      unitRef="usd">1887933000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTUtMy0xLTEtMA_4781a655-7e7f-4cf4-a99d-6c9c52b154b7"
      unitRef="usd">1977356000</us-gaap:Assets>
    <us-gaap:SeniorNotesCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTctMS0xLTEtMzE3MA_21c8ca83-58e0-4e36-bb4f-c87559e9f08c"
      unitRef="usd">254144000</us-gaap:SeniorNotesCurrent>
    <us-gaap:SeniorNotesCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTctMy0xLTEtMzE3Mg_9833d780-211a-4cbd-bea1-95fa6224880c"
      unitRef="usd">252891000</us-gaap:SeniorNotesCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTgtMS0xLTEtMA_16921e66-7b24-45e4-a6fc-64dd94481496"
      unitRef="usd">21789000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTgtMy0xLTEtMA_0b3bb4e4-b82b-4610-b97f-4a7e9a1f5848"
      unitRef="usd">19234000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTktMS0xLTEtMA_3d16f82c-b88b-4e93-8594-9161d810234c"
      unitRef="usd">22412000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMTktMy0xLTEtMA_132b86b5-5608-4c36-8a3f-e9db0de02ae2"
      unitRef="usd">11467000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjAtMS0xLTEtMA_e6c1f23d-fd1c-4671-a940-7c08214c3831"
      unitRef="usd">38624000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedClinicalTrialExpensesCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjAtMy0xLTEtMA_e671b9d8-6c04-441f-a42f-4de938eb18a2"
      unitRef="usd">32626000</nktr:AccruedClinicalTrialExpensesCurrent>
    <nktr:AccruedContractManufacturingExpenseCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjEtMS0xLTEtMA_b67f07a2-b727-4479-bf3a-38f02e1b4333"
      unitRef="usd">8579000</nktr:AccruedContractManufacturingExpenseCurrent>
    <nktr:AccruedContractManufacturingExpenseCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjEtMy0xLTEtMA_379ff9d1-0855-4c2d-be2e-8d56d73fabec"
      unitRef="usd">7304000</nktr:AccruedContractManufacturingExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjItMS0xLTEtMA_fc5db28a-0687-4bd3-90e7-f732200e5379"
      unitRef="usd">11844000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjItMy0xLTEtMA_24ca4565-4230-4814-afcb-7c8629f7988f"
      unitRef="usd">11414000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjQtMS0xLTEtMA_fbd101d5-3982-4a5f-a44b-24893dff95dc"
      unitRef="usd">15613000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjQtMy0xLTEtMA_11a9971c-fd6b-46b4-82eb-0c87c5b38c7e"
      unitRef="usd">12516000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjUtMS0xLTEtMA_b0e2b3fc-e2f2-4c76-9ad8-59954a651345"
      unitRef="usd">3007000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjUtMy0xLTEtMA_be4f4dd6-8901-4157-8037-72e08424b22d"
      unitRef="usd">5517000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjctMS0xLTEtMTMy_eb6c1ed5-ca4f-41c0-8d0a-8786bdbe9f05"
      unitRef="usd">1459000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjctMy0xLTEtMTM1_65d69e1d-f9ea-40d7-a6b8-aa6d4ef6ff16"
      unitRef="usd">1692000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjYtMS0xLTEtMA_556b8e1e-375f-411b-b347-fd0f3861b13f"
      unitRef="usd">377471000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjYtMy0xLTEtMA_4da7748c-18fb-4d94-a61b-207ab0ce2786"
      unitRef="usd">354661000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjgtMS0xLTEtMA_ac2f2690-36d6-44bc-be3e-2ec46e37b8c2"
      unitRef="usd">142297000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjgtMy0xLTEtMA_e948764a-7d14-47a3-a62f-df3c58a062fb"
      unitRef="usd">142730000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjktMS0xLTEtMA_005b2a17-6c2b-46a2-8084-725dd5480056"
      unitRef="usd">69185000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMjktMy0xLTEtMA_52e0e033-6be5-48b6-b6d6-12f674886d38"
      unitRef="usd">72020000</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzAtMS0xLTEtMA_2c72cad9-51c3-46a2-9fae-2a2e6b695785"
      unitRef="usd">2554000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzAtMy0xLTEtMA_c9fb5154-6c84-4e39-a11f-6b8730923804"
      unitRef="usd">2554000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzItMS0xLTEtMA_60759658-7aad-4e0a-aba7-c276a1f8344e"
      unitRef="usd">591507000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzItMy0xLTEtMA_84d48038-e9c9-4721-b177-0a6469502be7"
      unitRef="usd">571965000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzMtMS0xLTEtMA_7cf505a1-13e0-43fd-9711-cab1f930b30a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzMtMy0xLTEtMA_c03c1df4-3943-4140-bb28-206a2c1fd19d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA2OTE_b3c032fc-d829-4864-aa9b-adadcaf24dab"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA2OTE_bb06fa5a-3a0d-4bce-af96-4ea1d339f698"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjE_169b6dc8-dcda-4a13-93e5-9ecaf36d9a2b"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjE_c82d90cf-1382-4ac0-a597-61c11fd7dbb7"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjU_15d2710d-51b2-40cb-9c21-9eb95f21d5cc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nktr:PreferredStockShareDesignated
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjU_7e185be8-d6de-44d5-b8da-39a4b9541bf2"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <nktr:PreferredStockShareDesignated
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjU_b3a6f2c0-ee5e-4159-8560-6f737523cfda"
      unitRef="shares">0</nktr:PreferredStockShareDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMC0xLTEtMC90ZXh0cmVnaW9uOjQ2N2RmZGJhOTJlNjQxMjFiYmNmNmQ2MmY2NzdkOWIwXzcxNDY4MjU1ODA3MjU_ee53525d-82a9-422e-a9ad-8f72d3df92ca"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMS0xLTEtMA_8899405b-d29f-494e-bdbe-8cb54a4a72ca"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzUtMy0xLTEtMA_65b549b2-8409-4856-b512-d13102883a15"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjUwMjkwM2VmNGFhNjRiYWZhYjIzNDgwNjI0MjA0MGFmXzcxNDY4MjU1ODA3MTY_5fc6c4fc-0fa3-40ee-ac26-6031e7999888"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjUwMjkwM2VmNGFhNjRiYWZhYjIzNDgwNjI0MjA0MGFmXzcxNDY4MjU1ODA3MTY_ebd08346-db55-4be8-8874-4e78242ed29a"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjUwMjkwM2VmNGFhNjRiYWZhYjIzNDgwNjI0MjA0MGFmXzcxNDY4MjU1ODA3MjU_31c9c414-dfae-47f7-850c-66eab1b8d3b9"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjUwMjkwM2VmNGFhNjRiYWZhYjIzNDgwNjI0MjA0MGFmXzcxNDY4MjU1ODA3MjU_48ddbc38-7457-46bd-97e3-755a409b3c68"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMC0xLTEtMC90ZXh0cmVnaW9uOjUwMjkwM2VmNGFhNjRiYWZhYjIzNDgwNjI0MjA0MGFmXzcxNDY4MjU1ODE5MzE_bce84bdc-a1a7-45cd-8065-dc7a41c4a1c2"
      unitRef="shares">177863000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMS0xLTEtMA_bca12fb0-b436-4412-9f26-67858e0b880b"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzYtMy0xLTEtMA_a23beccd-8fdf-458b-b64d-812befbe7018"
      unitRef="usd">17000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzctMS0xLTEtMA_76908fb6-ae54-4b1a-8cf4-b74d92e4872b"
      unitRef="usd">3306655000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzctMy0xLTEtMA_b6d7d498-0f3e-4176-b180-f23ed8f2d678"
      unitRef="usd">3271097000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzgtMS0xLTEtMA_44245161-3d14-4670-b593-6ee41520ff06"
      unitRef="usd">-6877000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzgtMy0xLTEtMA_55c20a9d-f271-4e5f-bc61-caee2b70991e"
      unitRef="usd">-1005000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzktMS0xLTEtMA_5960de22-22c1-4a2e-9d49-69d88ffdb16a"
      unitRef="usd">-2003369000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfMzktMy0xLTEtMA_635a9130-3f59-482a-9039-e33f2dcb07bd"
      unitRef="usd">-1864718000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNDAtMS0xLTEtMA_deb52846-3da6-4b97-8fbf-747a4d2f0687"
      unitRef="usd">1296426000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNDAtMy0xLTEtMA_434784bc-aecd-4249-ac2e-689b35e82c4d"
      unitRef="usd">1405391000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNDEtMS0xLTEtMA_f82c3b8b-c338-4001-b170-fb7cba22b6ec"
      unitRef="usd">1887933000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xOS9mcmFnOjBmYjVjNjMzMTkyMTRiZTZiMGUxNTE5NzBiYTI4NTBjL3RhYmxlOmE1ZGNiYTU4MzUzNzQxNmI4NzhiYmFjYWE0MDBkZDU5L3RhYmxlcmFuZ2U6YTVkY2JhNTgzNTM3NDE2Yjg3OGJiYWNhYTQwMGRkNTlfNDEtMy0xLTEtMA_6037e7c9-28e3-4769-9466-108e84440d08"
      unitRef="usd">1977356000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i206c822e44844e6d8c9a8878d54cdb82_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMy0xLTEtMS0w_6b63a69f-a3a4-40de-a008-add91155fb4f"
      unitRef="usd">3444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a678b6b3e864f2eb9b2e381794c4da8_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMy0zLTEtMS0w_f4984c25-3157-45eb-ba1c-536836237f47"
      unitRef="usd">4398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0efadd0052274204bbd4eee79288b4ea_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNC0xLTEtMS0w_41ef7d11-c9e1-4eb8-a013-609d1f9dcc63"
      unitRef="usd">9719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i579879be3d9d4e9ba231135652799fc0_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNC0zLTEtMS0w_ef7eca45-4225-44fb-bc0b-1d3894d58235"
      unitRef="usd">11390000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i019e7c29ebdc411b8f4ab036df57ab24_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNS0xLTEtMS0w_cd6204d2-9f74-4b3c-936f-1d5205f12301"
      unitRef="usd">9895000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fbbd193f91f4e33836cd1cc651690b0_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNS0zLTEtMS0w_a1b5f381-af2b-4fbc-9a99-4d818998ec7a"
      unitRef="usd">8230000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia710b16c060f49b094bdb84fe9f40c6d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNi0xLTEtMS0w_6c96d918-147c-4ab4-8fa9-acc9a6921db3"
      unitRef="usd">27515000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5bc0b330b3b43cd89330149bc3a1b21_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNi0zLTEtMS0w_f6bc23dd-a70d-4f5c-bc19-905fea1cf688"
      unitRef="usd">4204000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNy0xLTEtMS0w_1f5775d6-d6fe-4f75-b99e-02dd74494f75"
      unitRef="usd">50573000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfNy0zLTEtMS0w_cd9a647d-9b1a-42d4-bbd3-c5659b0fc672"
      unitRef="usd">28222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfOS0xLTEtMS0w_ee003a05-afc9-4ab1-887c-e8d758747404"
      unitRef="usd">3811000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfOS0zLTEtMS0w_298026a3-5d5b-42db-9216-e4162ef73dfd"
      unitRef="usd">5440000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTAtMS0xLTEtMA_7f85e89d-48ac-436a-a5fe-90f5ec33f950"
      unitRef="usd">108987000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTAtMy0xLTEtMA_a73ca9ac-038d-4320-be92-5f01ba5d18fa"
      unitRef="usd">118463000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTEtMS0xLTEtMA_3134cf2e-a462-465e-8dee-588ca03041ad"
      unitRef="usd">26217000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTEtMy0xLTEtMA_0f9ce2dd-47bd-438b-8c0d-ed309d17d5a1"
      unitRef="usd">25006000</us-gaap:GeneralAndAdministrativeExpense>
    <nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTItMS0xLTEtOTI0_209c76df-92db-4032-a3ca-9c10d454ba97"
      unitRef="usd">45189000</nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram>
    <nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTItMy0xLTEtOTI0_a96cdd62-f127-4420-826b-a20638aa3d27"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram>
    <us-gaap:CostsAndExpenses
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTItMS0xLTEtMA_11f1823b-a9da-432a-9bb6-b76c7626e68f"
      unitRef="usd">184204000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTItMy0xLTEtMA_e1dde7bb-4b10-417c-aa80-dedbb0da36e5"
      unitRef="usd">148909000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTMtMS0xLTEtMA_87122ec5-d85a-4c44-9315-ab8e1c3f10e4"
      unitRef="usd">-133631000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTMtMy0xLTEtMA_3ad22c67-58b7-4502-b63d-c5d8685b90d9"
      unitRef="usd">-120687000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTUtMS0xLTEtMA_e27b4e10-0672-4893-bc0f-81ec75548afd"
      unitRef="usd">6204000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTUtMy0xLTEtMA_f9347927-46f6-4af6-95aa-f5f435dbd744"
      unitRef="usd">5226000</us-gaap:InterestExpense>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTYtMS0xLTEtMA_ccbc393e-5898-4192-be2d-7bbd152f4127"
      unitRef="usd">6968000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTYtMy0xLTEtMA_c03583f2-2099-4def-aed2-6f7de3499cfc"
      unitRef="usd">6065000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTctMS0xLTEtMA_215e15f1-37b4-40de-86c5-5807c36f46fa"
      unitRef="usd">8352000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTctMy0xLTEtMA_25df1d49-b934-47b3-835b-58a03e50875d"
      unitRef="usd">12483000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTgtMS0xLTEtMA_5467e223-a0e6-49d3-ae53-204e20f64030"
      unitRef="usd">-4820000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTgtMy0xLTEtMA_e759d5ea-141e-4a94-b6b0-8b5f5f2c8391"
      unitRef="usd">1192000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTktMS0xLTEtMA_142fb4ac-1f4e-40b5-9b2c-105ce2f154bc"
      unitRef="usd">-138451000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMTktMy0xLTEtMA_951e3ed3-efbe-4d8d-bbf8-23d8f7efd5d5"
      unitRef="usd">-119495000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjAtMS0xLTEtMA_87d2c655-22b8-4ef3-8936-6ed9e5c9c702"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjAtMy0xLTEtMA_6ace3d3d-8a85-42b6-9760-b77011f035a7"
      unitRef="usd">137000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjEtMS0xLTEtMA_884a2d3a-7e45-4223-94f7-a8371b86e6c2"
      unitRef="usd">-138651000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjEtMy0xLTEtMA_bb901078-84fa-4006-824f-10abae2d3566"
      unitRef="usd">-119632000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjQtMS0xLTEtMA_34481762-4efc-42ec-83c8-7f4cef6c25fc"
      unitRef="usdPerShare">-0.78</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjQtMy0xLTEtMA_da5a8816-805c-44ed-923f-abdefe6dca38"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjctMS0xLTEtMA_63e114b9-bcb8-4a6e-8342-98bc87bdf810"
      unitRef="shares">177185000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yNS9mcmFnOmZiNmVmOTY0YzJmNzRlNWZiNzYzNWFjYWM4YjE3MGY2L3RhYmxlOjA2OGZiYzBhODYzZjQ5NzNiZDNiODYxNjRmNDVmNjc5L3RhYmxlcmFuZ2U6MDY4ZmJjMGE4NjNmNDk3M2JkM2I4NjE2NGY0NWY2NzlfMjctMy0xLTEtMA_ebf9bafa-7dd0-4f5d-9eda-9081983a823a"
      unitRef="shares">173859000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfMi0xLTEtMS0xNzU1_b270297b-9ee8-4dca-a108-38ee45194706"
      unitRef="usd">-138651000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfMi0zLTEtMS0xNzU1_96186e66-7f08-48fa-b12c-c91a42679018"
      unitRef="usd">-119632000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNC0xLTEtMS0xNzUx_b3f7db49-16ae-409d-8f10-6387402e7793"
      unitRef="usd">-5121000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNC0zLTEtMS0xNzUx_feab4c82-9667-4e6c-84bf-0422616ccbbe"
      unitRef="usd">4685000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNS0xLTEtMS0xNzUx_0674c720-f6e4-4322-aeca-bb2f820e6308"
      unitRef="usd">-751000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNS0zLTEtMS0xNzUx_b7d8d1a9-93f9-4507-9af3-b139a6937ffd"
      unitRef="usd">35000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNi0xLTEtMS0xNzUx_cfc0d953-0c83-49e5-ba52-5f358b1484e5"
      unitRef="usd">-5872000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfNi0zLTEtMS0xNzUx_7333f9cc-441b-4cc7-b7c4-0152db8e694f"
      unitRef="usd">4720000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfMi0xLTEtMS0w_962080c8-63c1-4948-b423-5a7f6417fde4"
      unitRef="usd">-144523000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18yOC9mcmFnOmY2MDQxZGIxZDgzNjRiNDg5YWQ2NmNmMTczZGViYWVjL3RhYmxlOjBlYTJkZjE0YzI4ZjQ3ODhiNWZjYzJlNTkxOWI0YzJmL3RhYmxlcmFuZ2U6MGVhMmRmMTRjMjhmNDc4OGI1ZmNjMmU1OTE5YjRjMmZfMi0zLTEtMS0w_c6363303-0c00-4013-b652-48989e890b3f"
      unitRef="usd">-114912000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ie5fdaed97d5a4bbd8922f30a1bd1e928_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi0xLTEtMS0w_0b91bde2-03ad-4e70-a237-c200f07c8930"
      unitRef="shares">173530000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie5fdaed97d5a4bbd8922f30a1bd1e928_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi0zLTEtMS0w_65407806-081b-4f90-9f8d-3355b2f54289"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i241a6ffe64d345b9b815f1b853ee9a79_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi01LTEtMS0w_d59db208-2b26-4250-ad95-03ed960361f7"
      unitRef="usd">3147925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6be903b189ea47d2b3464ca31dbef069_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi03LTEtMS0w_48a78440-f391-4206-b27b-d9f4f563b58d"
      unitRef="usd">-6316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8fbb869dd6324f779968528868504d9f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi05LTEtMS0w_9f832e1e-5c02-41fc-b644-4009e6a20b62"
      unitRef="usd">-1424051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a0d62a4e534478a8f3dbd0b9c4a9d82_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMi0xMS0xLTEtMA_f77fdb38-8481-4ac3-8331-d5b3b458ca31"
      unitRef="usd">1717575000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0c2a3f7bdb424534b926f3598ed9653a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMy0xLTEtMS0w_ad4636ce-7379-413e-a80a-d14917d5bc0e"
      unitRef="shares">698000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0ab56b00693644e9a5c6ff7f3dc0c0b3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMy01LTEtMS0w_d813a0f4-b9c8-4e18-9492-ebc621b4b778"
      unitRef="usd">5463000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMy0xMS0xLTEtMA_5d5c2199-fc3e-4d7e-976f-33938e534f22"
      unitRef="usd">5463000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0ab56b00693644e9a5c6ff7f3dc0c0b3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNC01LTEtMS0w_199312ef-42df-42e9-92af-83ce8feef85e"
      unitRef="usd">25385000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNC0xMS0xLTEtMA_be829131-8c92-4e49-b39e-27de6f896942"
      unitRef="usd">25385000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id49c1db014fc497d8472960ad4070a17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNS03LTEtMS0w_334af554-d4d6-4b7f-a317-3637d6c1ea51"
      unitRef="usd">4720000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i768ed2c4850c48f6a6500688f1a016e3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNS05LTEtMS0w_9c36c295-6c7b-4fc3-a190-3d85ccc51fa8"
      unitRef="usd">-119632000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNS0xMS0xLTEtMA_0e524bba-3c7d-434d-b71d-2c901ef7e6c2"
      unitRef="usd">-114912000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ibc5d122cc68f41fc93209ede839c32a7_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy0xLTEtMS0w_3d0937bd-759a-4511-946e-80210b5de668"
      unitRef="shares">174228000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibc5d122cc68f41fc93209ede839c32a7_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy0zLTEtMS0w_42589fb8-c5ec-4385-b46f-d41ad5660894"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9b47f5237864755aefc5562482c7fbd_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy01LTEtMS0w_e7b63068-7262-44ab-9d61-1ac1f04cb678"
      unitRef="usd">3178773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8547a8cca34a4758b81996732bc8f2f1_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy03LTEtMS0w_f422e99e-9d94-4401-b085-a2036dbbe76b"
      unitRef="usd">-1596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1121ec1c4f3499a8e410586cc1cbf3d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy05LTEtMS0w_15de197f-4221-42fd-a1b8-4c576bd8a65c"
      unitRef="usd">-1543683000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i941b5c3651924990ab68ad8cb3e8b2de_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfNy0xMS0xLTEtMA_ca446f9e-bc86-4867-8b7a-1699a2fcec14"
      unitRef="usd">1633511000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i86ea8909183e4a519a2620f8ba50b115_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS0xLTEtMS0w_932aae0d-aac9-4c97-b4aa-9a8c357eb927"
      unitRef="shares">176505000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i86ea8909183e4a519a2620f8ba50b115_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS0zLTEtMS0w_d1a55cfb-41fa-4a02-8d95-acb24c88c37c"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic76656708b514c009c3d779f4b128f64_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS01LTEtMS0w_52d9c6ea-3b08-47dd-b311-1e316ba35e74"
      unitRef="usd">3271097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15e5dfd53d9c4e07acc0e26501a67651_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS03LTEtMS0w_66dc92b5-16df-4993-b3a6-06b9054d75a2"
      unitRef="usd">-1005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifaabcaf066d24b2686f0349b89851a2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS05LTEtMS0w_40b8489a-e027-45f5-9b1b-8d8b346e8d3a"
      unitRef="usd">-1864718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfOS0xMS0xLTEtMA_4c37ade7-a0cb-4803-8d5d-3bf1d8142bec"
      unitRef="usd">1405391000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7873bda1e2354f1ab9d6905b20c6b9e4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTAtMS0xLTEtMA_fb2ccf0c-9a21-4c7e-88c0-1714e668b721"
      unitRef="shares">1358000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iea1dfe0226d44464a9003812ad216e56_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTAtNS0xLTEtMA_fc0b232c-c716-41dc-9e2d-de9b0cf4a651"
      unitRef="usd">11347000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTAtMTEtMS0xLTA_e18bad5a-dc1d-4f35-8bdc-25d18941dcb8"
      unitRef="usd">11347000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iea1dfe0226d44464a9003812ad216e56_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTEtNS0xLTEtMA_23a4f680-2e11-43b0-b23d-2205d496ac28"
      unitRef="usd">24211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTEtMTEtMS0xLTA_b1cb957c-c24d-4ddc-bd51-140b94268785"
      unitRef="usd">24211000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia9377ff38abc4416a7a66a775c05241e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTItNy0xLTEtMA_1146ed6c-400e-46e7-8d23-325d7992a8bc"
      unitRef="usd">-5872000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0278c7d606b04e5eba2f454a342be177_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTItOS0xLTEtMA_f476251c-1ca9-47c5-bf1c-730844de3a3d"
      unitRef="usd">-138651000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTItMTEtMS0xLTA_37743885-8858-4bcb-8a19-c053fa17d889"
      unitRef="usd">-144523000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i6500865a65a8437f8ee292f8fd4d7655_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtMS0xLTEtMA_d975a248-b69c-4122-9d53-d8c864b7a2f7"
      unitRef="shares">177863000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6500865a65a8437f8ee292f8fd4d7655_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtMy0xLTEtMA_334de747-5a83-4860-b983-878a44e21592"
      unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida2d9e34320a44d7aa3415f6dd51c7fd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtNS0xLTEtMA_da4c8ca7-06be-4b39-a3d9-e2fbd65fb8e4"
      unitRef="usd">3306655000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie78ccec663024b2cb3701efac4a6e73c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtNy0xLTEtMA_ed015cad-88db-4c72-9657-334b723fd5c6"
      unitRef="usd">-6877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2052866c6650444f9b65d63e1fe916eb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtOS0xLTEtMA_b01e261d-86ac-4280-ad92-137a4819b940"
      unitRef="usd">-2003369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zMS9mcmFnOmU3OWMxODk3MjZhNzQ4MzZiMzY0YWQ1NjczNGM2ODNiL3RhYmxlOjVhOTQ4ZTQ5OWI0MjQ3N2M4NjlkODM2ODJhMzUwYTM3L3RhYmxlcmFuZ2U6NWE5NDhlNDk5YjQyNDc3Yzg2OWQ4MzY4MmEzNTBhMzdfMTQtMTEtMS0xLTA_3b464537-b3c2-4018-ad10-48162bb245f7"
      unitRef="usd">1296426000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMy0xLTEtMS0w_ea416e2c-bc2a-4ae8-86c6-639842fb6121"
      unitRef="usd">-138651000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMy0zLTEtMS0w_e74ef3cf-56a6-4cba-98ac-5cc9bc8ba979"
      unitRef="usd">-119632000</us-gaap:ProfitLoss>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNS0xLTEtMS0w_e77355ba-495c-49a9-b7d2-472aef5890e9"
      unitRef="usd">9895000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNS0zLTEtMS0w_fd21be6f-a894-41c8-a8b7-189c5ccf6795"
      unitRef="usd">8230000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNi0xLTEtMS0w_9f7dc4ce-996d-4afd-9ef9-f735da05d9ed"
      unitRef="usd">6968000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNi0zLTEtMS0w_c629bf66-00b6-4671-a005-1e456f10306c"
      unitRef="usd">6065000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNy0xLTEtMS0w_36e5770e-df9d-4be7-83fe-5478f71560ac"
      unitRef="usd">25236000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfNy0zLTEtMS0w_258d9d3a-45d8-4391-ad57-d61b83f61cab"
      unitRef="usd">25385000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOC0xLTEtMS0w_f19fd8b4-8876-47a3-ae2d-c6b899493c76"
      unitRef="usd">4502000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOC0zLTEtMS0w_fa66beb3-b92e-4324-831d-f0ab9e8505bd"
      unitRef="usd">3077000</us-gaap:DepreciationAndAmortization>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOS0xLTEtMS0zMjYy_64a6803d-ea4e-4694-931a-afc42ee0f9d7"
      unitRef="usd">20351000</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <nktr:ImpairmentOfEquipmentFromTerminatedProgram
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOS0zLTEtMS0zMjY0_10eff2f5-d9b6-4b25-bc60-0736fa303e8b"
      unitRef="usd">0</nktr:ImpairmentOfEquipmentFromTerminatedProgram>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOS0xLTEtMS0w_f63caf8a-61a5-45bb-ac6d-d6720c369c90"
      unitRef="usd">1289000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfOS0zLTEtMS0w_9d68d505-ae2f-462f-b505-0925081c0dbb"
      unitRef="usd">3183000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTEtMS0xLTEtMA_1155d163-cc67-4875-8f8d-187f2250364e"
      unitRef="usd">5229000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTEtMy0xLTEtMA_b8d97f4e-8520-4933-916d-2450b084fab2"
      unitRef="usd">-319000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTItMS0xLTEtMA_b4d6c257-4ea7-4a98-a965-73ec8cd9aefa"
      unitRef="usd">1655000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTItMy0xLTEtMA_77b95930-948c-4704-a49c-b01a53773909"
      unitRef="usd">397000</us-gaap:IncreaseDecreaseInInventories>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTQtMS0xLTEtOTQ4_b8dbd8d2-3441-49e3-acdd-f87ae16e75cb"
      unitRef="usd">-2940000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTQtMy0xLTEtOTQ4_2ffe92b7-6a2f-4598-b6f7-bb88ba15d108"
      unitRef="usd">-1168000</nktr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTMtMS0xLTEtMA_6256a2d3-5a3b-4f4f-a31b-87518e93c9ff"
      unitRef="usd">-1067000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTMtMy0xLTEtMA_53d60d3c-0c3a-427d-95d0-c22994d693bb"
      unitRef="usd">-4209000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTQtMS0xLTEtMA_5d31a051-ec6f-41a3-bedf-5842a7f55461"
      unitRef="usd">2687000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTQtMy0xLTEtMA_f44121a1-3959-4583-95bc-bd9cc8bcfbf1"
      unitRef="usd">5156000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTUtMS0xLTEtMA_0f52079a-8468-4d53-b371-863d4793399c"
      unitRef="usd">9920000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTUtMy0xLTEtMA_707499e5-cd36-4df0-9f9f-7c66323381fd"
      unitRef="usd">8434000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTYtMS0xLTEtMA_2174a998-80e4-4818-ac7b-635546c8bf00"
      unitRef="usd">7716000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTYtMy0xLTEtMA_93f5b20b-2b7f-44e3-b3c7-e35c132a5039"
      unitRef="usd">774000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTctMS0xLTEtMA_5e875593-cfc3-4c59-babc-6b31bdbcd606"
      unitRef="usd">-2510000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTctMy0xLTEtMA_b95b481b-9834-483b-9c71-c55326b82b1f"
      unitRef="usd">-4204000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTgtMS0xLTEtMA_b09cfacb-fe00-4bbb-a677-26ac456c3dbd"
      unitRef="usd">-233000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTgtMy0xLTEtMA_4a2caaf5-e35f-4644-b2a3-8dc769095e93"
      unitRef="usd">164000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTktMS0xLTEtMA_280683af-189a-4afe-b640-b40ec246141c"
      unitRef="usd">-78075000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMTktMy0xLTEtMA_bf0c4473-0856-4428-82c8-e79b8429b428"
      unitRef="usd">-80895000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjEtMS0xLTEtMA_4d9b7ec3-c8f4-410e-930d-2955444e2e04"
      unitRef="usd">241068000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjEtMy0xLTEtMA_3802080d-6e68-490c-9ac0-6b861c3628f7"
      unitRef="usd">368739000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjItMS0xLTEtMA_5646320c-d90c-4bec-a47f-457b080aa8d9"
      unitRef="usd">439735000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjItMy0xLTEtMA_47564f4a-54e1-4c3b-916f-00429a61e7e1"
      unitRef="usd">362249000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjQtMS0xLTEtMA_52bb663f-92d1-4d41-b7b7-0c9156d144c6"
      unitRef="usd">900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjQtMy0xLTEtMA_61aaa18b-94bc-45d5-a462-b01dbe7eebad"
      unitRef="usd">5648000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjYtMS0xLTEtMA_58e1eb44-b2b1-4fee-9ddb-962f85d37875"
      unitRef="usd">197767000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjYtMy0xLTEtMA_e8e8a2c6-5faa-44ab-879b-7456c7cae819"
      unitRef="usd">-12138000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjktMS0xLTEtMA_f5941e5f-136b-4926-8c9d-9e981689d183"
      unitRef="usd">11077000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMjktMy0xLTEtMA_0fd16df7-b9f5-497e-8d09-177a96cda5a9"
      unitRef="usd">4894000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzAtMS0xLTEtMA_164db39e-9985-4926-9782-54b5f8f7653d"
      unitRef="usd">11077000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzAtMy0xLTEtMA_5ce21e24-6c0b-42ae-a886-6cdc4302d1eb"
      unitRef="usd">4894000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzEtMS0xLTEtMA_86401d68-0870-4b6d-a71b-115868056caa"
      unitRef="usd">-97000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzEtMy0xLTEtMA_58ec73f6-65b7-4cfe-80a5-f73722217969"
      unitRef="usd">-14000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzItMS0xLTEtMA_caa1f130-8145-44bb-b5c9-55782497dca0"
      unitRef="usd">130672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzItMy0xLTEtMA_305dd0e0-5db8-44c8-acee-32940fca6558"
      unitRef="usd">-88153000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzMtMS0xLTEtMA_ed883e3c-c3b3-4d20-b87e-1c5a191a8fbe"
      unitRef="usd">96363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a0d62a4e534478a8f3dbd0b9c4a9d82_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzMtMy0xLTEtMA_ea4f9cc0-4fbf-4dca-8ec2-54e6e3d54fa6"
      unitRef="usd">194905000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzQtMS0xLTEtMA_ae380ad0-e00f-45fa-b147-1d584c2f7ecd"
      unitRef="usd">227035000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i941b5c3651924990ab68ad8cb3e8b2de_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzQtMy0xLTEtMA_72f23c55-0d6f-4870-8146-05f9bd61120b"
      unitRef="usd">106752000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzYtMS0xLTEtMA_5a0108e8-6664-4062-8a36-fa19bf6da575"
      unitRef="usd">4951000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzYtMy0xLTEtMA_b320f315-13f7-4476-b938-8c47ef9d2d1a"
      unitRef="usd">4805000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzctMS0xLTEtMA_dd446798-b5fd-4299-b3a4-788f62fac2e7"
      unitRef="usd">2133000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18zNC9mcmFnOjE3NGY1NzcxZGM5YzRhODE5ODA4NTkzMjk4ZGNlMmMyL3RhYmxlOjU5NjYyOTJkZjY1MzQ4YWQ5YzY0OWU0MTI2YWIxN2UzL3RhYmxlcmFuZ2U6NTk2NjI5MmRmNjUzNDhhZDljNjQ5ZTQxMjZhYjE3ZTNfMzctMy0xLTEtMA_2f3b9f56-8e34-4f2e-9b8f-e41e7335b0ed"
      unitRef="usd">1289000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4OTY_468eb2d4-b796-4c11-a15c-babe0cc1cc4c">Organization and Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer and autoimmune disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At March&#160;31, 2020, we had approximately $1.5 billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8&#160;million. See Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2019 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 filed with the SEC on February 28, 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss), which totaled $1.1&#160;million for the three months ended March 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of March 31, 2020, our accounts receivable includes $10.9&#160;million under customer contracts from our collaboration partners and $31.2 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $12.8&#160;million from customer contracts and $24.0 million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers&#x2019; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable. We have not recorded a reserve for credit losses at March 31, 2020 or December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services, automotive and food and beverage industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;License, Collaboration and other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;License Grants&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Milestone Payments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;subsequent to&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Research and Development Services&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Impairment of Assets and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#x2019;s plan for the wind-down of Inheris and the NKTR-181 program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended March 31, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Coronavirus Aid, Relief and Economic Security Act&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. We do not expect that the CARES Act will have a material effect on our results of operations or financial position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <nktr:OrganizationPolicyTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4OTc_6d790cb0-4e6f-44d7-842b-001533dc3d3b">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer and autoimmune disease.&lt;/span&gt;&lt;/div&gt;Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions.</nktr:OrganizationPolicyTextBlock>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMTAyNg_1dff61a0-3158-4b91-abf8-7b62768fe1e4"
      unitRef="usd">1500000000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:RepaymentsOfLongTermDebtIncludingInterest
      contextRef="i617c906b489448d0a219e5d6dd99ee13_D20200413-20200413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTI2Mw_68ccf2d9-ee5a-4d1a-9e0d-66190fa5e8b7"
      unitRef="usd">254800000</nktr:RepaymentsOfLongTermDebtIncludingInterest>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4ODI_1eaddfe0-c44d-45a0-a4f9-fd98430ec2c5">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#x2019;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#x2019; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2019 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 filed with the SEC on February 28, 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4NzU_68578dc1-7564-41de-b21c-384ef3e195c6">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTI3OA_c23d0f49-977d-4a3b-8271-211a466c6ba2">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In December 2019, the FASB issued ASU 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss), which totaled $1.1&#160;million for the three months ended March 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTI4MA_e3680c6b-adbb-465a-b876-a7ff746e40b8"
      unitRef="usd">1100000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4OTI_2b7ad6da-83f7-4db5-9b30-0595681ae979">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNDc0Ng_1951a8de-b982-438f-a8cc-bdb4b72d56e6"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNTA4OA_cbf26954-5f25-48c8-8ab6-95a01b7f2cae"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4OTA_c61dcdda-b7bc-4a98-91da-aacef8afa6b2">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Significant Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of March 31, 2020, our accounts receivable includes $10.9&#160;million under customer contracts from our collaboration partners and $31.2 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $12.8&#160;million from customer contracts and $24.0 million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers&#x2019; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable. We have not recorded a reserve for credit losses at March 31, 2020 or December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services, automotive and food and beverage industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#x2019;s credit rating has been &lt;/span&gt;&lt;/div&gt;downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie5764993ab504d65aacd5098dfb7222c_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTY2Mg_4d392d2d-efe9-4403-a890-3ed3c39fbed6"
      unitRef="usd">10900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i657f08c144a940829954faa0eeb0ad80_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMTM3NDM4OTUzOTAzNjI_aefc8e70-c726-43b4-ade5-959a643ad26a"
      unitRef="usd">31200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i25dac032704d462cb271e24170497260_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTY3Nw_1050d462-3a1c-4844-adba-376ad07a047c"
      unitRef="usd">12800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4ec364a7590642378be3d04fe71fb93b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMTM3NDM4OTUzOTAzNzU_1dd3e62c-f02a-4258-bc79-6af4a86b3feb"
      unitRef="usd">24000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4Nzg_8ed71eff-0238-4c39-bc89-cb811483d47f">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#x2019; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4Nzk_45f121d8-85bb-4964-a283-46ddbd6a49ab">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#x2019;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Royalty Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;License, Collaboration and other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;License Grants&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Milestone Payments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. Our partners generally pay development milestones&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;subsequent to&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;achievement of the triggering event.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Research and Development Services&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4ODY_bf2f9900-ad74-4633-9d60-5812ef5b2260">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#x2019;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Impairment of Assets and Other Costs for Terminated Program&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#x2019;s plan for the wind-down of Inheris and the NKTR-181 program.&lt;/span&gt;&lt;/div&gt;As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <nktr:WriteOffOfPrepayment
      contextRef="i68abed833c9c4661bbe068761870699a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTYzMg_29121db9-679f-44bd-b709-00a5818101c8"
      unitRef="usd">19700000</nktr:WriteOffOfPrepayment>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="i68abed833c9c4661bbe068761870699a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfNzE0NjgyNTYyNTY0Nw_1080d280-6d36-4fa2-b94c-5c37ce0ed061"
      unitRef="usd">25500000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4ODM_291b0190-2796-4923-800e-c8eda4205f8a">&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended March 31, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180MC9mcmFnOmM5Y2Y0N2NiNDg3OTRhMjFiNjBhZDQzYzAyMzdmNjlmL3RleHRyZWdpb246YzljZjQ3Y2I0ODc5NGEyMWI2MGFkNDNjMDIzN2Y2OWZfMjQ4ODQ_db03b480-6ca8-48fa-bed2-8390b23222c6">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfMjcxMQ_14929329-1b6d-4983-8bf6-1d8c37e0f1e3">Cash and Investments in Marketable Securities&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.545%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.367%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.370%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;227,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,118,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,228,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;185,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;279,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,531,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of March&#160;31, 2020 and December&#160;31, 2019, all of our long-term investments had maturities between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTUz_40a91577-8b0a-499f-ace6-b778d1948c9f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTUz_d3c2600b-5a29-4044-88bc-bc0629d86f53"&gt;one&lt;/span&gt;&lt;/span&gt; and two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March&#160;31, 2020 and March&#160;31, 2019, we sold no available-for-sale securities. The cost of securities sold is based on the specific identification method. To repay our senior notes and accrued interest of $254.8&#160;million on April 13, 2020, we did not sell any available-for-sale securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We report our accrued interest receivable, which totaled $6.2&#160;million and $6.5&#160;million at March 31, 2020 and December 31, 2019, respectively, in other current assets on our Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:25.729%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.626%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.374%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.374%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.367%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;989,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;986,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,132,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;373,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;373,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;375,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,362,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,359,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,507,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,531,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-63pt;padding-left:63pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level&#160;1&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-63pt;padding-left:63pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-63pt;padding-left:63pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level&#160;2&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-63pt;padding-left:63pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-63pt;padding-left:63pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-63pt;padding-left:63pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-63pt;padding-left:63pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level&#160;3&#160;&#x2014;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfMjcxMw_3a080a73-d7d9-47bf-b6f2-54335062871b">&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.545%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.367%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.370%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Estimated Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;227,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,118,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,228,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;185,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;279,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,531,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfMi0xLTEtMS0w_dd4fb041-248e-4e8a-8cdf-2b56d8e2e33c"
      unitRef="usd">227035000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfMi0zLTEtMS0w_c1049a3b-9299-48d2-9ab3-f00435090185"
      unitRef="usd">96363000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfMy0xLTEtMS0w_ce42cea7-0c2b-4184-b952-346c5b3a0da3"
      unitRef="usd">1118847000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfMy0zLTEtMS0w_b8f88b8a-15e5-4962-bbc9-66ed7368ec35"
      unitRef="usd">1228499000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfNC0xLTEtMS0w_863b7476-cef6-4f94-a74a-2b83779c533e"
      unitRef="usd">185900000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfNC0zLTEtMS0w_11d14e14-01c1-496e-8f33-ddfb08443691"
      unitRef="usd">279119000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfNS0xLTEtMS0w_23b217fd-5d41-466f-ba5d-7d84f42b3dc3"
      unitRef="usd">1531782000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmFiNjVkMjc5YmFjMzRhYTZiNzYyMjc4ODE0YmY2ZmJjL3RhYmxlcmFuZ2U6YWI2NWQyNzliYWMzNGFhNmI3NjIyNzg4MTRiZjZmYmNfNS0zLTEtMS0w_164eb8b5-7e42-4b18-9856-7433f1f8f87a"
      unitRef="usd">1603981000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:DebtInvestmentMaximumMaturityPeriod
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfMTE1NDQ4NzIwOTQzNzU_0565b32d-d495-4a96-87d4-74bb4687bb87">P2Y</nktr:DebtInvestmentMaximumMaturityPeriod>
    <nktr:DebtInvestmentMaturityTerm
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfMTE1NDQ4NzIwOTQzOTI_4efb5670-7a06-4edc-8b34-173f9a4bd0a3">P1Y</nktr:DebtInvestmentMaturityTerm>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="i9c8f5c54957945ab9e0c8833712982bb_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTYw_807909cc-ac55-4f36-a902-7ae5c98fcc10">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <nktr:LongTermInvestmentMaturityPeriod
      contextRef="id43bdc0f960a40e680fd02bc07f10995_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTYw_838bd4e0-3e1e-4f1e-99e0-afe09f21c067">P2Y</nktr:LongTermInvestmentMaturityPeriod>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzA4_56d98363-158e-46f4-b63f-fac271e167fa"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzA4_9ca08e40-8ef9-463e-9b44-3b0227e315cf"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:SeniorNotes
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzE0NjgyNTU4NzE5NQ_2a8d058a-49d1-47ed-850b-a2e736c1ce88"
      unitRef="usd">254800000</us-gaap:SeniorNotes>
    <us-gaap:InterestReceivableCurrent
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzE0NjgyNTU4NzE2Nw_688d32c7-ed89-44c2-9af1-aafb7e8a9040"
      unitRef="usd">6200000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzE0NjgyNTU4NzE4MQ_98752dd9-3173-47f6-8455-c1981e0b0ca9"
      unitRef="usd">6500000</us-gaap:InterestReceivableCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfMjcwOQ_a995261e-8a58-4ef7-88e1-a1771eecfd5e">&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our portfolio of cash and investments in marketable securities includes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:25.729%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:7.626%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.374%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.374%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.494%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.367%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;br/&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;989,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;986,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,132,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;373,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;373,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;375,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,362,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(4,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,359,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,507,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;158,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash and investments in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,531,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,603,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i51acd3b95c4149dc8cd83ecdfa9b12b1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMi0zLTEtMS0xNzcz_b44e9bc6-5b3c-4398-80f1-491c70d76e5f"
      unitRef="usd">989511000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i51acd3b95c4149dc8cd83ecdfa9b12b1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMi01LTEtMS0xNzcz_9139b52e-9826-46bf-9ee6-adfe24148f23"
      unitRef="usd">736000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i51acd3b95c4149dc8cd83ecdfa9b12b1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMi03LTEtMS0xNzcz_ce8d46be-7fdd-4d16-8b90-2b48d048e724"
      unitRef="usd">4010000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51acd3b95c4149dc8cd83ecdfa9b12b1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMi0zLTEtMS0w_62dbc076-d492-4a55-a0f0-f58b0547f21d"
      unitRef="usd">986237000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7f7eb1f87944780a02ca9ee1d9db1bf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMi01LTEtMS0w_d4b9794a-8ebd-4f1a-a205-3a171f6f15ba"
      unitRef="usd">1132182000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5afc4a43bd794ef8adb57279613cc1dd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMy0zLTEtMS0xNzcz_a2b09ac0-0701-4df9-8c86-9f0066acdc21"
      unitRef="usd">373237000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5afc4a43bd794ef8adb57279613cc1dd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMy01LTEtMS0xNzcz_54ca7ebe-9421-4a43-8cc5-3c823a1c8aa7"
      unitRef="usd">94000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5afc4a43bd794ef8adb57279613cc1dd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMy03LTEtMS0xNzcz_a11628ac-b12b-47d5-bfdf-b6c2669c776b"
      unitRef="usd">108000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5afc4a43bd794ef8adb57279613cc1dd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMy0zLTEtMS0w_8be862a4-c123-41d7-95a7-6b8a608a5f80"
      unitRef="usd">373223000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i938a9e31f4a64af492d8c31056483e3f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfMy01LTEtMS0w_2857ed96-238a-444a-8ea2-dc7957388c49"
      unitRef="usd">375473000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i07085c452e9e46fe9f8b9074ea3df31a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNC0zLTEtMS0yMTc3_d04b2b26-cd79-451b-81c5-478ff25d2395"
      unitRef="usd">1362748000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i07085c452e9e46fe9f8b9074ea3df31a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNC01LTEtMS0yMTc4_ac7838cb-bcf7-4fcc-af90-08037be230c4"
      unitRef="usd">830000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i07085c452e9e46fe9f8b9074ea3df31a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNC03LTEtMS0zOTAw_a374474a-ddc4-4204-8d61-a388efec1f93"
      unitRef="usd">4118000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07085c452e9e46fe9f8b9074ea3df31a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNS0zLTEtMS0w_3f5d8c03-1a49-4312-a751-87cdae15da2e"
      unitRef="usd">1359460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia82602267fa24e74b8fe2c74cf36b690_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNS01LTEtMS0w_635bde17-ab7f-4e07-98ad-7c160a0ae504"
      unitRef="usd">1507655000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib1849ac1a92f46c5ae1b8a55162ddd3c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNi0zLTEtMS0w_73030d6e-e525-48a6-bfad-351589a8d0d5"
      unitRef="usd">158080000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i392410be9f884e3dba660113995bcb25_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNi01LTEtMS0w_e043a0a6-1c67-4b2a-b148-2739a468f513"
      unitRef="usd">83546000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6c61034529c24a02ad03caceb320bacc_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNy0zLTEtMS0w_8aa763fd-6df8-45f5-aee1-3f248649cbc0"
      unitRef="usd">8248000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i848f5b28c13943a9a8360104ac654571_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfNy01LTEtMS0w_201b3ecf-48c2-4f02-95c3-e1e91eb4e962"
      unitRef="usd">6951000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:Cash
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfOC0zLTEtMS0w_6b65719f-9201-46f1-a4e3-ff67c65a4b17"
      unitRef="usd">5994000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfOC01LTEtMS0w_acbb3171-303f-4405-ae7a-7b50dabee3ae"
      unitRef="usd">5829000</us-gaap:Cash>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfOS0zLTEtMS0w_bca9b2b4-2751-43cb-bcd2-452878f2ce49"
      unitRef="usd">1531782000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RhYmxlOmJlMGRhOWYzN2U2MTQxMjM4MjM3YzE4Mjg5YmZjN2YyL3RhYmxlcmFuZ2U6YmUwZGE5ZjM3ZTYxNDEyMzgyMzdjMTgyODliZmM3ZjJfOS01LTEtMS0w_17bb1fab-b833-48a2-94c0-cba6df54e25b"
      unitRef="usd">1603981000</nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzE0NjgyNTU4NzIxMQ_0e8fd8fe-1893-44ac-bb7b-54d293c53040"
      unitRef="usd">2100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNzE0NjgyNTU4NzIyNQ_0ca219dc-81da-4a1f-8fbb-e9effb379c3a"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RleHRyZWdpb246ZDY4M2QyZDM1NzJiNDFiZWI0MGM4MTUyOTcwZmVjZThfMTA4OA_e0c4e21a-156c-4d89-983c-1841f871b00a">Inventory&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.545%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.367%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.370%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RleHRyZWdpb246ZDY4M2QyZDM1NzJiNDFiZWI0MGM4MTUyOTcwZmVjZThfMTA5MA_a22d3614-93a3-48a2-a7b9-90f2f74b945a">&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventory consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.545%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.367%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.518%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.370%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMS0xLTEtMS0w_21a6e118-9367-4e92-a26d-112a10aa8e08"
      unitRef="usd">1198000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMS0zLTEtMS0w_ab136da0-2d12-4916-86a3-e1c6d7b2c0da"
      unitRef="usd">1673000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMi0xLTEtMS0w_181b1424-3c9c-4ca1-9a25-20630531320d"
      unitRef="usd">11463000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMi0zLTEtMS0w_c5504c6b-321e-476d-985a-7db8da80794f"
      unitRef="usd">8267000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMy0xLTEtMS0w_7e36a477-3fbc-4065-9ff2-6b5cf42a8481"
      unitRef="usd">1659000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfMy0zLTEtMS0w_47fc3b91-394a-488b-ab00-44ebc15f7b52"
      unitRef="usd">2725000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfNC0xLTEtMS0w_9e5d7451-df7d-44b3-81a7-aca11babcddd"
      unitRef="usd">14320000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RhYmxlOjBiMWRlM2IyZDBmYTRhM2E4YzkxN2IwNzNjZGViNWUxL3RhYmxlcmFuZ2U6MGIxZGUzYjJkMGZhNGEzYThjOTE3YjA3M2NkZWI1ZTFfNC0zLTEtMS0w_7ae32da0-976b-422d-b531-bbc4865c79cf"
      unitRef="usd">12665000</us-gaap:InventoryNet>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M181Mi9mcmFnOmQ2ODNkMmQzNTcyYjQxYmViNDBjODE1Mjk3MGZlY2U4L3RleHRyZWdpb246ZDY4M2QyZDM1NzJiNDFiZWI0MGM4MTUyOTcwZmVjZThfMTE1NDQ4NzIwOTI3NDE_db60b192-c523-4c78-9d66-6c7aa59af8b8">We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased.</us-gaap:InventoryPolicyTextBlock>
    <nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMzE2MQ_72d43524-90ec-4178-9ec8-dc79e0df2ce0">Liability Related to Sale of Future Royalties&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February&#160;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the Royalty Entitlement.&#160;As part of this sale, we incurred approximately $4.4 million in transaction costs, which are amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; and MIRCERA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (Royalty Obligation) that is amortized using the interest method over the estimated life of the Purchase and Sale Agreement as royalties from the CIMZIA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; and MIRCERA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; products are remitted directly to RPI. During the three months ended March&#160;31, 2020 and 2019, we recognized $9.9 million and $8.2 million, respectively, in non-cash royalty revenue from net sales of CIMZIA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; and MIRCERA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, and we recorded $7.0&#160;million and $6.1&#160;million, respectively, of related non-cash interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation. From inception through 2017, our estimate of the total interest expense on the Royalty Obligation resulted in an effective annual interest rate of approximately 17%. During the three months ended December 31, 2017, our estimate of the effective annual interest rate over the life of the agreement increased to 17.6%, which resulted in a prospective interest rate of approximately 21%.&#160;&#160;During the three months ended December 31, 2018, primarily as a result of increases in the forecasted sales of MIRCERA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, our estimate of the effective annual interest rate over the life of the agreement increased to 18.7%, which results in a prospective interest rate of 29%. During the three month period ended December 31, 2019, primarily as a result of increases in the forecasted sales of CIMZIA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; and MIRCERA&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, our estimate of the effective annual interest rate over the life of the agreement increased to 19.5%, which results in a prospective interest rate of 38%. This rate remains unchanged for the three months ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty Entitlement and contains other representations and warranties, covenants and indemnification obligations that are customary for a transaction of this nature. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement; however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction.&lt;/span&gt;&lt;/div&gt;</nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i55ebaedb84964cd4b5712ade47ad52d9_D20120223-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfNjk4_9246a229-c031-445b-97f0-d9fe6c954378"
      unitRef="usd">124000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i420c7f47313d4e2793bf297d5ef97ff1_I20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfNzc4_d519b7f9-447c-48ee-90b2-6886d5ad7b03"
      unitRef="usd">4400000</us-gaap:DeferredFinanceCostsGross>
    <nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross
      contextRef="i55ebaedb84964cd4b5712ade47ad52d9_D20120223-20120224"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE4MA_f9f14294-fb30-4c22-b5e9-970fe8952eb3"
      unitRef="usd">124000000.0</nktr:ProceedsFromSaleOfPotentialFutureRoyaltiesGross>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTQ4NDM0MDY5Nzg3NzY_cb8c8abd-d7dc-49e3-8998-69f07dbc2787"
      unitRef="usd">9900000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTQ4NDM0MDY5Nzg3ODM_dfbd5265-3486-4692-abc6-871ad4e72087"
      unitRef="usd">8200000</nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTQ4NDM0MDY5Nzg3OTI_b5a1f58d-55da-4436-a307-e2e6e26f3a98"
      unitRef="usd">7000000.0</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTQ4NDM0MDY5Nzg4MDI_5891ca51-91e0-4de5-a652-72216cb15439"
      unitRef="usd">6100000</nktr:NonCashInterestExpenseRelatedToSaleOfRoyalties>
    <nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMzE2Mw_e64d7566-1f06-4f8a-a84e-284e5ba3f730">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation.</nktr:LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="ia994984450184042ba5fc3190eb272a1_D20120223-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUxODQ_c4e8ea73-abc6-45ff-91e9-e67cf4a75cd5"
      unitRef="number">0.17</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="ife966253eae849efaf2c94d1e31949be_D20171001-20171231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUxODk_692f2603-b06f-424e-ba66-8f354d32755b"
      unitRef="number">0.176</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="ife966253eae849efaf2c94d1e31949be_D20171001-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUxOTY_f6ba92d6-6dfa-4592-91cd-ef79a973b81e"
      unitRef="number">0.21</nktr:ProspectiveInterestRatePercentage>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="i39de4441ca0e49f2a86c258e4f2b6611_D20181001-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUyMDE_4a82af76-98fe-42da-8799-81b059cc5298"
      unitRef="number">0.187</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="i39de4441ca0e49f2a86c258e4f2b6611_D20181001-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUyMDg_74b97ed4-03f6-44bd-bf86-b0be26657f82"
      unitRef="number">0.29</nktr:ProspectiveInterestRatePercentage>
    <nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability
      contextRef="ia10a44927680469a914aaa3781e9e7dd_D20191001-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUyMTM_36c6f783-bbb5-4a3a-ae3a-0eeeeef6418c"
      unitRef="number">0.195</nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability>
    <nktr:ProspectiveInterestRatePercentage
      contextRef="ia10a44927680469a914aaa3781e9e7dd_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182MS9mcmFnOjdjNDlkMTUyNDZmZDRjM2ZiNWE0NTUwNzcyMWE0MWE4L3RleHRyZWdpb246N2M0OWQxNTI0NmZkNGMzZmI1YTQ1NTA3NzIxYTQxYThfMTE1NDQ4NzIwOTUyMjA_8b34f09b-9f77-4db0-8ada-a6385f89bc85"
      unitRef="number">0.38</nktr:ProspectiveInterestRatePercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182NC9mcmFnOjIyZDc3Zjg0NTkxZDRlZjNiODc4ZTY2NzY5ZDY2YTFkL3RleHRyZWdpb246MjJkNzdmODQ1OTFkNGVmM2I4NzhlNjY3NjlkNjZhMWRfNDM2OA_1eb9aca9-036d-4b58-a05e-11ac8b8c9d6d">Commitments and Contingencies&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on May 15, 2019. Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of Nektar&#x2019;s board. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California naming the CEO, CFO and certain members of Nektar&#x2019;s board. These class action and shareholder derivative actions assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. All of these cases are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Condensed Consolidated Balance Sheets at either March 31, 2020 or December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Indemnifications in Connection with Commercial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 4. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Condensed Consolidated Balance Sheets at either March&#160;31, 2020 or December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i428e2157a70c43f3a299cacec891a04c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182NC9mcmFnOjIyZDc3Zjg0NTkxZDRlZjNiODc4ZTY2NzY5ZDY2YTFkL3RleHRyZWdpb246MjJkNzdmODQ1OTFkNGVmM2I4NzhlNjY3NjlkNjZhMWRfNDI2Nw_d2acc95a-86ae-4c03-b9b2-8763de2ee296"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i8757df3c4b9949b5a56ec0f462c39d45_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M182NC9mcmFnOjIyZDc3Zjg0NTkxZDRlZjNiODc4ZTY2NzY5ZDY2YTFkL3RleHRyZWdpb246MjJkNzdmODQ1OTFkNGVmM2I4NzhlNjY3NjlkNjZhMWRfNDI2Nw_ec72c793-2bbf-41f6-a715-e1de9aac435d"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTk3NTk_1312a227-9c8d-455a-bc54-878591eb5469">License and Collaboration AgreementsWe have entered into various collaboration agreements including license agreements and collaborative research, development and commercialization agreements with various pharmaceutical and biotechnology companies. Under these collaboration arrangements, we are entitled to receive license fees, upfront payments, milestone and other contingent payments, royalties, sales milestone payments, and payments for the manufacture and supply of our proprietary PEGylation materials and/or reimbursement for research and development activities. We generally include our costs of performing these services in research and development expense, except for costs for product sales to our collaboration partners which we include in cost of goods sold. &lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We analyze our agreements to determine whether we should account for the agreements within the scope of ASC 808, and, if so, we analyze whether we should account for any elements under ASC 606. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.856%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.597%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.519%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.223%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.519%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.510%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.519%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Drug or Drug Candidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Bristol-Myers Squibb Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;NKTR-358&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amgen, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Neulasta&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March&#160;31, 2020 and 2019, we recognized $44.6&#160;million and $19.6&#160;million, respectively, of revenue for performance obligations that we had satisfied in prior periods. This amount includes all of our royalty revenue and non-cash royalty revenue, as well as the $25.0&#160;million milestone received under our BMS Collaboration Agreement during the three months ended March&#160;31, 2020 described below, because we had previously completed our performance obligations of granting the licenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the changes in our deferred revenue balance from our collaboration agreements during the three months ended March&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.712%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.734%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.266%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&#x2014;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Recognition of previously unearned revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&#x2014;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our balance of deferred revenue contains the transaction price from our collaboration agreements allocated to performance obligations which are partially unsatisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, our collaboration agreements with partners included potential future payments for development and regulatory milestones totaling approximately $1.7 billion, including amounts from our agreements with BMS and Eli Lilly and Company described below. In addition, under our collaboration agreements we are entitled to receive contingent sales milestone payments, other contingent payments and royalty payments, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;There have been no material changes to our collaboration agreements in the three months ended March&#160;31, 2020, except as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Bristol-Myers Squibb Company (BMS)&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;: Bempegaldesleukin, also referred to as NKTR-214 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) and a Share Purchase Agreement with BMS, both of which became effective on April 3, 2018. The agreement replaced the Clinical Trial Agreement we had entered into in September 2016. Pursuant to these current agreements, we and BMS are jointly developing bempegaldesleukin, including, without limitation, in combination with BMS&#x2019;s Opdivo&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (nivolumab) and Opdivo&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; plus Yervoy&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (ipilimumab), and other compounds of BMS, us or any third party. The parties have agreed to jointly commercialize bempegaldesleukin on a worldwide basis. We retained the right to record all worldwide sales for bempegaldesleukin. We will share global commercialization profits and losses with BMS for bempegaldesleukin, with Nektar sharing 65% and BMS sharing 35% of the net profits and losses. The parties share the internal and external development costs for bempegaldesleukin in combination regimens based on each party&#x2019;s relative ownership interest in the compounds included in the regimens. In accordance with the agreement, the parties share development costs for bempegaldesleukin in combination with Opdivo&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, 67.5% of costs to BMS and 32.5% to Nektar, and for bempegaldesleukin in a triplet combination with Opdivo&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; and Yervoy&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae; &lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;78% of costs to BMS and 22% to Nektar. The parties share costs for the manufacturing of bempegaldesleukin, 35% of costs to BMS and 65% to Nektar.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Upon the effective date of the BMS Collaboration Agreement in April 2018, BMS paid us a non-refundable upfront cash payment of $1.0 billion. We are eligible to receive additional cash payments up to a total of approximately $1.45 billion (including the milestones from Amendment No. 1 described below) upon the achievement of certain development and regulatory milestones and up to a total of $350.0 million upon the achievement of certain sales milestones. In April 2018, BMS also &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;purchased 8,284,600 shares of our common stock pursuant to the Share Purchase Agreement for total additional cash consideration of $850.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On January 9, 2020, we and BMS entered into Amendment No. 1 (the Amendment) to the BMS Collaboration Agreement. Pursuant to the Amendment, we and BMS agreed to update the Collaboration Development Plan under which we are collaborating and developing bempegaldesleukin. The cost sharing under the Amendment remains unchanged. Additionally, we are eligible to receive an additional non-refundable, non-creditable milestone payment of $25.0&#160;million following the achievement of the first patient, first visit in the registrational adjuvant melanoma trial, studying the combination of bempegaldesleukin and Opdivo&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. We are also eligible to receive non-refundable, creditable milestone payments of $25.0&#160;million and $75.0&#160;million following the achievement of the first patient, first visit in a registrational muscle-invasive bladder cancer trial and a registrational first-line non-small-cell lung cancer trial, respectively, in each case studying the combination of bempegaldesleukin and Opdivo&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. For the two creditable milestones, BMS is entitled to deduct the amounts paid pursuant to these milestones from future development milestones due to us under the original agreement. On January 30, 2020, the milestone for the first patient, first visit milestone for the registrational muscle-invasive bladder cancer trial was achieved, and BMS paid us the $25.0&#160;million milestone in March 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We determined that the BMS Collaboration Agreement falls within the scope of ASC 808, and we analogized to ASC 606 for the accounting for our performance obligation of the delivery of the licenses to develop and commercialize bempegaldesleukin.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During 2018, we aggregated the total consideration of $1.85 billion received under the agreements and allocated it between the stock purchase and the revenue-generating elements, because we and BMS negotiated the agreements together and the effective date of the BMS Collaboration Agreement was dependent upon the effective date of the Share Purchase Agreement. We recorded the estimated fair value of the shares of $790.2 million in stockholders&#x2019; equity. We allocated the remaining $1,059.8 million to the transaction price of the collaboration agreement, which we recognized in 2018. We consider the future potential development, regulatory and sales milestones of up to approximately $1.8 billion to be variable consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March 31, 2020, we updated the transaction price by $25.0&#160;million for the achievement of the first patient, first visit in the registrational muscle invasive bladder cancer trial. Since we had already completed our sole performance obligations of delivery of the licenses, we recognized this $25.0&#160;million in license, collaboration and other revenue during the three months ended March 31, 2020. We continue to exclude the other milestones from the transaction price as of March&#160;31, 2020 due to the significant uncertainties involved with clinical development and regulatory approval. We re-evaluate the transaction price at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As mentioned above, BMS shares certain percentages of development costs incurred by us and we share certain percentages of development costs incurred by BMS. We consider these activities to represent collaborative activities under ASC 808, and we recognize such cost sharing proportionately with the performance of the underlying services. We recognize BMS&#x2019; reimbursement of our costs as a reduction of research and development expense and our reimbursement of BMS&#x2019; costs as research and development expense. During the three months ended March&#160;31, 2020 and 2019, we recorded $30.7&#160;million and $28.8&#160;million, respectively, as a reduction of research and development expense for BMS&#x2019; share of our expenses, net of our share of BMS&#x2019; expenses.&#160;As of March&#160;31, 2020, we have recorded an unbilled receivable of $31.2&#160;million from BMS in accounts receivable in our Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Eli Lilly and Company (Lilly&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;): NKTR-358 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly), which became effective on August 23, 2017, to co-develop NKTR-358, a novel immunological drug candidate that we invented. Under the terms of the agreement, we (i) received an initial payment of $150.0 million in September 2017 and are eligible for up to $250.0 million in additional development milestones, (ii) will co-develop NKTR-358 with Lilly, for which we were responsible for completing Phase 1 clinical development and are responsible for certain drug product development and supply activities, (iii) will share with Lilly Phase 2 development costs with 75% of those costs borne by Lilly and 25% of the costs borne by us, (iv) will have the option to contribute funding to Phase 3 development on an indication-by-indication basis ranging from zero to 25% of development costs, and (v) will have the opportunity to receive up to double-digit sales royalty rates that escalate based upon our Phase 3 development cost contribution and the level of annual global product sales. Lilly will be responsible for all costs of global commercialization, and we will have an option to co-promote in the U.S. under certain conditions. A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The agreement will continue until Lilly no longer has any royalty payment obligations or, if earlier, the termination of the agreement in accordance with its terms. The agreement may be terminated by Lilly for convenience, and may also be terminated under certain other circumstances, including material breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We identified our license grant to Lilly, our ongoing Phase 1 clinical development obligation and our drug product development obligation as the significant performance obligations in the arrangement. The valuation of each performance obligation involves significant estimates and assumptions, including but not limited to, expected market opportunity and pricing, assumed royalty rates, clinical trial costs, timelines and likelihood of success; in each case these estimates and assumptions covering long time periods. We determined the selling price for the license based on a discounted cash flow analysis of projected revenues from NKTR-358 and development and commercial costs using a discount rate based on a market participant&#x2019;s weighted-average cost of capital adjusted for forecasting risk. We determined the selling prices for our Phase 1 clinical development and drug product development deliverables based on the nature of the services to be performed and estimates of the associated efforts and third-party rates for similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Although we are entitled to significant development milestones under this arrangement, through March&#160;31, 2020, we have excluded such milestones from the transaction price due to the significant uncertainties involved with clinical development. We have therefore determined the transaction price to consist of the upfront payment of $150.0 million in September 2017. Based on our estimates of the standalone selling prices of the performance obligations, we allocated the $150.0 million upfront payment as $125.9 million to the license, $17.6 million to our portion of the Phase 1 clinical development and $6.5 million to the drug product development.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognized the $125.9 million of revenue allocated to the license upon the effective date of the license agreement in August 2017, since we determined that the license was a right to use our intellectual property, for which, as of the effective date, we had provided all necessary information to Lilly to benefit from the license and the license term had begun. We recognized revenue for our portion of the Phase 1 clinical development and drug product development using an input method, using costs incurred, as this method depicts our progress towards providing Lilly with the results of clinical trials and drug production processes. As of March&#160;31, 2020, we completed our performance obligations and we have no deferred revenue related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Baxalta Inc. / Takeda Pharmaceutical Company Ltd&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;: Hemophilia&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We are a party to an exclusive research, development, license and manufacturing and supply agreement with Baxalta Inc. (Baxalta), a subsidiary of Takeda Pharmaceutical Company Ltd. (Takeda), entered into in September 2005 to develop products designed to improve therapies for Hemophilia A patients using our PEGylation technology. Under the terms of the agreement, we are entitled to research and development funding for our active programs, which are now complete for Factor VIII, and are responsible for supplying Takeda with its requirements for our proprietary materials. Takeda is responsible for all clinical development, regulatory, and commercialization expenses. The agreement is terminable by the parties under customary conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;This Hemophilia A program includes ADYNOVATE&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, which was approved by the United States Food and Drug Administration (FDA) in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A, and is now marketed in the U.S., the European Union, and many other countries. As a result of the marketing authorization in the EU in January 2018, we earned a $10.0 million development milestone, which we received in March 2018. During 2018, we earned an additional $10.0 million milestone for annual sales of ADYNOVATE&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;/ ADYNOVI&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;&#x2122;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; reaching a certain specified amount.&#160;In addition, we are entitled to an additional sales milestone upon achievement of an annual worldwide net sales target and royalties based on worldwide net sales of products resulting from this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;text-align:justify;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents that were previously exclusively licensed to Baxalta under our 2005 agreement. Under the right to sublicense agreement, Baxalta paid us $12.0 million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Our remaining unsatisfied performance obligation consists of our ongoing supply of PEGylation materials at a price less than the standalone selling price of these materials. As of March&#160;31, 2020, our deferred revenue from this arrangement is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Amgen, Inc&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;.: Neulasta&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In October 2010, we amended and restated an existing supply and license agreement by entering into a supply, dedicated suite and manufacturing guarantee agreement (the Amended and Restated Agreement) and a license agreement with Amgen, Inc. and Amgen Manufacturing, Limited (together referred to as Amgen). Under the terms of the Amended and Restated Agreement, we received a $50.0 million payment in the fourth quarter of 2010 in return for our guaranteeing the supply of certain quantities of our proprietary PEGylation materials to Amgen.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We determined that our obligation to manufacture and supply our PEGylation materials and to maintain the dedicated manufacturing suite solely for the production of such materials for Amgen represented an obligation to stand ready to manufacture such materials. We concluded that we should recognize revenue based on the passage of time as this method depicts the satisfaction of Amgen&#x2019;s right to require production of PEGylation materials at any time. As of March&#160;31, 2020, we have deferred revenue of approximately $2.9 million related to this agreement, which we expect to recognize through October 2020, the estimated end of our obligations under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;AstraZeneca AB&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;: MOVANTIK&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;(naloxegol oxalate), previously referred to as naloxegol and NKTR-118 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In September 2009, we entered into an agreement with AstraZeneca AB (AstraZeneca) under which we granted AstraZeneca a worldwide, exclusive license under our patents and other intellectual property to develop, market, and sell MOVANTIK&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. AstraZeneca is responsible for all research, development and commercialization costs and related decisions for MOVANTIK&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. In September 2014 and December 2014, MOVANTIK&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; /MOVENTIG&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; was approved in the US and EU, respectively. As of March&#160;31, 2020, we have received a total of $385.0 million of upfront and contingent milestone payments from this agreement, all of which was received in or before 2015. In addition, we are entitled to significant and escalating double-digit royalty payments and sales milestone payments based on annual worldwide net sales of MOVANTIK&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2016, AstraZeneca announced that it had entered into an agreement with ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in the EU, Iceland, Liechtenstein, Norway and Switzerland. Under our license agreement with AstraZeneca, we and AstraZeneca share the upfront payment, market access milestone payments, royalties and sales milestone payments made by Kirin to AstraZeneca with AstraZeneca receiving 60% and Nektar receiving 40%. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March&#160;31, 2020, we do not have deferred revenue related to our agreement with AstraZeneca.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2020, AstraZeneca announced that it had sublicensed its global commercialization rights for MOVANTIK&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;, excluding Europe, Canada and Israel, to RedHill Biopharma. This sublicense does not change our rights under the agreement with AstraZeneca and our royalty rate, royalty term and future potential sales milestones remain unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In addition, as of March&#160;31, 2020, we have other collaboration agreements, including with our collaboration partner UCB Pharma, under which we are entitled to up to a total of $40.0 million of development milestone payments upon achievement of certain development objectives, as well as sales milestones upon achievement of annual sales targets and royalties based on net sales of commercialized products, if any. However, given the current phase of development of the potential products under these collaboration agreements, we cannot estimate the probability or timing of achieving these milestones and, therefore, have excluded all development milestones from the respective transaction prices for these agreements. As of March&#160;31, 2020, we have deferred revenue of approximately $2.0 million related to these other collaboration agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTk3NTU_b1edaacc-0579-4e6b-9689-7355b676d4ea">&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.856%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:41.597%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.519%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.223%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.519%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.510%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.519%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.513%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Drug or Drug Candidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Bristol-Myers Squibb Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Bempegaldesleukin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Eli Lilly and Company&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;NKTR-358&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amgen, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Neulasta&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;License, collaboration and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i1492124b62b94996a7f0d95f8f8f292c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfMi00LTEtMS0w_1bdf1c78-e9c9-4e50-97c4-9ebd225370a9"
      unitRef="usd">25000000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i4c8b3e65156e43079d5d07536ba9b742_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfMi02LTEtMS0w_20ff9ae2-e212-4218-8bb1-955598042e56"
      unitRef="usd">0</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ie32189417fc6405184490d6c99a30561_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfMy00LTEtMS0w_0087f63e-3825-46d0-9de0-94c9ff1279e4"
      unitRef="usd">1259000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i473c9cb95deb4ee889c81eb1819eea3d_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfMy02LTEtMS0w_e44d1c9a-1816-48e4-b8a0-19a64a123007"
      unitRef="usd">2500000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="id516ba896043456c9bdbb51852afcdc0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNC00LTEtMS0w_0c7573ac-963d-4365-b6f3-926529651e3c"
      unitRef="usd">1250000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ib2341951fc6949bb9192ad91d2f02f07_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNC02LTEtMS0w_4fbfafc2-3b61-467f-b8ce-3547cf377334"
      unitRef="usd">1250000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="iefc95f69692243d1831202814f3ecaef_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNS00LTEtMS0w_52e29284-f028-4925-b1d3-a45b10193705"
      unitRef="usd">6000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i43f3a718f036485cabdfa41cfb7ef6b3_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNS02LTEtMS0w_cb774bd7-90df-4cbe-a2e1-c86b64b149bd"
      unitRef="usd">454000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNi00LTEtMS0w_8be81f43-9af7-40ee-855b-39971784dd2d"
      unitRef="usd">27515000</nktr:LicenseCollaborationOtherRevenue>
    <nktr:LicenseCollaborationOtherRevenue
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOmQzZjAzODUwYTkwYjRiNmFiYWQ2MjQ3NzljZTU1NWEyL3RhYmxlcmFuZ2U6ZDNmMDM4NTBhOTBiNGI2YWJhZDYyNDc3OWNlNTU1YTJfNi02LTEtMS0w_9681ff14-f720-4f47-b68b-bef4c5b35d77"
      unitRef="usd">4204000</nktr:LicenseCollaborationOtherRevenue>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjA5Nw_619675a5-cd2d-4a94-bcc6-0e4a78407d9a"
      unitRef="usd">44600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjExMg_da7a905b-6c53-4c46-82be-2d491338ce16"
      unitRef="usd">19600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <nktr:SalesMilestoneRevenue
      contextRef="i64f7bf13694b434da50607cc92511ae6_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjEyNw_54937233-f9ad-4176-938d-b33812383934"
      unitRef="usd">25000000.0</nktr:SalesMilestoneRevenue>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTk3NTc_1bb2726c-6d9f-46dc-89df-175e61743308">&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the changes in our deferred revenue balance from our collaboration agreements during the three months ended March&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.712%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:83.734%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.266%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&#x2014;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Recognition of previously unearned revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred revenue&#x2014;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i92b3ad4ac67b4455a3c9802320152891_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOjE3ZWMzM2ZkNjU4ODRjMjViODQ1OGUwNmQzZmE3MWMwL3RhYmxlcmFuZ2U6MTdlYzMzZmQ2NTg4NGMyNWI4NDU4ZTA2ZDNmYTcxYzBfMS0xLTEtMS0w_106930cc-2521-4ecf-8cbd-8d412d0ccb0e"
      unitRef="usd">8071000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOjE3ZWMzM2ZkNjU4ODRjMjViODQ1OGUwNmQzZmE3MWMwL3RhYmxlcmFuZ2U6MTdlYzMzZmQ2NTg4NGMyNWI4NDU4ZTA2ZDNmYTcxYzBfMi0xLTEtMS0w_bd4e965b-ddd4-4eb2-823e-56fd0cd12b21"
      unitRef="usd">2510000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RhYmxlOjE3ZWMzM2ZkNjU4ODRjMjViODQ1OGUwNmQzZmE3MWMwL3RhYmxlcmFuZ2U6MTdlYzMzZmQ2NTg4NGMyNWI4NDU4ZTA2ZDNmYTcxYzBfMy0xLTEtMS0w_83f8c132-7a14-44db-8207-48841144ab23"
      unitRef="usd">5561000</us-gaap:ContractWithCustomerLiability>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="ifbb4be8e78984f9b982e39128071667a_I20200331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMjYyNQ_72aec925-48f5-48d2-ba0c-b545fb289ae5"
      unitRef="usd">1700000000</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="iba0f97bcb4b4439498c18a0cee8d7459_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIwMg_0a312805-4159-4ecb-943c-2ada0267dd39"
      unitRef="number">0.65</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:ProfitsAndLossesSharingPercentage
      contextRef="i9195970c9dc0457185dab641c8cb1b46_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIwNw_d37f4528-3044-47a0-bd3d-aa93e7d8558f"
      unitRef="number">0.35</nktr:ProfitsAndLossesSharingPercentage>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i7669b30a20914aa29e59f95f80c6ce1d_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIxMg_f93a12a4-ecb0-43f0-bfbd-df7fb670303a"
      unitRef="number">0.675</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i60c9630119f2431abfe04edb5e2fb3ed_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIxOQ_266f530a-57d0-44ee-beff-abc28b5c7673"
      unitRef="number">0.325</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="ifd93624e0fb543c2b0ac79d91fd72357_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIyNg_d66fe02f-3678-4e5e-a760-cb78ece9a954"
      unitRef="number">0.78</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInDevelopmentCosts
      contextRef="i4279aa6d740d409f9971a4360326a569_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIzMQ_9f315392-e0e6-49f6-a1e4-aaf5fef12ec7"
      unitRef="number">0.22</nktr:PercentageOfSharingInDevelopmentCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="i9195970c9dc0457185dab641c8cb1b46_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjIzNg_238d5c9d-21e4-4981-acbb-65eef3776f31"
      unitRef="number">0.35</nktr:PercentageOfSharingInProductionCosts>
    <nktr:PercentageOfSharingInProductionCosts
      contextRef="iba0f97bcb4b4439498c18a0cee8d7459_D20180212-20180213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjI0MQ_761de0a6-5308-4992-8621-eccf8b7cae36"
      unitRef="number">0.65</nktr:PercentageOfSharingInProductionCosts>
    <nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
      contextRef="i78cc054f78e14454a10bbf7594a284a7_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNTI2OA_8cbd208f-c1d9-4b21-bf94-1986526fc198"
      unitRef="usd">1000000000.0</nktr:UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements>
    <nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones
      contextRef="ife19b7e801a54e7aaa7298b8de21446d_D20200101-20200331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNTM1NQ_1ecf336c-206b-4063-ba87-01f8e53f372e"
      unitRef="usd">1450000000</nktr:CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones>
    <nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones
      contextRef="i0111201aa93e4b82bb4611c26ba6b748_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNTQ0OQ_07d8edbc-118c-45f5-b302-c6e6be76d764"
      unitRef="usd">350000000.0</nktr:EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones>
    <us-gaap:SharesIssued
      contextRef="id3f27473571a48dd830b6f580001f835_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNTUzNg_39c5c95f-b244-4237-9020-b160a56be36f"
      unitRef="shares">8284600</us-gaap:SharesIssued>
    <nktr:SaleOfStockConsiderationReceived
      contextRef="if758da7137704b02aeb393bbd5f6d719_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNTY1MA_242ec68d-46f9-4ea8-a06c-1ae11e54b149"
      unitRef="usd">850000000.0</nktr:SaleOfStockConsiderationReceived>
    <nktr:PotentialDevelopmentMilestones
      contextRef="ib5a5a0cd127f4c7bb5c3c685ed7d0af3_I20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjE1Nw_93743b23-1bef-4c09-8d30-3881bcc7a8ad"
      unitRef="usd">25000000.0</nktr:PotentialDevelopmentMilestones>
    <nktr:PotentialDevelopmentMilestones
      contextRef="ifc7fd90c5f154037a6e40bfef3b6fc10_I20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjE3Mg_b9eb6ec9-3b65-47b1-b664-583767c11844"
      unitRef="usd">25000000.0</nktr:PotentialDevelopmentMilestones>
    <nktr:PotentialDevelopmentMilestones
      contextRef="idfbf1bae2fe14c92aa3559eb0012ec75_I20200109"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjE4Nw_cd793984-a516-4e2e-a59d-693d35244dda"
      unitRef="usd">75000000.0</nktr:PotentialDevelopmentMilestones>
    <nktr:SalesMilestoneRevenue
      contextRef="i013cfcd2f2bd4e028e742adb05277f94_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjE0Mg_33ee616e-f490-45aa-840f-a1bc3e31514c"
      unitRef="usd">25000000.0</nktr:SalesMilestoneRevenue>
    <nktr:AggregateConsiderationReceivedFromAgreements
      contextRef="ic5a469ebee04424493829d25d002dafe_D20180401-20180430"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTM3NDM4OTUzNzk4MjM_00909da9-e911-4053-b766-01c5dcd96d0a"
      unitRef="usd">1850000000</nktr:AggregateConsiderationReceivedFromAgreements>
    <nktr:EstimatedFairValueOfShares
      contextRef="i6952cb9044694778b60945d87960f80d_I20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTM3NDM4OTUzODAxNzQ_fbc005a4-39fc-4aa7-b706-d2b995fca6b0"
      unitRef="usd">790200000</nktr:EstimatedFairValueOfShares>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="ic5a469ebee04424493829d25d002dafe_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTM3NDM4OTUzODAyMjk_ff31b518-4c74-4ff8-96b2-41c7431927a2"
      unitRef="usd">1059800000</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:PotentialDevelopmentRegulatoryAndSalesMilestones
      contextRef="i6952cb9044694778b60945d87960f80d_I20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTM3NDM4OTUzODA0MTk_9882212f-0c94-4098-b1ab-9467e2b913d7"
      unitRef="usd">1800000000</nktr:PotentialDevelopmentRegulatoryAndSalesMilestones>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i502169e6083e4ed8aadfa58300dc99f2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjI0Ng_defc4a78-4a70-4e7c-841e-73afdd0af90d"
      unitRef="usd">25000000.0</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:RemainingAmountAllocatedToTransactionPrice
      contextRef="i502169e6083e4ed8aadfa58300dc99f2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjI2MQ_c1698b4a-af6e-41e0-b964-b2d135474d44"
      unitRef="usd">25000000.0</nktr:RemainingAmountAllocatedToTransactionPrice>
    <nktr:ReimbursementOfExpenses
      contextRef="i176a8a9518ea4b9299405db0af88f09a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjI3Ng_bb174327-7440-41bb-92f6-39220b5d6546"
      unitRef="usd">30700000</nktr:ReimbursementOfExpenses>
    <nktr:ReimbursementOfExpenses
      contextRef="i1bc208f913d540b49395ca3743b4185d_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjI5MQ_dedbb675-f720-4acf-ab1d-8c8f17552091"
      unitRef="usd">28800000</nktr:ReimbursementOfExpenses>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib630cc6da28d48d4b7c4878a9fd1f551_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfNzE0NjgyNTYxNjMwNg_57ed80ea-1454-4f96-ae25-a006c9ab5d4c"
      unitRef="usd">31200000</us-gaap:AccountsReceivableNetCurrent>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i29f2903dd705405e9a99ce471b09643c_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfODY5Ng_c6529a33-de56-46c6-8c26-77fc841925e5"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PotentialDevelopmentAndRegulatoryMilestones
      contextRef="i4abc773305a245a49879e92f7a2d8ec1_I20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfODc0NA_be12512b-d066-473b-88c8-3cf45590fbe1"
      unitRef="usd">250000000.0</nktr:PotentialDevelopmentAndRegulatoryMilestones>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="ic6cffd33a538441793df552a4a634722_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTAxOQ_bbc03c69-a4e5-4455-ac54-cfc87a3c79ab"
      unitRef="number">0.75</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts
      contextRef="ib6ef8d2feff24382b89a963a955b7de1_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTA1Ng_9570be7c-5ef1-4950-97b3-4766df723f36"
      unitRef="number">0.25</nktr:PercentageOfSharingInPhaseTwoDevelopmentCosts>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i8e09065b9a0547db82bcbd6ba0330136_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTIwNg_a6cb46e1-c5e2-48ea-972e-b424c772a8d9"
      unitRef="number">0</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
      contextRef="i7543f99a1365490685fe0784be6399be_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTIxMg_23722024-3792-4b25-9452-6f70ea97250f"
      unitRef="number">0.25</nktr:PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
      contextRef="ie216ce51a8a24a0baa754fcee329ca73_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTY0MA_f317f1ae-3164-4f3d-b041-6d871ba3f29b"
      unitRef="number">0.50</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions>
    <nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
      contextRef="ie216ce51a8a24a0baa754fcee329ca73_D20170822-20170823"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfOTg3NQ_e759a889-90f2-467a-8832-2930489b7c3d"
      unitRef="number">0.75</nktr:PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i29f2903dd705405e9a99ce471b09643c_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE1ODQ_3b629264-a130-41b3-985b-42b83f5ffa36"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i29f2903dd705405e9a99ce471b09643c_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE3MTE_9de8eec9-7a52-4b1b-b6d7-37314a803782"
      unitRef="usd">150000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i3ca1ed110b144083ad7a0642944f0a64_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE3MzM_ceac2a10-b51f-4729-9a97-59067667825e"
      unitRef="usd">125900000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i93c4b0f432a74b2e864cfce6498f7af2_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE3NTI_2073232d-1a6f-4054-ad15-cc199297ffe2"
      unitRef="usd">17600000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation
      contextRef="i69f7397d7d354dbca02775665425aeb3_D20170901-20170930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE3OTU_dbf1f1d4-1f89-495b-9f99-fc79207e3df8"
      unitRef="usd">6500000</nktr:AmountOfTransactionPriceAllocatedToPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7621d431c964328a7a71c7e9d1ac4bb_D20170801-20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTE4NDk_fb4bdeeb-2d15-45a6-bf72-cd08e55916f5"
      unitRef="usd">125900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7101cc04dec54a90adf4cbd5b102e5a2_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTM4MzI_0b0982db-15ff-4c3a-baee-d4bca19ebe61"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25fc7508773c488c99f151c7421c27ad_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTQzNDY_8ff41bfe-a35b-4906-af36-786e84dc9d2b"
      unitRef="usd">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nktr:PaymentsReceivedUnderRightsToSublicenseAgreement
      contextRef="i444f981b5fcd4ae183f9670a94a6d5c7_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTQ5NTQ_98f71ddb-ece8-45a1-8c1c-dbe37417d61b"
      unitRef="usd">12000000.0</nktr:PaymentsReceivedUnderRightsToSublicenseAgreement>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="ice87715efb8248b3aa2edabd0ba0a78d_D20101001-20101231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTU3NzU_4204019a-77b1-4c2e-b588-264c7cac6478"
      unitRef="usd">50000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i92df06331eee42a4bf5033fe820ebed9_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTY0MzQ_603817f7-b801-4e29-8e21-9d9d5df74200"
      unitRef="usd">2900000</us-gaap:ContractWithCustomerLiability>
    <nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
      contextRef="i0aee212710ce422485f665ac0f228b73_D20090901-20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTcxNzI_7a27b7d3-380f-4ea0-b0b5-fe4d0e1ab703"
      unitRef="usd">385000000.0</nktr:UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement>
    <nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner
      contextRef="i99c7aa64c9624c1aafe571608dc6df48_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTc5NDg_bb69232c-27d3-4d3a-8724-02e2800f5c6f"
      unitRef="number">0.60</nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner>
    <nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments
      contextRef="i134e5ae7cfac48ccac7b40ae651a24b6_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTc5NzI_596d83b5-be13-4642-8d4b-17f2690a159f"
      unitRef="number">0.40</nktr:PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments>
    <nktr:PotentialDevelopmentMilestones
      contextRef="i3701e7bc10234eaba431f6c02eacf26f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTkxMjA_df41dc08-a775-402b-8499-d8d4fc13df35"
      unitRef="usd">40000000.0</nktr:PotentialDevelopmentMilestones>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3701e7bc10234eaba431f6c02eacf26f_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183MC9mcmFnOjM2MmRiNzc4ZTgwODRmZTE4MWU3ZDc3OWNjZWM3NTUyL3RleHRyZWdpb246MzYyZGI3NzhlODA4NGZlMTgxZTdkNzc5Y2NlYzc1NTJfMTk3MDQ_68b0ee60-fa60-48cb-88d4-f93b0b96bf5f"
      unitRef="usd">2000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RleHRyZWdpb246MzI4YjFlNjNkZGFjNGNjOGI0NDhiNmEyNTAzNzk2MjRfMjg0_b69691d5-e9fc-42aa-8c0e-d7b9486b3d55">Stock-Based Compensation&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.994%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:74.052%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.611%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.612%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Impairment of assets and other costs for terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:10pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance, which we are currently accounting for as a liability award. However, we expect to settle this award in stock in the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:31.5pt;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.994%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:74.052%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.611%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.612%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Shares issued under equity compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RleHRyZWdpb246MzI4YjFlNjNkZGFjNGNjOGI0NDhiNmEyNTAzNzk2MjRfMjg1_3a67c0bd-c4c7-42ff-aebf-9929f3c81c2e">&lt;div style="text-indent:31.5pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.994%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:74.052%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.611%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.612%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Impairment of assets and other costs for terminated program&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88cf58db52e049eab981ed11e7041d46_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfMi0xLTEtMS0w_516cc601-f14b-41cf-a084-13878b866f9a"
      unitRef="usd">761000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ied569ed2fa4643aabebcfeb1c89e3250_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfMi0zLTEtMS0w_9d72b4da-ff26-40ac-86db-74d1487e18f1"
      unitRef="usd">820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic5081eafe45545ac99082fad3b96d97f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfMy0xLTEtMS0w_e7c200ac-77fc-40b0-83c3-99e98d0b652f"
      unitRef="usd">15453000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i902932094c3b42388c75a5e0aea65f9b_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfMy0zLTEtMS0w_6de2884f-3ab8-4e9f-a0e4-c0bae2c8620e"
      unitRef="usd">16623000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e337f5f20f943c6924b26a84f75f97c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNC0xLTEtMS0w_20d3d1cc-a3c5-40da-b25c-165cccab4308"
      unitRef="usd">7997000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if378fd08692e42a096dc6f036e090dde_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNC0zLTEtMS0w_2b153ca1-042c-42fe-bd33-7e43a5552270"
      unitRef="usd">7942000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4abfc9f996224586a3e2de8b4adc9c6f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNS0xLTEtMS0xNjM5_82175c47-07db-44ea-96ee-136aa24f39d5"
      unitRef="usd">1025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5af1e965432744c6bcbe50332144c39c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNS0zLTEtMS0xNjQy_4227ca30-3327-4f06-ab39-fe043e7edf30"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNS0xLTEtMS0w_b02ed49c-3bf9-40c9-b09a-4b19c4c0c1cf"
      unitRef="usd">25236000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOmRhZjViOWE3YjE2OTRhNTU5MmFkYmQyYTFmZDQ4ZTM4L3RhYmxlcmFuZ2U6ZGFmNWI5YTdiMTY5NGE1NTkyYWRiZDJhMWZkNDhlMzhfNS0zLTEtMS0w_ad56284e-0be6-4622-a02a-9cb8794e8043"
      unitRef="usd">25385000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RleHRyZWdpb246MzI4YjFlNjNkZGFjNGNjOGI0NDhiNmEyNTAzNzk2MjRfMjgy_c25fe833-8c30-4c8a-94c3-3497394411dd">&lt;div style="text-indent:31.5pt;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.994%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:74.052%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.611%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.525%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.612%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted-average grant-date fair value of options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Weighted-average grant-date fair value of RSUs granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;40.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Shares issued under equity compensation plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfMi0xLTEtMS0w_12435d0d-b891-4aeb-8b5c-b0c5325b752c"
      unitRef="shares">49000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfMi0zLTEtMS0w_9dbba0cc-1fd2-41cf-af76-4ed7125bd0be"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i5f68d2ae466140aeb768fa1c116b8abb_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfMy0xLTEtMS0w_c5fbb1ee-aa98-4e5e-ab33-f99ca9c737f3"
      unitRef="shares">11.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ifa8cd256275e4cdfa9d8471075320759_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfMy0zLTEtMS0w_5fdf51a8-ae9b-47a0-bf10-8f72e3503232"
      unitRef="shares">25.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5f68d2ae466140aeb768fa1c116b8abb_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNC0xLTEtMS0w_4ee4a6df-4da6-4d1c-b628-ff6b1030a42c"
      unitRef="usdPerShare">245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifa8cd256275e4cdfa9d8471075320759_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNC0zLTEtMS0w_30691b34-c601-4c38-a17c-29f03365affd"
      unitRef="usdPerShare">133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic56f9fb40dd94e43b2208c0ab8ecd6b1_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNS0xLTEtMS0w_174d22a5-2490-48d8-9795-9ebcf6efdb65"
      unitRef="shares">18.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8b46e908641040b989f8c417b89ce173_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNS0zLTEtMS0w_47a6259c-447d-45d0-b226-1807ed9278b0"
      unitRef="shares">40.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic56f9fb40dd94e43b2208c0ab8ecd6b1_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNi0xLTEtMS0w_df2c2c00-c664-49b3-87af-1bd645110c76"
      unitRef="usdPerShare">1358000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8b46e908641040b989f8c417b89ce173_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183Ni9mcmFnOjMyOGIxZTYzZGRhYzRjYzhiNDQ4YjZhMjUwMzc5NjI0L3RhYmxlOjc2NWRlYjdlOGI1ZDQwYmFiZTlkYTQ0YWYyNTQ2NGRjL3RhYmxlcmFuZ2U6NzY1ZGViN2U4YjVkNDBiYWJlOWRhNDRhZjI1NDY0ZGNfNi0zLTEtMS0w_dd9bf32b-924c-4c82-873e-47b84d0286a5"
      unitRef="usdPerShare">698000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183OS9mcmFnOjE2ZWI0ZjVlNmQyNzRiYjE5OWRiZmJhODgwNWJlNjI1L3RleHRyZWdpb246MTZlYjRmNWU2ZDI3NGJiMTk5ZGJmYmE4ODA1YmU2MjVfMTQwNw_7ce1ea58-a1b8-4948-9cdc-6e756e09d847">Net Loss Per ShareWe calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. For the three months ended March&#160;31, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three months ended March&#160;31, 2020 and March 31, 2019, potentially dilutive securities consisted of the weighted-average common shares underlying outstanding stock options and RSUs, which totaled 18.8 million and 18.9 million shares, respectively.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i432c6f2272a94bb69701de1fc16655e2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183OS9mcmFnOjE2ZWI0ZjVlNmQyNzRiYjE5OWRiZmJhODgwNWJlNjI1L3RleHRyZWdpb246MTZlYjRmNWU2ZDI3NGJiMTk5ZGJmYmE4ODA1YmU2MjVfMTM3NDM4OTUzNDkyMzg_9da9d946-11ce-4f13-907a-1c8e703f7c65"
      unitRef="shares">18800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib127735d3b564c8089872b75e9382773_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M183OS9mcmFnOjE2ZWI0ZjVlNmQyNzRiYjE5OWRiZmJhODgwNWJlNjI1L3RleHRyZWdpb246MTZlYjRmNWU2ZDI3NGJiMTk5ZGJmYmE4ODA1YmU2MjVfMTM3NDM4OTUzNDkyNzg_0ab37a4f-f831-4114-aca8-9a8f03c2e4b4"
      unitRef="shares">18900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ie6831483c81440988c8c7cb51951a5af_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xMjU0L2ZyYWc6ZTM1NjYzY2RlNDVmNGI1YWIzOTFiZTJkYmZmMDRlN2YvdGV4dHJlZ2lvbjplMzU2NjNjZGU0NWY0YjVhYjM5MWJlMmRiZmYwNGU3Zl83MTQ2ODI1NTg5MDI5_a7be1e23-0e1e-4c2e-918e-2d8ee816aec7">Subsequent EventOn October 5, 2015, we completed the sale and issuance of $250.0&#160;million in aggregate principal amount of 7.75% senior secured notes due 2020 (the Notes). The Notes were secured by a first-priority lien on substantially all of our assets (except our right-of-use assets) and bore interest at a rate of 7.75% per annum payable in cash quarterly in arrears on January 15, April 15, July 15, and October 15 of each year. Interest was calculated based on actual days outstanding over a 360 days year. The Notes were to mature on October 5, 2020, at which time the outstanding principal would be due and payable.On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $250.0&#160;million and accrued interest of $4.8&#160;million. As a result of the redemption and repayment, the liens discussed above were terminated.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SeniorNotes
      contextRef="idba37b08c6a74db5a4d1979fcb50d818_I20151005"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xMjU0L2ZyYWc6ZTM1NjYzY2RlNDVmNGI1YWIzOTFiZTJkYmZmMDRlN2YvdGV4dHJlZ2lvbjplMzU2NjNjZGU0NWY0YjVhYjM5MWJlMmRiZmYwNGU3Zl83MTQ2ODI1NTg5MDMx_b9acd0f1-5939-459e-92c4-4a0eb3579d0d"
      unitRef="usd">250000000.0</us-gaap:SeniorNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idba37b08c6a74db5a4d1979fcb50d818_I20151005"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xMjU0L2ZyYWc6ZTM1NjYzY2RlNDVmNGI1YWIzOTFiZTJkYmZmMDRlN2YvdGV4dHJlZ2lvbjplMzU2NjNjZGU0NWY0YjVhYjM5MWJlMmRiZmYwNGU3Zl8xMDk5NTExNjI4NjMwNw_d646dd2c-7537-433f-9bbe-b3c9589814b1"
      unitRef="number">0.0775</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i617c906b489448d0a219e5d6dd99ee13_D20200413-20200413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xMjU0L2ZyYWc6ZTM1NjYzY2RlNDVmNGI1YWIzOTFiZTJkYmZmMDRlN2YvdGV4dHJlZ2lvbjplMzU2NjNjZGU0NWY0YjVhYjM5MWJlMmRiZmYwNGU3Zl83MTQ2ODI1NTg5MDYx_5fccef9d-1ac3-42af-a125-2413861b7984"
      unitRef="usd">250000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i08a1e29f68774a94850704062f4a83db_D20200413-20200413"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M18xMjU0L2ZyYWc6ZTM1NjYzY2RlNDVmNGI1YWIzOTFiZTJkYmZmMDRlN2YvdGV4dHJlZ2lvbjplMzU2NjNjZGU0NWY0YjVhYjM5MWJlMmRiZmYwNGU3Zl83MTQ2ODI1NTg5MDc3_0779b20e-3169-49c0-989a-54c56e383235"
      unitRef="usd">-4800000</us-gaap:IncreaseDecreaseInInterestPayableNet>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821385216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 13, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Oct. 05, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember', window );">7.75% Senior Secured Notes Due October 2020 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior secured notes, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 7.75% Senior Secured Notes Due October 2020 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638106256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Beginning balance</a></td>
<td class="nump">$ 8,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of previously unearned revenue</a></td>
<td class="num">(2,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, Ending balance</a></td>
<td class="nump">$ 5,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>30
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nktr-20200331.htm": {
   "axisCustom": 1,
   "axisStandard": 21,
   "contextCount": 134,
   "dts": {
    "calculationLink": {
     "local": [
      "nktr-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nktr-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nktr-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nktr-20200331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nktr-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nktr-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd"
     ]
    }
   },
   "elementCount": 371,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 13,
    "http://www.nektar.com/20200331": 8,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 26
   },
   "keyCustom": 47,
   "keyStandard": 232,
   "memberCustom": 33,
   "memberStandard": 25,
   "nsprefix": "nktr",
   "nsuri": "http://www.nektar.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.nektar.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Inventory",
     "role": "http://www.nektar.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Liability Related to Sale of Future Royalties",
     "role": "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties",
     "shortName": "Liability Related to Sale of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Commitments and Contingencies",
     "role": "http://www.nektar.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - License and Collaboration Agreements",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Stock-Based Compensation",
     "role": "http://www.nektar.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Net Loss Per Share",
     "role": "http://www.nektar.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127109 - Disclosure - Subsequent Event",
     "role": "http://www.nektar.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables",
     "shortName": "Cash and Investments in Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Inventory (Tables)",
     "role": "http://www.nektar.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ifbb4be8e78984f9b982e39128071667a_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ifbb4be8e78984f9b982e39128071667a_I20200331",
      "decimals": "-3",
      "lang": null,
      "name": "nktr:AdvancePaymentsToContractManufacturers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - License and Collaboration Agreements (Tables)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables",
     "shortName": "License and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.nektar.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ifbb4be8e78984f9b982e39128071667a_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nktr:CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i3d4dc9f75ee6471fb7570b3494344d17_D20190101-20190331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ifbb4be8e78984f9b982e39128071667a_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
     "shortName": "Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DebtInvestmentMaximumMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash and Investments in Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nktr:DebtInvestmentMaximumMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i92b3ad4ac67b4455a3c9802320152891_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
     "shortName": "Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i92b3ad4ac67b4455a3c9802320152891_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ifbb4be8e78984f9b982e39128071667a_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Inventory (Details)",
     "role": "http://www.nektar.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ifbb4be8e78984f9b982e39128071667a_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nktr:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail",
     "shortName": "Liability Related to Sale of Future Royalties - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ia10a44927680469a914aaa3781e9e7dd_D20191001-20191231",
      "decimals": "3",
      "lang": null,
      "name": "nktr:EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i8757df3c4b9949b5a56ec0f462c39d45_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LossContingencyAccrualAtCarryingValue",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i8757df3c4b9949b5a56ec0f462c39d45_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail",
     "shortName": "License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nktr:LicenseCollaborationOtherRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i92b3ad4ac67b4455a3c9802320152891_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i92b3ad4ac67b4455a3c9802320152891_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
     "shortName": "License and Collaboration Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i92b3ad4ac67b4455a3c9802320152891_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)",
     "role": "http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail",
     "shortName": "License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i88cf58db52e049eab981ed11e7041d46_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Stock-Based Compensation - Activity (Detail)",
     "role": "http://www.nektar.com/role/StockBasedCompensationActivityDetail",
     "shortName": "Stock-Based Compensation - Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i5f68d2ae466140aeb768fa1c116b8abb_D20200101-20200331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i432c6f2272a94bb69701de1fc16655e2_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Net Loss Per Share - Additional Information (Detail)",
     "role": "http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail",
     "shortName": "Net Loss Per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "i432c6f2272a94bb69701de1fc16655e2_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ifbb4be8e78984f9b982e39128071667a_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeniorNotes",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Subsequent Event (Details)",
     "role": "http://www.nektar.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "idba37b08c6a74db5a4d1979fcb50d818_I20151005",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie5fdaed97d5a4bbd8922f30a1bd1e928_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie5fdaed97d5a4bbd8922f30a1bd1e928_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Cash and Investments in Marketable Securities",
     "role": "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities",
     "shortName": "Cash and Investments in Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nktr-20200331.htm",
      "contextRef": "ie6831483c81440988c8c7cb51951a5af_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.nektar.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nktr_AccruedClinicalTrialExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued clinical trial expenses current.",
        "label": "Accrued Clinical Trial Expenses Current",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesCurrent",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AccruedContractManufacturingExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued contract manufacturing expense current.",
        "label": "Accrued Contract Manufacturing Expense Current",
        "terseLabel": "Accrued contract manufacturing expenses"
       }
      }
     },
     "localname": "AccruedContractManufacturingExpenseCurrent",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AdvancePaymentsToContractManufacturers": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of advance payments to contract manufacturers, net of amortization.",
        "label": "Advance Payments To Contract Manufacturers",
        "terseLabel": "Advance payments to contract manufacturers"
       }
      }
     },
     "localname": "AdvancePaymentsToContractManufacturers",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AggregateConsiderationReceivedFromAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate consideration received from agreements.",
        "label": "Aggregate Consideration Received From Agreements",
        "terseLabel": "Total consideration received under agreements"
       }
      }
     },
     "localname": "AggregateConsiderationReceivedFromAgreements",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amgen Inc.",
        "label": "Amgen Inc [Member]",
        "terseLabel": "Amgen, Inc."
       }
      }
     },
     "localname": "AmgenIncMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AmountOfTransactionPriceAllocatedToPerformanceObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation.",
        "label": "Amount Of Transaction Price Allocated To Performance Obligation",
        "terseLabel": "Amount of transaction price allocated to performance obligation"
       }
      }
     },
     "localname": "AmountOfTransactionPriceAllocatedToPerformanceObligation",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_AnnualSalesLevelMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Annual sales level milestone.",
        "label": "Annual Sales Level Milestone [Member]",
        "terseLabel": "Annual Sales Level Milestone"
       }
      }
     },
     "localname": "AnnualSalesLevelMilestoneMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AstraZenecaAbMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca AB.",
        "label": "Astra Zeneca Ab [Member]",
        "terseLabel": "AstraZeneca AB"
       }
      }
     },
     "localname": "AstraZenecaAbMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_AstraZenecaAgreementWithKirinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca agreement with Kirin.",
        "label": "Astra Zeneca Agreement With Kirin [Member]",
        "terseLabel": "AstraZeneca-Kirin"
       }
      }
     },
     "localname": "AstraZenecaAgreementWithKirinMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BMSCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BMS collaboration agreement.",
        "label": "B M S Collaboration Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement"
       }
      }
     },
     "localname": "BMSCollaborationAgreementMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BaxaltaIncorporatedOrTakedaPLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Baxalta Incorporated or takeda PLC.",
        "label": "Baxalta Incorporated Or Takeda P L C [Member]",
        "terseLabel": "Baxalta Incorporated/Takeda"
       }
      }
     },
     "localname": "BaxaltaIncorporatedOrTakedaPLCMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol-Myers Squibb Company"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Line Items]",
        "label": "Cash And Investments In Marketable Securities [Line Items]",
        "terseLabel": "Cash and Investments in Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesLineItems",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashAndInvestmentsInMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and Investments in Marketable Securities [Table]",
        "label": "Cash And Investments In Marketable Securities [Table]",
        "terseLabel": "Cash And Investments In Marketable Securities [Table]"
       }
      }
     },
     "localname": "CashAndInvestmentsInMarketableSecuritiesTable",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, restricted cash, cash equivalents, and available for sale investments.",
        "label": "Cash Restricted Cash Cash Equivalents And Available For Sale Investments",
        "terseLabel": "Cash and investments in marketable securities",
        "totalLabel": "Total cash and investments in marketable securities"
       }
      }
     },
     "localname": "CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_CollaborationPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration partner.",
        "label": "Collaboration Partner [Member]",
        "terseLabel": "Collaboration Partner"
       }
      }
     },
     "localname": "CollaborationPartnerMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones.",
        "label": "Collaborative Arrangements Maximum Aggregate Additional Cash Payments Receivable Upon Achievement Of Development And Regulatory Milestones",
        "terseLabel": "Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_DebtInvestmentMaturityTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt investment maturity date description.",
        "label": "Debt Investment Maturity Term",
        "terseLabel": "Weighted average maturity term for debt securities investment (or less)"
       }
      }
     },
     "localname": "DebtInvestmentMaturityTerm",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DebtInvestmentMaximumMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt investment maximum maturity period.",
        "label": "Debt Investment Maximum Maturity Period",
        "terseLabel": "Maximum maturity term for debt securities investment"
       }
      }
     },
     "localname": "DebtInvestmentMaximumMaturityPeriod",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_DrugProductDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Drug product development.",
        "label": "Drug Product Development [Member]",
        "terseLabel": "Drug Product Development"
       }
      }
     },
     "localname": "DrugProductDevelopmentMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eli Lilly and Company.",
        "label": "Eli Lilly And Company [Member]",
        "terseLabel": "Eli Lilly and Company"
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eli Lilly.",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eligible additional cash payments receivable upon achievement of certain sales milestones.",
        "label": "Eligible Additional Cash Payments Receivable Upon Achievement Of Certain Sales Milestones",
        "terseLabel": "Eligible additional cash payments receivable upon achievement of certain sales milestones"
       }
      }
     },
     "localname": "EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated annual interest rate over life of royalty liability.",
        "label": "Estimated Annual Interest Rate Over Life Of Royalty Liability",
        "terseLabel": "Annual interest rate"
       }
      }
     },
     "localname": "EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_EstimatedFairValueOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated fair value of shares.",
        "label": "Estimated Fair Value Of Shares",
        "terseLabel": "Estimated fair value of shares"
       }
      }
     },
     "localname": "EstimatedFairValueOfShares",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_HemophiliaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hemophilia.",
        "label": "Hemophilia [Member]",
        "terseLabel": "Hemophilia"
       }
      }
     },
     "localname": "HemophiliaMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ImpairmentAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Impairment And Other",
        "label": "Impairment And Other [Member]",
        "terseLabel": "Impairment of assets and other costs for terminated program"
       }
      }
     },
     "localname": "ImpairmentAndOtherMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Impairment Of Equipment And Other Costs For Terminated Program",
        "label": "Impairment Of Equipment And Other Costs For Terminated Program",
        "terseLabel": "Impairment of assets and other costs for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ImpairmentOfEquipmentFromTerminatedProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Impairment Of Equipment From Terminated Program",
        "label": "Impairment Of Equipment From Terminated Program",
        "terseLabel": "Impairment of advance payments to contract manufacturers and equipment for terminated program"
       }
      }
     },
     "localname": "ImpairmentOfEquipmentFromTerminatedProgram",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Right-Of-Use Assets, Net Of Operating Lease Liabilities",
        "negatedLabel": "Operating leases, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilitiesAndStockholdersEquityDeficitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liabilities and stock holders equity (deficit) abstract..",
        "label": "Liabilities And Stockholders Equity Deficit [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityDeficitAbstract",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Line Items]",
        "terseLabel": "Liability Related to Sale of Future Royalties [Line Items]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesLineItems",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties Policy [Text Block]",
        "terseLabel": "Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LiabilityRelatedToSaleOfFutureRoyaltiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties [Table]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Table]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTable",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties non current net of issuance costs.",
        "label": "Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs",
        "terseLabel": "Liability related to the sale of future royalties, net"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability related to sale of potential future royalties.",
        "label": "Liability Related To Sale Of Potential Future Royalties [Text Block]",
        "terseLabel": "Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Abstract]",
        "terseLabel": "License And Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Line Items]",
        "terseLabel": "License And Collaboration Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsLineItems",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseAndCollaborationAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and collaboration agreements.",
        "label": "License And Collaboration Agreements [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsTable",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_LicenseCollaborationAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License collaboration and other revenue.",
        "label": "License Collaboration And Other Revenue [Member]",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationAndOtherRevenueMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_LicenseCollaborationOtherRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Revenue may contain one or more of the following elements: upfront fees, contract research, milestone payments, manufacturing and supply, royalties, and license fees.",
        "label": "License Collaboration Other Revenue",
        "terseLabel": "License, collaboration and other revenue"
       }
      }
     },
     "localname": "LicenseCollaborationOtherRevenue",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_LongTermInvestmentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long term investment maturity period.",
        "label": "Long Term Investment Maturity Period",
        "terseLabel": "Long term investment maturity period"
       }
      }
     },
     "localname": "LongTermInvestmentMaturityPeriod",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nktr_MOVANTIKAndMOVENTIGMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "MOVANTIK and MOVENTIG.",
        "label": "M O V A N T I K And M O V E N T I G [Member]",
        "terseLabel": "MOVANTIK and MOVENTIG"
       }
      }
     },
     "localname": "MOVANTIKAndMOVENTIGMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "terseLabel": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone",
        "label": "Milestone [Domain]",
        "terseLabel": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone One [Member]",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Three [Member]",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Two [Member]",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NKTR181Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NKTR - 181 [Member]",
        "label": "NKTR - 181 [Member]",
        "terseLabel": "NKTR - 181"
       }
      }
     },
     "localname": "NKTR181Member",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar [Member]",
        "label": "Nektar [Member]",
        "terseLabel": "Nektar"
       }
      }
     },
     "localname": "NektarMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarThreeFiveEightLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar three five eight license.",
        "label": "Nektar Three Five Eight License [Member]",
        "terseLabel": "NKTR-358 License"
       }
      }
     },
     "localname": "NektarThreeFiveEightLicenseMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarThreeFiveEightMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar three five eight.",
        "label": "Nektar Three Five Eight [Member]",
        "terseLabel": "NKTR-358"
       }
      }
     },
     "localname": "NektarThreeFiveEightMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NektarTwoOneFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nektar two one four.",
        "label": "Nektar Two One Four [Member]",
        "terseLabel": "Bempegaldesleukin"
       }
      }
     },
     "localname": "NektarTwoOneFourMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NeulastaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Neulasta.",
        "label": "Neulasta [Member]",
        "terseLabel": "Neulasta"
       }
      }
     },
     "localname": "NeulastaMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cash interest expense related to sale of royalties.",
        "label": "Non Cash Interest Expense Related To Sale Of Royalties",
        "negatedLabel": "Non-cash interest expense on liability related to sale of future royalties",
        "negatedTerseLabel": "Non-cash interest expense on liability related to sale of future royalties",
        "terseLabel": "Non-cash interest expense on liability related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non cash royalty revenue related to sale future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedLabel": "Non-cash royalty revenue related to sale of future royalties",
        "terseLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-cash royalty revenue related to sale of future royalties.",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties [Member]",
        "terseLabel": "Non-cash royalty revenue related to sale of future royalties"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OpdivoAndYervoyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Opdivo and yervoy.",
        "label": "Opdivo And Yervoy [Member]",
        "terseLabel": "Opdivo and Yervoy"
       }
      }
     },
     "localname": "OpdivoAndYervoyMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OpdivoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Opdivo.",
        "label": "Opdivo [Member]",
        "terseLabel": "Opdivo"
       }
      }
     },
     "localname": "OpdivoMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "nktr_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization.",
        "label": "Organization Policy [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nktr_OtherPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other.",
        "label": "Other Partner [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPartnerMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PaymentsReceivedUnderRightsToSublicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments received under rights to sublicense agreement.",
        "label": "Payments Received Under Rights To Sublicense Agreement",
        "terseLabel": "Received under right to sublicense agreement"
       }
      }
     },
     "localname": "PaymentsReceivedUnderRightsToSublicenseAgreement",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received, if conditions occur.",
        "label": "Percentage Of Development Milestones Payments To Be Received If Conditions Occur",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced if conditions occur"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of development milestones payments, to be received under certain conditions.",
        "label": "Percentage Of Development Milestones Payments To Be Received Under Certain Conditions",
        "terseLabel": "Percentage of regulatory milestones payments will be reduced under certain conditions"
       }
      }
     },
     "localname": "PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of funding Phase three development costs on an indication by indication basis borne.",
        "label": "Percentage Of Funding Phase Three Development Costs On An Indication By Indication Basis Borne",
        "terseLabel": "Percentage of funding phase 3 development costs on an indication by indication basis borne"
       }
      }
     },
     "localname": "PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of sharing in development costs.",
        "label": "Percentage Of Sharing In Development Costs",
        "terseLabel": "Percentage of sharing development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of sharing in Phase 2 development costs.",
        "label": "Percentage Of Sharing In Phase Two Development Costs",
        "terseLabel": "Percentage of sharing in Phase 2 development costs"
       }
      }
     },
     "localname": "PercentageOfSharingInPhaseTwoDevelopmentCosts",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfSharingInProductionCosts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of sharing in production costs.",
        "label": "Percentage Of Sharing In Production Costs",
        "terseLabel": "Percentage of sharing production costs"
       }
      }
     },
     "localname": "PercentageOfSharingInProductionCosts",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments.",
        "label": "Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments",
        "terseLabel": "Percentage of upfront payment, market access milestones, royalties and sales milestones"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner.",
        "label": "Percentage Of Upfront Payment Market Access Milestone Payments Royalties And Sales Milestone Payments From Sublicense Agreement Retained By Our Collaboration Partner",
        "terseLabel": "Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PhaseOneClinicalDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 1 clinical development.",
        "label": "Phase One Clinical Development [Member]",
        "terseLabel": "Phase 1 Clinical Development"
       }
      }
     },
     "localname": "PhaseOneClinicalDevelopmentMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_PotentialDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential development and regulatory milestones.",
        "label": "Potential Development And Regulatory Milestones",
        "terseLabel": "Potential future additional development and regulatory milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential development milestones.",
        "label": "Potential Development Milestones",
        "terseLabel": "Potential future additional payments for development milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestones",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PotentialDevelopmentRegulatoryAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential development regulatory and sales milestones.",
        "label": "Potential Development Regulatory And Sales Milestones",
        "terseLabel": "Potential future development, regulatory and sales milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentRegulatoryAndSalesMilestones",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_PreferredStockShareDesignated": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock, shares designated.",
        "label": "Preferred Stock Share Designated",
        "terseLabel": "Preferred stock, shares designated (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareDesignated",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from sale of potential future royalties gross.",
        "label": "Proceeds From Sale Of Potential Future Royalties Gross",
        "terseLabel": "Proceeds from sale of royalty rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPotentialFutureRoyaltiesGross",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_ProfitsAndLossesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profits and losses sharing percentage.",
        "label": "Profits And Losses Sharing Percentage",
        "terseLabel": "Global commercialization profits and losses sharing percentage"
       }
      }
     },
     "localname": "ProfitsAndLossesSharingPercentage",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_ProspectiveInterestRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prospective interest rate percentage.",
        "label": "Prospective Interest Rate Percentage",
        "terseLabel": "Prospective interest rate"
       }
      }
     },
     "localname": "ProspectiveInterestRatePercentage",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nktr_PurchaseAndSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase and sale agreement.",
        "label": "Purchase And Sale Agreement [Member]",
        "terseLabel": "Purchase and Sale Agreement with RPI"
       }
      }
     },
     "localname": "PurchaseAndSaleAgreementMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_ReimbursementOfExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reimbursement of expenses.",
        "label": "Reimbursement Of Expenses",
        "terseLabel": "Reimbursement of expenses"
       }
      }
     },
     "localname": "ReimbursementOfExpenses",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RemainingAmountAllocatedToTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amount allocated to transaction price.",
        "label": "Remaining Amount Allocated To Transaction Price",
        "terseLabel": "Remaining amount allocated to transaction price"
       }
      }
     },
     "localname": "RemainingAmountAllocatedToTransactionPrice",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_RepaymentsOfLongTermDebtIncludingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayments Of Long Term Debt, Including Interest",
        "label": "Repayments Of Long Term Debt, Including Interest",
        "terseLabel": "Repayments of long term debt, including interest"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtIncludingInterest",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SaleOfStockConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of stock consideration received.",
        "label": "Sale Of Stock Consideration Received",
        "terseLabel": "Sale of stock consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceived",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SalesMilestoneRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Milestone Revenue",
        "label": "Sales Milestone Revenue",
        "terseLabel": "Sales Milestone Revenue"
       }
      }
     },
     "localname": "SalesMilestoneRevenue",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Seven point seven five percent senior secured notes due October two thousand and twenty.",
        "label": "Seven Point Seven Five Percent Senior Secured Notes Due October Two Thousand And Twenty [Member]",
        "terseLabel": "7.75% Senior Secured Notes Due October 2020"
       }
      }
     },
     "localname": "SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share purchase agreement.",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock options and restricted stock units.",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock Options and Restricted Stock Units"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront and milestone payments received from license agreements.",
        "label": "Upfront And Milestone Payments Received From License Agreements",
        "verboseLabel": "Upfront and milestone payments received from license agreements"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront and milestone payments received under license agreement.",
        "label": "Upfront And Milestone Payments Received Under License Agreement",
        "terseLabel": "Received upfront and milestone payment"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nktr_WriteOffOfPrepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Write Off Of Prepayment",
        "label": "Write Off Of Prepayment",
        "terseLabel": "Write off of prepayment"
       }
      }
     },
     "localname": "WriteOffOfPrepayment",
     "nsuri": "http://www.nektar.com/20200331",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Nektar's"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r112",
      "r156",
      "r159",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r113",
      "r156",
      "r160",
      "r260",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASC 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r19",
      "r157"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable",
        "verboseLabel": "Accounts receivable for expense reimbursements from collaboration partner"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r51",
      "r52",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r167",
      "r169",
      "r184",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r169",
      "r180",
      "r183"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Weighted average antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r233",
      "r246"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r43"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt securities, available-for-sale, accumulated gross unrealized gain, before tax"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Debt securities, available-for-sale accumulated gross unrealized loss, before tax"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Debt securities, available-for-sale, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r115",
      "r119"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r171",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r31",
      "r83"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail": {
       "order": 1.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail",
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r77",
      "r83",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r219"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r86",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Corporate Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r133",
      "r239",
      "r251"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000 shares authorized; 177,863 shares and 176,505 shares outstanding at March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r101",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Significant Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r203",
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Changes in Deferred Revenue Balance from Collaboration Agreements"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r150",
      "r151",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred revenue, Ending balance",
        "periodStartLabel": "Deferred revenue, Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r150",
      "r151",
      "r157"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r150",
      "r151",
      "r157"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, less current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedLabel": "Recognition of previously unearned revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized in period related to performance in prior periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelAxis": {
     "auth_ref": [
      "r156",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by sales channel for delivery of good or service in contract with customer.",
        "label": "Contract with Customer, Sales Channel [Axis]",
        "terseLabel": "Contract with Customer, Sales Channel"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerSalesChannelDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.",
        "label": "Contract with Customer, Sales Channel [Domain]",
        "terseLabel": "Contract with Customer, Sales Channel"
       }
      }
     },
     "localname": "ContractWithCustomerSalesChannelDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r164",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Notes and Bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r234",
      "r235",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior secured notes, interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Transaction costs related to sale of potential future royalties"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r81",
      "r129"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r149",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Economic and political union of member states, located primarily in Europe.",
        "label": "European Union [Member]",
        "terseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeanUnionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Portfolio of Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r214",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r214",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value Hierarchy Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r214",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value Hierarchy Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r93",
      "r232",
      "r240",
      "r254"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r89",
      "r109",
      "r196"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r198",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "negatedLabel": "Accrued interest"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndemnificationGuaranteeMember": {
     "auth_ref": [
      "r141",
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.",
        "label": "Indemnification Agreement [Member]",
        "terseLabel": "Indemnification Obligation"
       }
      }
     },
     "localname": "IndemnificationGuaranteeMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r60",
      "r108",
      "r221",
      "r222",
      "r242"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r75",
      "r78",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r25",
      "r125"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r40",
      "r122"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.nektar.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r41",
      "r87",
      "r98",
      "r123",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r125"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r26",
      "r125"
     ],
     "calculation": {
      "http://www.nektar.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r237",
      "r249"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r37",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r142",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r142",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Litigation matters, liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r142",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r53",
      "r56",
      "r62",
      "r82",
      "r96",
      "r241",
      "r253"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total non-operating income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease, right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r91",
      "r107",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r34"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r45",
      "r220"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Net foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r54",
      "r57",
      "r59",
      "r147"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r49",
      "r195",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Tax provision on unrealized gain on available-for-sale securities, offset by benefit in continuing operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Accretion of premiums (discounts), net and other non-cash transactions"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r69",
      "r71",
      "r116"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at March 31, 2020 or December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.",
        "label": "Reclassification, Policy [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r73",
      "r182"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based compensation arrangement, excluding stock option exercises.",
        "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options",
        "terseLabel": "Proceeds from shares issued under equity compensation plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r69",
      "r70",
      "r116"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r69",
      "r70",
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "verboseLabel": "Available-for-sale securities, sold"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r53",
      "r56",
      "r76",
      "r110",
      "r111",
      "r202",
      "r204",
      "r205",
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r130",
      "r250"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r16",
      "r236",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Purchase commitment, remaining minimum amount committed"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r187",
      "r264"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r87",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r148",
      "r248"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r152",
      "r155",
      "r156"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset recognized in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "verboseLabel": "Royalty revenue"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Cash and Investments in Marketable Securities, Including Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]",
        "terseLabel": "License, Collaboration and Other Revenue"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r169",
      "r179",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that sets forth the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r169",
      "r179",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r174",
      "r176",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for share-based compensation plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Activity [Table Text Block]",
        "terseLabel": "Share-based Compensation, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r171",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotes": {
     "auth_ref": [
      "r238",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior Notes",
        "terseLabel": "Senior secured notes",
        "verboseLabel": "Senior secured notes, principal amount"
       }
      }
     },
     "localname": "SeniorNotes",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail",
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.",
        "label": "Senior Notes, Current",
        "terseLabel": "Senior secured notes, net and interest payable"
       }
      }
     },
     "localname": "SeniorNotesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, RSUs (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted stock options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value, options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r168",
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r147",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Shares issued under equity compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.nektar.com/role/StockBasedCompensationActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r148",
      "r170",
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Shares issued under equity compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r114"
     ],
     "calculation": {
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.nektar.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail",
      "http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r99",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average shares outstanding used in computing basic and diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26626-111562"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=99404985&loc=d3e10037-110241"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=82913499&loc=d3e13051-110250"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208855"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL108322424-203045"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.16)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=50488274&loc=d3e64164-112818"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r265": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r266": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r267": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r268": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r269": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=109236672&loc=d3e543-108305"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801487792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Legal Matters</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On October 30, 2018, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on May 15, 2019. Also, on February 13, 2019, and February 18, 2019, shareholder derivative complaints were filed in the U.S. District Court for the District of Delaware naming the CEO, CFO and certain members of Nektar&#8217;s board. These class action and shareholder derivative actions assert, among other things, that for a period beginning at least from November 11, 2017 through October 2, 2018, our stock was inflated due to alleged misrepresentations about the efficacy and safety of bempegaldesleukin. In addition, on August 19, 2019, we and certain of our executives were named in a putative securities class action complaint filed in the U.S. District Court for the Northern District of California, which complaint was subsequently amended on January 24, 2020. Also, on February 11, 2020, and on February 20, 2020, shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California naming the CEO, CFO and certain members of Nektar&#8217;s board. These class action and shareholder derivative actions assert, among other things, that for a period between February 15, 2019 and August 8, 2019, inclusive, our stock was inflated due to an alleged failure to disclose a reduction in the planned number of bempegaldesleukin clinical trials and a bempegaldesleukin manufacturing issue. All of these cases are in the early stages. Accordingly, we cannot reasonably estimate a potential future loss or a range of potential future losses. However, an unfavorable resolution could potentially have a material adverse effect on our business, financial condition, and results of operations or prospects, and potentially result in paying monetary damages. We have recorded no liability for these matters in our Condensed Consolidated Balance Sheets at either March 31, 2020 or December 31, 2019.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Indemnifications in Connection with Commercial Agreements</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of our collaboration agreements with our partners related to the license, development, manufacture and supply of drugs and PEGylation materials based on our proprietary technologies and drug candidates, we generally agree to defend, indemnify and hold harmless our partners from and against third party liabilities arising out of the agreement, including product liability (with respect to our activities) and infringement of intellectual property to the extent the intellectual property is developed by us and licensed to our partners. The term of these indemnification obligations is generally perpetual any time after execution of the agreement. There is generally no limitation on the potential amount of future payments we could be required to make under these indemnification obligations.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we enter into other strategic agreements such as divestitures and financing transactions pursuant to which we are required to make representations and warranties and undertake to perform or comply with certain covenants, including our obligation to RPI described in Note 4. In the event it is determined that we breached certain of the representations and warranties or covenants made by us in any such agreements, we could incur substantial indemnification liabilities depending on the timing, nature, and amount of any such claims.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification obligations, representations or warranties. Because the aggregate amount of any potential indemnification obligation is not a stated amount, we cannot reasonably estimate the overall maximum amount of any such obligations. We have recorded no liabilities for these obligations in our Condensed Consolidated Balance Sheets at either March&#160;31, 2020 or December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821731536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent EventOn October 5, 2015, we completed the sale and issuance of $250.0&#160;million in aggregate principal amount of 7.75% senior secured notes due 2020 (the Notes). The Notes were secured by a first-priority lien on substantially all of our assets (except our right-of-use assets) and bore interest at a rate of 7.75% per annum payable in cash quarterly in arrears on January 15, April 15, July 15, and October 15 of each year. Interest was calculated based on actual days outstanding over a 360 days year. The Notes were to mature on October 5, 2020, at which time the outstanding principal would be due and payable.On April 13, 2020, we redeemed the Notes at par and therefore repaid the principal of $250.0&#160;million and accrued interest of $4.8&#160;million. As a result of the redemption and repayment, the liens discussed above were terminated.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6822699776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 50,573<span></span>
</td>
<td class="nump">$ 28,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">3,811<span></span>
</td>
<td class="nump">5,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">108,987<span></span>
</td>
<td class="nump">118,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">26,217<span></span>
</td>
<td class="nump">25,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram', window );">Impairment of assets and other costs for terminated program</a></td>
<td class="nump">45,189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">184,204<span></span>
</td>
<td class="nump">148,909<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(133,631)<span></span>
</td>
<td class="num">(120,687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,204)<span></span>
</td>
<td class="num">(5,226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="num">(6,968)<span></span>
</td>
<td class="num">(6,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">8,352<span></span>
</td>
<td class="nump">12,483<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income (expense), net</a></td>
<td class="num">(4,820)<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(138,451)<span></span>
</td>
<td class="num">(119,495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (138,651)<span></span>
</td>
<td class="num">$ (119,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding used in computing basic and diluted net loss per share (in shares)</a></td>
<td class="nump">177,185<span></span>
</td>
<td class="nump">173,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 3,444<span></span>
</td>
<td class="nump">$ 4,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">9,719<span></span>
</td>
<td class="nump">11,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">9,895<span></span>
</td>
<td class="nump">8,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember', window );">License, collaboration and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 27,515<span></span>
</td>
<td class="nump">$ 4,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment Of Equipment And Other Costs For Terminated Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_LicenseCollaborationAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801487792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">Organization and Summary of Significant Accounting Policies<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Organization</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a research-based biopharmaceutical company headquartered in San Francisco, California and incorporated in Delaware. We are developing a pipeline of drug candidates that utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Our research and development pipeline of new investigational drugs includes investigational treatments for cancer and autoimmune disease.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our research and development activities have required significant ongoing investment to date and are expected to continue to require significant investment. As a result, we expect to continue to incur substantial losses and negative cash flows from operations in the future. We have financed our operations primarily through cash generated from licensing, collaboration and manufacturing agreements and financing transactions. At March&#160;31, 2020, we had approximately $1.5 billion in cash and investments in marketable securities. On April 13, 2020, we repaid the principal and accrued interest of our senior notes totaling $254.8&#160;million. See Note 9 for additional information.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Principles of Consolidation</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our consolidated financial statements include the financial position, results of operations and cash flows of our wholly-owned subsidiaries: Inheris Biopharma, Inc. (Inheris), Nektar Therapeutics (India) Private Limited (Nektar India) and Nektar Therapeutics UK Limited. We have eliminated all intercompany accounts and transactions in consolidation.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We prepared our Condensed Consolidated Financial Statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, we may condense or omit certain footnotes or other financial information that are normally required by U.S. generally accepted accounting principles (GAAP) for annual periods. In the opinion of management, these financial statements include all normal and recurring adjustments that we consider necessary for the fair presentation of our financial position and operating results.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Condensed Consolidated Financial Statements are denominated in U.S. dollars. Accordingly, changes in exchange rates between the applicable foreign currency and the U.S. dollar will affect the translation of each foreign subsidiary&#8217;s financial results into U.S. dollars for purposes of reporting our consolidated financial results. We include translation gains and losses in accumulated other comprehensive loss in the stockholders&#8217; equity section of our Condensed Consolidated Balance Sheets. To date, such cumulative currency translation adjustments have not been significant to our consolidated financial position.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our comprehensive loss consists of our net loss plus our foreign currency translation gains and losses and unrealized holding gains and losses on available-for-sale securities. There were no significant reclassifications out of accumulated other comprehensive loss to the statements of operations during the three months ended March&#160;31, 2020 and 2019.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying Condensed Consolidated Financial Statements are unaudited. The Condensed Consolidated Balance Sheet data as of December&#160;31, 2019 was derived from the audited consolidated financial statements which are included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 filed with the SEC on February 28, 2020. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and the accompanying notes to those financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Revenue, expenses, assets, and liabilities can vary during each quarter of the year. The results and trends in these interim Condensed Consolidated Financial Statements are not necessarily indicative of the results to be expected for the full year or any other period.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassifications</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss), which totaled $1.1&#160;million for the three months ended March 31, 2019. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders&#8217; equity.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Segment Information</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate in one business segment which focuses on applying our technology platform to develop novel drug candidates. Our business offerings have similar economics and other characteristics, including the nature of products and manufacturing processes, types of customers, distribution methods and regulatory environment. We are comprehensively managed as one business segment by our Chief Executive Officer.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Concentrations</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S.&#160;and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of March 31, 2020, our accounts receivable includes $10.9&#160;million under customer contracts from our collaboration partners and $31.2 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $12.8&#160;million from customer contracts and $24.0 million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers&#8217; credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable. We have not recorded a reserve for credit losses at March 31, 2020 or December 31, 2019.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services, automotive and food and beverage industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer&#8217;s credit rating has been </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Collaborative Arrangements</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We enter into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which we may grant licenses to our collaboration partners to further develop and commercialize one of our proprietary drug candidates, either alone or in combination with the collaboration partners&#8217; compounds, or grant licenses to partners to use our technology to research and develop their own proprietary drug candidates. We may also perform research, development, manufacturing and supply activities under our collaboration agreements. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments. Additionally, these contracts may provide options for the customer to purchase our proprietary PEGylation materials, drug candidates or additional contract research and development services under separate contracts.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">When we enter into collaboration agreements, we assess whether the arrangements fall within the scope of ASC 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Arrangements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASC 808) based on whether the arrangements involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards of the arrangement. To the extent that the arrangement falls within the scope of ASC 808, we assess whether the payments between us and our collaboration partner fall within the scope of other accounting literature. If we conclude that payments from the collaboration partner to us represent consideration from a customer, such as license fees and contract research and development activities, we account for those payments within the scope of ASC 606, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Revenue from Contracts with Customers</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (ASC 606). However, if we conclude that our collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, we present such payments as a reduction of research and development expense or general and administrative expense, based on where we present the underlying expense.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For elements of those arrangements that we determine should be accounted for under ASC 606, we assess which activities in our collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. For arrangements that include multiple performance obligations, such as granting a license or performing contract research and development activities or participation on joint steering or other committees, we allocate upfront and milestone payments under a relative standalone selling price method. Accordingly, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include revenue forecasts, clinical development timelines and costs, discount rates and probabilities of clinical and regulatory success.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Product Sales</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product sales are primarily derived from manufacturing and supply agreements with our customers. We have assessed our current manufacturing and supply arrangements and have generally determined that they provide the customer an option to purchase our proprietary PEGylation materials. Accordingly, we treat each purchase order as a discrete exercise of the customer&#8217;s option (i.e. a separate contract) rather than as a component of the overall arrangement. The pricing for the manufacturing and supply is generally at a fixed price and may be subject to annual producer price index (PPI) adjustments. We invoice and recognize product sales when title and risk of loss pass to the customer, which generally occurs upon shipment. Customer payments are generally due 30 days from receipt of invoice. We test our products for adherence to technical specifications before shipment; accordingly, we have not experienced any significant returns from our customers.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Royalty Revenue</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Generally, we are entitled to royalties from our collaboration partners based on the net sales of their approved drugs that are marketed and sold in one or more countries where we hold royalty rights. For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, we have concluded that the license is the predominant item to which the royalties relate. Accordingly, we recognize royalty revenue, including for our non-cash royalties, when the underlying sales occur based on our best estimates of sales of the drugs. Our partners generally pay royalties or commercial </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">milestones after the end of the calendar quarter in accordance with contractual terms. We present commercial milestone payments within license, collaboration and other revenue.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">License, Collaboration and other Revenue</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">License Grants</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;For collaboration arrangements that include a grant of a license to our intellectual property, we consider whether the license grant is distinct from the other performance obligations included in the arrangement. Generally, we would conclude that the license is distinct if the customer is able to benefit from the license with the resources available to it. For licenses that are distinct, we recognize revenues from nonrefundable, upfront payments and other consideration allocated to the license when the license term has begun and we have provided all necessary information regarding the underlying intellectual property to the customer, which generally occurs at or near the inception of the arrangement.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Milestone Payments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;At the inception of the arrangement and at each reporting date thereafter, we assess whether we should include any milestone payments or other</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">forms of variable consideration in the transaction price, based on whether a significant reversal of revenue previously recognized is not probable upon resolution of the uncertainty. Since milestone payments may become payable to us upon the initiation of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a clinical study, filing for or receipt of regulatory approval or the first commercial sale of a product, we review the relevant facts and circumstances to determine when we should update the transaction price, which may occur before the triggering event. When we do update the transaction price</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">for milestone payments, we allocate it on a relative standalone selling price basis and record revenue on a cumulative catch-up basis, which results in recognizing revenue for previously satisfied performance obligations in such period. Our partners generally pay development milestones</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">subsequent to</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">achievement of the triggering event.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Services</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: For amounts allocated to our research and development obligations in a collaboration arrangement, we recognize revenue over time using a proportional performance model, representing the transfer of goods or services as we perform activities over the term of the agreement.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expense</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development costs are expensed as incurred and include salaries, benefits and other operating costs such as outside services, supplies and allocated overhead costs. We perform research and development for our proprietary drug candidates and technology development and for certain third parties under collaboration agreements. For our proprietary drug candidates and our internal technology development programs, we invest our own funds without reimbursement from a third party. Where we perform research and development activities under a joint development collaboration, such as our collaboration with BMS, we record the cost reimbursement from our partner as a reduction to research and development expense when reimbursement amounts are due to us under the agreement.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record an accrued expense for the estimated costs of our clinical trial activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of certain clinical trial activities. We generally accrue costs associated with the start-up and reporting phases of the clinical trials ratably over the estimated duration of the start-up and reporting phases. We generally accrue costs associated with the treatment phase of clinical trials based on the estimated activities performed by our third parties. We may also accrue expenses based on the total estimated cost of the treatment phase on a per patient basis and expense the per patient cost ratably over the estimated patient treatment period based on patient enrollment in the trials. In specific circumstances, such as for certain time-based costs, we recognize clinical trial expenses using a methodology that we consider to be more reflective of the timing of costs incurred.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We record an accrued expense for the estimated costs of our contract manufacturing activities performed by third parties. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to our vendors. Payments under the contracts include upfront payments and milestone payments, which depend on factors such as the achievement of the completion of certain stages of the manufacturing process. For purposes of recognizing expense, we assess whether we consider the production process is sufficiently defined such that the resulting product can be considered the delivery of a good, as evidenced by predictive or contractually required yields in the production process or payment terms based on the actual yield, or the delivery of a service, where processes and yields are developing and less certain. If we consider the process to be the delivery of a good, we recognize expense when the drug product is delivered, or we otherwise bear risk of loss. If we consider the process to be the delivery of a service, we recognize expense based on our best estimates of the contract manufacturer&#8217;s progress towards completion of the stages in the contracts. We recognize and amortize upfront payments and accrue liabilities based on the specific terms of each arrangement. Certain arrangements may provide upfront payments for certain stages of the arrangement and milestone payments for the completion of certain stages, and, accordingly, we </span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">may record advance payments for services that have not been completed or goods not delivered and liabilities for stages where the contract manufacturer is entitled to a milestone payment.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We capitalize advance payments for goods or services that will be used or rendered for future research and development activities and recognize expense as the related goods are delivered or services performed. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. We generally consider such increases or decreases in cost as changes in estimates and reflect them in research and development expenses in the period identified.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impairment of Assets and Other Costs for Terminated Program</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 14, 2020, the joint FDA Anesthetic Drug Products Advisory Committee and Drug Safety and Risk Management Committee did not recommend approval of our NDA for NKTR-181. As a result, we withdrew our NDA and decided to make no further investments in this program. On February 26, 2020, the Audit Committee of our Board of Directors approved management&#8217;s plan for the wind-down of Inheris and the NKTR-181 program.</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result, in the three months ended March 31, 2020, we wrote off $19.7&#160;million of advance payments to contract manufacturers for commercial batches of NKTR-181. We also incurred $25.5&#160;million of additional costs, primarily for non-cancellable commitments to our contract manufacturers and certain severance costs. We present these costs in the Impairment of assets and other costs for terminated program line in our Condensed Consolidated Statement of Operations. </span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Income Taxes</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020 and 2019, our income tax expense primarily results from taxable income in our Nektar India subsidiary. We have fully reserved our U.S. federal deferred tax assets generated from our net operating losses, as we believe it is not more likely than not that the benefit will be realized.</span></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Coronavirus Aid, Relief and Economic Security Act</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during 2020 after the date of enactment. We do not expect that the CARES Act will have a material effect on our results of operations or financial position.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Recently Adopted Accounting Pronouncements</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2020, we adopted Accounting Standards Update 2018-18: Clarifying the Interaction between Topic 808 and Topic 606 (ASU 2018-18). The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606 when the collaborative arrangement participant is a customer for a promised good or service that is distinct within the collaborative arrangement. The guidance also precludes entities from presenting amounts related to transactions with a collaborative arrangement participant that is not a customer as revenue, unless those transactions are directly related to third-party sales. ASU 2018-18 is applied retrospectively to January 1, 2018, when we adopted ASC 606. Our adoption of ASU 2018-18 did not materially affect our revenue recognition.</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On January 1, 2020, we adopted ASU 2016-13: Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The guidance modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. As a result of adoption, we present these financial assets, which include our accounts receivable and available-for-sale debt securities, at the net amount we expect to collect. The amendment also requires that we record credit losses related to available-for-sale debt securities as an allowance through net income rather than reducing the carrying amount under the historical, other-than-temporary-impairment model. Our adoption of ASU 2016-13 did not materially affect our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6823052160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 13, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 05, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Cash and investments in marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,531,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,603,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision on unrealized gain on available-for-sale securities, offset by benefit in continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable for expense reimbursements from collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember', window );">7.75% Senior Secured Notes Due October 2020 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Senior secured notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember', window );">7.75% Senior Secured Notes Due October 2020 | Senior Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_RepaymentsOfLongTermDebtIncludingInterest', window );">Repayments of long term debt, including interest</a></td>
<td class="nump">$ 254,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nktr_NKTR181Member', window );">NKTR - 181</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_WriteOffOfPrepayment', window );">Write off of prepayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase commitment, remaining minimum amount committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember', window );">Collaboration Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable for expense reimbursements from collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=nktr_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable for expense reimbursements from collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_RepaymentsOfLongTermDebtIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Long Term Debt, Including Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_RepaymentsOfLongTermDebtIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_WriteOffOfPrepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write Off Of Prepayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_WriteOffOfPrepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nktr_SevenPointSevenFivePercentSeniorSecuredNotesDueOctoberTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nktr_NKTR181Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nktr_NKTR181Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_CollaborationPartnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=nktr_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=nktr_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>37
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"[";O>V+W]Q\970=G"K[N07U!+ P04    " !9JZ=0F5R<(Q &  "<)P
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MKJJT\&XEEF.GR];]1KM+:W0U9+%+J?+W_EK4[GKKGT@YA.$ /@3P,:!_.<$
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M:LV'D3ML).O&V\2;KK3B'U!+ P04    " !9JZ=0.N,AT9T#   M#P  &
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M.2YX;6Q]4V%OVR 0_2N('U 2QTNCR+;4=)HV:9.B5EL_$_MLHP+G 8Z[?U_
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MY>;)20@-QI?XR<1<F2^&<<'AI.WKRKS+?FSV"RVZX9,@&K]+BK]02P,$%
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M<-%VFIBY[.^%/M"B':X\--Z[Q5]02P,$%     @ 6:NG4-**&JZ- @  +PD
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M@]A5/]A5#+J*@7A'1S"+/^IJ#KJ: Z[\D:OY)'&1-W1D3CR "Y\(0BY<!%Q
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M?NR0.'*NJ,X1/&FY<GUOZ#:,'I59SO1:-,.SV2A>MQ>#H+N=I'\!4$L#!!0
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M'HPY8%!IN]V:O?1CXP,M^NE%P/.SE/\!4$L#!!0    ( %FKIU"*3!LU=@(
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MZ(G G8I>.Z$NE)EUFCI;/706]IV:1OKZ?*<QH^P[8I>FX\Z1"GD)ZZOR3*G
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MO+OGL>_(M8>KI/%+<A[ Q@RY#\) 87;7Y+D/)GD)8U4BV(U^T(/VY#Z#/5Z
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M<=&6>X)9P_A.ZW/F4YSRZ2:I3QCR<JHY>U(O35U#H$H.!^E0O#LXT+9K>ZK
M2+\1IQ!PN$ R2?H('5PV3'XHJ8DSM<5=,1=@-R8.%<'?R:N&&Y[\]^99JK ,
M6M^#VCJIS\]B=?S%(;X%Y'7G^<I@.04K#R& B-?77;QUT) -*D7%BF)[A(9&
ML[%=8EU$03FTU,V",8[(,9AIG3=NMTR)W.%8?W_CAY=")]!B@489DRXCC95J
M W+T,Y"W^.:)_)"%T+*GN&4(L/-4Y.7,5V[&\ZZ=JUP(+6!$XINC45(U+\/)
MB8:9BF?75:[0J<OG^UAUF"I*76:TO-NE4P1[3!/DVSNV*0&7"'04]6ZZG487
M%H^0\UH>Q7_VB(&;&W2BV##$-TW*;\;0O-8X9NUM"M+/712)]%7^/J?7A%=!
MI.*=+]6UR4UV1F0#,"+NR'T5^61+MP+*<,S=L2?R#P4>IPO-W+#>4IL>%GW9
MBH3P0O<=4@/.%I=DMH(_D.:31A$99H7,[/OPO[?65*2;',+LR.<X'YZ-2_R;
MH[4(C8$&Y,7QG1D]>*19&\G)XF5S&3M#HM/)#DT_-GE92")HP$W.J+OD7:J8
M!>$[BOV_@143!OJ4VH6!*U0!ST'*!V1G[(R<0*05W6C,UMP0283G/'13R^[\
MR,)D49<P.4C#D'G6-1=XHI>M<5D1?@/^2B$],M8C$$*(XK<Z/;QPLF,A(!F>
MX(/Z-B2ZZKBS@%X3U?6@L%>;86W\/<_UA&F[")><E"ZWE9"<\MY 47;<CN26
M9HP3[2BPKF"AM(@V$D")!7 &BC[0(1H!><8V6)$HJJAJ6ER!$)_[W&.<**"_
M=GKYY-&WK]BT1[!&5X5]J*5O^!TVN=^\.D_.*Y@Z=6]*7J' N-*0[_GLH6CK
MAAMH4KH+.WKPH>OL-I=JGH\H-=YY^!?_]*R8N3JF^1RU'.^J947Q/7P?9X[=
M4G<FIY.X!!I-E%F3/[K'>0.G%'%0LJQ\/G@/PY(H4/P<!%WI 92.[7:<(^*3
MF;K,[V6-_7BQA([@4U [<T%@CWCC!529^6KIQZ*:[6#:/[ZOZ(X*"*(+]G,+
M%J[6Q#IH+=ZBIB9@F]ODQ>1L]\25XCT/S/TVC&_>H*^7Y8\_'*PA0^O-.>I>
M[!_M'H4?-#G)9,CX])K;6@.Z,*6RE/B&;Y3G0=K&P.:=,*.J'JY4=6X[GQ38
MYLZ:H6W\CE9)"0'M2A;?NDX"./H'4Q 5H'*\V:R(WL"EI>+$<R ,*EK\E@;0
M O"(UG#B&S)IBP-J@ <-C.V2568J,&3'(947W^8SRLV<*;P]87_PYO6P;!43
M+ZR(=Q6]6/&"5@S&)"2^1#RX++[DA)(+MP9_Z>P$C:.JA%9L!ZPZ (TI>R@:
M$$KGQ0R3<TNLSJ9::(7)<7V6SZ=82B_[ZR\[8VZBY5\Q#ZZRJ6(LC'P@'?\"
M*=,7YQ]?7_._>FF5\WIFDF-<G!6HWJ49NL+SJ+45?C3>6(_MX'+B4)]$!J+&
M#-4HDEK*F$EDYJ"S@EM%>?0+I#>7OZ (6;0A3KV2FEP%5]9#<DOF8^H7%X9%
MA<, 4_40*"@!Z; 5>8[@(HB28[#(X7AJC#XRS[#RS;#$+'[QFL)?:#5\YM :
M]ID!MO9C<H$!!@^MXQIDX\E(&CU#\9SNG=)^\[^.]XX=U X.M,V>"\4"2:8T
MK*OB=ZX>"YJKXX=)VE;9=SFIN-JQ9&"JE^=H49":[)6BC3[ &#Y!]CD%F^9%
M*QJL45DE[\,D1I@D^M'/]?:("Y80D(/N2JXXZ0J5HD$L];';5J]V'QD69\-5
MZL1[R?9^$[% C0QT3A(/OL0Y&8*E%G2>+9K9#@5#M,[.T ;M+ 6@4#7L/ 1.
M2=D.(5#.:>I"S(Z.^3P%N6%6NV0%^PU5M^(:4KZ!VN?,)<7OKKT^//KQSN3@
M1X-@>%FU7;/D"[B37'#QXENN-134JH/]X^T?DW>@,"\;WXHL>!*3\H>&[)$(
M\T_)3Y^; 8W9Y8S=L-">TN^ FWH>8V2_*_84M;'W_6RN3> Y$L_?=[.BL6DR
MZM%A2X9"D<$LT+'7_[XL@_)*U \A;NX;0IHILZFR(U0N]_=^<BH7#DN_F_S$
M\5Z'"25/.H#(Z,FH@E8I*:CKZ'I0T0IC$\BU40 )<I[$!>"S_*8+BE5%B%"O
M'[K<??Q^2@OJGP7QBZA$6XS(<-_-W5P_'PH%5AZO,%'D_BIW;2%MAC(%#?6$
MIL!HGCR7,LYA#SPF("@[^/8.:(O8UJ)YVBF\9BHG-'+!\0JNN>#/ ![='>W?
M<AF:3^]\"P"/M]Y_^0T"?E/W.3"3? .7\18DS_I:<O&<]@1!.FRO%TW*_4H4
M7)Z[NW7:T@O8U6L7S3!+BO$U8JS>\?8W+Y+]_9-T[^ (?CH[3@^.#Y+K>[CP
M.Y1285<T22? ^4\/3^"G_?W3]/#L##AE=3?PY.E1>K:WE^R?G,$[9XGT7'_.
M-L%L)ND1S/_D=)]^/MX[2,_ '/W5)0)0<BFL!%1@Q#QP@!Z]F\,4V_MF=+O"
M2(U3<\F'A%YGJHJD:GATH5%D21$4)*2.MU/@*MK[XI;F%XP39#&0C>@^3PQR
M'K2TZAYKPLPE'91D/8>$"H;ES&"L7F=3AXD@<"**N%M29&4(8TC28B+L'<R3
M%/]".7C V++#3%>51/SJJ^?B;H< ;;1'E*%>#;+%'K2XB[R:S>3\]C%WN/JM
M!!]2ZY@^(=?&C*VH\X=WMH<M0L)&(/B=@:8CRA )$(':4ZQ>TJ\*(*CB*_RL
M%V,1'-ZQP6\BT*-CX_?XIF[SJ<'ED^H@T0[JE=Z&/EP^I<?!DH"I%34I0<]B
M!,Y.[3/#M4S/\,ASI\-0)^R?&S12/WM(QI\)3"SZM2B"9B#SXX7V?C*$<E-C
M4A)RK+/3L_1H,H&?3@Z.X?^W#M.]R=XV_>4XW3\X(:XV.=A/)\#A_%C&P[5
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M9]!-*TSCM!#H)[N8!0ZWKR!8Z2EU% <56RKS&8<0/XG W>TV9Q?0SQPXU%?
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MI_05V$4L&7*N7I,*>&5=K3WG<I"JMQXJN#6 %H%?C;40NDJ2G:Z!G?%![7W
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M? %WD@LNX7K+-:0"=7.P?[S]8_(.1/RR<?9V^"1F(0\-V2.1>3W36X2)H'Y
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M7'O)1#G3Q/]L*^'AR&]6ZU:(2]=V)Z>*=1^)_1R[#^UGOP%02P,$%     @
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M;',O+G)E;'-02P$"% ,4    " !9JZ=0)^B'#H(   "Q    $
M    @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %FKIU!'1!$;
M[@   "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( %FKIU"97)PC$ 8  )PG   3              "  ;8"  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 6:NG4*<'I\@V P  .P\
M !@              ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( %FKIU C]N4'I 0  -T6   8              "  6,,  !X
M;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !9JZ=0FL:Z"2L"
M   I!P  &               @ $]$0  >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&UL4$L! A0#%     @ 6:NG4#T24K#Q P  Q1$  !@              ( !
MGA,  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( %FKIU ]
M(O471@(  -X&   8              "  <47  !X;"]W;W)K<VAE971S+W-H
M965T-2YX;6Q02P$"% ,4    " !9JZ=0.N,AT9T#   M#P  &
M    @ %!&@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M6:NG4-;;%PF(!   :Q4  !@              ( !%!X  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( %FKIU >?/L4L0$  -(#   8
M          "  =(B  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " !9JZ=0Z)3@ [0!  #2 P  &               @ &Y)   >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 6:NG4- 8@@2V 0  T ,
M !D              ( !HR8  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " !9JZ=02(UXD+4!  #4 P  &0              @ &0*
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( %FKIU#-T6%Y
MM0$  -(#   9              "  7PJ  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ 6:NG4.?^U6:Q 0  T@,  !D
M ( !:"P  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !9
MJZ=0'^-J7+4!  #2 P  &0              @ %0+@  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %FKIU"P=J.\LP$  -(#   9
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M970Q.2YX;6Q02P$"% ,4    " !9JZ=0%YIL?,$!   W!   &0
M    @ &..@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M %FKIU#:NV!WQ $  #<$   9              "  88\  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ 6:NG4!F;61OV @  D P  !D
M             ( !@3X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " !9JZ=0U!<$V0D"  "#!0  &0              @ &N00  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( %FKIU#2BAJNC0(
M "\)   9              "  >Y#  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ 6:NG4-\N*0A( P  5@X  !D              ( !
MLD8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !9JZ=0
M[+NQ$/T!  !V!0  &0              @ $Q2@  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( %FKIU"A'[6N<0(  -H(   9
M      "  65,  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ 6:NG4,A# YZV 0  #00  !D              ( !#4\  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !9JZ=0;4="074"  "I"
M&0              @ 'Z4   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( %FKIU"'7I[LT0<  +8S   9              "  :93  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 6:NG4'^$&]/D
M 0  H@0  !D              ( !KEL  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " !9JZ=0BDP;-78"  "M"   &0
M@ ')70  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( %FK
MIU!*/U/':0(  *\'   9              "  79@  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ 6:NG4&98^6GD 0  J 0  !D
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M='EL97,N>&UL4$L! A0#%     @ 6:NG4 _W5TE- P  [!<   \
M     ( !8-L  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %FKIU!E0E[)
MB $  /X5   :              "  =K>  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( %FKIU ).8A[F0$  ($6   3
M  "  9K@  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     L "P Y@L  &3B
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6652353168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,198<span></span>
</td>
<td class="nump">$ 1,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">11,463<span></span>
</td>
<td class="nump">8,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">2,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 14,320<span></span>
</td>
<td class="nump">$ 12,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6801487792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.545%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.367%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.370%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,198&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We manufacture finished goods inventory upon receipt of firm purchase orders, and we may manufacture certain intermediate work-in-process materials and purchase raw materials based on purchase forecasts from our collaboration partners. We include direct materials, direct labor, and manufacturing overhead in inventory and determine cost on a first-in, first-out basis for raw materials and on a specific identification basis for work-in-process and finished goods. We value inventory at the lower of cost or net realizable value, and we write down defective or excess inventory to net realizable value based on historical experience or projected usage. We expense inventory related to our research and development activities as manufactured by us or when purchased. Before the regulatory approval of our drug candidates, we recognize research and development expense for the manufacture of drug products that could potentially be available to support the commercial launch of our drug candidates, if approved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639997264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in&#160;thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.994%;"><tr><td style="width:1.0%;"/><td style="width:74.052%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.611%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.612%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">761&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">820&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,453&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,623&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,997&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,942&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Impairment of assets and other costs for terminated program</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,025&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stock-based compensation</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,236&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,385&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The stock-based compensation expense reported in impairment of assets and other costs for terminated program results from executive severance, which we are currently accounting for as a liability award. However, we expect to settle this award in stock in the second quarter of 2020.</span></div><div style="text-indent:31.5pt;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.994%;"><tr><td style="width:1.0%;"/><td style="width:74.052%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.611%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.525%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.612%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Options granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">49&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted-average grant-date fair value of options granted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.88&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RSUs granted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Weighted-average grant-date fair value of RSUs granted</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.91&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40.95&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Shares issued under equity compensation plans</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,358&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">698&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6607676448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Investments in Marketable Securities, Including Cash Equivalents</a></td>
<td class="text"><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.545%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.367%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.370%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value at</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">227,035&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,118,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,228,499&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">279,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and investments in marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,531,782&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,603,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Portfolio of Cash and Investments in Marketable Securities</a></td>
<td class="text"><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:25.729%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.626%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.367%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes and bonds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">989,511&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,010)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">986,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,132,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">373,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(108)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">373,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">375,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,362,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,118)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,359,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,507,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,080&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,994&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,829&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,531,782&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,603,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>134</ContextCount>
  <ElementCount>279</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Cash and Investments in Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</Role>
      <ShortName>Cash and Investments in Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Liability Related to Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2127109 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Cash and Investments in Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesTables</Role>
      <ShortName>Cash and Investments in Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/CashandInvestmentsinMarketableSecurities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/Inventory</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nektar.com/role/StockBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesCashandInvestmentsinMarketableSecuritiesIncludingCashEquivalentsDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Cash and Investments in Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CashandInvestmentsinMarketableSecuritiesPortfolioofCashandInvestmentsinMarketableSecuritiesDetail</Role>
      <ShortName>Cash and Investments in Marketable Securities - Portfolio of Cash and Investments in Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/InventoryTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LiabilityRelatedtoSaleofFutureRoyaltiesAdditionalInformationDetail</Role>
      <ShortName>Liability Related to Sale of Future Royalties - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsLicenseCollaborationandOtherRevenueDetail</Role>
      <ShortName>License and Collaboration Agreements - License, Collaboration and Other Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsAdditionalInformationDetail</Role>
      <ShortName>License and Collaboration Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/LicenseandCollaborationAgreementsChangesinDeferredRevenueBalancefromCollaborationAgreementsDetail</Role>
      <ShortName>License and Collaboration Agreements - Changes in Deferred Revenue Balance from Collaboration Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Stock-Based Compensation - Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/StockBasedCompensationActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Net Loss Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/NetLossPerShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nktr-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nektar.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nektar.com/role/SubsequentEvent</ParentRole>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nktr-20200331.htm">nktr-20200331.htm</File>
    <File>nktr-20200331.xsd</File>
    <File>nktr-20200331_cal.xml</File>
    <File>nktr-20200331_def.xml</File>
    <File>nktr-20200331_lab.xml</File>
    <File>nktr-20200331_pre.xml</File>
    <File>nktr2020-03x31ex101.htm</File>
    <File>nktr2020-03x31xexx311.htm</File>
    <File>nktr2020-03x31xexx312.htm</File>
    <File>nktr2020-03x31xexx321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809165936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Activity (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued under equity compensation plans (in shares)</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted stock options (in shares)</a></td>
<td class="nump">11.88<span></span>
</td>
<td class="nump">25.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, options (in dollars per share)</a></td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="nump">18.91<span></span>
</td>
<td class="nump">40.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, RSUs (in dollars per share)</a></td>
<td class="nump">$ 1,358,000<span></span>
</td>
<td class="nump">$ 698,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638106256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventory consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.545%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.367%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.370%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,198&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,673&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,463&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,267&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,320&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805623680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock', window );">Liability Related to Sale of Future Royalties</a></td>
<td class="text">Liability Related to Sale of Future Royalties<div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February&#160;24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January&#160;1, 2012, of (a)&#160;CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b)&#160;MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, under our license, manufacturing and supply agreement with F. Hoffmann-La&#160;Roche Ltd and Hoffmann-La&#160;Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the Royalty Entitlement.&#160;As part of this sale, we incurred approximately $4.4 million in transaction costs, which are amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we continue to account for these royalties as revenue. We recorded the $124.0 million in proceeds from this transaction as a liability (Royalty Obligation) that is amortized using the interest method over the estimated life of the Purchase and Sale Agreement as royalties from the CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> products are remitted directly to RPI. During the three months ended March&#160;31, 2020 and 2019, we recognized $9.9 million and $8.2 million, respectively, in non-cash royalty revenue from net sales of CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and we recorded $7.0&#160;million and $6.1&#160;million, respectively, of related non-cash interest expense.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We periodically assess the estimated royalty payments to RPI from UCB and Roche, and, to the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different from our original estimates, we will prospectively adjust the amortization of the Royalty Obligation. From inception through 2017, our estimate of the total interest expense on the Royalty Obligation resulted in an effective annual interest rate of approximately 17%. During the three months ended December 31, 2017, our estimate of the effective annual interest rate over the life of the agreement increased to 17.6%, which resulted in a prospective interest rate of approximately 21%.&#160;&#160;During the three months ended December 31, 2018, primarily as a result of increases in the forecasted sales of MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, our estimate of the effective annual interest rate over the life of the agreement increased to 18.7%, which results in a prospective interest rate of 29%. During the three month period ended December 31, 2019, primarily as a result of increases in the forecasted sales of CIMZIA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> and MIRCERA</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, our estimate of the effective annual interest rate over the life of the agreement increased to 19.5%, which results in a prospective interest rate of 38%. This rate remains unchanged for the three months ended March 31, 2020.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty Entitlement and contains other representations and warranties, covenants and indemnification obligations that are customary for a transaction of this nature. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement; however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of potential future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638398576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareWe calculate basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculate diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For all periods presented in the accompanying Condensed Consolidated Statements of Operations, our net loss available to common stockholders equals the reported net loss. For the three months ended March&#160;31, 2020 and 2019, basic and diluted net loss per share are the same due to our net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three months ended March&#160;31, 2020 and March 31, 2019, potentially dilutive securities consisted of the weighted-average common shares underlying outstanding stock options and RSUs, which totaled 18.8 million and 18.9 million shares, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6805022000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 25,236<span></span>
</td>
<td class="nump">$ 25,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">15,453<span></span>
</td>
<td class="nump">16,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">7,997<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentAndOtherMember', window );">Impairment of assets and other costs for terminated program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=nktr_ImpairmentAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0000906709-20-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000906709-20-000009-xbrl.zip
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M**,!!Y D_*'!>#(3 ]*18+!,^7-)WI@YO1Z?,$VQ=XXY2ADQQECD=3226*Q
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M8/J7!4<%,Y+#8+%4E9)6;2,60UIRI*F=6YD\B[$\H&"$,C9X16G:+UX(;&U
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M(\9;Q(F444].?Z8O-'GU .D=^N3I'<<-$P!3(2#&"&.:*J(]X1XAXDT,<Q#
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M> X4IO)FSZ8]*B0Y<JL-<"'I4W&JLUY8 WP882KF1'ON=7KSK.EEM9G>\]B
MY(Q&K0VH.V>@EXK'@*1B-@BJ+S;4GWD;6%!-?0E,\OEM(! L7.#8*)..G[+&
M@%5$%P(EVAE)*QNHT'HV-)4Z@X/'&%G,&%+4>&F08$0S%I$1; ZR-T\-GS]/
M15_1FO=PR>/G@I\E>:/3R0XH,DJ,9)8$)9@#E!-,JRA-)'.@/+<Z9RI-K6YU
MPYLV$&%GVE.)_GF"O4IWKU;H1$FU]-)3SKQU!A$IN0#.2GA:,S,'NKL0RO,@
M%KI># _&K;N]<<ZEVAHI"/:,8I<F5X@RTDCL9- >&P!C.V&6$[55LS</=P]5
MFB>8G>CKFC\<CHX)[;_M%8UPLN9<;]A-1P9![[OPHRO5N']U0OGRJIV!Z7I3
M^/[N<6+@($Z&]%-PT%OKM'J8*66)$78.,1\<9T8CXR-SUG.+$0G<D''%+YY4
M_.+9U.F+2H%WH7=0F.-6X@I7A;LQ+'K'P71WNW#7(TXIFU/3'IA4P% <IYGL
MX+>*ICD*WGQX_^8I /F?H=.# 6CGC[W+N[I]#41YZ8,H+.'128Z4E$" E4HE
ME)@#"C."'9'&7U/863Z4;K);T.=\T'H#>-7KA"(5&O;?M$RW.SD2?'1&0+<[
M-.WRR_(L\(L5(Y4B/[4B/]BABA#E:X4MZ+-G)F!%HP8-,YH9X;F3X\-/\>3P
M4SQ/)/@%*8_,\&V5I[ST0:BH"P" F(=H%6'*4F,(#*WUR!IDI!JA()J<9(IF
M$05_^4"47Q4<NOU1JNC!K%X3'Y&@%(<0&#',1HXHC4$1%&SP>G9+^)[N )MY
M8>^/4M*'3 @$$^#E#A0$C)M'(;AQ*!*B[&CZ J0ZSHWP.;/L/A">_= -SJS9
MI_ "]:U/:XWFYK\AQ(0?-^#'=X^+*BDM<=O,!'\X5-%.&B.8TX(PAXV)@4LL
MD/).0$ WVI9+C-?BIA\JI?F!TDR_<%*#G#CZO_,B_UGD^*M.2=QZV>_HTH=9
M&D$9Q/I!NF@@IG+..&D9 )'@V*3#B.= ?6X_K[B( J02X2"MPXB *(TUC.(H
M'"+!N$A$G$=6\;B'9CV*[]9,4^R=8XY2('?&6.1U-))8B.ZL9_,HAD5'WT=1
M!*5<Y,I;3@)B&@P2 OTTTQ\D8MBS>3H0[58KL=[T^H.M6*:G'A=>GV?I8/!<
MZ.!)-$PPB+5ML"X&BYW2@1*.YF#IX&R*\WF6T3F.P!R!(S/.&8166B,%LO74
M:N&UG(>#0N=EG>3SV*M&1%."-/AARP@%-);<\ ",U@@>M5TT>WUQ"V%%H%1&
M'@F*FE$G-$0I1!C%H@3Y2K=H%OP.Z%!AVB#?-=_)NWFB2(,T0;^X-ARI5-$C
M!;)-B5($T.Q$.ATX+?/P/BR:#3^KB)_'BIFQT:7#;P0AC"MA:" ^*,N,=QJ$
MO2A67(8UFYUCDQ=EK-/U96R[B%;+3<1!"\XHD8PY89T-:8(CG6?AJ':+8K7/
M(M+GL5(>A?+$!"8$3DE!*X6*!CN,A55F5/4V)U:Z=F(*?WD.TT5E4.>XW3L+
MH=S>:>MX\//ZH+FTS6B4\X0+(GE@SD>CO6(2(\F!*\OQB=[S89NS(LCGBE]%
MU-$RH$&:!48M(4@Y9*P*S@N+Y]\B(: 9%+D;!%^*<K>;#_K;.[N+:)5 =T30
MP',91@Q9K714CF%IE78!CY>KS;55/HLPGXG14@*\E1!)C&;6"BT1]@%'AX7@
M/,S37H]K\ 2?MX<I!MD);EB4*Q W3EU[Z(-_6_0ZJ69[."A)T5;<,$4W[Q[T
M/X2BW!7Q[[.;'S"]>^(E2O>!0-VD)HMH\!83*2GWU'+!G$)**TDL^.2TV;*<
M+X-??!UY'ASQUE!IP:D+(YFWW#"/M=3168Z\PJK<F8ECA/BLJL9ZL(/-+DAK
M>&UZ;R=\#=T/O;P[*']*RTQ 'UQ(OW?S7E&J0?"-WB#TUX=ARPUZ\(KF2:_9
MZ@W[INM!#9HG</F#+19YW^L>#$+124W^UGN-6E4VYS$G'U,Q$& ,?X#)1Z0,
M#D1#V"8E S^D.)) +02)S"CJ)P$;PS2;_#"K6I0VX W_&:9D-NC*3=*Y>L'C
M^PLV=5;M3_P%N\>QMJ_RT]=%Z/>&8!']T:^M8'S9>)]_7?T3_AA'<TAS&;&+
M"AFF5-J05U)AB3:>"R?HE^0U+N_I#\[:27PA+>EZ3<7QX(^3W ]:KP%$_N\?
M2^5%JW_VCTUW<JDU[NB@Z V[/G.]=J]X71S8WPCGRY/_:V@%_?['Z+M_)/G'
M^$>$CF31=/+VV>O_:8) ^[5&.*EM]SJF^S_+8+[]K ]='U_8S\\#- #:4OYZ
M,FH<0^B/=MX-V;BQF$ +T_!D/KCQWI"O:]"N4*3+4N/-_#6ZUBI"_&OI'S\7
MI%Q:;1K;#K7>GZ_,XO<UUEY$-]/B'P">?MG95\GP)N;ZC=&6[S3M_*#[.OG)
M4"25']UABU?7[O[A?1U3'.3=S/8&@U[G=0(!>-*@5*[Q/>,KVB$.7IOAH#>Y
MI2B'H/S$]@KH<A)&VQSWP^O)#W],O2_=/_H][R8_\#H-KL_[QVUS!KZM'-;R
MO9<HM(+&2#0 L!OX28/&WZ^,OGLU\-]^J=7%O3=^?^7F5^7C1Z^ EJ>A^VN)
M+ET'2&CN+17O>J^_AF*05A^./QN-]630QB,/CZ_YWC"->ZFQH&G'QGL@QZ.1
MQ_#ZR0>CD<<C65UVX54Y?'>1^J!W_)J-'O-K. ^MO8]]D6OV)6^RKZ75W<9F
M<V.]MM-<:V[LW$&W9[Q;.QMO=K<WFYL;.[6UQGIMXW_?_'.M\6ZC]F:K7M_<
MV=G<:LQ!7Z]#Y'?Z^GEMYY^;C7?-K<9R;7WES4J-(,[T[/=/W:Y[7Q[FG[OC
M=K)@\8P6S&XW/F^WMNNU/X&Z=GO=!L1_$+'7Q@QW.SG(/ A%,5/4J;3QD5;*
M*2<AML6:8\/-C1._M:Y)\4<J5%WON3*J3.' TN0LYD]G=KWW]3W9_KI'ZT-_
MN/%U_YT^W.KLG6PU=^G^X=O#_<.#D[WF1[:U?L0;ZVNT?KZ?UP_;K?WU7;)W
MOG?^GC;:>^?'G?KZ$6Z0O=,]LL?J[S;0UOH!WVI^/&F<U\G>X2;?^_P1-SIU
M4L?J]#W9/]O[[,3>^>[)'MG.Z^]VS^'OH\:[35(_;[7WWVVW]PX_LKW.+H/W
MT\;AP5?_[A/S__Q7>Y^TO]K#X\-&\^_#_7>;)_O-!OS]$>T=[IUOO?MTM/_N
M4]Y8;^7[S59G:]V1K;?JK'ZX1[X((4/DC&;(1)\QYWAFL&:9B%+"^.F@-%M:
MA7#R8QE 7$IAM5;9X"UM<#&9$EF1#-^2*-V-@M$5PO7#4+ )\4EH1XY/+XC0
M6!;IHX>A9O""6]*N:4.8PD-\0\1P1>77BMRT:[O=W/5\J-5WKNC\55.Y99>@
M,0\-K+%7=,P [H;!Z@<'C+77MJ;=[@UL[_0FW/TX- 4@1/ML.QSWBL%<0O#;
MW+[;%?7.Q[-]@-O]=W5:;_[=;KS[>%IOM@[KYW5H;[N]?^@/&Y_3%9-[/L&[
M>'>_V3O;7_]7IW'8.-H[=Z?P3K2_OG&Z]0[N//>=K<^?.@UHW3Y< ;!]\KZY
M-JCOH%/X^XO3TFG'7:8L=1D3*F0J6IDYD)9AW%/L(3S\[W]HR<0?UP'\ J_&
M1K90YB/OXC'N:3T?=]>VFQO;[_=JVQL?MK:;M0^[VSN[:XUFK;E5 X[>!")>
MP[2VM5W#_#?_>VWK;:WYSXW:%'V_H.YK;YKI:ZPINR*77XC/GI/=W9+<O^T5
MM4$KU/XS08':*)E9"^"__,/SOBEX>IU6<W?@B2UOSLY"V@/U)GSZ4+9G8Y1R
MG4MTNC=!/&VL'Z#Z.;3E\(BF]C0^?C'$6ZV"R4+$. ,?%3,5I,RP-1YIH8!%
M\J75>BH@_^]_8('^H'BYEL;_N^ S-RI]$\+<H-*]HN*!%0^L>. =>6"S@$[D
M*0V^ $1PX[3^&>C<YXVSO</M3F.]<50_/$![3=\">MAJ'&X?U3^_S;<^[WY#
M!/>:&]"^.MYK_BMOO-M#=?+Q;&M]N]4@;P\;G0V22.7>YTV^_^DJ$6186!L=
MR2PS(6.<J$P9JS/&*$=&$.&P'1-!5A'!AR:"S>VUQLYF2?=&3'"GHH+WI8*#
M"R"8<,%8]#HC,O'C/VN#WFTN&_TY?_SCEN/XIM?IY/U4^E![FP.S ".WH7C]
MF#G4C;+F(;UM]+*YQ.Y?R:,Z]"4([Z((,D-!BHQA",>M$S&C2L5H&$L+1I=6
M44; GXLJE7K?5.H/K9,^GW42>KOQ>70KW X'Y7*_[J !W[PX2]RC7Z@P@E,K
MP-1,S)A#+#-$R"R=14F9"%PH"%$;&_]NKFTG'[R]]F%CM[GY9F<.K?*V3N&W
MC5/C!J6RU'JQ5EPH2<WT:_WCX%)MG:_EW5H^Z-=<J\S&_#[[_9\15%K,P)Z)
M%2+Y8T3V>(7K1TD90),Q93.<,AB;RT,'/3?!P&,'/8^>,^BGY;+'1>]K@JVK
MV=F1K[O<$1C8;KFX]DW:M+,X>]/S\^GZ1@D$<&GM^OI^&]K']C]_:C?>U<^W
M/O^KL_5Y$X+_75H_W$1;G_<XN,-K"83C]M:[W9-&9Y<WX!G[GW?1WGF=[W7V
M^-[AV]9^TX&+_,CW#]M'^]=FDHADR K$,XP]RM+FCYGU7F0X&LN<]VEOFZ75
M]= V)Z8(]\@@/&@%W!T*W"KCG@GCOFZ[37.Z.2[J'ZV%G^/0\:FM=O/2:GW@
M41((*STF&=-49P9)E0FNI1.>.2[QTJIF&06WJ-GW9V%FRQ_>R<IOMIJ;F.%C
M&\UOI0^J]8I:+VW@4#L<%GG?YZY,9O5B66"=3_NL\M+BP'3S\_+WWRL<73RE
MV-S>J8TW$RA*%;B*>[5&;^7W%Y3G?73/LN9]$?K]\5_OH05X+KW*+Z5!V!?#
MG4,RJLSJR#(6@LZT WZ'L F21<FP\$NKC/-:?9PN_MN<U?[N#=OAJRE\;:<W
M'+06."7R5'KX!G[<*IJ]D^[+TT+^Q;A(D>4QT\&#%DK*X*=(@:I(A2,S%"FQ
MM+H#:O*V,%V7]UWONLXM/VH9T.TBS;$L2_^^57R *\&/SV>(^4OS'"=?+):(
MF91==0(8IY,VTQZCS%,A./5IBSV($]\ $L @=W/S+8(\D=U]Z(%4V_OY\=PF
M WY)4J=?4#08&R*S(,H\.$FE6L9D7$0?,(O>6I-B \S5',+\+3._OXVU(66]
MCPLPVOS8M&OA-+ARGPCX&'A8Z-\EU5W1K;&Y)<^V5@3S,@WL[(NCBF.@49G"
MPF;,@)59YM,>'P1#Y!V9"@P8%N;7S2M[1*&DK07;'UJ][HN=BS__(@*.!F&?
M$1@X$$P4F0999,(8'9#W'$<%@E$DXQ1]DQ-9(/"[G S^[W\H@N4?_=H@M,-Q
M4H]:M]2/Y1J 8GN8(NB: 6.NI:K"[\/AS,YT:74Q677W"E:UHO5M9XWN]B4\
M&8G'FNGZM77J>DZ3.,^2#[_<4&H\>1Z*X&O'PZ(_3+/H@UX-KBC3.9C\9G]/
M=",5LZVYP>M;Y/0F>@TH%'Z2<+OQTIG+W(XM/+T09%GK]]JY+W<GF'PS$?ST
M5W.G%,U\T"[K*8)QK9IKFW[_N4II*VFL-@M3>K'^6<?VVK_U;Y-,GU=9C*^]
M$,5-%\^JG!KC(J32:,*I:Z5SFVJ G">M'#ZYA-<9G9Q*\[D_E>+XO<]D;M^L
M&9FO&>*QLSW#Q)80.Y<QS'A2^'"3I86[^X?_.MQ:3VLZ-O$>2>T\XO71Y/!)
M8[W1JC>OKP6!-AZV.GL$6M&ILWIG$^*>3X=[GQN=K>;1Z6AR> W5R<9IXY,Z
M>]_<N)@4CER6&\=FTAF5UH)XB% 9REQ02CAMC-5N5"<.1E?N?;E<^S]EG1BN
M'9NB]M6TA_>I\*AL<(%L<.Q-=TIG6AG@+0SPLBK#&8FEYR0C6-F,!2LSA2+*
ME+96"JH5E1+\X+^;VY65/2*9F4L+O#XUE0C2M[-2$P^Y,:9/<UOK_]1&6K\P
M4B]#U"K$3&A%,H9\R&S:^(AS8C (C$?OP4C7=M;7/M;>M7O6M"'&;T.47ZN;
MXB@,?EY+]>,:CG%>BT]MHW>;/1AON.W9YQYNW-UR:76SZU.12ZC9LYIK!7=4
MZ\#( <\/97E42I!,K43X#?\^6IK7,OU:S-O!UTR[#5>DY< I[?*?89Z2+H->
MS8;Q!?#@<=YE="NFJ:1JM,)RG(*9RMQ,K"6E9=+7:85ES<.W$#6F2X^+X$(9
M0V)2*[>&Z-=^@^>!3=;Z0XA-^JU>6A@Q69@X:)G!]5Z<F*M-3>T<W3SNR._+
M-=/UM=_(5&\MF#=<9 ^3=L%-Y?5P9VK*^&%IC72_;$G94M,?U#2J>7/67[FR
MK/&Q9U??#(L"FC):I)T(PL ,AOVYQ)Y?*FTX_T("(I)YG'F.@6839S(E4<PD
M8R$2$;2E?&EU+_2_.\'PL+;[&:21E+=_RTF#[QCMZ>.T[F&195KE&[W:Q;KV
M%PF<"4$ /#KY8 "84[JHHM=-/*Y]5@O Z<YJFXG>&5=.>:^;@1DM#;X&J9?/
MF,YK;P_A2H9X LSM<#!LCZH6=[)F[;<D /D'H61E?,&@E9?+QX[3\K''AM91
M>R_ ,O1_?UHHG!K4-*9C9'QY4(B^:,_3B0 D0Y+2C$6?]J%P,K,V!FZY<0B+
M"@HK*'QT* 3T,;6V*8#C&>< "@N3\"RA0Y%XUXV?UD ALQN_Z'< 0^$MQ83M
M (IT8+#.EA/-A,<!+4N3VP<U&+*306OR]0JPSE"VS8>8=\O=+,H2I#0-3Z"?
MWVEA^37^8W+93R_X?OLF%R:J.;[X.VV=7)EW1U"/B<W(A#Q/,^:5.2P*T"N*
MBWL6!: 5BLAC3-T3O(+%HZRK_:4GHY4?+,DE*T+*>][[>,/\DR9S2A^CR7B%
M\=O6=,S*MF2/47>Q&/FUDLJ5Z)K<S$&O.+NI #SQY>+-^(*YI'CC3-OZVGGC
M\P9J'+8.&VEKQW<;O'%X1/;(OPZWF@[M?VZTMYH'T+:UZYFVH_IZVI?L(]EZ
M5Z?0%[37/");S?W#O4Z=-\[AG627;ZWO']:O;U++F!96R@S%B#/&F() F9E,
M,R:Y\-@YZI96W]_L$ZN5QD]IXL^R^>#%]L259!<+O-<NC7D4GXPMNI+S(EHP
M^^,N!3N/=3;2/:4M9K5A=R@2K?KP?'VH>/XO%@7>E(*I/,6+\!259!? @'=&
MJ<@1S[O(1XY^'6<:*Z$OG#D_W[[QH[1,J75_#_MY-_3GLPCA2=,R9^^;>Q=I
M&8VYC,C:#'F",Q:<SZST(4,X:HTUU33<<LOXBNI7-/GE]*&B^K_F,S9NGH>L
MV$'%#AZ8'4PT[5VI:&]&>E:QA)^Q!#2]EB$JHPU&+%-6^8Q1;C+%O<\P]28H
M&7%T^%<.EIDMFZY:,WNMN5\I_<S6,\4?U VES3AN+'?*XTU%GV6I9_"U;J^L
MU!SV1S5',"*CXQ-O.$JG5Y3O:I^EEY_D\&IX;:T+G>NE,J*O>;],OG737FS@
M#XQS:4?M<EGUP'2]*7R_EC9*R_WWMC^@OYG?;RP?NGKNSL/*Z(?>ZSXU=2^^
MB*[?"NWV1"]KOX&VE:5LHS47/RX4NUJ&NP?]F NA/S=;V4DC/L\DY9>*B/$7
MK05P#:$RKP/*6. NT\;YM#Z+6TLCDVE!UD^8QBQ;X;5*W;DPBNNU&?..A,W6
M9..KA%R]X:!T:Z5_:YDB]"=X5GR[<]9/%LPOE^L3;B74?\3RGZ?K]1C:WI:K
M%: /PVX^ K91IY>N@AT" ^1:86V=9<IJ$YT!]*/2@P5R)+YLEAC'$6"<#R[O
MF';_KZ7-QMNKYRO#,/O>8'S!#0O)RN$L1W.G;,76I3" <P)CA,O1RP)"6D\1
MVOHF;C0/SK::&_Q+#%@QJ0$48;@SQBV HO4\BPQ$H(QASHFE52SELE9Z67$Y
M <:)K%=KO7G QFZM;L[&:SA'!T9_O]S\N#<BM:^+D!8C?9TZ[.C__C'))8ZK
MT&^ZS=A^KST<A#_&F1HT??_HGN\OQYW^,SV\5,^(-(=0V$6%#%-*:X8D%99H
MX[EP@GZ12Y-[6L5E_N@@9+8(YB@S<1"*UZ9]8L[Z2Z^NM'K<'T96)(<N?:>E
M]Q=KC(\GUM(Y  ",3SMX#;CC0Y$N2XTW\]?H6JM("/F/6PF\62Z  .LSB]_7
M6'L1W7R3W&1WT"\[>P,LS.)>H;?=*/C& Q%G?2/4VW9NL[&^\;_SMW[IEX[O
MXRN*/\HA>TJL:'7_H_]^^"46>H;W-/VU \L?UX >"$"_,2 T!X[\SHV^/>IC
MNK3Z86V[6=M\77N[V5AKO-E<>U^#8&=KN[Z63G6_P1<LUD:OOYS%GV&6.@_*
M?>=&WT&Y(7;<'(1.#:_<28WG %S'#C;34S>43] /D:2JHJ9'H=A)'X%C@^32
M-!3\5.X$5Q:$O[V8DRH/X1EMAU3FYL@?M=VN&?H<+GL]FVI\5[B\@2:4E\P,
MS;X1DWY-.Q^S9=]HY\BIWDTQV7=TZR<^>;8F\2ODKI#[49!;?Q>Y_S9M0.Y0
MVVF%,(79BY\P2F-2-X5KO8RNUNC+Z"=^&=U,LS OHZ<OI9_E9E#KP85R^IN6
M\VPO1)EU%1=4<<%CQ 6ZB@NJN*"*"[YK((1_-RZ8RN/T8FWK.(Q>=+G)]0#>
M$A;?/Z4AFFR).ZK;?AE]?B&A42G>%Q :I7Z^ #:9NODR0J/4TY?2SS(T>A'1
M4.IM%0U5T=!C1$-)MW@5#5714!4-?<= U"VCH;0,K @MN"Z=V/$"O!(,S/M>
MO_\R>GHUPGTAXGUI$:YZ.1&N>B$1KGH9$:YZ,1&N>B$1KGI1$:ZJ(MPJPGVD
M"!=T2U01;A7A5A'NS09"\2TCW'+A?ZO7AG?TQULLU#;^,\P'9R\N.DIC]L*B
MH]3E^LOHYLN( 5-/7T(,F/KY CATZN;+B %33U]*/U].#)AZ.P,QX"A86Y!]
MF\5=]GROHITJVGD!T0Z[[7R>Z;=J;]N]D\OJQA< PC Z+Z2&,W7UI=5PICZ_
MA!B.O9@8CKV0&(Z]C!B.O9@8CKV0&(Z]J!B.S40,5\WCS5[+?GD>+^F6JN;Q
MJLBVBFR_8R RG<D[@%8->K4[;,E4X76%UX^!U_+[7*#:$[':$_$!]T149+PG
M(JGV1)P)T;YP3YSTL6ZZYJ!TL!>GD:SG?3?L]]-I'BDB7.N:]ED_+Y/-EWXY
M.>[1^5_IFNW0'[:OK[:?31VO'/:<.^RDM814'GLFG-_(G]&5V;/SRI>]*%^&
M"=-+JQ_3F9'YH#RZIW1,\$%[\GOR:^U>?YC.XEJSO>&@5C?%41C4MO/^4>6L
M*F?U&+MXE6K)<>6N9L-=S2((/ER J>78(;,JP)P)T;YPIZS'!UL5H'*E._Y0
M]%SPR0//IGY6_G;._6W2N/MZVW%#$J#,UDQ<U;#O-ZPZJVLVCKV:!4_VF&=U
M(30YK&OS=6TK'658G=15!0VSV^B[J#:MCNJ:*=F^\*BA5,CWX<"T1_%"2&*K
M H8J8'B4!%U2-DZK_-Q,>*V91+:'=+47IV*N7?&ULVSZM?E'W<H<9M<<TN1;
M[:UQ@UY1^?C*QS^.CP<]HY6/GPU\6'A0TU65YTS)]L6'TZ"0N]TB'.3]02C2
M!@*F'<I:S?&N:#O!#8M\D(?1)-UN/Z0OQ[%WY90KI_PX3EE7@??,^+>9Q, '
M=,J83)6JSB*>54YY#A3R 9UR4LCU$$VY;&+WN-<%+]S->\64,YY-1:T<[[P[
MWJ1ZE>.=$1\VDSCWD(Z75R6I,R7;%^]XT_FP<!-$P3% \#NU*F0V%;1RN'/O
M<'GE<&?&=\TDOCVDPU5CA\LKASL3LGWQ#A<4<FO0"D5MLQM[1:=\V&RJ9N5J
MY][5JLK5SHS7FDED>T!72_#8U8K*U<Z$;%^ZJTT*N7':RFU>;9=7>=A'VM
M=(RSNWA840'?<V/(P@,?6UK= <&;P9WS>'=8C5>A9(62=U!(SG^$DJ\&QK;#
MY/,+EK_ZIRU>7;MI2L+'O7ZYZ][K(K3+78W^.,G]H#5J]K@+C*Q(_HUN7-QI
M;+_7'@["'V.U1=./>/3UR8\E-E(VGEP;[:D_4[=R_]?2;2J3EB8WM8I+VS\(
MF2V".<I,A)%X;=HGYJR_].K*@$TDD(;_FU&MG,=,.@^YM-I,IECK+?[!!]#7
M^ +.#QIO._.=7<.O NZS0]DWNQ:,H.QMKS@QA<_>]WI'X/.O;(3^'><P36 I
M7DD@U#'%0=XM&8MX" +[N/#=;.7]6A&.>\6@EG==>^CAX6E?6I)>.QJ/]G@\
M^A?C45Z _ZB=Y(-6WBU/0.L$TTT7I=.@@TN:]-__P +]0>1:^BQ=,E7TO.8&
MZ5.L*5VNF7[-=$8';?UV]9K?E\ORZ*L/Q!LW/'#CU+5,]R!,/9E=??+T%;^O
MU-;:[:D.U7IENGS0*B4U?=@;C,^@5R2F6(L&GFV*</OQ2<?#'0\+( *CZN]!
M&NW_#$T![JQ]-AGW7K<&JM>I891]7!Y+(3W/=,]JQT7O<-3[\@&=T?:)2<3+
MM6"*-.3]97C0U] =PD>@(@':VPVU8W-6-@6^[)V9=AJDY5I_5(9>C+L;+_86
MSJ'A_>7RC5>[GX89R'IW5*?>LV5COH9Q8R8;&9<=C<,4"M1Z%[L1UWZ[Z,MR
MS0X'P.D&M7;>R=-Y X/>,G0N.-#)<G ]=*'=.TY/6ZY=?#HHH'6C=\/;ADD"
M(/'NP>_?M+5D9^5S:[WA=-?<E6V3QXT\Z16ER)PYS@=P43>5W=_PS .0;[KN
MN)>@+3UN_(#Q\Y.4VB#,;LD,OWT"O-R%4DI)DDD/?,T7P_1B:%4Z>>%';RW/
M38?Q@A\G!PW"=4ECBG0P79+!]9&";_I#V\E'FTG#!?"T(8Q,KSBKF6-HP]?4
MA[P]TIOOOGG<2_ *W5XG=Y>#6+X!)%Q.*T'??M)Z:!R,6KIQN78Q$[4\:J5S
MH5_J49(7 %[;V+$/ B,KDJF.%7@\!*FWO4XG%*58VV;8=:WQ^@GHEQ^"<8[T
MNYU4J5^S9S<\^1B&KQN*_K0R3$PEF?\ ].PLO2?4_# D;1KV1QXQ]:<?KC7M
MNYU/;[[1;N")XT$):1A@8 <YF.YU0?Y(OR^4,5T$06Q^G+XI1[77/>BEU[?A
M#0?CP?Z^2@)4Y)VD@^-!##Z_A)HDOC=;GS;7,ZQAB& (0!'^IU_+.\<)!Y-V
M01_ML ].I3]ZPDUF^RVDF'Y_V#D>O6?$-<XF:#=^+6A**/NQ4ML$/$["<*:?
M3.7[D)LLJF9!XY(OSF,.0P4*D)XV'"VN 2L%-0*_>G"6E*^5G,,8R$'DRQ/(
M'G]TDK?;US\+I\<@Q?[UCTLQ7__P4C#??'4QZM\\:"+7R><@T/%7$S59GOHJ
M]:T;#D8[[28\#\F6)M@.*@RZ7K+LJ9XGOS=H]88'K=I)@.%JYZ&\&?0^/6[4
MPS%Z _5KPV\PD&,7_Z/!A_894 1?2^W(NZ6;A-"MW^NF)BR/1OS*XZ&E5T7^
MO6<G@TS 55ICDG 7N"IXCL%(O\ C@,85X^WP76_8!HC-8X0Q2*.<-!%<;2QZ
M'7@1 /#$I4);4Q.2,MZFBRNUK6%Q#?V_\2[%Y:;\EVZPI"$G ?A&HB/0Y>^_
M9+D<-P#PU, 15*3Q! =;Y/VCD4$-D_FFP1ZY])^XV-2I=&])7GJ >_U0>NM!
M*W7Y0W(FFYO+M32G-J)7>&VB<]/+Q"=J!QK3.QEAYU@#1T+N@__NNR*W\%K
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M+V<48T^SR*W-6!0V4Y;A#/M L"%$.!I2J3%=UJ@JO*ORP14 /E.M<06 #PF
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MGP_>[WW]?Q?V6W,GCLGI.W2PLX4/CG8_&1*1& <+G,31\Y:< JV5 =II9W7
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M>DDIA0ZF#;4-)42#L$7$Y#)W_=P%_6V@XV5<^D.WMS6V/MZEY:N.+H];W=$
MP158>#GQA;8IMU]WSU/5EVYOD-S#,K[<+5KQDH[+Z#J>Z7*0-LH.3GS?1WC2
M0]=*&4T1FISO]D>/*F.H$IU"JZN[ME4MZ<07JHZP+ZX[E=,+5KU^M47I9>G;
M.I61>?6UY08G\1KB*8Y/E[*;ZUR7AVD3?WDX\*_&A@>GC[^S#?5XOFH^/_0[
M5WSJ;[JL"GX#5$P$9(.$FHZJ?0O"#5;:,6XY^839QN5!)^4$+(X],*77GX$.
M<21>ZO97?=[?^.W:@%T./QXEV]T8V,>.7@A/-WK59$>.ZY6ZLI-HMQ&>TL?2
MR>O5.^GBI$P:X!\_GW$1[^P$647O7[_I];_64#R+RTP=M1.45A=["RZL!-")
MVX&NN?O?HZVWQ=&_=]]NO=E]=[2W?7@G8:S<Q6T?1!G8/-S=*>*CPX,_]W:V
MCN*3PZ/XS_YN\^BP.'A='+R)EWZT%S^P/A?^RUXW:H;>,'Z)ZS>JBAM1%9[Y
M<E1P+@J,D5<2;XM?U^BJWUT*I%DN:JP<QR*&C_1.)3POCQE_H@H.Z.&@=WG(
M2$Y7KXPE>+S4MC[K^Y>7#VY$+ZKGK:3>HC\<?\NU^F=M??ZRU:TNJ/K="=VG
M<KX5Y8\78\8G-'[_Q>B][[R1T9L"O:!"WOW^#P_^\9OPA50/_6;X OWH38;I
M X_]V2DK>-_K_<GBUSV-_DFS"-2CEN)^>L+C&^,QIWR[<REON8^?VK<\BDSO
MBT[\E9-^X>.-YR;E->\1+;V\/[N]D7R=]:,K8$V/6]A]G#4])D6E=J:65J\>
M$H!_S)S/80"S03R=04RUQLN)%?,+S[SU7WQWZ%_^)#]Y;HM>3WN7+6>+3^T&
M)Z?\+^+6>5/VW-#&:=)M?T<IF>4->+V6)>:Z[/J8?>VKO'"*(;<28T^II-1S
M)ZW24@KI&+7.2/QIITKZ01"!1V?_C&GA==GKI)A=.KOWK<')]K ?Q]27N]]L
M>YB&=:O?]_%_KD8U(\Z;EXNJG8^M9N?OSL'1!_CAXC^=YL7;=O-]?"U^;_-]
M6B#=IQ].=\G^'Q_PU:+JZ18^^.-CZ\/%[R<'.Q\N/I[^Q9H7S=;'G68K/O_6
M/'W;:>[\W6F>VAN+JOL['^C'SG].X_G1YFDS?NXSV<?_^;R/]^+S7=S\XP-L
MOD\MB]OA:D'U$'[]Q TGFJL --$44.@\T!!*$"U7(<18,#2D&FR4TMHE[*[@
M@F@-=C%D7LB\,#=>8)H+:;@A7G(:L#?*8$\D$HI:ZK1,O(#4F!?B@\P+M>:%
MBRM>"%1):C$#!*7N3<P;8#2R@!$N"<=$!"HV-FF#J)M[I#,OK/%>C57VFM[V
MSG5[<%Z4(R3)I806PA'0AW@M$#*,!<60&N.H]UXH+*6A7F??874XHKD]Y3M0
MY(-P" &K?*HV9Z+; !$!'"J'@G+6<K*QJ1H"W2PJM.Q4S!7DB#J%'3,VSDD_
M"R6%,IXX%4%1&8T)0H1QAH52P<*LGU<*&R?Z.2*CMYHR0'$4T92&J)\M-  Y
M(A5U3&+"-C81B@+Z9O/3#(ZU$-!YV>%&GF&O"ZSNGQ3E=25=5,GGWA6#7K4D
MD;+=PW P+/WXDZV[5BGFQ2CK7=IY%K6-E!<6*V^<I0@9&:@VD' 7F- &TZRV
M5XA1#J?4MG4\.D\N]445J6L4L4 1'B*C, Q90)A E-2V5(OH&+7V$9D:1.HS
M-LY;;0=C'%(D*!2H)T02;AV*;BI#7$&3U?9J8>-$;6MD6" 2 1VP 5%L1VS4
M2@'J)))*26^%WMB4C8B1&1OK*;9SM/I[L?UGRZ;=H8VBVH9@QAN@JN)#HZ92
M.8R]2/+0 D&#N(4<!JH,5-0X(VGP*E!HN<O">H7(HS6= F,5=PI)@*BP('I+
M%,B@4_$ZJS17&#E#-C:Q:#"4>['F.'8&QUO T;(4W20D_F<HL4ZJ^!A%F+0D
M:C.,LK)>*7"<R@/AQF+B'- "NJBLF07&(@449,%K9 .7,N6!8+B(_,"UQ\;5
M"6/76SN/:G8N1"#G:L[W(0C/)4%4$BL1I5!)::45UC"D&-),AZR>5X@@IA/(
M46!",,>!X\%'@A ,&*4\@-@Y0:E*KVQL,MA@8A'%))]WR>=G&[1^KK!*''56
MQ5O,>TX%"D8P$35XO.T(I0Z)K+M7"E8OIE;[E(XSZH R2 .*'07&. (LXTP9
M&"P7>&,3RP;&.,/J"JKRY[CA^^#,IR!V]SB.8G\PJJ/OOYVE*'=_^;O E[X%
M>]F_/Y>161T/=I77AK;C_9.2K(Y[/==/,^7JY.2NL>!:I!^;)OD@_)&F.)62
M]N67EO7]PSC965?-H*L.IK.HO(]SHB$#.EB5%GL0D%)8X*433 HJ**1IO[-$
M]6M0M(+*Z=DZI&L,@8OT.3,$S@L")ZXE3BT/N": .6:2:VF PH@#3Q''/@CB
M@MO89(W(;QD"GY/SN,J"^*WO^ZH@9/(IG?_BV[VS5#D_)T>MG2R^G.I("#N3
MB=X=Q1$R+<Q2\>'H6LMC$23S4CE I;: $JZ!9L$#!0/SEI"@&-S81% VE!1Y
MM3]G0F4D7/:*3$;".2+AI-&4%L1J%4$0$AGAD& (C%<8L "1T<PA&73:O2L;
ME->O1>(*(F&.&B]")/_ANSXUI$H:6;M.J]OJ#\JJ:52.'J^=3!Y/=N2&K6M3
MG>GA(?1PK8<N083:@#W0E&- .?- .N\!BQ.J(8$4:;>QB7D#HT7HY+4/H>0H
M\OI!X2)U<H;".4/A1"G#H*S'+HID89)2E@9("QWPCJ0J8,(QC2(4L@:$B^C'
MNO906+-H,KX+-VLTBGN=,]TJDV><,B9TO^_'J4>C7;2C5*2()<7 EQ$=JCHV
M9V7ON-2=.UDH1TM61Q!W/P_*EQ,C. BI$7<5*8F$<)!L(*TR]E_WRJ,K W@S
MFO_,##,QP]Z52#XXVH.?,%16<!> 2FN,%!(,-+$:*(N@HXP:K5(-8=9 ,A>(
M7&HX^1'H4[^1J=6Y7,Y/YI%5\B8N?-ESNG^2*60)%'(^12%:<>L<QR @+ "E
M& *)N0$:0TZDUL1AD;!08H1?90ZIIW_Q?#<@]WZPX:%.(??GNGUNT=G<*8EQ
M''3J9V)XH&^QO_4)H8 D)I$'E--I?38Z%<9P8 2/'@?F<5[#QB:2BZI+\;RW
MQSW;\/QSA<U%9X!GV)R#GHZPZ9%S7A@#J$$04"0LT%I"X+PS!CI-N$]%Z:EL
M*+B(B,SSALV:A?+'*2QU'\@_>_U^$<I>YU)<][K]>H17UHH-?EFLBN['<8R/
M9N"%J[WD>UW;Z_AD%ID:9J*&_6E%+07"V%L&G&1145M*@2*( 6VD1Y8$!#V-
MU$!(@Y.;.R-_75Z,9=U8X=GFA#];^)R#FL[PN13XG"AKHAW&E@O I$GM4B$&
MAI-H)<Q)+IE1T*D(GQ@V^"U;9S)\UEI4/\?X=>KT-(E>MRJ0*'X9QZY_?4RQ
MGD5$@9[C[]?,G5S3+11[D;A+WQ]<+N/D_<4KXV/>6QM=SG%.#WZ(+GHW[59Z
M+ SU" +(!094*I+:8 8@D;>",2IUJC7!;UVF6:(J6D'A\VS]QG5&O44NM&34
M>R3J3;S!H @5*B4L\< !U?&/8EJ#P (ES)E4&#M5V,'XYIZ(C'KKZ>ZMLNB]
M:OO;^D[]%A&^VBUM6NU6U0PX-P&N"7$L;%]%-(WM:!G?D<?;D24<]0ZC'1R$
MMY?3GTEE)E+Y,"VEK366*))V&2L)*%(8&(\=$*FG*<.!HI0*RQN*RZ<EE;7?
M8[?L2$Y&Q!65TAD1%X"($YEM(6&2!!PGK.KUZP/0WF' @W ^SJRRP29$A/QF
MW\:,B,N6V3FV?&=L>;S<,MFC_/WZ2Z/H^ES:<OWV"%1;R2*!]*ZOSN>0S$.X
MPDZK9XR81RP@0(2A@$+G@>2613$-A24\4!ZJ#O&$+:*=SMK'97(T>OV <)'!
MZ R$\P7"B6C&S 7DJ )&$9JJ]A @"3,1"#4DGD$IF$N92HU(>1D)ZRF=GV-"
MTFA#;?>':4D+D,7/>(-8[;<$9+Z8#U\<3PMG1KGP&!.@H>> *A<?>4;BM%&/
M8> 4$I@:P$M\LUO($H,LZY;7^FQCTFL%H355VQDXYP:<4YMM!5..>0T011Y0
MK2@PW$ @#0LL8"N)0E%H-Y#*#7Q7480_0>BB1H-8;;,U/D*(3\4PO[3Z":]2
ME<RQZ![H;SYOO'V&*GNR8>RR$WRK.XP#>G"U'?OWRFQ&GSM*9K+[;5#J.$FM
MKB[/]P:^TX^,DZZD[+7;%>>,%CXRW<Q$-Y^OE<2A.!BJ+4"!1KJ!A@%E<'P*
MF?4X($:-31MX98.RO(&W!DI][4+?SQ:&E[*!-\-PC6!XHOHC\WKB'0$^F C#
M3CI@3)  $R>#\,$QETKL(-6@ZHFS4IXW#*](W+U&@_AFX3)_O;,3%ROD;V.'
MB/KC0,[OONM#*R/[3,A^NG6]0H[#EC,&,#824!\(D(IPP+U3GEEE!<0;FW%R
M:A?-J3OPY'#WLP"Y.<CD#')/ G(3^<JU]<01!Z26#%!L.%""0V"$@ @%2)@6
M*8J0V]K55**N=U2ZZ0=%.[J\3^LF_6#$9HMQU&OP_KD2SF7M&*[V ?EX4^0B
M;@\DOVMM7:6D&CNB@? TD1\F0-$@@)9$(".YYQ:/0N@\A]#KH/Z?,(2>&24S
M2AT892EK"YE1'L4H$W?*F#0U0@))@P;1MCB0F : H#;:1ZYAG(]6 SBYF064
M&651KM9EJCF-9[OLBI%S/)>I621Q%EUO:-K^ODNR"SW3.IW+W$8M^_>SWKF_
MZW[+5ON>7:L]3+6$NF./OSCS9=$_T:5?FN^?Q=C]8F^KI;?>^/(PF=5\/7D\
M);NN:ZM=77;C6/4O?[<R^:VNVQD9_)7:@EEMW4-M_37MOT=%+)'@."W.V>B_
M>PO2! (1J/4A.N\LU0.!+\03%TA:^SV-S\D_SZC_C%#_D=YV1OV%H?[$QW:1
MCJ5$T;.&+*(^]0XH3 +0QOG@N;.:R(3Z_&9'NXSZRUZN7.^,NO?53T4O1L<+
MTL=^Y,#TB]YPT!]$+R?M81_VX_NM;AS1SMFPVM5N'N $+7UOYBV>\OC=\>_-
M[DK7CE'N))31M"ZQ;M2EH6V-[*PY[!A?'H2*:@XFQG87Z^3([GU8YUH]*4X\
M0M0H8&S*!M3<1U^#8J"DL5(8%R2"&YM(B :2-_.\EYTL,Z<;MZZXFQ,*,T;?
M"Z,7N<D^8_1B,'IJ![X)RNB@@7 . AI8] R\TT!!B90D6F*B$T:3AF2U;G?]
M3#"Z<C!^&^AX&9?EFZ8JNDX-F_5II]JKCBZ/6]W1(B6L?WG7HQ-?:)MTONZ>
M)Z'?[0WBU\?;/XK]JK7"<:G;Q9DN!ZEUPN#$]WW$+SUTK>0$1.!R*<NY>E0M
MR%;-%D*KJ[NV%0^,"#+PG3@T_1?7:V ]9! W_V7*WS;O_)ZS7K^5[I*75<^'
MUA?_ZFO+#4[B5\1+'5\VQ2\$NUF8]_)(;>)%1(A[-;9A./T5&S\YZYI/-?NN
M"-G4WW19%9 'J)@(R 8)-952*0H%X08K[1BWG'S"<N/RH)-R CS''IC2Z\]
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M+8461LLS<$B]!JZ.K716EF9OV;/V8([]CDBG).I(EF8FG8U))^GIG%$H).0
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MIIX12H74,A!G'#3*4JV<Q#ET7 .&_;9_V:]NZU.40\$9(H&D,OJRVA(@"4'
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M%)V]RB=?GYA:KV:.68R4 L$2#Z@3'BC! R!$$9FR#@+&V:^L]8KT>M=?JN
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M$JT!B5K!.>,"2L,0M1 J2YP0*E"#L R<SL-1S?SZ2'Z=U$AEV"D;=0\@!DI
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M5PWY:Q\)CH:Q'>WB3=G[TG+>_7[^+AK(5/6?K2OKR.PP$SM\OI;R(&&<7!T
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M S/0K6ZJ?G2Y,^)UK[RZ<_],-^&?XWOP/+/U3&QMIWTTYRCE0DE@6'" 8J6
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MGNR?OFXU3W^/W_]7_/:M\_T+%]W1=B>ZJVW_[[?G']^[,X,I_W#1CN?V%_F
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M^C9CX]J3BU1LAJ@7M,#U-=:,O)A6VJ2>#"P-$G&&:S960I4E^FIQ4/KTLZS
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MI".]:^XQ;]'!7,O=;B\W5XVM,*Q>7U-Q^[:FV5AREA^VD[C6+XO17%!1'D^
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M 3,'8T6-OV1%/C8ES;;X?TYQ!J%ID@#0=]B=H2=VAHYW*;K@>$K")*!.D)+
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M3?-^%6\W5; M1'MB%J1>Z(>)\CAEW.<!=[U84C\ 3AY3N3Z^\P34C=5+=&.
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M^###6)SI?'206K#N"IR?M?*R:EC1U6_40A.+?TP=40TT8:[2-[.:NS:%K58
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M]ZH6^0?C$L2!<9(XO3W3SO9OTWWV-W/J?1+^_KQWJ%@Y+6I?Q/R5L#,K'[E
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MFQH_P7'?,<\GJE!WS/-!F6>C6O,XC6,>,\<+5.#0)"0.YR)QPE#)R ]C)?P
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MJSDKPK@AKIV,'G,5=A\QJ>R9K-PB>I'K16^%JK7?2NO_$V:.P2(-MUF45)?
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M7,(/F,*U7J+3I'!1E(82I\"<*)!P>HE330(6AFUZ9%0#<5&^ADD(1*KZ@H1
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MDAX:*U0P)Q;RT7(0,L\I?C&=V8 \[GU5B/D,\S\F!GZKM)PE7.(LY)<"SJN
MY^'=KEBXW6^FOY"#L&N4XXL&WLT(+]6@O\61R#CH>(E"["PI5"PXF/:>'\;7
M(;R>M ;M7:+$!D5;U7JRE2A_,[,V)(E>VU6B/)[L3P[:>?ZZZ/V,4_X5E_J'
MA:DX/CE QP"/I6"Q]ET9Z<!EJ>9 MX%V!0L8:%X!3U7VZ.EG797K,AW([8:-
M,R(6YEG&@28B!B231KGVDI0)'8=9)O07<*BO2PP_(!>CQAI!"/J"%S W3+(
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MRR1"I45IZ@8QDXGD,@99A: [EUFN31F$#;;E8'H Z?X7#L0,W24YG4_\MM)
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MS@PVE=W4KE;DDMA&@]'?!Z4?M+]1*0E>DL\IG6/:=*I>5;EJ6X"!D-0T$/6
M \W'&*9YT/&RSD_"K_;V-5@//<6QH[BE]@E$?4AMRQ=/C9KIO'GVJP7W6:LF
M7/75F#:-MW0OAHGGZT1(WPM L^*"L]#/8PG*')<@I_,O2*?9VL]]U\(=E*0/
MGP[/]T_!)/*5]%*7)TGD,B\0;LJRS%6@*N72#U4>1J@D7>$ZW(CWT)E^FRJ+
MVS;J2SU(SHUONR9BO\!P*OR[QM\V5RKWZOY-87*]K3)YR=O7%\1=_\*:&NGP
MR6+/^7=Y >^I!LX9C,P8Z02=AU8R(?2M+$!3+]CRY[9RL)4"U.1[VQE%U#M4
M);H^*$UVH+ Y8.A.[?HJFH6P.:#]UH<T_T'77V"PTO0 /;9;NBJTP(9=O&&]
M'4'=9"[V'0Y7(OI]@YR\;\A$=CEY5["1\/#Y7Z=Q*CRM8P^D(/P%=C&P$> @
M;IZ%PA-9+/((^P1?QD66&XW65XFR:U58TEY<79$4/[H/FM'E>M 1M@I.'$JL
M#7YIG!I'<R#30JZT-8W3T&=I*%.$S\_25*8RD2+RL\CG$<_1A0&GQ93!-\=F
M^30\+VHY*FM00X]SQ/S35.=;3EZ93:0&VZ_1ITA=)MJ^IC"$7T>E_/ /GY*C
MHCTEB^/?#X"RWWU^__NKX;O/K\[??1X61\__8N_.WP\/S]]<' +%'YT?>.NG
MY "N^6UT='[TX?WOOYT?_7YT#L_RCI[#_>,7BZ.3_<]'GS\$A^>O\L/S,^]4
MQ%F<^2IR=99+EP6<NZGTM*L2D;$T%J&*HM6F>!P&&\?"SV0F6,*#3,A,9;[P
M@U@#6TL?45QLBHIN-=>/GKZ>P>*ZIK-'?UN:4V?)8:7H;F.YW=6O7AFJ#B,I
M%(]RWV>1$FD0\,A7(3 %S7,,0'YCDGPMAUK-1T"0+\;34;G0^K5IGM3187])
M+*PZ_'2<OVH1>5]2$RXBWQ^86/W3D,>)] 3P-B83(-8\=[D6N8O(_#GND@ST
M*O$]*+MK!1:=+)N:3I=1(F6/E!H<3(IS@T&%#9N-NP=^JLM1H7@+*6CT85!V
MCJ>Z:L"+48\"<KRHG<?%Q&A,V!(+)J#J)S]?9;O;LG^[J#,JEUZ^8J3SV<]\
M/BN;32"GA/D$1"OHI"Z)V6FM?VY^Z&/JX/V_]+<4%U$5]73$%S\7$UH^>J^M
MJ\_2/9"R5%H_J^"/:L9CR^[W3-G]3S.U_F7"]KPHV/[]I3=?^F6V%_O^+>_U
M]BZYT]N+@NB6]UXYXNLNQ4^TTF:U80^19/[?1^&C&YZOU4U?<>X94OMEBBZ)
MR9FA*Q]HH?G T)5O*+$9<SN:K!U-<STR@V#ZJ;W?DC)^=/,!6T2++QERGR-U
M/"/=H(%=F_4L<ZQKS@KQ8D'1=<;PEF'MF.I2DTT IE3+$%87N-ONYG BH-/&
MO;CBTGM 3>$_2$V6:9)M,)TYQ..=9H_O&ZFA0G4-DOJJ>_X5%G!'$-^.('JP
M.]?@!K=9[O^14NL\_ZHLXBO ^'Q;I?*9;75[5I:J1B)1*TZ,92G_[=?U9F2[
ME4@WSO];4^F_5GG6UUTUHJPO639#FD9#NT/+=@.O*ECA>90J$07:8YGF(DNI
M[:)./.8K%F\TRGONU7#51&];F6TVR5\8,ZIUIH;WT_(>OAM_&AV/7PW?G_]=
M'+]]$;X[?Q$<G[P:'IV\B0['OWUX-_YK\>[DM_%[N/_]R2%K[H%WS=\';V*P
MT,=';V$L)ZHX/'D7'?W^PC\Z^;!X]_95\?[Y'\/#M^\_@.4^.OP\S \+[].?
M)R]FAZ^]B]/(CZ6,83MRGPF7^1*L=B]EKA^F22K2.,XS_NAI$OMK7EAC=-Z+
M$W7W.-'FQ;N."O4MI.!.B.R$R!T2(EI%<:95D',6LY!SH87,M?!EFNDPB#S*
ME\P: /YL)T3^&2'RN14BF4H"P11W\SR(7>9QZ::Q$F["E,_21/MI[C]ZF@;K
MH;R=$/FZ0N1;F%TY_>_',KM>;6G>M=GX:E<Z^-HK?1GM7K'4]UD"R,@#NX'G
MFD41B[C,,B\%<:!"D<4J2S;']I8EP+6S-';"X>L+AT7/PM")A!T"D9 D&,3V
MA.>FH0S=+--9JCP11T'^Z*D?#5@4?@?Y<+LS=H]$P'7MB&_ UG?\\!OQP\P+
MLC#P,B9#P8(P3642\4A[7/,XRC-Q#8UXQP__47[8*<NQTD&:LMP-N4A=IC/T
MN&CF2D]P'<@T#CP-_# >Q,&.']Y1E?A'C$3\KB>ZXB/;F;+K:OE1?UNE^&8&
MW0,6 K$.PR2/\L#+,Q;*. N8"&(.K"0!&9#(G5)\IX7 T;.>4AQX*E2^E"X/
M)=90*.Z*()*N'T=22BY8Z*6/GB:#+$ONG,_D'LJ .^!;W['#K\P.\S!)<^6E
MP <15-G+8B7CW MC[66>4GJG$]]U=MCIQ('PHU!RW_58@(GNN7:%"D,WT2SD
M410%0>(1.V3!CAW>397X&[@3[M B'HRGO*C:NL&ZUDN0KP8%E"K;J$$ )6]/
MJ_*LXN.M@FCG'/DZ@H!QD<LLS[(X"%B4QCS4@=*I8%S)#$3"3B^^VX+@=:L7
M?SHZ/XQ.L<U#)%GB>HD2+F.:NUFLM>N',><!R\-,18^>^@,OB';^D0?A+_[G
MY,[=VIVOFEKR)81[G\5!Q'-?9W'$PB!A3,9""HWM5@(??@LS>4.[X+.N2L7K
MX4X2? ])\+F3!'\M3AGH_9*'G@N[E[@L]V*7BS!S<^VQ4"=:Y:&'/(WJEW>R
MX&X:!C^BK_SDTN+/NYS!;[^T;POA>X.=O,O._+)<LFNOZ_T7P+<JS-_98W=(
M"G=Q"N$%6K%,NJ'(,Y=Y,G.%EW&7(<H#DY[T)8*T *V$\9WSS'W- WGW.-W=
M#'/LI-A.BCT(*18JIF26)Y'6,4O\7"11XHF092QD3/G)+KQTUZ58%UY"U*X@
M9=KUA(Y=%@>!R[V NYD4:9(QG8(Y25(L3+^'2W$GQ:XV0G\B<)@^5-L2%M5&
MZ+9F3\J:P$]_)GBXXF,#,>-[P(^LG<:BUI)<NXT+6./Y3/]B5]7KW[\!LVBI
MUO^.8Q3U8!O,PO;^'E8=59]I5U2:?W!Y#K/ZF8\N^*)^]-/2Y/M+N;9"7[H,
M>?[MEH%V#5BQ10C\V6!LXF4X>'[_!NT,*Y19_W,-W,)'3T\([:G\OY_XPY]K
M[OP0TT2@400)H\EN.-^;T?JN1M][4"#\)]A8_BHXMDI/RVIF^H\5MX_Y(P3N
M?-1T/=.?M)P3'&Z-H,!\(O5@&1K;8@./%M@S!Y:,&BI1.U)XHS-J,&,=?L$K
MU4,77NHY#N.;C;3ML887XB1HQDV?H!IH#<;_WSF'.58X*W3 K,"B?B_(Q2T8
MBX@;#%,E+O4#XRDN3F40Y3H-0S>5H><RF8*^RF3H@@F2A!ECOJ_4[?$4[Q(\
M[78\Q:*NYUHM'5NB[*;C+AXR/"K4BXHP$@TZ_7A<-J3?1TJTE]%IV&$E[K 2
M=UB).ZS$'5;B#AIOAY6X(X@=5N*]S[HXGAIP;&I6J[< )?XS=3A?0L#W)XIB
M].NOFP[0ZW[9VI"HV!^0:?!\7L%"&0A^,BCKS6;EPXB=G,O@Z.VKT;MS-8)[
M_??/_[IX-_ZM>'\R^@#C]-Z]?0=FY%_!T>^OSE=C)T>?W_GO?_^[. K>P//_
M_G#T_-?BW=L_1L=O7PV/GF-,YL _>O[.>__[T3) H!^P,%*><D6:^2[C6KBI
MB*0K/!F%0222*)"/GK+L?L5-[F%8Y X$]W>\\SOSSB\,0N]XYS_!._NX>$)P
M3TK7SU5@P57S)':95HD/O%-Y0IN8W(YWWKN\YA\1%N\M_::5RS&.<::-JNUB
MLQHGYT7E?.0CTYBOO(XNOJO[V=7]?$UQ&>5QJ@*N61S[S -5-8G3G/O2]V.1
M<B%N86IL#E)5%?9(QM#@KXNUGG7[&*&PMNCO2/[UP<1(V5:2>CM)>K4D[8,(
MRB@7PM?:Y3Q#T*Q(8R50Z.99)GDFDS#)PT=/?7\O37=U0-_/UMC5A.YDPSV1
M#3E/I0JB. !CBDF5\TRE8%)Y210&\%=V"U-J)QO^0=G065E1KO+(YZG+=29<
MEG#/%;GON6F>!#J,O# ( \SNW8N^1Q.+!R\;=M&*KP0Q_OK-G0Q5/!B/VKS&
MWKS$@K^NG1!\6TG0&-G[QL:F+Y^#A?T;&-A_HWV]<\C=0%0LP2XRK1F/5>XR
MQ6/XRY>NB(/4S?-8^%[H<8;!C(#=O2J0>R@H?MB Q0_ 0;]0F]YQT/O%03ME
M._3BS!<A<ZEI'),AJ-U^(MT@RV&3XXCGN7KTU ^_!W3Y@^>@N[#%]PY;7*V4
M[_Q2.[_4U_1+R2C.LUPP3ZF,:1:*(/!2Z7&1:JE *_V.,8L7_YT7L\7!I)Y5
M<_RP/L9"IY,AG^P\5E\L1/NH*G["%%;;N0'+/)>E*G6S)(O<#!L=QCI7(D:$
MRW0OVWFL=M&,G=3828U5J9$*%NO,2V/F>\P369KEJ61^(M),:C\)OV,T8R<U
MOJG4Z$POEO XB#+I,I8HET7*<T%9B%T_]1*MLB!)A??H*?/VLATN\ATUOG[$
M.,=K6W1K2GD)XL#1Q#.62_"G(WC++A#R7=UX7VA\!#? N/I>\F7G^_NJ JA?
M"J+R0 ;2\UP9Q\QEF0C=-.&YZPL5L\CW/9G$",P?1M\C">O!>_]V\9.'RWB_
M4'__>O&3'7?]9[EKI]Z#"!9Y& @W"YA$O)< N&NH709$P907I#&/'CV-LQUO
M_5K*_2TP!LV\GOZ?J'Y:0=I"X!@B^*L!N[)'V]%FJ.3F+H'S))NU^J-RIIW4
ML;T7G&^,&O6"5Q.@L+KAIG<%&.KX=<-D7@3OWQYX[\__'AV-_UH<?7Y5O#M_
M$1TC,NGXCR$\X^((F  P&7\-&.KD/3":5^.CMV^"]\\/PJ/?_R@.3SY$[W__
M8_QN_ +&N^^_&[\)#L__S@]Q'!>G"<@(S2,,O6(+Z8RE;B:5=&.=1-C^$&/Q
M1N  \0*S1OU<IY$4J<AB+PU8F$69%$&B)<MRYD5,\54HJ2,]<_XLZ]J!-7=H
MT==/R!;@I,N1I^([1-Q;3-;-@'E7K^#RBF>1%XC43U08ABQ)@RP.O5AE(3 $
MJ?!Z1+@"9BKG(PQ$"E[#R9G LH]PV:>P[.3Z<PSN56D@W"Y60YE@= F#Y=;
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M->W'TB@ORNJ#HW%+.4UF?:0TAK% YT8[ O-,..9(H?1)FY5FXZ/X<"3$K0>
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M@ ZVO!VF@]>@X)/ '@H<B?/XU;-G3TSP>3ROY4C#V?O(:U2NQ8@KW,+FJ<0
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M0"D-Y'.3Z YM-:!=0.!.4=9#CE[/9W6A6B_%<GK-4G@?0[PFW^;P]: +\$[
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MV!+ARQYS;?EP/3\[0ZG4KB+LW;I)T&/[)/L,25HYU^J<7<D"OI%J;? LP$G
M(]-RLGZR96-K/-M_Y9[TZ0AX(IE/,-Z9"4IVRD8["Z-DM 2$-(!!)@K1T=#0
M:SZM389JI?.*RAT7I#+\NU1G>&) IYT.28VO.LMAO(##:?/86]9LN%C'FMMA
M=%FVM!&CXK_SH@TV-^3;&4D/5HZU13@HSUL3O)=13=L41FG#?U=$@RRKBE2?
M9?5H63@48P'<!&FF)V[,:2\EL(=ZG8ELJGUKAK(Z!DH")!JWA6'V% >=P6+L
M^$_+F;FM5)MBAF.N>S(+JQEF%#OOQ>J718,=R";1@%8VU5G,+@II,:A18]6C
MW&V23:QIW<@,U'AY#^5]??XU GBA=9YLLLY!VQJI"_2ZC."5)"[:7 5:T!>C
MPOFSH,11Y#5-*1-]],3LI&MGT<Z/SI*-T2DC\0IB+TU(E])<HI5<@->PY,:;
M@(,U?!?CRDW<#Z=J<B36PLO>4@BO6O;S$%A,NQE=BD1[XE<3NBR,).[/&AM:
M?;*M,C=5?4 /Z(%:NXC,MD7/X[2:HF1>$VPP1F@/:+$'O9_7AIPL9ZFM?AV8
M%+49E6?:1+6WNI</0<!J!ES'&B.VEAUCJV1=E&T"^E+!Y<1L;Y-BX8J%VTNX
M('-IX&"[(WP(E=:#I5KBX[HQ;7RR':69;I=,M#PO2B9N4OW.1J4PKJ*5="_*
M%^G/%H;<GZS;**"]+!:;ZM!L;YOH43]@_VLCASL8U4X.DW9G-8D590X9VI+/
M#BX9:9?7P$],GXNR-HTG.OXW,6DZGPH$7D ,0L]#I]IH-ERT#'VO1<&PD P(
MAT!:@ )M9V)<ISC&1I2[8 6UAC+MYCH3-H=H4F*NX.2,+D+]R031/Q+S7=')
M3.P$*=,H97 O+0;E\)FC05I/T0 :E@(VX".6>S>'O(=+VZ^ZZU:WG<'RHC7Y
MZ+W%[2_ABOK<6 JC^70.VE:U %J&Y2UK^.WQZS]?/&E.$^4,HN/!B,%&[6K'
M$]AE1I[\YPMRLQ;*;;L>D A$N(EE-KQV+Y]8-SF()'=9)G4U"J9B?$G+PX6T
M[N?F\4W5U>RB84.^:*]=6XEI7<*ZU879+UB!*:P*G&98#'A:(WJK^01]9[0D
M#[UD^OCH_8O]/Y_;8HC'1)2F"KXI:O:]8." S*L*1+X%,] !:[,</3&6%LRS
M+.K2>H0/>G[<[97M8"*9O;*-,U94^5YZ+=H9%F;RUQ?[SXZ/FBNZLC<[@5UP
M\5M7&Y'?R#+P,Y-P;(JZ4=Q>  4TD8FF'K 77<',&TR4)1\":9U$.288S7NH
M1VD4=$?6,G?=Q*1W6_U]MAJS9 M*S':"/=\8&Y@)B\FS8YOMCN@EJ"Q1$&[4
M\T-0VO=2!?D0-A>4KDGK/I'#$HV8QR<OL<;3'/:VI,BZHXAPC*=A!\1XJ[RX
M<)<7M\N+V^7%/:QI/MR\N"ZJ*4E![$<YUZ2,T!.=%P9VOC&JR$8'*V!:Z28*
MH]'!(G"64[#CIG,3?ZAMMYT5]Z S1(">BCS)HN(DXTB!:7K0+5^/ 4Y27T8%
MBKS^M4W<&RZN%F3K$20Z,=B>*YN*)4Y.]@]:K9:W_HXV<#XU);5K*[#NWFS4
MKB5=RW2'6)W-Q; T]KS0H+7U0(V6@CHFIV18<;E !1TS-YP9_\0GVK:@Q$6>
M<4&!^.-)!_01)$L((PUD4 ,4! 8<[AM8RRLZQ89MGEW0")N9&L\A+LA.%_Q.
M:G^?\+OE!]6-TE &QBYHZ["L+^VBP)0ZLB)'HVVY=6@W[+9QEQKZQ:Y)\JVM
M!IC\U-^,:"6'53E!9UAYX>!DL()TTH8,.V)'RA]RDB#C8F8:[SI'S_?IJ<TK
M0%)UX&? @HL:)0@ZFO$6Q+DQT8*A'JFE9BNL89%X\WE9P-CP$?L37<,G:#,_
M1Y_)2Q,WJ)W]YMG/VF?C .FBUP:KA="!$<^U QKN7=T86%AUBSE*JBOM;/RO
M,)^MAWHV5!7L&#7\P*E2RJPD*[')2P*&GL\K"US7Y"'9M;"(O*7QU5H0KH<;
M \7\!W(,-[7$7>7HYI3CWH(1 S5!=)-PUH7P@(X1OF(-Q;B7%-2ZTLKY#)8>
M,X;LNQNGJ&VC:ZHQC=+0;$AM*NBZ4F)+(8.V^ "(9U*.,0.RJ92'.[HD ?NJ
ME=P[$OQCRJXP+7OG4S>'0SAK"_ &2XMA(TN#I:)E"M:5"SZRL,U+N'!-,C!A
MPQ'%4B+X5=ES_72YWFK@AL&#1JM^RQ:X\^$2;A/H,;JPS?, 4\6$:[OF9* R
MZHGMI]1+B+3%__W2:*HLF2(^L?'GX=W+R:9M6+E/QU>B#_5AUUI_<0MOH+!:
MWHO;8GF*^'1#;J$'_I5DWE[0CS7WXA8$+4"I3W;\9=7KE6XFTNN7CLT$.TR9
M607[T$)G#HM1&T2< &T9@-:+94C9+N?3Y*1BQ&Q;=[AF-K2F*^M98515VX.U
MO*3=444T@;"_/M>*C*_@^2R]>-!,$'V#\[&+$VG!:$W?=CJ5IHJAFV+O0/9P
M"Y8FV(\E3!N1V,UL$T9?@2<9%EB5)/:(JG&!X3'X33\6;/J%V:=2ZE178Z'5
MAK!Q69WQB?UET)@T-A#=/PU;0.<)W\UPRCZ8I8'O[=XV6'I/PX5;Q &#J6'@
M,) E/F2>1&&IIK2[E0(&'K"C31,ON"@[H <"QN[2R/BF-/=]#!>_!VJ4G$[X
MX?'?^T<G!__9V23?&JH)XP<HM?%03H<F"=_EIDYK/'=!F2\I@V[6Y"=OU.?-
M9:[)B,3S,ZEGQ;0%'UG1ZFV0?^*V^:R8_6[D!^]!A(A%I]9;&6<:]P(;-C H
MAM4?DCJ'33%-D<7QWR^ >'[?$<^W)IZO00N-&XP2E;B"#4:!U*9'H_SBGRBP
MU":+KQ*)24W!3(9A:3K/-U+PQ1R$EH9'OYDTJ494AV?31E%/JO!R0A"<V#(<
M("3698=L9UJ_PKA&,UO_])CC5/#P8*&)(=9"%=SX,D] ZU7<%DRU'0V:=+T_
M9VKO"2WF_O-W1\#Z3E[L:/=;TZZIJ=G";C ;&<F0> IE-M:ZE]%LDLY+$'K2
M*'A@ZBO'#QI5 E4$1/P?=.3];STNIZ"!%MS9W[/[?'!O=SEE:7 ?MOF:K,*P
MB>5R?RR7->ZGVC "\M/WX:LV<9*'JP%B/;2PS6G0?.@!A_6M!U*W5RT>HX,7
M$U32;9AAOIP&K',X97B2+ !>B^TU7\ON']B;386#I,;$9/'PZH-Q]-F'X7ZO
M6[H(68J5@(,5>V 5=*T4^%4#1JXG\$@J!@/)9<X\];74DS-,BK35-'I"J!(;
MO#=HVTA<.8L,-]4SDSIG['$BHL;\,1B9O-]JJ\T.-J4,X[8*W]R)Q>;;[!Q.
MQ2A-VY-F!P=.K35UHW)\X$=++:@>+ D;#P!!1RT9)V93+NE4T._F95J78@8D
MKKH>Z1:]JN=CK.=2TBKWBC:+&95-V2(W3/0<8VT@N4]L?>>ZHZQGR*[TMFD<
M9(6NW!I[N&]UE+6F5^.A6^UQ0\@B]"3'/&GC6E#Q+ATO*FHU/+!UIC93H")P
M[/Y:V;STQJ%'%0T$'$$/7[6_EPM\NMK+9LR&T#>,?%NAJM4 VZY/!^[Q8*DH
MAJ0T/776597WDN7-D)8Z_Q BY<8M65J+5<?RQD(N6[/8YYW4'PBQ,Q$]!HN@
M2H-]2?QN9>:]).NZRX]N5\*RT$%CL-<;F1*U*^A>->;G^"/QT;I?F%@OP6L:
MVMXS<8_MWG1;3&EX/J&B-^GZ#2]L8_YG0V)?.-><%R,D"EAMW/F%I<AI592F
M(-".W=0W(DRXY=#6U]Z'Y+0)VHTX,<V'P%898TX[MO\K)-HB,\I7@&V?[3G/
M-I&2G;%U=M@1UK@;C74 K!K=8P:[U.3,+^6LZS-N"Q3[4):]:FRR3&PS,D2\
M0"<DA@W6L2R;FMSFDNU F&8C;=>IZS-UR\2?_I^H?GJZ];:[UG7NIBWX7I!8
MK!LY^@RT\>>NGSDO8>4P3_\!"D$OP8D_G[=X! 8G%@SN:F9B6R8:BKT ,&R&
MW*4P&+=E!63]L:BH5F'_U6OW6?FW&SSIC"@+.:L,/1O9\'8^Q!XKSX9 Q Z<
M#T1EP;J^%8T9,Y$;#PZ^OMD*HV$U)0F&S-LRI?Z(BDENRNT&-!0%\H!7E#EK
M:XZF=D_W,"J[Z%Z]JJ:^F1#L\^N9Z?P&1^@ #AT?V"(L$,BXJWI*OO,:8]?$
M.97QH5,EL9FE)2H:GL'5)\@N/>UU&N7 OVW]JCG%V/;#5*Q4B"LR #96U@:T
M85B6(QM^PP '?3C4"/P/E.A.1YSJ$F$<^+8#C"^/J3$KL-P10JX,8:@8!;!*
MY!A6E#B8!9 >V^"[>9#%[VTDX]KU0ML"9V!HV]G*+BWXDK1@MDL+WJ4%[]*"
M']8T;]EJ_3[J$,\:[(]! ^Y0-U%S4ZK<%-TW5C&7-D+:P0&"<-/4N0SD3&,J
M(GR6I)-Q-@==8D2M>TFY;X3;B[IN()0Z9;=G>PU66HH8/1@!1R862:]!)Z"1
M6SNZ&U\#58AFN T'<(EY"G1WA]*GJW%!KIFZ;;=IHO)GF$ [L0:S(O4==9Q]
M"1I[;9('X(78MXW&3NMAX37J63&;FYK9F4;? #HBJ<THJ3Q#M&ZF):S0HJVN
M+M&&T1:I:P(Z&_J;;;1]8MORT1,P0:*86<=",6G,,$)D_&@04VSW"C"I=#<J
M?%!/J^-M*_:F0A<5NGFU]*Q^YEKGN6J4"--CW4+N48]V>M# =!ZBOL"F@42C
M$E%=;J<186REKQ!M483:+NZ@WI"G!_-&.EL;7H%JI0*2>K":/AK(=9>6B$ O
MKO'@V&,)1#8J%[K)["+"7LJ\)&>Y-"X=*D>K6M?3BHW=.,H&CNW780P"LI=+
MW()ZUOJ[)%$-:<:K#I99-^1.Z30, ]3OYD#C4:GFG5.3 !&,\Y)8$'K.#$]H
M8XA+-EYC#U!F*&$C4H\6 [\$C(>&:-)O*$W/^MQ,:A&=Q=XI)W-\+N!8-L$%
M.I3HJ88)/ESJ>JNMVZ5J7>J&>;:X4'IR1G&QIO572S'8-[VCPDN[;UNR7-\Z
M1.DJ+?Y2/WEIB-7*P$_JAC-=[M?MH8]AI8AQS?4=Y<;/I#_^_^Q]^9/;QK7N
MOX)RG%M2%8:>X>S63:K&LI7H)K;\)"6N]WZY!1)-$A8(,%AFQ/SU[VR] 2!G
MD2;B4/WJW5@S0P*]G#Y]EN]\I\P)<P]*M-4(+R)@&QP=G )RM\Q]8;U77U2,
MM!EIMW2U7!?2-APY)=VF/=$%MOI!OPY\S6M8-^;FP=!2K;,A#UEMSJG0AP4_
M-Q@8C:.YPN5;+;!P']FMD8RDTPY'=^J 2T=R)=V_8%Q/H,Z([]-4'E@<$WMB
M)36KIKD37,=X.382QD=.[$TG7)K:(955V@/7S7)8?;RONC$@(V046Y9VIFM4
M:4L$I1$K!@'&=+?9G'\G?C%?;CIP87E-RB'-*7/MA.Y\"?3[[% (@P\9)JW@
M$VX'#+4AKF5%TX]YZ(CDS!^UCE :)CT]:'-RDEHGJ#"SJJ@=+3V@'U;5Z!V=
M+^0;?Y^O7K\[L8;);&@-W&4O>RBWN]/5EG%53BY#4C<Y9\&%A^B9)F7$[K;<
M.NGQ6@\C92ZH/&I%[UJ7-:HYA<:%& ;21%JL@?ZAQ&P**KY-3:)4495Y+KV)
M= A+GS4*>W+:R97\H?>P#C3?1>&FA,0F"3>^T!Q9NIGU$>SAM.UM,6M%[8 T
M$AVDRH"8]052?L+:HF[7L!1'YZ+\,)B*KR_X\YKN,'(K]MNHQ=0XBZ^A,N@V
MB+UO[UMJ/!MOD3;P1).UV(=2.JIO.[FU.!&8S3&_)KMK8"4:M89/HCO=]:<X
M2682P=HO),EU!%F3E$L[Z>@'S>RK>Q^::XE<-\<&,W!VA\,Q-VZ!I7^$!R%E
M4D& -:D!-08T7;8I,BS/&)IMGJ.87L)A[Z:@_0#9*+?WG98+@F;H^T9:!+.(
M4[4-9R$B49E#*8JCO:RD$ZO:5R$=2=<72(^0R65N?68YV_!,O/WIGS]=_9T7
M^GF'IMA3/1W;,D?21>*RPX !2QMZ61_Z:MQ"^@6<XECAC/6%U>D=$><H(?EB
M66#*(2?4A'M9]H\DAPW@62"BHL0;S@4K)D0E>D 7-:-G.%EWB,V:!?8F)7*5
MO<2]6)TY)#*W^0,>$Y=KD7,[7D+&>97E<92VF]WM&"$P^"4-<TE%Q9%?C^U-
M,W95!K0IQHQ625N3.^EJX$'1JIT &77$M+<KLYU*#9S1,&SSF"Z#K)6T\RF=
MX38U#1+> &;^M:U*'F2\=5MJ6@[ZP<L)P=%L*= 5Q1&<JOR=R>,T 4*ZPM)6
MA'S)+\RU4ADGF_]$Q'&U8S;!-A_D\B@Y0)H/@(\.H?\^R@G"J-V&_9BBH#28
M._Q7FTT_8(1/<S# =?;&RI9AT]2TM"!^A:?SQ!QS" MC$R_-D(^UK0D:2!5F
M5<MUK\P<VGE$:E/A0YYC=RNXSZ'=#U(X%**>,=7:IZZ[=17=7:U9=#:O.KY=
M:TM&)IOJ.<-'V#O^L%5(D#AGX=2-;N /S]1H/HK-*8-GXI:Z=BN"HR7W#9]:
M:BQ;0I/O"RDAL)Z;>*R :69MOK\*MW.+4RN 7WX\4 76LQ5S)UMA[M+-UN>4
MU5XKA<&&%]^6))LXKFDFHK%J''WA?AELJG'=(K_^@!M$V*]KQ5Q+U2[1Y0IV
MMM3)" D &^"7DSQY9DXM)4@:FQ81T*5)[PQE27H-A0< D11^( 0R6YK:EIYZ
M%T+G(MMG?^@U4?PRXIE6B0^UB(C&G=T6%=H0FXJ>T:V&:PW[60_$]ZP.Y, \
M*)%*0FH=;GAT'Y[;Q%('30.6WVHHK^!>)28<G($\*8Q!N>(A&0KNC<4P:.HS
M4+4KRJF1UA';)+,]%$ V?G423Z9^%A^-5>W#&/0HS2J'H56/45>$2A,_*8JJ
M.0*D/B9HF9H,:"*=_<RA-:UJY%(@9=L00P^CC)TH,44>K@F<2!^&V3<E"%UT
MG96Y3BV2.("&QE;S&#5,LQI70YO&IFB+&A?RYS'9N5R6%(.A6XV7B3^B[R/1
M2& ,$,NNM[I.SLC-^J*E0DC>.=ZCL"T%"^82C/XRY3M,)R;[M[T5K%ASW*+=
MBK3T4D9N!LJ+0KZJH3R8H*\QRUOV4,39'+KQ]UE+D+LMB7HK@VC2@#4L$76^
MFZ:T@B3@VGF?Y6"<4Y7SVC)33M8>J-B6U&S'U;TJR]3RIEP)<7YE"@317F<\
M();@4##@+SI-\JQ=I52B<05.2QX=G<72F%/I]N;H*X\/7V 1E_D6//>E7&8@
M]P;B^]X8DC]C$"\CFF1=@BZV80\7.J(7'+V(WN-ZFE=D1AF1.<2>DQXL+)2N
M8>5?,79XHFP3'RD\,Y[^C9J0CXSPRIN;T2Q-1G!G,FNKZ?=^HTB\*S7CU@<F
MFY26TW9IZ5L#2.\A(+W3 -(+(+T TMNO:>XC=R=?\0RK=R_D.=@[=!M+FJ]C
MAGKU\7(#PGBN\&NVS9;<IZ^7Y+MQ+K%3$:!SQL_T9?D<;S2V[+@%&)(2<;T*
MV=/=*#;;U/IB-7<B7GQJF8P4#A+_XS:+D\X-&Z[<O0\M&+RE5 @)$LK2&IE2
M780!UL0FAQ$ =!,7G*Y'6TMV]V]J'?UHT1'L:+UGHC/XU-^IC99NMO=2F)C>
MJAI>"79_K'<.PY62AS)^GG9N-'\3#KD5A(-&,9BQ(C410F J"HF [9,3C:JA
M&&MN5'Y]>[P^F#5;S)JS8-8$LR:8-?LUS0>:-1>[<-_=MW+STRZK!QD&.U'A
M>BM!F[E[=2W^8U_ &*['Z D&:Z2-T)'#.DX@+2_=_NW1Z-2E.YPF]4("QQZW
M 5<NDYJJ%0Q2NO*]*73<Y]AY#9(-9()>KS*PA5;2R3693BLF@Y1^WQ++K56!
MQ>3820E#EBAXL#[?CD]/1A>:A7(4O5,J^@7;SEWJ% [&D+ '(_99+*B?*$5W
M7ID:;0IP2=P%\\\V#Y<A?<B2#OEFL^7)G\RWMA3]C<&S/OT*\HW\PIB*_9ES
ML#]1PIG#EOH0D!".#X\NG_X2;-QPY@=]1DF3LH7'HZ^!Y12K!G. :!.#*5D_
MOVT)Q-*659"C[WTB5[/F>VQ6IQ5S12.AWTRHYN> B'Y6M?I>_^.%8Y[C]U^X
M2AYGG1+*=?U]5M#LZ+UBREY>CD[/+LB:;2KXOU2/1RS=$5NZWS5I_X\G%Z/S
MR^/-?]_ZY:U_O!Q=GI\]\+N'HZ-M?SP=;_WSEC_NW8A/3TZ>W(@O[OC=[TB:
M6:+AG."Q_-,WQ]_<4^ET#U:')XZ/\XL57H'%G,_N$9PW_0L^NT=\VO68S6@N
MS6CTYU%#CE<?S?=%7>"O[C]@<=0_9<BNFK:*]*)CJIW?1Q_[:OR.L]I^"QFE
MVUU@N]U: 18E^[Z?YZ-?0(B&=V30>G[L+=FIL6@1N%42PE&[;2U?2^OB[X@9
MZ=F/BG]\3C^2P7<-3HIG\(4C$H[(UW1$?C4F?_3 T_($S),O*1#BZ5", %PL
MBD)$>IN>FK2@%/RG5>6C+6#0HSNL1_?LV 0+8T]/1E!U84/#(=RG/0N'\#^Y
MH;=X#P\Q//XPG2HUFWW6(_H9X#&/FTT6&'Q4)WDW9=Z),#_^DM[O!.V6C'[;
M53>?=]5(J#YEV5@J.3NP0\MV')^<G#"BX$DLX.X)WO#BW>6R>PQ]%W1&T!F/
MO6PG\?'E1= 906=\MF'MUNY\0;6PXR?_V>7IR?-=69W=$YS=/-;F_>//[9W=
M9:\VC''W1'L\#I*]<77^^.B^_XS^W]?E^[^EUMYKW?Q]V/O_7,>WO\#[='PO
MX_.CR\]ODSYLT7;U%'_"_?0(QS,(^'WV[N@(O*[#(.%!PO=5PI\=Q6?G1Y_5
M" O"'81[-_;NV=%ID.POZ%Y\C:G%7\KB@.H^*]_/B(BL@1GU,.U(3828J9\_
MF6W*1(90PMU\D8O+TR\=']_U(Q]B94]7P"_B\?$CN")!P(. [\;>@2=R%C1X
M$/"]%?!Q4-]?W"7Y&C,>?\^FR.L2XR(*V[TF/M:LBB$5\JEG^SP^/7J$VVN_
M0@XAF/9T)?PD'A\^ F@U"'@0\-W8N_%Q?'QT%"0\2/B^2OA_S9L72&$;9/S>
M,A[2(Y_'%WF/?)3;'8[=J**0/\K;CN'O:=DB;5\HL_BD*H$[K^N.ZM#3P_CT
M_/A+!W(^YQ+OGNSN9I SZ*6@EW97+XTOXO%X'/12T$M!+P6]M#OK.A['QZ>/
M$%4)>FG7]5)("M]E[\X?H8!F[Y/"WQ&3_9_WJ?T9AT?>M"8;BSU702UEURKE
M-J?4T<3/X,XKI:0%<TM]R+F!G&F<.E78A'CELMWHQ\<6=LI-AW/.$D<SI;B?
MVHW*L:\=#,(THZ$/\F-@]JIN2MT:FQ/)W+!NCI]<)>LE-Z#^35$3XWF!?9KU
MY&X6JL!Q-A4L%_9WA4$N,VP^,B^Q87*)?4RJ:QA3K?N3^'-?)553J J>_QY[
MKR]A#ZD#2KN"Q8)_XC3T"N@N[?@4/4T<]*;5C)(\+Z<:K2M=^#+L03?)I0^V
M;3OHK0^U>2[:63)MN,$N+5B[6N7K"#M/9[IC-FPN+).JJ+>?69Z4UQT;4<.P
M*[USM!RZ ;C[.KU$G<[RN!=*MX:NX:A3!WEL<YU4F30YE#[@3;:DB<UXK5:T
MAH1?UAO(VTMR2:/4_;5E)VE_J7<]?F:"?6A,HQYIQR[OH)XU9I_,U&B%]%:K
MCRO3=WR"TO*O-JOXQUF;SS*02'S-2E74<(:Z']L]&45_@67CB;78I!S;;:.$
MXVQA<10QQ^,+W47TI #WU5FPW]MT3A^BYM)V,#1A>$UMVQ)M:=CWY#O?:+ZL
M=WV^K/UI,>61@DF+;U2>*@7-5( TP$F=91]! %85".OF@^XH$M/S?EAY\9FH
M2)3D]%)=0%8MHU4+PHI]1\DZE5;7S:*$W_BZSQ[A>I%)SS 0UTF"VA0L7>Q,
M)2VX4[6D-\+_B33SQZ5SU)9!P@.+LHG@3]2[1EIHE2TWSUK#R=K'GJ1#@I$*
MTW=*3;!(OU&/"FX:%JFA3DF@^F$U675L^X;;9>SH$N4,E@IF%*5P9<)W$_-V
MU&CZ7I==W6 D6&'!'FJD7SL6@9X':-B<MA+E@<;-6C@O;[ !^P)VB(8E@VD6
M6>V-A\<!=U'#?P/!5-3"+"U)>. (9=B^3+=P QM5]\S%UYM>]"OI10^G!P:4
MP=)A9_NV\H>]Q^I64Q2\'4J3[8_"9<.03-1NL13)LES@MV@GUG.LX#)L$:S%
MFMHX+Y>JHN9UVMX816^[[[KE&/NM_YSS#[;: P_VX'&V(Y^L!R<LQ[AWO,!2
MP>/E]$=4MY\MN1&\Y<)?#"S9':X'M@_Q_L*KJ+.;^WQ43;E?Y\S"?TVYWSLI
M]WO%Y7YOA\O]]N=<O\+FD-@V?=K6M7@+*"";2B/C:)73(:@5>Q'.5[F5M_3Q
MQ@>\'%IL%$'SQ]>Z'^9/<-F!JS>2_MW[*X0&X/VR!_!^0W[YGE\D=P6X:Z.^
M%GO;\V=UX$#[O;$-<6R/<-@H [9\+8L"%"\^T]C^=PLYX!_EPMOHJH(AE%U+
MM]C0'OX!DC(^#^WA0WOXT!Y^OZ;YL/;P3^!BP_!.COH?+ZC\KK=<JE:Z6SP:
MZ7"SB;&?3!<9?(8CU;-;0_CX.+P'V2V@('BB;TOU,:O)UN]&3QLO&B]^P?!M
MIJ.^G'^@^P.?F!5@,Q>P@IN3'=D,OK+>WXC3?0P:<493#D/>PY']--]UP(+"
M7WT[/AT=ZB[SC@5E8DQ95:/I!#9,T<3RXW4&IH?.2%1J#J+%,P8G=-G6TQPG
M>IW4&"F8Y$F*N9PI!O_AF15ZJC:]\\//[SI6\)66&S< 1O$GQS:[?:4Y%B7+
M[>8(\K4>>3]^YBXQ+5YBTS1ZQ7J+F-4=RQ,_M2I1PV6$G7[\14_2W]MKS'\L
MP80L0*!YG>,(3,+%'5=[;P^G$W.GL"M[]74[!55F8B5IU<X]9;>JRGF5+&O9
M40SCWQ)6H8=.?B=QQ5A1T2XGBF2KRNH/_" ORS6*WL$!?MVH)1_9HZL1_^,M
M?#YZ!<Y#67&TU_?-20#XD75=3C.*6Y#W(@$A<,\_1D5"\QP<M-7->QSJ>5G6
M=&C_0@GJ=V7.B12='?A+5<+V_TRSC)[1N2I;&$(*]Y7Z.%6K!M.6TCZT?G[;
M.HGS)48*9UW\3Q#")6F;4A\@!G#0;P321+NTJM7W^A\]H(][&'%E=!?LK* 5
MH/>*=W-Y.3H_&I.#(X4P,IX[=' _N1A=G#VTZ?PMO>$O3R\?JYO]0[^[=R,^
M'9\_M1$?W_6[3Z E[V7HT7QGN-A[,F-_9C/V)S\;>P>(I%: 1<GAD,_ST2\@
M1#N$X-NIL>QP&]^G=M0>V ,]')%P1+Z6(_*K,?FC!YZ6)V">A-;GGXTA;GP8
M.O@&/1J.S3V/3; P]O1D!%47-C0<PGW:LW (_Y,;&GBK/D_23R=_N#H1A#;=
M9?*JP+6PCRW C^.+Q^"G#"W  X%+T!E[JC-.XY.3+]YV(.B,IZLS@EJX&V_*
MSIU\[.PYO@SMU9_8P9X&UJ2["/?Q89#LT$;GB]! S GHN:K*6=:$ECF?<H;/
MSD-[WM!H81]%^R@^/!D'X0["O8?"?78>^IP%\=Y;\7YV=AH4]Q=T+;[&[*+O
M6G YU^.Z%GL>'C@Z"N&!.Y[A$/-Z*D(]/@E"_02%.KS_/__^_6>))[8&-5\C
M,R\14FLR8N52$:_*?+TD%HMD3C1C\%'\4UD91M55E:DFJ=9,63"%+V<ITEDC
MYSA^I%ED57J M 1KI^H?F01NB&;\1D6+Y!K>JH>437N4\994,OLW,P8P-UE9
M(&4QOLD\BRGOD?F@;A)FO%#3LBB1LW*B"C7+F,B#WJERPQ9>%C!=0KPS@0R^
M=HG$" F7XM==PF9W!'WF@[Q$=:JJY6;&-N;:USS12^2^7&&1/BS:E/DT#;^A
MH>6_SD $%F6.Y#E3XGXG<F5\+CQX#N^WDTL&N:>G"$1#SM/>D'&S.IS4#EV<
M1Q#ODNFZX6Q9-:(P(/X)G^:$F'CA=9,U,4,LLX_TA>LR;Y?*(W5'@!Q.2R4P
M[Q5L:9GN+R'(D/4>W21U5.".HC3?G2D:U]/]U=&E*Q"=[:VJI)@SG1-)0*+9
M0YC?QK =)AYON<AM'>7(5T*TSIJ]9AU-V@KV0:6=5Y'4Z5F(,F':IAN'4P>>
M66>-D$39S@E*DXG W_4 886$. 4)<T ^7X/$@3;77^TP5",=L+PV0HY;9*.I
M6<EEEL%(/YR5"0HY?QU%V4X6?W_K9(E8%]Y1;J<HICEY&H)F<O>]QAUFTJP[
M/I^X1!0^C;>"66:-I+FG>7]/7)_)W#M[KNAAYX@</M$B,[*5.M9)M7"EX:X+
M1QK3K9$>!/6&+&F>;+AD_,2#T]9@FFAZ]6E;58ITY2W#FRB[95DAXM#GAMI\
MWN%83ZML@BS4D_):[3'MSEN7/NY'Q[ 0>M_]Y-HY'XW/#Q_(M7,^.CM^*)W.
M]C\>CL:/1EUS?/$81#!/<,B7HXNCLZ<VXO$XL.W<<<![Q6\0V'9V+A*V4V/9
MX1+XIW;4 MM.."+AB&Q=R\"V\\@"L6>T(8%M)^C1<&SN?6R"A;&G)R.HNK"A
MX1#NTYZ%0QC8=G9Y1]]N:@ZD.+OSN("WP)7QN6&"3YDKX^CP(KZ\. ]L&7M7
M5!^T1M :CZ8UCB[BD[/CH#6"U@@<.X];=;!S9__997QR?A:J,I[8P9Z&>J.[
M"/=%$.S[U,'N;;G);3XZ@FWKK&X0=YS!W& ("&"=PJ-P8V%:;;HF5'4=$S"W
M2J;- .8:_IIF%<)FZ2=N-=G46:I,#^'8HK]C#?^&?TD75^Z).5/XCSJZ47F.
M_UVIJBZ+0N7RV&>,B\>WUDD.P\4G2&F)]"*NFW+ZX6!"C76Q_R4\G,#7ST?1
MK8M!H'$#O9?VG%$)8KY020I_SLLI%Y[H=2-<\<S4Y= <DFF64^7&@89XT^!'
MT6^Z4 :F-2NKY>;VRK;Z0SJV)G9+?B\S A';3WL@<UQ;?&(]T.N3L/P__/R.
M$/+8C+9B*+J>?Z6RY:2M:L8I&Z"T[6O*,&>$10O6?^,,Y)&FT$#>1L#^16*;
MD>IG_]<?+L9'YR_T]_A=A>W:>X=W;092K\J:JA.^Y\*A:PW5/3J$0R('YN34
M%)SWOI9,P"9O&_5"M.2A^_UO^@K#2RONN(887PRU7>?_753VVIBK@PELQ8>#
M9 :S^C[);Y)U_<UWWN3=I>RMT*<NPY=J9__G_TZ>WJ"C1:5F?_KF#]GL\/+T
M?'8TG5T<)B<7%Y>7)X?GQV>3\662GIY-SX[_]_R;/[\GU'SYW]\E^S_76?15
M3/,EO DK'6FR ^?[:S)Q4L&/I;?6\K'+HXN\^">W#_Q=OWMTR3]9FRKE<J95
MI0YL0>V0'45C_.5O[]\>'%T<<2W@#=8947D2S(\_>H<B-:P^O,JQN&9.Y:NZ
MJBK=/@C'\O!&(B_&Y])"PY+#M'"9R)A8X>5<--)U7"Q ^ &-*O^)=ZNOD][V
MKV'MLXIV$YZ7U+5JV% LX:^5O$E;6;A!JL*:VX9F24W;(Y08?!P:&W J4A2)
M%/]%83;ZZ+L&_L.%P?"6-V"=B9'7*>NBYO!JFM5B_* YE5;)#?WAEQ^OO!4;
M1>_=M2!C3)MP \WEX\B:MA,%9NL\R<$(S57[(0.;CIYZ?'HA_QJ?C6D9^ <\
M<S=H6HI1BH^=J.9&J>WEC+ZX1P^3]%'TX^TRV7F3K9XTEB$50C;6N*SO8O'1
M@H,]*\9C[1NP=MUE$W@4WQX?CLXCT$0Y%87#D[\=7XPN]&]B?"L6 (*9F*]'
M_)U_D!&.,X2W@?"X1O65+BN/Z8]S\$8J*@^?8'5L='8^.OTCCL2WV/51[^TU
MRBKLQ 3%V-CL;U:@L$NMR,';^$\KX[/1Z5VT<2<@ %<(!Y+.3S"0U*YV^R8A
M83CFW;([Y.O'WGZ-HE]S\E!JD/Q?RD9%9\1IL%G=O$)6 %*]CN+!-^DB:OA+
M5J"#J/D6YDG%=:YMM4T OX:BX5M50E-:IQ$7M:?:Z JS-W-'QR?I-6X.++;[
M</A#_Z"V=U$*7G4\5Z:3HC8?AC?1$?][ACH#QB?O=50^3I7_C%7X>5(4=%-;
M:<$H#85"F!\ W\#+Q3.>J#GK%;ZN9\39(:P6^%E4>'ASH!= 2^8< :J-YB&3
M_4":O@3=7L$4P'N'>QW%%TDGHK2LU8&JX?SS(ORZP$TX^FXL821S/>+U-:3F
M!@Z7O)TB,\X0\"3(XWNOE=5P7G=ZBJ\S-!_+-2SP,J%U+<KBX*]E.L<-S=?+
MU0+^P%=WDRUIF>%#R1*.@C$!I S=W.99<:WJ1HA%8)NB:Z1D\?DW.![5PC+3
M(]1UD@O7 CZTF)=D .HGLCBRI8/R53=52_PPL8Q*0EW3<L7<'27>^:A1_'B/
M#JX03<JS#*2[6#_75EBMM.U1[Z_BZ%!3D 77X<K1-C8>+!)MWALR&@<M-F,*
MBR4S46M0]'2V)RK/%/("-'A4K[%2GLE7R@H9<3QV PJ%.50Y5HSX-*VRE2+C
M%3:X@.7HC=MG2IBT6<[2@N,W\37_6_:A9$3#WR=M#3_6<,Z1F2C-0*;@$E];
M/5M6\Z30U#\PJ0QE(9NM<0F&AC4!E8K\1?J4:AHC&.OO+;+D@)$^710@ /,U
MKGE#D5!D_8'#@^%BY$D@\H8R5],VQX.&AG_M6LCU$A;6?((/2@Z222+=J*R
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MVC1SAR[C^Z%,*D(L_9C!))!34J9 H"\]96$PK[F%M^[E=@."<Y"6-T2@^+J
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MN+>HH?AAJ*DF*Z&UK==U0^7&>;L".0=;!\8%]U-9MP@TK4L80)U)(0;(%O%
M4/BSR7C9*4[JDD8Q&X1' Y'H<7TWIH&MMZ\T[KFS"+2FAM\*.2WTH^DOS +=
MM' +Z+M/#(S"(!,L=Y1=,S,H7PFLS9(A@18./J4[5@J[J<]URAQ LXHR#9C\
M* [^6J9S''R^7JX6<$+H8H)O9G !1\LU7%[+1/,4.+#0KOZQN90Y&8_D><=Z
M41/79+3<5V9!R/O1.#"FT*FG"[A'T C BI(&8^2CZ.6 12-Q=J=>V+6KS:VD
M+R/Z"E6-*"87$(O(.5;?WTE['9#ZZJ<D=UR#X0D?GQG>V-T=JK>RQ^,1IP&L
M>MU6I_1O44.EX7QQ?7<Z+B_")N_ 4&_;9#B<TP7=-#ZR'XP4,,$H/#Y0I98Q
M]TAWRS'S"L94V/E=&.KPSA-+25^+/]L8'K&\D6 I/-?&ADF=2PT#IN^IZD$D
MBVQL,I(=4^[%W<I$@F!\"<'(EH:=C,J$S,DF/+@4$KWZ\8K,<]KUA0)W=^'J
M!%T$A;8*4_"A70'F V4)'-)+3*0*11[C=GTZ0[8^.C1J_#L8HJJ#@MF%H0[+
M$?@'6#Y$.UI1';<VUWVQX@N#O.C8\_=B5](0?P0WRJ8[*#5TM$0[1@$WAZ\N
M87\0C5TFXS%E%B1,08QV8:BW6RC3JLW((ZQ;0P@J?@V&28A:E0D=R:4,>[LS
M0[UM;\'S)M"8WD[MH#J;*F'E1-\)Z%\3UR/SK=7-@0VRS$HD8SMH5V'W=V&H
MP[MO;P"\RD%#EZL50Q6D0)DW6K!UJ8(?=46!PR>*:+I@!^S$4&\[Y/#\%J&W
MK>FN '_+*'V*].PV;H5YSGP]8 CJO%C8\)T8ZH9S+9CL;*.U1H2I&2?+YDA:
M2F$C&V@0,'@GAA_V?!>&NO606V^?A(!,M08V,*F8JQ6+#C0!D[VMN62T?H$J
MX6GO\7VSEONVZ\-$M<^P@)2R0)T*#(-[QYJ*Z.@JDEPW+<OACBS+QCW=@IPR
M&!B3%!'/%'DX'!KV#JVZ!%+4*J.%\Z!,FKX%SDMOA7=CH>Z@X(Y>/+\K14PG
M8_T4"&)>]V%"58=RP9:J;"21,]S4O?XCM9]:LX^B[D\V'F?R;$(#U8/<$:
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MTF)Y*<F'K,!C1'5]1LZL:TS8-RIXXX@54M +K3U(H2)=R$)._:#-2_;VPM
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M6]/ 11%OO5B\-A4$I,2+0@E/9LLT=8GPLN*4!']4V1%+3UHVD.-^9:81"%V
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M%1I&X=U_Q[^JAA"_*6-Y@5G*KJ\3$B/8/0$X-<H7I16MDY22F%XUG&?JBS]
MR*(.H0(:;YS9Y)<,%.#/R6@#:Q7S$+IP0<-J+;GJ/E>1H*M6I%YU%?M<TB%
MIT01W=JR3V4;RQ$=J$<LQ:4,\\S7BZJ@36CKX<T>WNA5TBPP)<0FGR#*AZ&Q
M&#&T :\I@I4HY*J_14,9\C9);?ZK16C5VO!XW#(<4AWPO UT6O1($JQ8:LI
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M::$:-^36@F^7>^OA_H-:M/87+YE72D+3=!/K LA.W@79<K+2:1UNRYF?B0V
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M"K4!B^V.;8^"0.["4(<%$G=-(TJ9YMQC<M,]?6++@O:1:,0:IBTS:I+JZU$
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MOCVJ\AI=?'2MV%Z1<$E)I$-MP89OMV/BUQ;#["7MP3*#?V;")+)$ESW)-O6
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M$ *_$):;<O4)H8I?!K*IV:7L_HK67H&36X8R$)\LR S7642$1*%\IBS%K%2
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MP&L2WQ;G_*YV!'HFBS^;R6*(_6^&IAP)Q2&EHJ[;B",_]1FDB,';*QW,]I6
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M?$H $1='5^DECES#SNM<!JV- >-= T*#2I(9]Y_*W[ 7'#O/\9^CC_9',:T
MZMU4]H(6])@_8)?:E)@/CR.3\H:!M@1^H20CM8A?8+4PE++PDX+0M8[I-*D0
M:SDQ].\M/5M<QOB VLRTYU&:=#9JR@IO,5]K=\K30/M?E<G, PKA:]]B:%.2
M"J2_I!/Y:,\#O!9+73$LA$^87$ 2:/8!+Y.L,N+".]5-'[2WF5$K-&D\(D)(
M+1.(@I+'O\9GG="SAM:[V'I],MQNZXEN->%%O>*Y%:D'6WBU ;X#_(QU J#J
MA-_#R _-))87(O@FC4"WGQ$)CIWXQC[MU.$M.,0G[1(8;/ &F@P9GA#W^)'
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M)"<\VA]/?SE=*3XTM"F3+W;4@$,Z4FG8HLNE>7LJA @!T(TS4JD?8ELUX%_
MAN[O[>^U G LLN+)HF-*TP6K: B9I_\QN1DGH@N8MVKB\P XL![: 3Q?Z!!4
M\Z=HB_][FH_)#^&_GQ3E?'<[CMZ>OXO>2"L3'/S[:WM9WM2379+#85,6(VNK
MK0)$[L+HY_-A=/KNQ#XL8U/15([(##IO)G*M1R.@UG-0+G20 H:SK>&[E\-J
M6_*')GK]<D@]<CA*+'&O!5X))SG>6C%\=W'Z$Q_<UONDM!YZ,I]&I[]$)V[P
M.9/N=6Q>75Q1AV) ,Q>$$=P\R^*D*II5QTZ+8K,_NV4MU$1H+:CI> 2Q)+K$
M4B[Q2APP$;XK=J/C>&^P'Q\^/8Z15(U\ > ,T82GS/!&G"FL5 1!$#2^-@3,
ME/Y6"DI!!CDW)POU1FY8D\!3A)RC)T"UWH+WU/[:&::&HQ=%\=&:%)R]YZ+9
MEMO;.DW"SV'2:0K;H5;NM[YJ[;VB@,RCMP#4B0;/$7JS9P6 SOK"M\Q4=!56
MFQXE,X'>>9FD5LNF.^=)_K&(^4*)9FF]B-<CX0G:%3^-GPT.XL/G=HG/XV>'
MS^/#0_SC\^<'\?/!,_PJ>\Q/!_'>_B'-T9.!(91E*UONDR>"#:TV,0N^:L#6
M(^P,U\ ,EF1QHO6 'ZS,G:WPOS5]YWJ\P>WK%8K1CN.YDVJ4PH@P=$!"- SB
M.18P+A*(/+._Y"_8Y>^BF'1A0)CB 8'>6D;R;[N^R$J(."GS$U(Y/^ZP3S8L
M$4([%4*L\,&#2,G>XC,;7@#%]L$>:#'091S[M#)3#$N&] LR0.:)Y^QL:FK8
M5Z-#K2<+A;LQ)XU%[9$BU-F*ERDU"%H? 1QD&1[PKD#"Y=S_W*[CQ J@_4">
M)C[7)$\&_S; 6 J:#?7T(AH<X?L="_^U57'X_J_-J"0 Y0%]@#P1_\_/Y9]Q
M1BG//,8\3>)K2N03XL;<^Q7UF[EILW9;Q54]>7461R>OSX+3F!D@1$<WF:R%
M<S!QT+/$6,'V8XFE>_&NKYMSR5T=->AN83U*N)2QCSD/XE]T#M_9^XQ\[0-$
MHUK[(E&\2-F^")F;$8L'9RT8R>V$\J3BG=A8J33<C2,5V!%$J[ _!G260SXE
MEX;"DY&9S>&B3$R5F<9&Z<MV>]A<-7;-<*ATM)LG\@(+WC^,V?WOD/B!."Z8
M4%4_@7_KP5@/ 6,][\%8/1BK!V-MUFL^C _N6_ R2?W_WI[-'9;L\YV<__,'
MNS?U#=0OO*%DWY%S5.@\.+<0X4L5@K7N<&H\G ?H>J!2#,5-::%*B-->0%8(
M[<Z2'/J@_!2<)>>FQ>I$L5+2\;E@%A\%8AL</=&  9EB$>$D.>M]N$*6KV@@
M1[,O170,LO'H)@ /N40(X!23:V!3T.1)4DN-N;C=8A*[)^9J-_I9QBWQ*,:@
M1QID0]Z'+P /7?732]P0@%O>3"JS./*%4O*&NL^HNT\-F>'""D,(F;W,5VC3
MF0KTF8="P["D7B9$Z &B4_76PVP#KAOH,K.,;.H<!P#K[J"N@RLMSUKJ,0_W
M!=,8IJZI1XEHU^U*ML+FRCM]?L^$N%HCR6>V"1['<Q)KQ?7NEDJ#Y5UQ7B$<
M<78O-4.=8'9R\:C0;&<-#]7)>1AI QFZ:E%!NPZ3FX!&E8ES#H1AK_$$FTA/
M/IS!_W][5OEK(5!6YEA#SK\,>QQC!/$@Q1KB,+$YQK7:,!RJ6CUTQR$>K*XO
M&T=7I4D8]55SR%263/N_2S<9-P PM8C%9<KRJL]L+)[NI8%^7D+ONE9#IPK=
M2<U, CU85<PJ8X4$<1_O[1(DTN(U9E%>)3G/CZJB+1"Q;?6YT/ZV/VPE<5OU
M3FM99.TNPDBU^28#ZB)F>638#JHV]S+7:=G@9-<FYRFU_X(2!.)Q8P^M-S,0
M:_@M^]LI4 'E,#.&A#6I:@(\F;*T#ZAF5L:Y/E&;#(F"FES00<@O!_G&$MT1
M=G%@@@V #!$:)?:&L&%X 'P?'(^F0O1@JE(F=/! /*;^G9?&^3TXJAMU/91I
M:2['PE$GMCDO9<Z)OGP*1]6^O#0,3>Q]>^J:HMHC#(<SDV@!@H%%UI:4.**$
M;C'V%UR0#L>&;*%, 0X[I2:6% W/WRFZQGH1A(RDH2Y(S&%;F"Q*H2'%[:3I
M0/>%17HEA$8'U:1L,"L?GA[$LV%04\+\IZ#QH31D2HG',"EGJG<!&O_MA?#4
M0#BF!=N#L3CG*DP?' @<_/"G3YX^L[XX<&KDPL_Q/53P[#>\!,%X[_FA_6_B
MOC"-Q_<OWW\0HHX$2;? NOJ8Y80X8$O[).JW1"(%__LG)^^'_/O;TK:!EE[^
MXOHV@FX.J_<4M6;0]ZR# ^3[P_./E9J @X%SIY2V0U(*$T'G:/650@_LWB#M
M.(97)TR)Y1&\2\-=+^HLH=:.-U\N%EY#Q<;=B=H7II\$A RSM@'#I'L!<OD2
M]GC$V=-ZFH=C,B,A^M3252"+D$5QJT#8OB.\M*'U#K@<221#=_Z6T&D#'2Z(
MIGZV\8:]@C_95YL4,Q>R0&%]4B8WH/$E-'%WU/X.<.N]^GD;-U]FN@J_LP=^
M7F7%2(^2=H!/$ 4W'T7\&T)LL)0H'>QFIL>W]PJU[,RF>D5GO@IPX#+]]=)1
M1EL__[3-YP@<2.X4?XZV7I3F4UIO^^C$FM&K*ZK9)M3"SE@ RIP0B!]JQLP@
MC&6%EV9,92&_C FY071,N*:?G-*R7TQC>,Q54:?<E96ZKD#-9_K #,8W<'@_
M%#<&IZ=B!"!A-/Q%W3B\4 O:ZY$ \=RV4;:L[1#[$EZB,UQT,(Z*RFO\QOXW
M6S["W>BE-&W:\QX,=JP%KZ?\]%B.-'P4Z%)D;!7P(YVVTR5ED[&BA2 :^E (
M">_/FQY8@M.:.XZ!W<AMEK8Q*GKWH7,WIVR=?")2" !,4?^+;\2([\!(=QD\
M@-4CB<1X"BL%L$(%:*#87@GKF%/')B2)F*1!53"[5XC3 ("^R0^@7&;&G<W2
M*X9&NJ<8>_H%Y5;@W[;;,F.-50GV<\*HS0P(,L CS!(BDG!=+?8X.VTY7]N4
M(RK.A2#@RM[DE4U[8@7 -29(J(P!)R[4D'>)!2KV;C2ZT$ '!>7ARIL.^/YK
MYP253#^LK,@X0>XGNAQNJCE.2,#I>I+N^?DG)Y@(O "*J8QFA-*SW5>V))3A
MA?;EL;@7D1)UDZ(C:D"D=J*J]GS[G-;#J)2=8V?IB*4NZ.LDA*MU1"\SZ.=5
M0VN?A"C[MOF3BZ5ZC2#,X(:G<6ECB9T1$L(BJMTU?08YNZT;'KT@NX"W")HV
M*MP@WC)EG?6BMNU.+(H\G$-*^[2QYI@J%\HCEU25 :T)PQ60BU."0%*/,_9A
MBK$][EA[45H4ECMI5CM4SLQZT;-?Q9_WBC+PL3B<ZQC *[_((-HLM?'+1)K$
M/$9,?=-'I(##3[O&<HYV2-2,[IM86A#&)O2+@$ZT"D$:\1"TF)F$*!K5V&](
MG@ #/7,5^PN/&.C,<:"RS0HG>8R2'!/7?C\\8UPAS/1.QCD:@2>3$[P;#2MP
MAH!4S4V)EHMK/EGS .#5DCC_/4$T_ OFYY&."%XLC+I$"TYD*Z^Q(QSV>'-=
MHM/+#D\1Y[WDD@GS+J,:5Q+J.6A21\5E?_DM^31 )0NM;$T);9K>OXKMZ9<V
M0BUWT#%@$R+50;66%0^$FB(6'(.@R)&F#>T11EBM0"=)8O 4"2"FU#>EB0(N
M, %F(TMD*J>[7GG%2;X1#=G"QEK@%?"O#I-\T+AS=6.[ZT5D4R'_D8;W#!^G
M+8 4>^VO8DZG#H=9VL?PG9%Z$/O\.FY .@NZI]+BA<U!"&?JZ: >A$ Z[A%(
M/0*I1R!MUFL^(CHH5^GW+7PK/;@B[_"^C/*_O%7K-+]L5%LQ+T&,*3=ES9A/
M2X1#>2C#P06CN7T(C^<@)(3Q[!K=#PAH33'GT,(;\)1Q7US[Y/\.-3#LD!MC
MFY%U$;?5:$&I2<;<>=.1OO"1-+U*F&%O@XJX30J](:!>P) <?(;2%0UX5C44
MKJRS0A6)UPWBP&+V2K#N)K.C;MU5-<$OF13SFDNVKFKIO"651:#HUG[W8\K,
M?[\ZSFLE63CX;SS/SRRY0MX01[J+;%44@"YS]VQL7'[68GB#RI$IL>8)>"(,
MMX'.P-/PA-6PV$D>U"=OJV2L&A4DX?LM07L' .SD[)?3ESN#8^NE T]'.MZ-
MS@WW[KD;?4GL =(Z? IC? ;#J$YK@')RZ7(]NMH^MR_OK%,AM+-=OAE5!4R<
M=37S%#=NB48?6I[SNF.'UV.G[L'U//@NBH98.264@$_Q=$IF!80*'7-K0-H9
M'(A%?!]I5_:Z5)<+U\8;T/UY3JC=Z,=BQ.,\%=N.K,&:L G-I7.)#E8] B?@
M'*S+(-7X"9B'H]@&D_!-?79D7.S,:?$3PM:B8^R7%T=7F%@E1$94&8Q+K_F+
M;%1=,57Q78^!Z=1Z11UXQ +K];P#L#[<'D7D@>Z"NO.H>;!OV*7@M.:15!<E
MX@"M.<,:!E,/"4=2-_^3;"NVR4O'=5@VO1]=C\ )D+Q!X8H>(5&/\W:P!&#5
MK_#K^'P^^7DUB!F1;6H=)@6"90WFYAPBW +UN4AX;5W6RTLVVQX21*4$^1!?
M_188BCFXVG>GM=Z\"KQ.#[L"R<$J%Q) J+1HS=AKXE]D\7%H#1YFC;XM(JDE
M\PK]!!?T-C%O5*F'1R)W@(!E%"+(_;)"<C9Y77KB*5<SJHDN?6P<W.Q!MT1Y
M1_?[?:6\-.D77_G6TQ$=A-4>N7%0GH00"/O\QBVVK^6WWM6:/XXHQ\P8^&5A
MA*(6#%-0'VM70%T0A;N>BBB(Z 4'<Z\#$:% ][X#G-&I.*A"N\P)]JC\_6ZG
M9ZF62C=C7)3S BLJ,!+S7R:7F384G3'K*@LG_1L/@]I89]\E%W HINC'RV+<
M,"A-@B&J/B/4ETKH1BHT)-)VZSXRO+_2E>.'[[F;A<)#>0*D@'P%(TL+'BDA
M%7)R)$@>9!3XS!@"*(ZXP(@D/H#!"#Y  %0@86DS&=^V%5^R$U&X"9%[_\X6
M"(478YP 5 J#:=./30$HG4BLL$1@/DW^9=WIHJE:1A?YZO18]PX$2GP7!&47
M.TTT,W/MZ*Z7LCB0O$-"YEAXD%;Q"CM.47:7\ ZB82481XH62;"E(*L-P?([
M7G9CE9:8<\SI[1#;["@MP@2@ V7CX6ATP,J>+LIG!&T)B@B>:0"UY'Q"S_7:
M/%"&PC ; +;A))M;CA;GLW_&BRR)CV&WU/HA!9'+TI?!@$7,G\81P&**Q!/%
M@P $.K]S8:[3$)$&X16Y>YM:MT9=#B*PQ8HJ(O/#:U 9=<F)*CZT%X <M_)Q
M95R_ $-('#I_! ,2,B+@I5%S6./URM?1 $+DFHP#H$,B0.T0-0U]A>+!$<TZ
M12OM8/A1^6RGP/UI0\-_-M90ZH:SI$YL?&/O<3J6_AB(=SZ:[L 0KOMMZ>UO
M7,N=81@E/H.]*Q.[825Y!FH^1F! <&J6[TM9J2"T7L-Q(,68*,$ID#H'*"Q(
M* QK!]Y&+ [%J'6OX/G45W*)W3C X.EAAMQO[9EII5>JAOCHRK0G)M\@:RK<
M)^'.%QR%(LNC%B<.E6DP-=K$R37<H@G$;(L9M8G]UM#<"D6*!6_U XR<OTXS
M2"\/;61JKS(ILANJ)674BH2L7_0+"ZRO)1/@FINDB73<(B=1$8&P-//VLKF-
MN=. Z#WN6(UC:"7.;!I3[Z^)OR7M=C0%P]3X2<+2N;VGIZ:Y@M)5?.P^\Z+"
M<KWYY*(B?-?KV,MNTNVV%6H_UKK87;L4DN9C L'ZQ,4,7.@;UTT>X.U<;<U]
MCV?*_JQXV7\!*Y3H;#5-/-8/J0YIWY"['_T.I3C<O% LZ2N>LP+'UJ$"?=E4
M*<TXNLR* JSQM"FAOS!'>MJBS!,DEL7<$B?IJZAC7@R\:JA4MU958T:^ 2^_
M"G#<E=H*SEKQ@)/V0)3MSSP3#-\PX0H\F@@2@*@*I\%BLY/]=9BRF62+*G6=
M %[I!-FA5GSTN>+!O5FSY#?8E8X;N7QH:M"B?62)I6\,\:RTNI;-X@;;&=P5
M=1K4/;C'>SW ;![M]7BO'N_5X[TVZS4?QCCU#7CYWHU#'[WP(V/!V<;X$*?\
ML+>-]1$A(F@3.7;SOL@<6O0TA%^%2R\P PW<91FP1I@H+D\[[@!-3-"V[)$;
MZH/Q=$<TED[^ZR]WG_'QX"]WL(>M1:Q[>V1[4K(C/AQCB0<<IO=03TK9)WM5
M$8ZKNE_0.L!YS]^60%]@3=%83]?52+U7A4.;J88&32T%4BF SX/I(2R271%+
M 13 L&6!2#ID-^<V7ABG<X#*;7T_'+[?%HJ 2O%'40!C730CVTU1:54UL[G@
MZCRJBQ N7']-9O!5Z*$!25K';#>\IVVV"%@<QCPK?J<..KO@SYV;(H7%KN7(
M!"2&/M)PH8DTG<KOX"9A"\$]$R-+,O8M0 M^I2%CQ$KK#ME*VS2%R@S>0=BC
M,H400.A<@5X!LI7D72^)PXV:(8.!&8%2&&0[,926: T*IYUW\03%6#21#;1D
M N$),3%@V]1OS>2*C]KQ]@*,= $_A*8H<XODD="6%!3!7*&4QGG T'1F'.82
M%(]TA"C*4*M5QU[!+!P>&(/KW 4*C\9/#"6TDQI]3CEJ_PS:%/H$"[_;46*,
M8NB.#:EK1\S-B @/L<"&.$"U2AU]:A#7P:U?4.5*2\HH>$5PU:03M'/V<1-3
MC<MT1+F5=S8(C 82]%F_80(W98)\)07QM4^BU^[RG;O+Q_4V#W"$/(]#^P@<
M0-(3HNFU;M*:WN\2Z(H&1]PP:\XPSV&7/^!]19IA$)?!WLY/+O=%7:/1PH:;
M$5$82\,YE4BIZWQP_&!S.]@_/-8&EZ[[W__OJ'SR]Z5GKHDN6)5.!@SGP6[4
M^K]_-) 3988Z.!'[#YG\_:73WW(1WU+?X(>T^KBYMOD,,V_XH@1N3FJ:V:&E
M:G_/9UY(Z@. BM($@63C,3P;BG]X#R&_4[JQV3[-?'TU.G]U\G /\UF7AZG/
M=.?9OMW'H.*"__*->:%P$K21A]QW<$)E/M),[Z$K9 *BOU+0U^Z%/[?$Y.]W
M]+GO_LU?\E\AY+,A&\[']/LPUOLP=_O@G0IK1=.KG" Q)L??(?H:Q7?&SK;0
M10D=ES-MYYX)])4T<P^)[GAP?' 8;>E_W6:7%2N]$.O"R+78=2U-8IS8E2!1
MG[!7L%L,"H%K53@VF#S>*H+A2>EEZBM9OJM&N,%$CPBG5E)35*U?$_!0-IJ=
M-<173'ACX?:CM_?1AJ[&H<LQA7FIKV16 H^2(6@D_<Q['_PSA(LJ-KJ89SX4
M-_AZ.'&0QK3!1ETE)1/!\&'X4]YDGW_H3@\;NB^%*0*ZI3'9(?!7E"80%"KN
MJR8M**DYYH%8.?558Q]TC3O,E#]L<!PE@\Y]_,YG+V\EHW-S+J 081U<2@I@
MVM/F[W&YL86?RS/!A?Q@[T4T.$AV!D>[T0M$T,!T89Y^Z+^> M:8=E7OW0/?
M%@%Q .>;^.:Z>[P'8C;<!JV6\F_><)UXU/&I\+&R!8O.8/ZWW]$/$N]OM"GC
M#@^:N^I&;P$[*T.8#*<T>>[-TBUJ4=N2?#&YDP2Z2'P"M(:.:-*WSO+$'@G6
MA5\ZTH1D,&HX02INOF)L#MO?B^P6FKC:I6SH,HRQQ=<9+QI8B$1B%3O*7=XZ
M3QNN A@YMTH0TVGE4QE [OX1+$I=+']^B0CX]E7O1N=D;V$^^0*Z6CWM\"4B
M4S$WS& PS#]XO"SL65%^)$,V*["W=2)3X3NZ^5"9<WX\&/5+2)#?&D;^P@.F
MUG#>T/,IEE%OZ@#AG8)QR[O^&M)^VF-)ZZ*4S"*EPG4-6@:[7JYZ'Y_L(S>C
MFIK,+L?>V!WJGM;LI[$T&"TO&=$'=9E2W@K84F;02\$-"HGO35HZV&7K0I2]
M_@9ML*I] VQ,@O&F"_>JK3PD>-A<%7OV^_LS;K0QP>@_R] S:N;^BA-)?N8E
MX9N . CQ%'0K,^!@39H)S V6!Q%\).;<'G0ZDK+(N*4 FP+\A0 -.DYPMN=U
M.C$T*];GA6-\3X%3Q)@!I?*;S.2-"@3WX- T5@7A4E 3S@ 7]\(0#SA_+,VG
ME%;-E*"F.#.E]8@*7\=[9U*3P W6JY>%MM>I'XF34!CHQ%SCN'+<R1CHHJSY
MBW4$)D!KGSB=F)JH!W@\S8I7H;X.4H&)SG'[+#E"RBCTV>$4.KP0D'LFUG0O
M5!2':(Y)<9/3.Z,QM1]T>UHA\2?)!PK:+,56#<A[<PV5S%BP=2/)^(. ^08[
M>^53NZ4-9H I]8\]PU9H*L338;M1!H-P.*E]4RA.IP)6TL-['@+O&?3PGA[>
MT\-[-NLU-Q;> ^V&"PU- $>F1$\B< :H;X;]<01_+\0_T,8<(<,VG*.>)V8D
MQ,R-ZT[415A?8\:@+YT6Q #*#,8",/;#!=CB66^B[2' & Y:'7I<B//EX:]C
MZPAB'TZ*#1L8RUP5 !*G!!MX%SXLDD$DNC@,SAT-M7=O2CT>8["I?BB!-N>J
M/ULS=W!M:6*@6[NK!XF"-*[4%J5V/HG= R)%[+FXOT>&#4\[+G!:<C:MIZ%
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M*Q-5S>@W^TQ8 CPH2Y-1FJ7U@IZ<U%%%WQC;)9>\^*H93V7>Y-);W#9ETFX
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MJW>](?XV;_%F>:(_IEF6VM6 7$Z+667R>WFBVL/D'W:YH,/QV*X!7-7>!]T
MT?_F-.\]?- EO/A]4Z7?0/5TS;/K1T>K"Z5/1L5D8?\SK6?9W_\_4$L#!!0
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MDT(PX7ATMB?]4R.VJ'_8R/T,E,1-,ATL*H1\W000.W#5<&^2\<08I(2<[?G
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M$2T5/6)*&%=+#MBY8P+[EP'NVX(!X8-7-IBP0/XP%"CFX!6:%\S$]ONI?.I
M7SE&\C+O\&^/]J=J99V.;^1W5=;OCYY\W/5]+'QU"=5BDU2U)-\5;+F;VE;+
MP:'Y4RQOO<;IVK;9FF<19,55<)4G&MUDMZIEY:)^SZ-?Y%">5]U&<HE],E:!
MB(8M6J@2!>LRA3]U58IY_?:5]2F^9H'1X:)LZ\I9$YWSBN4^VA^YY%Z-CXL9
MHZD\Z%1W_?KV!'OHVZ?_ 5!+ P04    " !9JZ=0U#9/V24:  !A!0$ %0
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M("(HDX36+(N]C,\Q^S1[9];6_LU=M%DQF?&LE\_]M!\67Y].%W'6+8YZF-"
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MSMB..!]$4'H7EFPXR:RFEPH>S#Q8/KD6+1\(B+@U2TD@6$VDT);XQ *144<
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MG&DY[F.G2PWQ]W@(.(?ZZV0ZO"BP3D:C63'YEL7M\$>GGV'\9I@OH7Z[%."
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M"(,@K=4Q26*<1YR\M*."% BWGJ&1#2[E=NQH/^9394LEK6Q@3[?H^J8#Z*M
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M0Z- K$3C+^I2H%U#M+)*U+BW&1PJO^?8)#V*QA]*&L\"_JJ_6DR:Z1 H"38
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M.K>:#LN*>R+.AR7%+C*O3X9EM%(IKH(O+8%"UK@FXH[JA3<D4\&8,3JBQWT
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MQ62=;]K:D?X(V(8/]4T:G/%8?X2>^P?[8QH8>6L6E]_4_U65CF>\5BU^D=N
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M/E4'9C&"Q">JU(&'8R$BGX6&C'S0P]((5@FHHEGO<\F4H,S7_?-/$T)=]KL
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M :.IS9[+1?>=L=< 'QYX05.\OL5R=]9\MG*\$:=) K$?)Q"%-(!QHHK=^&[
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MN#0>:C54A\-[.H*NDM5.5ZH):=\CW3+):O^F=#5DL@F^!ST2?-U1GI@_7V>
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M$KH(:YEU>MTM;7Y6 @,7M )WW5$F/JBS,.LX[VR"-[7_KL)-"GL2N?-)L\=
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M)R.UDH949PCT/("6@9V8_1I,O]:82H'EAPMJD>O,F2K19IVXTYX'T  BFPY
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MYU<@8DY,5T4D>G@!2: [8B+2E]K;T2ZGC^WJCHYZ4.":UME**3<EN2KWKQ^
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M4-,#(H>XB'F:Q2EEQ"J=MG>7J4GIFE#0D'BW^P%4+^S#TC*ALQ_8?O'I#:[
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MEDH+:QJ$\1:Y;G+%$G*ABEA#2V$>I]0D&4A(:99#O68L"H)S1.7LARS9ZO5
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M/0%)RC"D7$0:89Q%8H?L^Z7E+ ,/N.[V"H?J^]HN# "II??_%I!">^TKVNY
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M4YGQ5*8Y9%HK,LEH&#*D$)1)3A3).<>2NF7:6^PZ.7%1$]TNM'/-&;?!VDZ
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MN#LJ%Q/WQO9R ? L98U4@70#I6[UT,"9]7I*GX6+FZ"!R9IJAPD<;0S:%SQ
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M+K&FD_;B3O7#SK#FO^&=<2:$-+Y/;GC2Q1JCF 0Z=VV=8&+!<V$ O==D%(1
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M.H6(G\>+-)DM+N>KYYBGU/^1-/X3K?O[J-C,I,\6>*P%E#Y+B%Q[2"$EQTU
MWL\5\+D9'=;O./_.>-"5JF5@_8F.CK,?(8,?)=_!D5)D1IMB ,N" A5XA*A5
M@IH6)+(0DO#8G)$[]4A9]1BY2\%*45>W.Y052;Z=)_M1JG-G@R>_S@80F>>8
MI5)A.R)\I/'+$XO\&<SN(>BYU^"E*^$W$!7>D]XV+_7BS;'L0;)@0*6B(1II
M0*80HPI.>.QI7N'C1 T;UPT'O,X5U@#X*'1]6WY9+,<4%=?NZ\+Q8#R#Q%,
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M9P@:^-9HS^''P^1> WX>%L (/2_FDT:'T#)6%I)#TRL$<<XH28'))/II^O1
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M.V[])BT4=*G\TN"F W"Y[>\VMO]KVOYK0W&K%Z@K>]T?+'@"3_KKD% 7W58
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MN2_J?**$L9%,V>^9Q&FAA'UPM32YT$>>"]U<?7[]R'*A*VPI:N]!J[X@;('
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MPQ,=AM.("VY6EMALZ]8ZJT.R ZGWLPW1!G5S*>ZF&E!1J@*=1#LB%L=2,6>
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MDT:X&*6!:;7TO6??_JP^_454=R7V^#]02P,$%     @ 6:NG4#V#2FUH"
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MZ!7,N#;(D0VA]F73R:&7S1IV=>7,AK>O#;Z#%PO?Z=IBO]E[VPL.)[I$:$G
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M^OHR?V8WJ>9.=_\?4$L! A0#%     @ 6:NG4%I)).7U'@( KQ45 !$
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M,3$N:'1M4$L! A0#%     @ 6:NG4#V#2FUH"   >BL  !D
M ( !Y+8# &YK='(R,#(P+3 S>#,Q>&5X>#,Q,BYH=&U02P$"% ,4    " !9
MJZ=0!D&)$CT&   N'@  &0              @ &#OP, ;FMT<C(P,C M,#-X
C,S%X97AX,S(Q+FAT;5!+!08     "@ * *0"  #WQ0,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634773952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Cash and Investments in Marketable Securities</a></td>
<td class="text">Cash and Investments in Marketable Securities<div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash and investments in marketable securities, including cash equivalents, are as follows (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.545%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.367%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.370%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Estimated Fair Value at</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">227,035&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,363&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,118,847&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,228,499&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">185,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">279,119&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and investments in marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,531,782&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,603,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We invest in liquid, high quality debt securities. Our investments in debt securities are subject to interest rate risk. To minimize the exposure due to an adverse shift in interest rates, we invest in securities with maturities of two years or less and maintain a weighted average maturity of one year or less. As of March&#160;31, 2020 and December&#160;31, 2019, all of our long-term investments had maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTUz_40a91577-8b0a-499f-ace6-b778d1948c9f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmYwOTU3ZjFjZjgwYTQ4ODk5NDA3MzZiMjlhZDU2YzYzL3NlYzpmMDk1N2YxY2Y4MGE0ODg5OTQwNzM2YjI5YWQ1NmM2M180Ni9mcmFnOmRhNGZkMzI2ZTg0ODQ3YjE4ZjEzZmRmNjQ4NjFlNjU5L3RleHRyZWdpb246ZGE0ZmQzMjZlODQ4NDdiMThmMTNmZGY2NDg2MWU2NTlfNTUz_d3c2600b-5a29-4044-88bc-bc0629d86f53">one</span></span> and two years.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March&#160;31, 2020 and March&#160;31, 2019, we sold no available-for-sale securities. The cost of securities sold is based on the specific identification method. To repay our senior notes and accrued interest of $254.8&#160;million on April 13, 2020, we did not sell any available-for-sale securities.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We report our accrued interest receivable, which totaled $6.2&#160;million and $6.5&#160;million at March 31, 2020 and December 31, 2019, respectively, in other current assets on our Condensed Consolidated Balance Sheets.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our portfolio of cash and investments in marketable securities includes (in thousands):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:25.729%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:7.626%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.518%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.367%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortized Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Gains</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross Unrealized Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate notes and bonds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">989,511&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,010)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">986,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,132,182&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate commercial paper</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">373,237&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(108)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">373,223&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">375,473&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,362,748&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">830&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,118)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,359,460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,507,655&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">158,080&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83,546&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,951&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">N/A</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,994&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,829&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash and investments in marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,531,782&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,603,981&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;1&#160;&#8212;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-63pt;padding-left:63pt;"><span><br/></span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;2&#160;&#8212;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We use a market approach to value our Level 2 investments. The disclosed fair value related to our investments is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or has been derived from observable market data. </span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:-63pt;padding-left:63pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level&#160;3&#160;&#8212;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821677888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEKTAR THERAPEUTICS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3134940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">455 Mission Bay Boulevard South<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">482-5300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NKTR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,989,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000906709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6821333696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (138,651)<span></span>
</td>
<td class="num">$ (119,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(5,121)<span></span>
</td>
<td class="nump">4,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign currency translation gain (loss)</a></td>
<td class="num">(751)<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(5,872)<span></span>
</td>
<td class="nump">4,720<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (144,523)<span></span>
</td>
<td class="num">$ (114,912)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6651024592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments in Marketable Securities - Cash and Investments in Marketable Securities, Including Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 227,035<span></span>
</td>
<td class="nump">$ 96,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">1,118,847<span></span>
</td>
<td class="nump">1,228,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">185,900<span></span>
</td>
<td class="nump">279,119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments', window );">Total cash and investments in marketable securities</a></td>
<td class="nump">$ 1,531,782<span></span>
</td>
<td class="nump">$ 1,603,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, restricted cash, cash equivalents, and available for sale investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6814293856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to Sale of Future Royalties - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">70 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2012</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties', window );">Non-cash interest expense on liability related to sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,968)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability', window );">Annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="nump">17.60%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProspectiveInterestRatePercentage', window );">Prospective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember', window );">Purchase and Sale Agreement with RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems', window );"><strong>Liability Related to Sale of Future Royalties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross', window );">Proceeds from sale of royalty rights</a></td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Transaction costs related to sale of potential future royalties</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated annual interest rate over life of royalty liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense related to sale of royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashInterestExpenseRelatedToSaleOfRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash royalty revenue related to sale future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of potential future royalties gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProceedsFromSaleOfPotentialFutureRoyaltiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nktr_ProspectiveInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prospective interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nktr_ProspectiveInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nktr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nktr_PurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
